<SEC-DOCUMENT>0001193125-18-233467.txt : 20180731
<SEC-HEADER>0001193125-18-233467.hdr.sgml : 20180731
<ACCEPTANCE-DATETIME>20180731172519
ACCESSION NUMBER:		0001193125-18-233467
CONFORMED SUBMISSION TYPE:	424B5
PUBLIC DOCUMENT COUNT:		6
FILED AS OF DATE:		20180731
DATE AS OF CHANGE:		20180731

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			TherapeuticsMD, Inc.
		CENTRAL INDEX KEY:			0000025743
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				870233535
		STATE OF INCORPORATION:			NV
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		424B5
		SEC ACT:		1933 Act
		SEC FILE NUMBER:	333-226452
		FILM NUMBER:		18982121

	BUSINESS ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487
		BUSINESS PHONE:		561-961-1911

	MAIL ADDRESS:	
		STREET 1:		6800 BROKEN SOUND PARKWAY NW
		STREET 2:		THIRD FLOOR
		CITY:			BOCA RATON
		STATE:			FL
		ZIP:			33487

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	AMHN, Inc.
		DATE OF NAME CHANGE:	20090930

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF ENTERPRISES INC
		DATE OF NAME CHANGE:	19970915

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CROFF OIL CO
		DATE OF NAME CHANGE:	19920703
</SEC-HEADER>
<DOCUMENT>
<TYPE>424B5
<SEQUENCE>1
<FILENAME>d554088d424b5.htm
<DESCRIPTION>FORM 424(B)(5)
<TEXT>
<HTML><HEAD>
<TITLE>Form 424(b)(5)</TITLE>
</HEAD>
 <BODY BGCOLOR="WHITE">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="right"><B>Filed pursuant to Rule 424(b)(5) <BR>Registration No. 333-226452 </B></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Arial Narrow"><FONT COLOR="#cc062a">The information in this preliminary prospectus supplement is not
complete and may be changed. This preliminary prospectus supplement is not an offer to sell nor does it seek an offer to buy these securities in any jurisdiction where the offer or sale is not permitted. </FONT></P>
<p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><FONT COLOR="#cc062a">Subject to Completion. Dated July&nbsp;31, 2018. </FONT></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>Prospectus Supplement </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B>to Prospectus dated July&nbsp;31, 2018 </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center">$65,000,000 </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g554088g96q94.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL" ALIGN="center"><B>TherapeuticsMD, Inc. </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center">Common Stock </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are offering
$65,000,000 of shares of our common stock, par value $0.001 per share, at an offering price per share of $&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our common stock is listed on the Nasdaq Global Select Market of The Nasdaq Stock Market LLC under the symbol &#147;TXMD.&#148; The last reported sale
price of our common stock on the Nasdaq Global Select Market on July&nbsp;30, 2018 was $5.52 per share. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>Investing in our
common stock involves a high degree of risk. See &#147;<A HREF="#supprom554088_3">Risk Factors</A>&#148; on page <FONT STYLE="white-space:nowrap">S-13</FONT> of this prospectus supplement, page 1 of the accompanying prospectus and in the documents
we incorporate by reference in this prospectus supplement to read about factors you should consider before buying shares of our common stock. </I></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><B>Neither the Securities
and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the accuracy or adequacy of this prospectus supplement or the accompanying prospectus. Any representation to the contrary is a
criminal offense. </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="80%"></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="4%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Per&nbsp;Share</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Total</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Public offering price</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Underwriting discounts</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Proceeds, before expenses, to us</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right"></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters have the option to purchase up to an
additional&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of common stock from us at the public offering price less the underwriting discounts. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Concurrently with this offering and pursuant to a separate prospectus supplement, we are offering to sell directly to Knight Therapeutics Inc., in a
registered direct offering, $20&nbsp;million of shares of our common stock at the public offering price per share in this offering. We refer to this transaction as the concurrent offering. The closing of the concurrent offering is contingent upon
the closing of this offering, but the closing of this offering is not contingent upon the closing of the concurrent offering. See &#147;Underwriting&#148; on page <FONT STYLE="white-space:nowrap">S-33</FONT> of this prospectus supplement for more
information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters expect to deliver the shares against payment in New York, New York on or about August&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;,
2018. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Goldman Sachs&nbsp;&amp; Co. LLC </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Cantor </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">Prospectus Supplement
dated&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;, 2018. </P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="94%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000">Page</TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Prospectus Supplement</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#supprom554088_1">About this Prospectus Supplement</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-iii</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#supprom554088_2">Prospectus Supplement Summary</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-1</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#supprom554088_3">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-13</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#supprom554088_4">Cautionary Statement About Forward-Looking Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-29</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#supprom554088_5">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-31</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#supprom554088_6">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-32</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#supprom554088_7">Underwriting</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-33</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#supprom554088_8">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-39</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#supprom554088_9">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-39</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#supprom554088_10">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-39</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#supprom554088_11">Incorporation of Certain Information by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right"><FONT STYLE="white-space:nowrap">S-40</FONT></TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1pt">
<TD HEIGHT="8"></TD>
<TD HEIGHT="8" COLSPAN="4"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><B>Prospectus</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom368527_1">About this Prospectus</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom368527_2">Risk Factors</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom368527_3">Forward-Looking Statements</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom368527_4">Our Company</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom368527_5">Ratio of Earnings to Fixed Charges</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom368527_7">Use of Proceeds</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom368527_7a">Selling Stockholders </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom368527_6">Dilution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom368527_8">Description of Common Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom368527_9">Description of Preferred Stock</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom368527_10">Description of Debt Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom368527_11">Description of Depositary Shares</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom368527_12">Description of Warrants</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom368527_13">Description of Purchase Contracts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom368527_14">Description of Units</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom368527_15">Certain Provisions of Nevada Law and Our Charter and Bylaws</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom368527_16">Legal Ownership of Securities</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom368527_17">Plan of Distribution</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom368527_18">Legal Matters</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom368527_19">Experts</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom368527_20">Where You Can Find More Information</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL"><A HREF="#rom368527_21">Incorporation of Certain Information by Reference</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have not, and the underwriters have not, authorized anyone to provide any information or to make any representations other than those contained or
incorporated by reference in this prospectus supplement, the accompanying prospectus or in any free writing prospectuses we have prepared. We take no responsibility for, and can provide no assurance as to the reliability of, any other information
that others may give you. This prospectus supplement and the accompanying prospectus is an offer to sell only the shares offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this
prospectus supplement and the accompanying prospectus is current only as of the respective dates of such documents. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-i </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="supprom554088_1"></A>ABOUT THIS PROSPECTUS SUPPLEMENT </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Unless the context otherwise requires, all references in this prospectus supplement to &#147;TherapeuticsMD,&#148; &#147;TXMD,&#148;
&#147;Company,&#148; &#147;our company,&#148; &#147;we,&#148; &#147;us,&#148; or &#147;our&#148; refer to TherapeuticsMD, Inc., a Nevada corporation, and its subsidiaries, VitaMedMD, LLC, a Delaware limited liability company, BocagreenMD, Inc., a
Nevada corporation, and VitaCare Prescription Services, Inc., a Florida corporation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This prospectus supplement and the accompanying prospectus
form part of a registration statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> that we filed with the Securities and Exchange Commission, or SEC, using a &#147;shelf&#148; registration process. This document contains two parts. The first
part consists of this prospectus supplement, which provides you with specific information about this offering. The second part consists of the accompanying prospectus, which provides more general information, some of which may not apply to this
offering. Generally, when we refer only to the &#147;prospectus,&#148; we are referring to both parts combined. This prospectus supplement may add, update, or change information contained in the accompanying prospectus. To the extent that any
statement we make in this prospectus supplement is inconsistent with statements made in the accompanying prospectus or any documents incorporated by reference herein or therein, the statements made in this prospectus supplement will be deemed to
modify or supersede those made in the accompanying prospectus and such documents incorporated by reference herein and therein. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This prospectus
supplement and the accompanying prospectus relate to the offering of shares of our common stock. Before buying any shares of our common stock offered hereby, we urge you to carefully read this prospectus supplement and the accompanying prospectus,
together with the information incorporated herein and therein by reference as described under the headings &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain Information by Reference.&#148; These documents contain
important information that you should consider when making your investment decision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">You should rely only on the information contained in or
incorporated by reference into this prospectus supplement, the accompanying prospectus and any free writing prospectus authorized by us. To the extent the information contained in this prospectus supplement differs or varies from the information
contained in the accompanying prospectus or any document filed prior to the date of this prospectus supplement and incorporated by reference, the information in this prospectus supplement will control. You should read this prospectus supplement, the
accompanying prospectus, the documents incorporated by reference into this prospectus supplement and the accompanying prospectus, and any free writing prospectus that we have authorized for use in connection with this offering, in their entirety
before making an investment decision. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The industry and market data and other statistical information contained in the documents we incorporate by
reference are based on management&#146;s own estimates, independent publications, government publications, reports by market research firms or other published independent sources and, in each case, are believed by management to be reasonable
estimates. Although we believe these sources are reliable, we have not independently verified the information. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">TherapeuticsMD<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, vitaMedMD<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>, and BocaGreenMD<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> are registered trademarks of our company. This
prospectus supplement also contains trademarks and trade names of other companies. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-ii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="supprom554088_2"></A>PROSPECTUS SUPPLEMENT SUMMARY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>The following summary of our business highlights some of the information contained elsewhere in or incorporated by reference into this prospectus
supplement or the accompanying prospectus. Because this is only a summary, however, it does not contain all of the information that may be important to you. You should carefully read this prospectus supplement and the accompanying prospectus,
including the documents incorporated by reference herein and therein, which are described under &#147;Incorporation of Certain Information by Reference&#148; in this prospectus supplement and under &#147;Incorporation of Certain Information by
Reference&#148; in the accompanying prospectus. You should also carefully consider the matters discussed in the section in this prospectus supplement entitled &#147;Risk Factors&#148; and in the accompanying prospectus, in our Annual Report on Form <FONT
STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017 and in other documents incorporated herein by reference. </I></P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Our Company </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are a women&#146;s health care company focused on creating and commercializing products targeted exclusively for women. Currently, we are focused on
commercializing our recently U.S. Food and Drug Administration, or FDA, approved product, IMVEXXY&#153; (estradiol vaginal inserts) for the treatment of
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> dyspareunia (vaginal pain associated with sexual activity), a symptom of vulvar and vaginal atrophy, or VVA, due to menopause, and pursuing the
regulatory approvals and <FONT STYLE="white-space:nowrap">pre-commercialization</FONT> activities necessary for commercialization of <FONT STYLE="white-space:nowrap">TX-001HR,</FONT> our <FONT STYLE="white-space:nowrap">bio-identical</FONT> hormone
therapy combination of 17&szlig;- estradiol and progesterone in a single, oral softgel drug candidate, for the treatment of moderate to severe vasomotor symptoms, or VMS, due to menopause in menopausal women with an intact uterus, and our <FONT
STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system candidate <FONT STYLE="white-space:nowrap">in-licensed</FONT> from the Population Council. The new drug applications, or NDAs, for
<FONT STYLE="white-space:nowrap">TX-001HR</FONT> and our <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system candidate have Prescription Drug User Fee Act, or PDUFA, target action dates for the completion of the FDA&#146;s
review of October&nbsp;28, 2018 and August&nbsp;17, 2018, respectively. IMVEXXY&#153; and <FONT STYLE="white-space:nowrap">TX-001HR</FONT> are designed to alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone
deficiencies, including hot flashes, osteoporosis and vaginal discomfort. More than 32 million women in the U.S. have symptoms of VVA due to menopause and more than 36 million women in the U.S. may experience VMS due to menopause, representing
potential total addressable markets for IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> and TX-001HR, if approved, of approximately $20 billion and $25 billion, respectively. With our SYMBODA&#153; technology, we are developing
advanced hormone therapy pharmaceutical products to enable delivery of <FONT STYLE="white-space:nowrap">bio-identical</FONT> hormones through a variety of dosage forms and administration routes. In addition, we manufacture and distribute branded and
generic prescription prenatal vitamins. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P ALIGN="center" STYLE="font-family:ARIAL; font-size:0.5pt"><FONT COLOR="#FFFFFF">vitaMedMD 1 Year Vaginal Contraceptive Ring*
~60,000 New Prenatal Patients Many will go on Contraception after breastfeeding Vasomotor symptoms affect up to 75% of Perimenopausal women PRENATAL CARE CONTRACEPTION/ FAMILY PLANNING -PERIMENOPAUSE VASOMOTOR SYMPTOMS VULVAR &amp; VAGINAL ATROPHY
(Dyspareunia) REPRODUCTIVE HEALTH MENOPAUSE MANAGEMENT * investigational products, pending FDA approval


<IMG SRC="g554088g47b56.jpg" ALT="LOGO">
 </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are a Nevada corporation. We maintain our principal executive offices at 6800 Broken Sound Parkway NW,
Third Floor, Boca Raton, Florida 33487. Our telephone number is (561) <FONT STYLE="white-space:nowrap">961-1900.</FONT> We maintain websites at <I>www.therapeuticsmd.com</I>, <I>www.vitamedmdrx.com</I> and <I>www.bocagreenmd.com</I>. The information
contained on our websites or that can be accessed through our websites does not constitute part of this prospectus supplement or the accompanying prospectus. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Recent Developments </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>FDA Approval of IMVEXXY&#153; </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On May&nbsp;30, 2018,
we announced that the FDA had approved the 4 mcg and 10 mcg doses of IMVEXXY&#153; (estradiol vaginal inserts) for the treatment of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> dyspareunia
(vaginal pain associated with sexual activity), a symptom of VVA, due to menopause. VVA is diagnosed in approximately 50% of post-menopausal women. The 4 mcg dose of IMVEXXY&#153; represents the lowest approved dose of vaginal estradiol available.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On July&nbsp;9, 2018, we initiated our early experience program for IMVEXXY&#153; with a limited launch of the 10 mcg dose to a targeted sample of
healthcare providers throughout the country. In the first three weeks of our early experience program (July 9 &#150; 27, 2018), approximately 1,363 healthcare providers have initiated at least one patient on treatment of the starter pack of
IMVEXXY&#153; and sent in the <FONT STYLE="white-space:nowrap">follow-on</FONT> prescription for continuation of treatment on the maintenance pack. We anticipate that the national launch of the 10 mcg dose of IMVEXXY&#153; will begin on
August&nbsp;6, 2018 and that our <FONT STYLE="white-space:nowrap">Bio-Ignite</FONT> compounding pharmacy customers will begin to receive IMVEXXY&#153; in late August 2018. We plan to launch the 4 mcg dose of IMVEXXY&#153; in September 2018. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe the patient engagement programs that we created and piloted around our prescription prenatal vitamin business have the potential to improve
patient compliance for IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, compared to other products in the VVA category. For example, in our prescription prenatal vitamin business, our patient engagement programs have achieved over 75%
utilization of our co-pay assistance program, compared to an industry standard of 30%. We plan to use our patient engagement programs to help patients manage out pocket costs IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> and improve
education regarding VVA, with the goal of increasing patient compliance. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As part of the FDA&#146;s approval, we have committed to conduct a
post-approval observational study to evaluate the risk of endometrial cancer in post-menopausal women with a uterus who use a <FONT STYLE="white-space:nowrap">low-dose</FONT> vaginal estrogen unopposed by a progestogen such as IMVEXXY&#153;. In
connection with the observational study, we will be required to provide progress reports to the FDA on an annual basis. In addition, the FDA asked for post-approval information with respect to certain characteristics related to the product&#146;s
specifications, which we expect to submit to FDA before the end of 2018. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>License Agreement with Knight Therapeutics Inc. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On July&nbsp;30, 2018, we entered into a license and supply agreement, or the Knight License Agreement, with Knight Therapeutics Inc., or Knight,
pursuant to which we granted Knight an exclusive license to commercialize IMVEXXY&#153; and <FONT STYLE="white-space:nowrap">TX-001HR</FONT> in Canada and Israel. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to the terms of the Knight License Agreement, Knight will pay us a milestone fee upon first regulatory approval in Canada of each of
IMVEXXY&#153; and <FONT STYLE="white-space:nowrap">TX-001HR,</FONT> sales milestone fees based upon certain aggregate annual sales in Canada and Israel of each of IMVEXXY&#153; and <FONT STYLE="white-space:nowrap">TX-001HR</FONT> and royalties based
on aggregate annual sales of each of IMVEXXY&#153; and <FONT STYLE="white-space:nowrap">TX-001HR</FONT> in Canada and Israel. Knight will be responsible for all regulatory and commercial activities in Canada and Israel related to IMVEXXY&#153; and <FONT
STYLE="white-space:nowrap">TX-001HR.</FONT> </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We may terminate the Knight License Agreement if Knight does not submit all regulatory applications,
submissions and/or registrations required for regulatory approval to use and commercialize IMVEXXY&#153; and <FONT STYLE="white-space:nowrap">TX-001HR</FONT> in Canada and Israel within certain specified time periods. We also may terminate the
Knight License Agreement if Knight challenges our patents. Either party may terminate the </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Knight License Agreement for any material breach by the other party that is not cured within certain specified time periods or if the other party files for bankruptcy or other related matters.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with the Knight License Agreement, Knight entered into a subscription agreement, or the Subscription Agreement, with us pursuant to
which Knight agreed to purchase from us $20&nbsp;million of shares of our common stock concurrently with the closing of the first underwritten public offering of our common stock to occur within 60 days following the date of the Knight License
Agreement with gross proceeds to us of not less than $50&nbsp;million, at a price per share equal to the price per share to the public in such public offering. In the event that such an offering does not close, Knight will, in lieu of such
$20&nbsp;million investment, pay us a previously negotiated upfront license fee. An uncured breach of the Subscription Agreement by Knight will give us the right to terminate the Knight License Agreement. Knight will be effectuating such purchase
pursuant to the terms of the concurrent offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with the concurrent offering, Knight has agreed that, without our prior written
consent, which cannot be given without Goldman Sachs&nbsp;&amp; Co. LLC&#146;s prior written consent, Knight will not offer or contract to sell any shares of our common stock until the date that is 90 days after the date of the prospectus supplement
for the concurrent offering, after which date, the agreement will terminate and Knight will be released from its related obligations. Knight&#146;s agreement is subject to certain customary exceptions, including in respect of bona fide gifts of
shares.&nbsp;Additionally, provided that no public disclosure is required pursuant to the Securities Exchange Act of 1934, as amended, or the Exchange Act, Knight may, immediately and without restriction, sell or contract to sell up to 50% of the
shares of common stock acquired by Knight in the concurrent offering, as well as up to an additional 16.67% of such shares on or after each of the 30<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day and the 60<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> day following the date of the prospectus supplement of the concurrent offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>License Agreement with the
Population Council </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On July&nbsp;30, 2018, we entered into an exclusive license agreement, or the Council License Agreement, with the
Population Council to commercialize in the U.S. the Population Council&#146;s investigational segesterone acetate/ethinyl estradiol <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal system for contraception. The
<FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system is in the shape of a ring and combines a novel progestin, segesterone acetate (Nestorone<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>), with a widely used
estrogen (ethinyl estradiol) to prevent ovulation for an entire year (13 cycles). </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The NDA for the <FONT STYLE="white-space:nowrap">one-year</FONT>
vaginal contraceptive system is currently under review by the FDA and has a PDUFA target action date for the completion of the FDA&#146;s review of the NDA of August&nbsp;17, 2018. If approved, the <FONT STYLE="white-space:nowrap">one-year</FONT>
vaginal contraceptive system would be the first and only procedure-free, reversible prescription contraceptive to provide a full year of protection against unintended pregnancy while fully under a woman&#146;s control. If approved by its PDUFA
target action date, we currently estimate that the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system would be commercially available as early as the third quarter of 2019 with commercial launch as early as the fourth
quarter of 2019 or first quarter of 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the terms of the Council License Agreement, we are required to pay the Population Council milestone
payments of $20&nbsp;million within 30 days following approval by the FDA of the NDA for the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system and $20&nbsp;million within 30 days following the release of the first
commercial batch of the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system. The Population Council is also eligible to receive milestone payments and royalties from commercial sales of the
<FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system, as detailed below. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We will assume responsibility for marketing
expenses related to the commercialization of the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Council License Agreement includes exclusive rights for us to negotiate <FONT
STYLE="white-space:nowrap">co-development</FONT> of two other investigational vaginal contraceptive systems in development by the Population Council. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Population Council has previously developed long-acting, reversible contraception products including intrauterine devices, or IUDs, like ParaGard<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and Mirena<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>; implants like Norplant<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP> and Jadelle<SUP
STYLE="font-size:85%; vertical-align:top">&reg;</SUP>; and the contraceptive vaginal ring for breastfeeding women Progering<SUP STYLE="font-size:85%; vertical-align:top">&reg;</SUP>. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:ARIAL"><I>Contraceptive Market </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">An estimated
18&nbsp;million women in the U.S. want to avoid pregnancy and nearly half of all pregnancies that occur each year in the U.S. are unintended. The U.S. market for prescription contraceptives generated more than $5&nbsp;billion in net sales in 2017
based on approximately 90&nbsp;million prescriptions. The U.S. market for prescription contraceptives includes oral contraceptives, patches, rings, IUDs and implants. U.S. net sales of prescription oral contraceptives have fallen from approximately
$3.5&nbsp;billion in 2012 to approximately $2.8&nbsp;billion in 2017, while during such time net sales of long acting reversible contraceptives have grown from approximately $800&nbsp;million to approximately $1.5&nbsp;billion. According to the
National Center for Health and Statistics, the use of long acting reversible contraceptives in the U.S. has increased nearly five-fold in the last decade among women aged 15 to 44. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">NuvaRing (etonogestrel/ethinyl estradiol vaginal ring), a monthly contraceptive ring marketed by Merck, generated approximately $564&nbsp;million,
$576&nbsp;million and $515&nbsp;million in net sales in 2017, 2016 and 2015, respectively, based on approximately 4.3&nbsp;million, 4.5&nbsp;million and 4.4&nbsp;million prescriptions, respectively. We believe that the
<FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system, if approved, will have significant competitive advantages to NuvaRing and anticipated generic versions of NuvaRing, including an anticipated price 40% lower than its
current annual pricing, the ability to fill a <FONT STYLE="white-space:nowrap">one-year</FONT> prescription in one pharmacy visit and the lack of a requirement to refrigerate the ring. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:ARIAL"><I>Product </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The
<FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system is a combination of Nestorone with a widely used estrogen (ethinyl estradiol). Nestorone is a progesterone-derived unique progestin with high progestational potency and
antiovulatory activity and no androgenic, estrogenic or glucocorticoid effects at contraceptive doses. The active pharmaceutical ingredients are contained within a single ring that can prevent ovulation for an entire year with cyclical use (13
cycles). During each cycle, the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system is intended to be used following a 21/7 regimen, remaining in the vagina for three weeks (21 days) followed by one week (7 days) in which
the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system is removed from the vagina and placed in the accompanying case. The <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system is composed of a
soft, flexible silicone elastomer. It is roughly 2<SUP STYLE="vertical-align:top">&nbsp;1</SUP>&#8260;<SUB STYLE="vertical-align:bottom">4</SUB> inches in diameter, and can be inserted and removed by the woman without the help of a healthcare
professional. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In a phase 3 acceptability study of 905 subjects, the <FONT STYLE="white-space:nowrap">one-year</FONT>
vaginal contraceptive system had overall satisfaction of 89% related to ease of use, side effects, expulsions/feeling the product and physical effect during sexual activity. The study also demonstrated high rates of adherence (94.3%) and
continuation (78%). </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:8pt" ALIGN="center">


<TR>
<TD WIDTH="21%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="18%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD WIDTH="17%"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Ease of<BR>inserting<BR>(N=905)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Ease of<BR>removing<BR>(N=905)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Ease of<BR>remembering<BR>CVR insertion<BR>(N=905)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>Ease of<BR>remembering<BR>CVR removal<BR>(N=905)</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"> <P STYLE="margin-top:0pt; margin-bottom:1pt; font-size:8pt; font-family:ARIAL" ALIGN="center"><B>No side effects<BR>reported
on<BR>questionnaire<BR>(N=905)</B></P></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top" ALIGN="center">90.8%<BR>(823)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">88.2%<BR>(798)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">87.6%<BR>(793)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">85.2%<BR>(771)</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="top" ALIGN="center">81.8%<BR>(740)</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe that the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system will serve significant
unmet needs in the U.S. contraceptive market for both patients and healthcare providers, if approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For patients, if approved, the <FONT
STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system would provide a single long-acting reversible birth control product that would not require a procedure for insertion at a doctor&#146;s office, empowering women to be in
complete control of their fertility and menstruation with a 21/7 regimen. The <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system would allow women to receive an entire year&#146;s worth of contraception with a single
annual pharmacy visit. In addition, if approved, we anticipate that the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system would be acceptable for nulliparous women, or women who have never given birth. Further, the <FONT
STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system is softer and more pliable than NuvaRing and, unlike NuvaRing, does not require refrigeration before being prescribed. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe that the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system, if approved, may allow healthcare providers to more
easily follow medical standards of care and society guidelines to promote long-acting reversible birth control as first-line option. Existing long-acting reversible contraceptives, including IUDs and implants, require a procedure by a healthcare
provider for both insertion and removal and often require healthcare providers to buy, hold and manage inventory of the product. The <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system, if approved, could be prescribed by
healthcare providers to a broader range of patients than many existing long-acting reversible contraceptive methods, including nulliparous women, without the need for providers to maintain inventory, since the prescription for the <FONT
STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system would be filled at a pharmacy. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The below chart sets certain comparative information between the
<FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system and currently-approved contraceptive products. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt">


<IMG SRC="g554088g63f13.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:ARIAL"><I>Regulatory Status </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The NDA for the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system was submitted to the FDA by the Population Council on
August&nbsp;17, 2017 and has a PDUFA target action date for the completion of the FDA&#146;s review of the NDA of August&nbsp;17, 2018. The NDA for the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system is supported by
data from two pivotal phase 3 open-label safety and efficacy trials that were completed involving&nbsp;2,308&nbsp;healthy women at 27 sites in the U.S., Latin America, Europe, and Australia. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The phase 3 trials of the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system demonstrated efficacy consistent with existing
combination hormonal contraceptives, or CHCs, such as birth control pills, patches and hormonal rings. Approximately 1 to 3 women out of 100 women may get pregnant during the first year of use of the <FONT STYLE="white-space:nowrap">one-year</FONT>
vaginal contraceptive system, consistent with other CHCs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The phase 3 trials of the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal
contraceptive system also demonstrated safety consistent with existing CHCs. Consistent with other CHCs, women are at increased risk of a venous thrombotic event, or VTE, when using the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal
contraceptive system. Limited data are available on use of the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system in women with a Body Mass Index, or BMI, greater than 29 because this population was excluded from the
clinical trials after VTEs were reported. Consistent with other CHCs, the most common adverse reactions are headache and nausea/vomiting and the most common adverse reactions leading to discontinuation are mild, and include:&nbsp;irregular bleeding,
headache, vaginal discharge, and nausea/vomiting. We anticipate that the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system will receive class labeling for CHCs, if approved. All CHCs carry a boxed warning that the product
should not be used by patients who smoke cigarettes and are over age 35. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We anticipate that the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system
will be classified as a &#147;new chemical entity,&#148; or NCE, by the FDA and thus have five years of regulatory exclusivity under the Drug Price Competition and Patent Term Restoration Act of 1984, otherwise known as the Hatch-Waxman Act, if
approved. However, such classification is not guaranteed. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:ARIAL"><I>Council License Agreement </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the terms of the Council License Agreement, we are required to pay the Population Council milestone payments of $20&nbsp;million within 30 days
following approval by the FDA of the NDA for the one-year vaginal contraceptive system and $20&nbsp;million within 30 days following the release of the first commercial batch of the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal
contraceptive system. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">However, if a complete response letter or continuance of greater than 90 days is received by the Population Council with
respect to the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system or the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system is approved with additional post-marketing requirements or commitments
in excess of $1.0&nbsp;million, beyond the post-approval studies that may be required by the FDA noted below, then we or the Population Council may terminate the Council License Agreement, provided that we cannot agree with the Population Council on
a strategy to address such issues. If the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system is approved with shelf life of less than 18 months of stability or is not approved as an NCE that is entitled to five years
regulatory exclusivity in the U.S., then we may terminate the Council License Agreement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are required to pay the Population Council milestone
payments of $40&nbsp;million upon cumulative net sales of the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system in the U.S. by us and our affiliates and permitted sublicensees of $200.0&nbsp;million, $400.0&nbsp;million
and $1.0&nbsp;billion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, we are required to pay the Population Council, on a quarterly basis, step-based royalty payments based on
annual net sales of the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system in the U.S. by us and our affiliates and permitted sublicensees as follows: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="88%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; width:65.35pt; display:inline; font-size:8pt; font-family:ARIAL; "><B>Annual Net Sales</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Royalty&nbsp;Rate</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Less than or equal to $50.0&nbsp;million</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Greater than $50.0&nbsp;million and less than or equal to $150.0&nbsp;million</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">10</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Greater than $150.0&nbsp;million</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">%&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The annual royalty rate will be reduced to 50% of the initial rate during the
<FONT STYLE="white-space:nowrap">six-month</FONT> period beginning on the date of the first arms-length commercial sale of a generic equivalent of the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system that is launched by
a third party in the U.S., and thereafter will be reduced to 20% of the initial rate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Population Council has agreed to perform and pay the
costs and expenses associated with four post-approval studies that may be required by the FDA for the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system. We have agreed to perform and pay the costs and expenses associated
with a post-approval study that may be required by the FDA to measure risk for venous thromboembolism, provided that if the costs and expenses associated with such post-approval study exceed $20&nbsp;million, half of such excess will offset against
royalties or other payments owed by us to the Population Council under the Council License. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We and the Population Council have agreed to form a
joint product committee responsible for overseeing activities under the Council License Agreement. We will be responsible for all aspects of promotion, product positioning, pricing, education programs, publications, sales messages and any
</P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
additional desired clinical studies for the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system, subject to oversight and decisions made by the joint product committee.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Unless earlier terminated, the Council License Agreement will remain in effect until the later of the expiration of the <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">last-to-expire</FONT></FONT> of the Population Council&#146;s U.S. patents that are licensed to us, or the date following such expiration that follows a continuous period of six months
during which we and our affiliates have not made a commercial sale of the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system in the U.S. The Council License Agreement may also be terminated for certain breach and
bankruptcy-related events and by us on 180 days prior notice to the Population Council. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:ARIAL"><I>Population Council Contraceptive Ring Pipeline </I></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P ALIGN="center" STYLE="font-family:ARIAL; font-size:0.5pt"><FONT COLOR="#FFFFFF">Pre-Clinical Phase 1 Phase
2 Phase 3 PDUFA Date 1-Year Contraceptive Vaginal Ring (NES/EE) 08/17/2018 3-Month Contraceptive Vaginal Ring (NES/E2) Next Generation 1-Year Contraceptive Vaginal Ring (NES/EE)


<IMG SRC="g554088g80a28.jpg" ALT="LOGO">
 </FONT></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As part of the Council License Agreement, we have the exclusive right to negotiate <FONT
STYLE="white-space:nowrap">co-development</FONT> and U.S. marketing rights for two other investigational vaginal contraceptive systems in development by the Population Council: a three-month contraceptive ring using Nestorone plus <FONT
STYLE="white-space:nowrap">bio-identical</FONT> estradiol, which is currently in phase 2 clinical trials, and a new <FONT STYLE="white-space:nowrap">one-year</FONT> contraceptive ring using Nestorone plus ethinyl estradiol, which is designed as a
life cycle management product for the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system that we have licensed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:5%; font-size:10pt; font-family:ARIAL"><I>Commercialization Strategy </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If the <FONT
STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system is approved by its PDUFA date, we currently estimate that it would be commercially available as early as the third quarter of 2019, with commercial launch as early as the fourth
quarter of 2019 or first quarter of 2020. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We intend to leverage our existing infrastructure, including our sales force, to commercialize the <FONT
STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system, if approved, together with our recently-approved IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> (estradiol vaginal inserts) and
<FONT STYLE="white-space:nowrap">TX-001HR</FONT> product candidate, if approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We believe that our existing sales force overlaps with over 80% of
existing prescribers of the leading monthly contraceptive ring and that no additional sales representatives would be needed for us to commercialize the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system, if approved. We
intend to add a dedicated marketing team exclusively focused on the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system. We also believe that we are uniquely positioned to market the
<FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system, if approved, to the more than 60,000 annual vitaMedMD prenatal customers, who may proceed to contraception following pregnancy. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We currently intend to price the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system at parity or discount to current
prescription contraceptive pricing levels and anticipate an annual wholesale acquisition cost, or WAC, of between $1000 and $1400, which reflects a 40% decrease to the annual WAC of NuvaRing. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
We believe that the unique characteristics of the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system will assist us in pursuing favorable commercial payor coverage,
including only one pharmacy fill fee per year, an estimated savings of $33 annually per patient, and no office visit or procedure fees, an estimated savings of several hundred dollars annually per patient. However, obtaining and maintaining
favorable reimbursement can be a time-consuming and expensive process, and there is no guarantee that we will be able to negotiate or continue to negotiate reimbursement or pricing terms for our products, including the
<FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system, with payors at levels that are profitable to us, or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In
addition, the Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act of 2010, or the ACA, mandates that private health plans provide coverage for women&#146;s preventative services, without
imposing patient cost-sharing requirements, as recommended by the Health Resources and Services Administration, or HRSA. HRSA Guidelines require private health plans to cover, without cost-sharing, at least one form of contraception, or product, in
each of the methods, or classes, identified by the FDA for women in its Birth Control Guide, which currently includes 18 separate classes. For classes with more than one type of treatment, private payors need only provide <FONT
STYLE="white-space:nowrap">no-cost</FONT> coverage for one product in each class, and may use reasonable medical management to determine whether and to what extent to cover other products in the class. We believe that if the <FONT
STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system is classified by the FDA as a &#147;vaginal system,&#148; and if the FDA determines that a &#147;vaginal system&#148; constitutes a new class of birth control, this designation
could allow for coverage of the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system by private health plans with no <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> cost for
patients. However, the FDA may not designate the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system as a new class, and, even if the FDA does designate it as a new class, it is possible that other <FONT
STYLE="white-space:nowrap">FDA-approved</FONT> products could also be included in this new class. To the extent the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system is not the only
<FONT STYLE="white-space:nowrap">FDA-approved</FONT> product in a designated class of contraception, private payors may choose not to cover our <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system, or may require patient
cost-sharing obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As part of the Council License Agreement, we have agreed to provide significantly reduced pricing to federally designated
Title X family planning clinics serving underrepresented women. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Population Council has previously entered into a supply agreement with Crystal
Pharma SAU for the supply of Nestorone, one of the active pharmaceutical ingredients for the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system, and a letter agreement with QPharma AB for the optimization of the commercial
manufacturing process for the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system. We intend to enter into agreements Crystal Pharma SAU and QPharma AB for the supply of Nestorone for, and the manufacturing of, the <FONT
STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system, respectively, and the Population Council has agreed to use commercially reasonable efforts to assist us in doing so. However, either or both of these contract manufacturers
could decline to enter into similar agreements with us on the terms we anticipate, or at all. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Amendment to MidCap Credit Agreement </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On July&nbsp;30, 2018, we entered into Amendment No.&nbsp;1 to that certain Credit and Security Agreement, or the Credit Agreement, by and among our
company, as borrower, our company&#146;s subsidiaries party thereto from time to time, each as a borrower, MidCap Financial Trust, as agent and as lender, and the additional lenders party thereto from time to time, in order to permit our entry into
the Council License Agreement.&nbsp;As part of the amendment, we are required to receive aggregate net cash proceeds of at least $75&nbsp;million from the issuance of our equity securities within thirty days of entering into the Council License
Agreement.&nbsp;Failure to complete this obligation will constitute an automatic event of default under the Credit Agreement. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">

 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>The Offering </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Common stock offered by us </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares, or &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares if the underwriters&#146; option to purchase additional shares is exercised in
full. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Concurrent offering </P></TD>
<TD>Concurrently with this offering, we are offering to sell &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares of our common stock in the concurrent offering. The closing of the concurrent offering is contingent
upon the closing of this offering, but the closing of this offering is not contingent upon the closing of the concurrent offering. See &#147;Underwriting&#148; on page <FONT STYLE="white-space:nowrap">S-33</FONT> of this prospectus supplement.
</TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Shares of common stock to be outstanding immediately after this offering and the concurrent offering(1) </P></TD>
<TD>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; shares, or &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares if the underwriters&#146; option to purchase additional shares is exercised
in full. </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Use of proceeds </P></TD>
<TD>We intend to use the net proceeds from this offering and the concurrent offering to fund a portion of the costs for the commercial launch of our recently FDA approved product, IMVEXXY&#153; (estradiol vaginal inserts) for the treatment of <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> dyspareunia (vaginal pain associated with sexual activity), a symptom of VVA, due to menopause, and to fund a portion of the costs for pre-commercialization
and commercialization activities for <FONT STYLE="white-space:nowrap">TX-001HR,</FONT> our <FONT STYLE="white-space:nowrap">bio-identical</FONT> hormone therapy combination of 17&szlig;- estradiol and progesterone in a single, oral softgel drug
candidate, for the treatment of moderate to severe VMS due to menopause in menopausal women with an intact uterus, and our <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system candidate
<FONT STYLE="white-space:nowrap">in-licensed</FONT> from the Population Council. We additionally intend to use a portion of the net proceeds from this offering and the concurrent offering for working capital and general corporate purposes. We may
also use a portion of the net proceeds from this offering and the concurrent offering to acquire or invest in businesses and products that we believe would complement our women&#146;s health products and drug candidates. We can offer no assurance
that the concurrent offering will close, and if it does not close, the amount of our net proceeds will be limited to the net proceeds from this offering. Please see the section entitled &#147;Use of Proceeds&#148; on page <FONT
STYLE="white-space:nowrap">S-31</FONT> of this prospectus supplement. </TD></TR></TABLE>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<div style ="BORDER-BOTTOM:1.00pt solid #000000;BORDER-LEFT:1.00pt solid #000000;BORDER-RIGHT:1.00pt solid #000000;BORDER-TOP:1.00pt solid #000000;MARGIN-LEFT:0px; MARGIN-RIGHT:0px;max-width:100%"><div style="width:97%; margin-top:1.5%; margin-left:1.5%; margin-right:-1.25%">


<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Risk factors </P></TD>
<TD>Investing in our common stock involves a high degree of risk. You should carefully read and consider the information set forth under &#147;Risk Factors&#148; on page <FONT STYLE="white-space:nowrap">S-13</FONT> of this prospectus supplement and
page 1 of the accompanying prospectus and in the documents incorporated by reference herein and therein to read about factors you should consider before buying shares of our common stock. </TD></TR></TABLE>
<P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL">Common stock symbol </P></TD>
<TD>Our common stock is listed on the Nasdaq Global Select Market under the symbol &#147;TXMD.&#148; </TD></TR></TABLE> <P STYLE="font-size:4pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR VALIGN="TOP">
<TD WIDTH="52%"> <P STYLE=" margin-top:0pt; margin-bottom:1pt; margin-left:2%; text-indent:-2%; font-size:10pt; font-family:ARIAL"><FONT STYLE="white-space:nowrap">Lock-Up</FONT> agreements </P></TD>
<TD>We, our directors and executive officers have agreed with Goldman Sachs&nbsp;&amp; Co. LLC that, without its prior written consent, subject to certain exceptions, we and our directors and executive officers will not, for a period of 90 days
following the date of this prospectus supplement, offer or contract to sell any of our common stock. In connection with the concurrent offering, Knight has agreed that, without our prior written consent, which may not be given without Goldman
Sachs&nbsp;&amp; Co. LLC&#146;s prior written consent, subject to certain exceptions, Knight will not offer or contract to sell any of the shares of our common stock for a period of up to 90 days following the date of this prospectus supplement.
Notwithstanding the foregoing, Knight may, immediately and without restriction, sell or contract to sell up to 50% of the shares of common stock acquired by Knight in the concurrent offering, as well as up to an additional 16.67% of such shares on
or after each of the 30<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day and the 60<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day following the date of the prospectus supplement of the concurrent offering. See
&#147;Underwriting&#148; on page <FONT STYLE="white-space:nowrap">S-33</FONT> of this prospectus supplement. </TD></TR></TABLE> <P STYLE="line-height:8.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000;width:10%">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%" VALIGN="top" ALIGN="left">(1)</TD>
<TD ALIGN="left" VALIGN="top">The number of shares of common stock to be outstanding immediately after this offering and the concurrent offering is based on 216,834,059 shares outstanding on June&nbsp;30, 2018 and excludes the following as of that
date: </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">outstanding options representing the right to purchase a total of 25,210,899 shares of common stock at a weighted average exercise price of $3.92 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">outstanding warrants representing the right to purchase a total of 3,007,571 shares of common stock at a weighted-average exercise price of $2.78 per share; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">5,052,120 shares of common stock reserved for future issuance under our <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock option plans. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Except as otherwise noted, all information in this prospectus supplement assumes no exercise of the underwriters&#146; option to purchase additional
shares. </P>
</div><br clear="All"></div><br clear="All">

 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="supprom554088_3"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL"><I>An investment in our common stock involves a high degree of risk. Before deciding whether to invest in our common stock, you should carefully
consider the risks described below and the risks described under &#147;Risk Factors&#148; in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the year ended December&nbsp;31, 2017, as well as the other risks and
uncertainties described in the other documents incorporated by reference in this prospectus supplement and the accompanying prospectus and the information contained in our other filings with the SEC, which are incorporated by reference in this
prospectus supplement and the accompanying prospectus in their entirety, and in any free writing prospectus that we have authorized for use in connection with this offering. If any of these risks actually occurs, our business, financial condition,
results of operations or cash flow could be seriously harmed. This could cause the trading price of our common stock to decline, resulting in a loss of all or part of your investment. </I></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Additional Risks Related to this Offering and our Common Stock </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>You will experience immediate and substantial dilution in the book value per share of the common stock you purchase and may experience further dilution in the
future as a result of equity offerings and other issuances of our common stock or other securities. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The offering price of our common stock
being offered in this offering and the concurrent offering is substantially higher than the net tangible book value per share of our common stock outstanding prior to this offering. Therefore, if you purchase our common stock in this offering at the
assumed public offering price of $5.52&nbsp;per share, which was the last reported sale price of our common stock on the Nasdaq Global Select Market on July&nbsp;30, 2018, you will incur an immediate substantial dilution of $4.85&nbsp;in net
tangible book value per share from the price you paid based on our net tangible book value and outstanding shares as of June&nbsp;30, 2018. For a further description of the dilution that you will experience immediately after this offering, see the
section titled &#147;Dilution.&#148; </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To raise additional capital, we may in the future offer additional shares of our common stock or other
securities convertible into or exchangeable for our common stock at prices that may not be the same as the price per share in this offering. We cannot assure you that we will be able to sell shares or other securities in any other offering at a
price per share that is equal to or greater than the price per share paid by investors in this offering, and investors purchasing shares or other securities in the future could have rights superior to existing stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of June 30, 2018, there were outstanding options representing the right to purchase a total of 25,210,899 shares of our common stock at a weighted
average exercise price of $3.92 per share, outstanding warrants representing the right to purchase a total of 3,007,571 shares of our common stock at a weighted-average exercise price of $2.78 per share and 5,052,120 shares of our common stock
reserved for future issuance under our <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock option plans. You will incur dilution upon exercise of any outstanding stock options or warrants or upon the issuance of shares of common stock under
our stock incentive programs. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, the sale of shares in this offering and the concurrent offering and any future sales of a substantial
number of shares of our common stock in the public market, or the perception that such sales may occur, could adversely affect the price of our common stock. We cannot predict the effect, if any, that market sales of those shares of common stock or
the availability of those shares of common stock for sale will have on the market price of our common stock. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We have broad discretion to determine how to use the proceeds raised in this offering and the concurrent
offering, and we may not use the proceeds effectively. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our management will have broad discretion over the use of proceeds from this offering
and the concurrent offering, and we could spend the proceeds from this offering in ways with which you may not agree or that do not yield a favorable return. We intend to use the net proceeds from this offering and the concurrent offering to fund a
portion of the costs for the commercial launch of our recently approved product, IMVEXXY&#153; (estradiol vaginal inserts) for the treatment of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT>
dyspareunia (vaginal pain associated with sexual activity), a symptom of VVA, due to menopause, and to fund a portion of the costs for <FONT STYLE="white-space:nowrap">pre-commercialization</FONT> and commercialization activities for <FONT
STYLE="white-space:nowrap">TX-001HR,</FONT> our <FONT STYLE="white-space:nowrap">bio-identical</FONT> hormone therapy combination of 17&szlig;-estradiol and progesterone in a single, oral softgel drug candidate, for the treatment of moderate to
severe VMS due to menopause in menopausal women with an intact uterus, and our <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system candidate. We additionally intend to use a portion of the net proceeds from this offering
and the concurrent offering for working capital and general corporate purposes. We may also use a portion of the net proceeds from this offering and the concurrent offering to acquire or invest in businesses and products that we believe would
complement our women&#146;s health products and drug candidates. If we do not invest or apply the proceeds of this offering and the concurrent offering in ways that improve our operating results, we may fail to achieve expected financial results,
which could cause our stock price to decline. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Sales of a substantial number of shares of our common stock, or the perception that such sales might occur,
could adversely affect the trading price of our common stock. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of June&nbsp;30, 2018, we had 216,834,059 shares of our common stock
outstanding. Also, we had, as of June&nbsp;30, 2018, 28,218,470 shares of our common stock issuable upon the exercise of outstanding options and warrants. If this offering and the concurrent offering are completed, the number of shares of common
stock that we have outstanding will increase. Sales of a substantial number of shares of our common stock, or the perception that such sales might occur, could adversely affect the trading price of our common stock. Further, sales of shares
underlying stock options and warrants, or the perception in the market that the holders of a large number of shares intend to sell shares, could reduce the market price of our common stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We may not be able to complete the development and commercialization of our hormone therapy drug candidates if we fail to obtain additional financing.
</I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We need substantial amounts of cash to complete the commercialization of IMVEXXY&#153; and the clinical development and commercialization of
our hormone therapy drug candidates and our <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system candidate. Our existing cash may not be sufficient to fund these requirements. In addition, changing circumstances may cause us
to consume funds significantly faster than we currently anticipate, and we may need to spend more money than currently expected on these programs. We may attempt to raise additional capital from the issuance of equity securities, collaborations with
third parties, licensing of rights to our products, the issuance of debt securities and the incurrence of debt, to the extent permitted under our $200&nbsp;million term loan facility with MidCap Financial Trust, as agent and as lender, and the
additional lenders party thereto from time to time, or the Credit Agreement, or other means, or a combination of any of the foregoing. Securing additional financing will require a substantial amount of time and attention from our management and may
divert a disproportionate amount of management&#146;s attention away from our <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> activities, which may adversely affect our ability to conduct our <FONT
STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">day-to-day</FONT></FONT> operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We cannot guarantee that future debt or equity financing will be available in sufficient amounts or on
terms acceptable to us, if at all. If we are unable to raise additional capital when required or on acceptable terms, we may be required to take one or more of the following actions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">significantly delay, scale back, or discontinue our product development and commercialization efforts;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">seek collaborators for our hormone therapy drug products and candidates at an earlier stage than otherwise would be
desirable or on terms that are less favorable than might otherwise be the case; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">license, potentially on unfavorable terms, our rights to our hormone therapy drug products and candidates that we otherwise
would seek to develop or commercialize ourselves. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Credit Agreement does, and any agreements governing future debt financing,
if available, may, include covenants limiting or restricting our ability to take specific actions, such as incurring additional debt, making capital expenditures, or declaring dividends. To the extent that we raise additional capital through the
sale of equity or convertible debt securities, the ownership interest of our existing stockholders will be diluted, and the terms of these new securities may include liquidation or other preferences that adversely affect the rights of our existing
stockholders. If we raise additional funds through collaborations, strategic alliances, or licensing arrangements with third parties, we may have to relinquish valuable rights to our technologies, future revenue streams, research programs, or
proposed products or grant licenses on terms that may not be favorable to us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we are unable to raise additional capital in sufficient amounts or
on terms acceptable to us, we will be prevented from pursuing discovery, development and commercialization efforts, and our ability to generate revenue and achieve or sustain profitability will be substantially harmed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>We are subject to extensive and costly government regulation. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The products we currently market, including IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> and our prenatal vitamins, and the
pharmaceutical products we are developing and planning to develop in the future, are subject to extensive and rigorous domestic government regulation, including regulation by the FDA, the Centers for Medicare&nbsp;&amp; Medicaid Services, or CMS,
other divisions of the U.S. Department of Health and Human Services, including its Office of Inspector General, the U.S. Department of Justice, the Departments of Defense and Veterans Affairs, to the extent our products are paid for directly or
indirectly by those departments, state and local governments, and their respective foreign equivalents. The FDA regulates dietary supplements, cosmetics, and drugs under different regulatory schemes. For example, the FDA regulates the processing,
formulation, safety, manufacturing, packaging, labeling, and distribution of dietary supplements and cosmetics under its dietary supplement and cosmetic authority, respectively. The FDA also regulates the research, development, <FONT
STYLE="white-space:nowrap">pre-clinical</FONT> and clinical testing, manufacture, safety, effectiveness, record keeping, reporting, labeling, storage, approval, advertising, promotion, sale, distribution, import, and export of pharmaceutical
products under various regulatory provisions. If any drug products we develop are tested or marketed abroad, they will also be subject to extensive regulation by foreign governments, whether or not we have obtained FDA approval for a given product
and its uses. Such foreign regulation may be equally or more demanding than corresponding U.S. regulation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are also subject to additional health
care regulation and enforcement by the federal government and the states in which we conduct our business. Applicable federal and state health care laws and regulations include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The federal health care Anti-Kickback Statute, or AKS, prohibits, among other things, persons from knowingly and willfully
soliciting, offering, receiving, or providing remuneration, directly or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
indirectly, in cash or in kind, to induce or reward either the referral of an individual for, or the purchase, order, or recommendation of, any good or service, for which payment may be made
under federal health care programs, such as Medicare, Medicaid, TriCare, and Children&#146;s Health Insurance Program. Liability may be established without proving actual knowledge of the statute or specific intent to violate it. In addition,
federal law provides that the government may assert that a claim including items or services resulting from a violation of the AKS constitutes a false or fraudulent claim for purposes of the FCA, described below. Violations of the AKS carry
potentially significant civil and criminal penalties, including imprisonment, fines, administrative civil monetary penalties, and exclusion from participation in government health care programs.</P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The Ethics in Patient Referrals Act of 1989, commonly referred to as the Stark Law, and its corresponding regulations,
prohibit physicians from referring patients for designated health services, including outpatient drugs, reimbursed under the Medicare or Medicaid programs to entities with which the physicians or their immediate family members have a financial
relationship or an ownership interest, subject to narrow regulatory exceptions, and prohibits those entities from submitting claims to Medicare or Medicaid for payment of items or services provided to a referred beneficiary. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The federal False Claims Act, or FCA, imposes criminal and civil penalties, and authorizes civil whistleblower or qui tam
actions, against individuals or entities for knowingly presenting, or causing to be presented, claims for payment involving federally funded programs that are false or fraudulent or making a false statement to avoid, decrease, or conceal an
obligation to pay money with respect to a federal program. The FCA prohibits knowingly and willfully falsifying, concealing, or covering up a material fact or making any materially false statement in connection with the delivery of or payment for
health care benefits, items, or services. Government enforcement agencies and private whistleblowers have asserted liability under the FCA for, among other things, claims for items or services not provided as claimed, with inaccurate coding or for
medically unnecessary items or services, kickbacks, promotion of <FONT STYLE="white-space:nowrap">off-label</FONT> uses, and misreporting of drug prices to federal agencies. </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Health Insurance Portability and Accountability Act of 1996, as amended by the Health Information Technology for Economic
and Clinical Health Act of 2009, and their respective implementing regulations, or collectively, HIPAA, imposes criminal and civil liability for executing a scheme to defraud any health care benefit program, including private payors, or falsifying,
concealing, or covering up a material fact, or making any materially false statements in connection with the delivery of or payment for health care benefits, items, or services. HIPAA also imposes obligations, including mandatory contractual terms,
with respect to safeguarding the privacy, security, and transmission of individually identifiable health information. State laws may also govern the privacy and security of health information or other personal information in certain circumstances.
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Federal laws require pharmaceutical manufacturers to report certain calculated product prices to the government or provide
certain discounts or rebates to government authorities or private entities, often as a condition of reimbursement under government health care programs. </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">The Physician Payments Sunshine Act, enacted as part of the Patient Protection and Affordable Care Act, as amended by the
Health Care and Education Reconciliation Act of 2010, or the ACA, imposes annual reporting requirements for certain manufacturers of drugs, devices, biologics, and medical supplies for which payment is available under certain government health care
programs for certain payments and &#147;transfers of value&#148; provided to physicians and teaching hospitals, as well as ownership and investment interests held by physicians and their immediate family members. Numerous state laws may also require
disclosure of transfers of value to health care providers, pharmaceutical pricing information and marketing expenditures. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">Analogous state laws and regulations, such as state anti-kickback and false claims laws, may apply to interactions between
pharmaceutical manufacturers and health care providers, sales or marketing arrangements, and claims involving health care items or services reimbursed by commercial third-party payors, including private health care insurers and health maintenance
organizations; further, some state laws require pharmaceutical companies to comply with the pharmaceutical industry&#146;s voluntary compliance guidelines and the relevant compliance guidance promulgated by the federal government.
</P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Many aspects of these laws have not been definitively interpreted by the regulatory authorities or the courts, and their
provisions are open to a variety of subjective interpretations that increases the risk of potential violations. In addition, these laws and their interpretations are subject to change. Many state laws differ from each other in significant ways and
often are not preempted by federal laws, thus complicating compliance efforts. Moreover, the number and complexity of both federal and state laws continues to increase, and additional governmental resources are being used to enforce these laws and
to prosecute companies and individuals who are believed to be violating them. In particular, the ACA includes a number of provisions aimed at strengthening the government&#146;s ability to pursue AKS and FCA cases against pharmaceutical
manufacturers and other health care entities, including substantially increased funding for health care fraud enforcement activities, enhanced investigative powers, and amendments to the FCA that make it easier for the government and whistleblowers
to pursue cases for alleged kickback and false claim violations. We anticipate that government scrutiny of pharmaceutical sales and marketing practices will continue for the foreseeable future and subject us to the risk of government investigations
and enforcement actions. For example, federal enforcement agencies recently have shown interest in pharmaceutical companies&#146; product and patient assistance programs, including manufacturer reimbursement support services and relationships with
specialty pharmacies. Some of these investigations have resulted in significant civil and criminal settlements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Efforts to ensure that our
operations, including our business arrangements with third parties, comply with applicable health care laws and regulations could be costly. In connection with the commercial launch of IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>,
we have grown our compliance program and are in the process of expanding our compliance team to focus on developing a program based on industry best practices. As this program has not yet been tested and the requirements in this area are constantly
evolving, our program may not eliminate all areas of potential exposure. Although effective compliance programs can help mitigate the risk of investigation, regulatory and enforcement actions, and prosecution for violations of these laws, the risks
cannot be entirely eliminated. Moreover, achieving and sustaining compliance with applicable federal and state fraud, privacy, security, and reporting laws may prove costly. Although we believe that our business practices are structured to be
compliant with applicable laws, it is possible that governmental authorities will conclude that our business practices may not comply with current or future statutes, regulations, or case law involving applicable fraud and abuse or other health care
laws and regulations. If our past or present operations, including activities conducted by our sales team or agents, are found to be in violation of any of these laws or any other governmental regulations that may apply to us, we may be subject to
significant civil, criminal, and administrative penalties, damages, fines, exclusion from government health care programs, and the curtailment or restructuring of our operations. If any of the physicians, providers, or entities with whom we do
business are found to be not in compliance with applicable laws, they may be subject to criminal, civil, or administrative sanctions, including exclusion from government health care programs. Any action against us for violation of these laws, even
if we successfully defend against it, could cause us to incur significant legal expenses, divert our management&#146;s attention from the operation of our business, and damage our reputation. In addition, even if we are not determined to have
violated these laws, government investigations into these issues typically require the expenditure of significant resources and generate negative publicity, and could result in related shareholder suits, any of which could also have an adverse
effect on our business, financial condition and results of operations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, from time to time in the future, we may become subject to additional laws or regulations
administered by the FDA, the FTC, or by other federal, state, local, or foreign regulatory authorities, to the repeal of laws or regulations that we generally consider favorable, such as the Dietary Supplement Health and Education Act of 1994, or to
more stringent interpretations of current laws or regulations. We are not able to predict the nature of such future laws, regulations, repeals, or interpretations, and we cannot predict what effect additional governmental regulation, if it occurs,
would have on our business in the future. Such developments could, however, require reformulation of certain products to meet new standards, recalls or discontinuance of certain products not able to be reformulated, additional record-keeping
requirements, increased documentation of the properties of certain products, additional or different labeling, additional scientific substantiation, additional personnel, or other new requirements. Any such developments could have a material adverse
effect on our business. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Coverage and reimbursement may not be available for our products, which could make it difficult for us to sell our products
profitably, or if available, government mandated rebates may be too high and may adversely affect our profitability. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Market acceptance and
sales of our products, including IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, our <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system candidate and our hormone therapy drug candidates or prescription
vitamins, will depend on coverage and reimbursement policies and may be affected by health care reform measures. Government health care programs and third-party payors decide which prescription drug products they will pay for and establish
reimbursement levels. Payors generally do not cover OTC products, and coverage for prescription vitamins and dietary supplements varies. Many private third-party payors, such as managed care plans, manage access to drug products&#146; coverage
partly to control costs to their plans, and may use drug formularies and medical policies to limit their exposure. Factors considered by these payors include product efficacy, cost effectiveness, and safety, as well as the availability of other
treatments including generic prescription drugs. Our ability to commercialize IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> successfully depends on coverage and reimbursement levels set by government health care programs and
third-party private payors. Obtaining and maintaining favorable reimbursement can be a time-consuming and expensive process, and we may not be able to negotiate or continue to negotiate reimbursement or pricing terms for our products, including
IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, our <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system candidate and our hormone therapy drug candidates with payors at levels that are profitable to us, or
at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In both the United States and some foreign jurisdictions, there have been a number of legislative and regulatory proposals to change the
health care system in ways that could affect our ability to sell our products profitably. In the United States, the Medicare Prescription Drug, Improvement, and Modernization Act of 2003, also called the Medicare Modernization Act, or MMA, changed
the way Medicare covers and pays for pharmaceutical products. The legislation expanded Medicare coverage for drug purchases by the elderly and certain others by establishing a new Part D to the Medicare program. However, unlike Medicare Part A and
Part B&#151;through which Medicare provides coverage for certain drugs in certain circumstances&#151;coverage under Part D is provided by private insurers operating under contract with CMS. In addition, this legislation provided authority for
limiting the number of certain outpatient drugs that will be covered in any therapeutic class. As a result of this legislation and the expansion of federal coverage of drug products, we expect that there will be additional pressure to contain and
reduce costs. These and future cost-reduction initiatives could decrease the coverage and price that we receive for our products from Medicare, if any, including IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> and our other hormone
therapy drug candidates, if approved, and could significantly harm our business. It was historically unclear whether products approved to treat&nbsp;moderate to severe dyspareunia, a symptom of vulvar and vaginal atrophy due to menopause, such as
IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, were excluded under Medicare Part D, which resulted in limited Medicare coverage for such products. Recent clarification issued by CMS in May 2018 indicated that drugs, such as IMVEXXY<SUP
STYLE="font-size:85%; vertical-align:top">TM</SUP>, that are </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
approved for the treatment of moderate to severe dyspareunia (as well as drugs approved for the treatment of moderate to severe symptoms of vulvar and vaginal atrophy associated with menopause)
are not excluded from Medicare Part D coverage. CMS&#146;s clarification, however, is no guarantee that such coverage will be obtained for IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, and obtaining Medicare or other government
health care program reimbursement for any new drug products may take up to several years following FDA approval. While the MMA applies only to drug benefits for Medicare beneficiaries, third-party payors often follow Medicare coverage policies and
payment limitations in setting their own reimbursement rates, and any reduction in reimbursement under Medicare may result in a similar reduction in payments from third-party payors. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our ability to commercialize successfully the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system, if approved, depends on
coverage and reimbursement levels set by government health care programs and third-party private payors. The ACA mandates that private health plans provide coverage for women&#146;s preventative services, without imposing patient cost-sharing
requirements, as recommended by HRSA. HRSA Guidelines require private health plans to cover, with no patient <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs, at least one form of treatment (e.g.,
one product) in each of the methods (e.g., classes of contraception) identified by the FDA for women in its Birth Control Guide. If the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system is deemed a new class of
contraception by the FDA, this designation could allow for coverage by private health plans with no patient <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> costs. However, there is no guarantee that the
FDA will designate the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system as a new class of contraception, or that such coverage will be obtained. Even if the FDA does designate it as a new class of contraception, it is
possible that other <FONT STYLE="white-space:nowrap">FDA-approved</FONT> products could also be included in this new class. Pursuant to HRSA Guidelines, private payors need only provide <FONT STYLE="white-space:nowrap">no-cost</FONT> coverage for
one product in each class, and may use reasonable medical management to determine whether and to what extent to cover other products in the class. To the extent the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system is not
the only <FONT STYLE="white-space:nowrap">FDA-approved</FONT> product in a designated class of contraception, private payors may choose not to cover our <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system, or may require
patient cost-sharing obligations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To the extent we obtain coverage for our products by state Medicaid programs, we may be required to pay a rebate
to each state Medicaid program for any covered outpatient drugs that are dispensed to Medicaid beneficiaries and paid for by a state Medicaid program, and to comply with all Medicaid rebate requirements of the Omnibus Budget Reconciliation Act of
1990 and the Veterans Healthcare Act of 1992. Moreover, federal law requires that any company participating in the Medicaid Drug Rebate program also participate in the Public Health Service&#146;s 340B Program, which impose additional requirements.
In addition, if our products are made available to authorized users of the Federal Supply Schedule of the General Services Administration or to low income patients of certain hospitals, additional laws and requirements may apply. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect to experience pricing pressures in connection with the sale of our products generally due to the trend toward managed health care, the
increasing influence of health maintenance organizations, the scrutiny of pharmaceutical pricing, the ongoing debates on reducing government spending and additional legislative proposals. As discussed more below, the goal of the ACA, as enacted in
2010, was to reduce the cost of health care and substantially change the way health care is financed by both government health care programs and third-party payors. Among other measures, the ACA increased rebates on manufacturers for certain covered
drug products reimbursed by state Medicaid programs. While we cannot predict the full effect that the ACA will have on government health care programs&#146; reimbursement policies in general or on our business specifically, the ACA may result in
downward pressure on drug reimbursement, which could negatively affect market acceptance of our products. In addition, we cannot predict whether new proposals will be made or adopted, when they may be adopted, or what impact they may have on us if
they are adopted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The availability of generic products at lower prices than branded products may substantially reduce
the likelihood of reimbursement for branded products, such as IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, our <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system candidate, or our other hormone therapy
drug candidates, if approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we fail to successfully secure and maintain adequate coverage and reimbursement for our products or are
significantly delayed in doing so, we could have difficulty achieving market acceptance of our products and our business, financial condition, results of operations, and prospects could be harmed. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Future legislation or regulations may adversely affect reimbursement from government health care programs and third-party payors. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Legislative changes have been proposed and adopted since the ACA was enacted. In August 2011, President Obama signed into law the Budget Control Act of
2011, which, among other things, created the Joint Select Committee on Deficit Reduction to recommend to Congress proposals in spending reductions. The Joint Select Committee did not achieve a targeted deficit reduction, triggering the
legislation&#146;s automatic reduction of several government programs. This includes aggregate reductions to Medicare payments to health care providers of up to 2.0% per fiscal year, starting in 2013. In January 2013, President Obama signed into law
the American Taxpayer Relief Act of 2012, which, among other things, reduced Medicare payments to several categories of health care providers and increased the statute of limitations period for the government to recover overpayments to providers
from three to five years. Under the Trump administration, there have been ongoing efforts to modify or repeal all or certain provisions of the ACA. If the ACA or parts of it are repealed, it is unclear what impact that would have on drug
reimbursements or coverage and it is also unclear what programs, if any, Congress might enact to replace the repealed portions of the ACA. The Trump administration may also take executive action in the absence of legislative action.&nbsp;For
example, in October 2017, the President announced that the administration will withhold the cost-sharing subsidies paid to health insurance exchange plans serving <FONT STYLE="white-space:nowrap">low-income</FONT> enrollees.&nbsp;With respect to
IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, and to the extent we ever obtain regulatory approval and commercialization of our other drug candidates, these new laws and policies (as well as proposed legislation, if enacted) may
result in additional reductions in Medicare and other health care funding, which could have a material adverse effect on our customers and accordingly, our financial operations. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">On December&nbsp;13, 2016, President Obama signed into law the 21st Century Cures Act, which, among other things, may increase the types of clinical
trial designs that would be acceptable to support an NDA. It is unclear, at this time, how these provisions will be implemented or whether they would have any effect on our company. Legislative and regulatory proposals have been made to expand
post-approval requirements and restrict sales and promotional activities for pharmaceutical products. We cannot be sure whether additional legislative changes will be enacted, or whether the FDA regulations, guidance or interpretations will be
changed, or what the impact of such changes on our drug product and drug candidates may be. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">There have also been efforts by government officials or
legislators to implement measures to regulate prices or payment for pharmaceutical products, including legislation on drug importation. Recently, there has been considerable public and government scrutiny of pharmaceutical pricing and proposals to
address the perceived high cost of pharmaceuticals; proposed and enacted legislation generally have focused on increasing transparency around drug costs or limiting drug prices. For example, in 2017, California enacted a new law, which went into
effect on January&nbsp;1, 2018, to facilitate greater transparency in brand-name and generic drug pricing through the implementation of specific price reporting requirements for pharmaceutical manufacturers. If adequate reimbursement levels are not
maintained by government and third-party payors for our products, our ability to sell our products may be limited and/or our ability to establish acceptable pricing levels may be impaired, thereby reducing anticipated revenues and profitability.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our dependence upon third parties for the manufacture and supply of our existing women&#146;s health care
products and our hormone therapy drug candidates may cause delays in, or prevent us from, successfully developing, commercializing, and marketing our products. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We do not currently have, nor do we currently plan to build or acquire, the infrastructure or capability to internally manufacture our existing
women&#146;s health care products, our <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system candidate, or our hormone therapy drug candidates. We have relied, and will continue to rely, on third parties to manufacture these
products in accordance with our specifications and in compliance with applicable regulatory requirements.&nbsp;We have entered into long-term supply agreements with Catalent for the commercial supply of IMVEXXY<SUP
STYLE="font-size:85%; vertical-align:top">TM</SUP> and our <FONT STYLE="white-space:nowrap">TX-001HR</FONT> hormone therapy drug candidate, if approved. Under the terms of the agreements, we will be obligated to purchase certain minimum annual
amounts of each product once we commence commercial sales of such product following regulatory approval of Catalent as a manufacturer of such product.&nbsp;We depend on Lang, a full-service, private label and corporate brand manufacturer, to supply
approximately 100% of our vitaMedMD and BocaGreen products.&nbsp;We do not have long-term contracts for the commercial supply of our existing women&#146;s health care products, however, in certain circumstances, including our failure to satisfy our
production forecasts to Lang, we may be obligated to reimburse Lang for the costs of excess raw materials purchased by Lang that it cannot use in another product category that it then sells. We intend to enter into agreements with Crystal Pharma SAU
and QPharma AB for the commercial supply of one of the active pharmaceutical ingredients for, and the manufacturing of, our <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system, respectively. However, if we experience delays
in finalizing these agreements or are unable to execute these agreements on commercially reasonable terms, we may need to find alternative manufacturing facilities, which would result in disruption in our commercialization of the <FONT
STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system, if approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Regulatory requirements could pose barriers to the
manufacture of our existing women&#146;s health care products and our hormone therapy drug product and drug candidates. Our third-party manufacturers are required to comply with cGMP regulations. As a result, the facilities used by any of our
current or future manufacturers may be subject to an NDA <FONT STYLE="white-space:nowrap">pre-approval</FONT> inspection, or PAI, by the FDA, and any noncompliance could cause the NDA to be disapproved or delayed in approval. Holders of NDAs, or
other forms of FDA approvals or clearances, or those distributing a regulated product under their own name, are ultimately responsible for compliance with manufacturing obligations even if the manufacturing is conducted by a third-party contract
manufacturing organization, or CMO. All of our existing products are, and our hormone therapy drug candidates, if approved, will be manufactured by CMOs. These CMOs are required by the terms of our contracts to manufacture our products in compliance
with the applicable regulatory requirements. The CMO that will manufacture IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> and our <FONT STYLE="white-space:nowrap">TX-001HR</FONT> hormone therapy drug candidate, if approved, has
previously been inspected by the FDA and received Form 483 observations with respect to its softgel manufacturing plant that will be used for the manufacture of the commercial supply of IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>
and <FONT STYLE="white-space:nowrap">TX-001HR,</FONT> if approved.&nbsp;We anticipate that as part of a PAI of our NDA for <FONT STYLE="white-space:nowrap">TX-001HR,</FONT> the FDA may inspect Catalent&#146;s manufacturing facilities that would be
used to manufacture that product. If this inspection results in Form 483 observations, the approval of our NDA could be delayed significantly. The CMO that manufactured the hormone therapy drug candidate used in our phase 3 clinical trial for
TX-001HR was previously inspected by the FDA, which issued it a Form FDA 483 listing various observations, some of which pertained to the clinical supply of TX-001HR. The CMO has submitted its written response to the Form 483 observations to the
FDA. We believe the responses satisfactorily address the FDA&#146;s observations with respect to the clinical supply of TX-001HR and in a subsequent inspection the FDA did not find the CMO out of compliance with the commitments and associated
deliverables contained in its response to the Form 483 observations. However, if the FDA were to determine that this CMO did not comply with cGMP regulations, it could cause the NDA for TX-001HR to be disapproved or delayed in approval. As noted
above, we have contracted with a different CMO, Catalent, to provide the commercial supply of IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> and our TX-001HR drug candidate, if approved. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">QPharma, the CMO that will manufacture our <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal
contraceptive system, if approved, has previously been inspected by the FDA and received Form 483 observations on December&nbsp;15, 2017, with respect to its facility that will be used for the commercial supply of the
<FONT STYLE="white-space:nowrap">one-year</FONT> contraceptive system. The FDA classified the inspection as Voluntary Action Indicated, meaning that the FDA found instances of noncompliance but the problems likely would not result in further
regulatory action. QPharma submitted its written response to the Form 483 observations to the FDA on December&nbsp;22, 2017, however neither we nor QPharma has been informed by the FDA as to whether QPharma&#146;s response addresses and remediates
these observations in a manner satisfactory to the FDA. If QPharma is unable to address and remediate the FDA&#146;s observations, it could have a material adverse effect on the manufacture of the commercial supply of our <FONT
STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system, if approved. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If our manufacturers cannot successfully manufacture material
that conforms to our specifications and the strict regulatory requirements of the FDA and any applicable foreign regulatory authority, our regulatory submissions may be delayed or disapproved, and our marketed products may be affected. If these
facilities are not in compliance for the manufacture of our vitamin products, our hormone therapy drug product and our drug candidates, we may need to find alternative manufacturing facilities, which would result in disruptions of our sales and
significant delays of up to several years in obtaining approval for our hormone therapy drug candidates. In addition, our manufacturers will be subject to ongoing periodic unannounced inspections by the FDA and corresponding state and foreign
agencies for compliance with cGMPs and similar regulatory requirements. Failure by any of our manufacturers to comply with applicable cGMP regulations or other applicable requirements could result in sanctions being imposed on us, including fines,
injunctions, civil penalties, violation letters, delays, suspensions or withdrawals of approvals, operating restrictions, interruptions in supply, recalls, withdrawals, issuance of safety alerts, and criminal prosecutions, any of which could have a
material adverse impact on our business, financial condition, results of operations, and prospects. We do not currently have alternative manufacturers, and we may not be able to enter into a long-term agreement with alternative manufacturers, or do
so on commercially reasonable terms, which could have a material adverse impact on our business. Finally, we also could experience manufacturing delays if our CMOs give greater priority to the supply of other products over our products and proposed
products to the delay or other detriment of our products and proposed products, or otherwise do not satisfactorily perform according to the terms of their agreements with us. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We also do not have long-term contracts for the supply of the API used in IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, our hormone
therapy drug candidates or the <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system candidate.&nbsp;If any supplier of the API or other products used in our hormone therapy drug candidates experiences any significant
difficulties in its respective manufacturing processes, does not comply with the terms of an agreement between us, or does not devote sufficient time, energy, and care to providing our manufacturing needs, we could experience significant
interruptions in the supply of our hormone therapy drug candidates, which could impair our ability to supply our hormone therapy drug candidates at the levels required for commercialization and prevent or delay their successful commercialization.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Even after the approval of IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, and even if we obtain regulatory approval for our <FONT
STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system candidate and for our other hormone therapy drug candidates, we will still face extensive, ongoing regulatory requirements and review, and our products may face future
development and regulatory difficulties. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Even if we obtain regulatory approval for our <FONT STYLE="white-space:nowrap">one-year</FONT>
vaginal contraceptive system or for one or more of our hormone therapy drug candidates in the United States, and with respect to IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
the FDA may still impose significant restrictions on a product&#146;s indicated uses or marketing or to the conditions for approval, or impose ongoing requirements for potentially costly
post-approval studies, including phase 4 clinical trials or post-market surveillance. As a condition to granting marketing approval of a product, the FDA may require a company to conduct additional clinical trials. The results generated in these
post-approval clinical trials could result in loss of marketing approval, changes in product labeling, or new or increased concerns about side effects or efficacy of a product. For example, the labeling for IMVEXXY<SUP
STYLE="font-size:85%; vertical-align:top">TM</SUP> contains restrictions on use and warnings, and the labeling for our hormone therapy drug candidates and our <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system candidate,
if approved, may also include restrictions on use or warnings. The Food and Drug Administration Amendments Act of 2007, or FDAAA, gives the FDA enhanced post-market authority, including the explicit authority to require post-market studies and
clinical trials, labeling changes based on new safety information, and compliance with <FONT STYLE="white-space:nowrap">FDA-approved</FONT> REMS programs. IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> and our hormone therapy drug
candidates and our <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system candidate, if approved, will also be subject to ongoing FDA requirements governing the manufacturing, labeling, packaging, storage, distribution, safety
surveillance, advertising, promotion, record keeping, and reporting of safety and other post-market information. The FDA&#146;s exercise of its authority could result in delays or increased costs during product development, clinical trials and
regulatory review, increased costs to comply with additional post-approval regulatory requirements, and potential restrictions on sales of approved products. As part of the FDA&#146;s approval of
IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, we have committed to conduct a post-approval observational study to evaluate the risk of endometrial cancer in post-menopausal women with a uterus who use a <FONT
STYLE="white-space:nowrap">low-dose</FONT> vaginal estrogen unopposed by a progestogen such as IMVEXXY&#153;. Foreign regulatory agencies often have similar authority and may impose comparable costs. Post-marketing studies, whether conducted by us
or by others and whether mandated by regulatory agencies or voluntary, and other emerging data about marketed products, such as adverse event reports, may also adversely affect sales of our hormone therapy drug candidates once approved, and
potentially our other marketed products. Further, the discovery of significant problems with a product similar to one of our products that implicate (or are perceived to implicate) an entire class of products could have an adverse effect on sales of
our approved products. Accordingly, new data about our products could negatively affect demand because of real or perceived side effects or uncertainty regarding efficacy and, in some cases, could result in product withdrawal or recall. Furthermore,
new data and information, including information about product misuse, may lead government agencies, professional societies, and practice management groups or organizations involved with various diseases to publish guidelines or recommendations
related to the use of our products or the use of related therapies or place restrictions on sales. Such guidelines or recommendations may lead to lower sales of our products. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The holder of an approved NDA also is subject to obligations to monitor and report adverse events and instances of the failure of a product to meet the
specifications in the NDA. Application holders must submit new or supplemental applications and obtain FDA approval for certain changes to the approved product, product labeling, or manufacturing process. Application holders must also submit
advertising and other promotional material to the FDA and report on ongoing clinical trials. Legal requirements have also been enacted to require disclosure of certain clinical trial results on a publicly available database. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, manufacturers of drug products and their facilities are subject to continual review and periodic inspections by the FDA and other
regulatory authorities for compliance with the FDA&#146;s cGMPs regulations and other regulatory requirements, such as adverse event reporting. If we or a regulatory agency discovers problems with a product, such as adverse events of unanticipated
severity or frequency or problems with the facility where the product is manufactured, a regulatory agency may impose restrictions on that product, the manufacturing facility, or us, including requiring recall or withdrawal of the product from the
market or suspension of manufacturing, requiring new warnings or other labeling changes to limit use of the drug, requiring that we conduct additional clinical trials, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
imposing new monitoring requirements, or requiring that we establish a REMS program. Advertising and promotional materials must comply with FDA rules in addition to other potentially applicable
federal and state laws, and are subject to review by FDA. If the FDA raises concerns regarding our&nbsp;promotional materials&nbsp;or messages, we may be required to modify or discontinue using them and may be required to provide corrective
information. Should we fail to comply with these requirements, we may be subject to significant liability including civil and administrative actions as well as criminal sanctions. The distribution of product samples to physicians must comply with
the requirements of the Prescription Drug Marketing Act and its implementing regulations. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our activities are also potentially subject to federal
and state consumer protection and unfair competition laws. If we or our third-party collaborators fail to comply with applicable regulatory requirements, a regulatory agency may take any of the following actions: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">conduct an investigation into our practices and any alleged violation of law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">issue warning letters or untitled letters asserting that we are in violation of the law; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">seek an injunction or impose civil or criminal penalties or monetary fines; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">suspend or withdraw regulatory approval; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">require that we suspend or terminate any ongoing clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">refuse to approve pending applications or supplements to applications filed by us; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">suspend or impose restrictions on operations, including costly new manufacturing requirements; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">seize or detain products, refuse to permit the import or export of products, or require us to initiate a product recall; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">exclude us from providing our products to those participating in government health care programs, such as Medicare and
Medicaid, and refuse to allow us to enter into supply contracts, including government contracts. </P></TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Recent government enforcement has targeted
pharmaceutical companies for violations of fraud and abuse laws. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The AKS has been interpreted to apply to arrangements between
pharmaceutical manufacturers on one hand and prescribers, purchasers, pharmacies, and formulary managers on the other.&nbsp;Although there are a number of statutory exemptions and regulatory safe harbors protecting certain common activities from
prosecution, the exemptions and safe harbors are drawn narrowly and practices that involve remuneration to those who prescribe, purchase, or recommend pharmaceutical products, including certain discounts, or engagement of speakers or consultants,
may be subject to scrutiny if they do not fit squarely within an exemption or safe harbor.&nbsp;Our practices with respect to interactions with health care professionals, including but not limited to consultant relationships, speaker programs,
advisory boards, and scientific/educational grant programs, as well as our arrangements with pharmacies, may not in all cases meet all of the criteria for safe harbor protection from AKS liability. Moreover, there are no safe harbors for many common
practices, such as educational and research grants or patient assistance programs. In addition, several states have recently enacted legislation requiring pharmaceutical companies to establish marketing and promotional compliance programs or codes
of conduct and/or to file periodic reports with the state or make periodic public disclosures on sales, marketing, pricing, clinical trials, and other activities. Several states have also adopted laws that prohibit certain marketing-related
activities, including the provision of gifts, meals or other items to certain health care providers. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Though we are continuing to develop our
compliance program, we cannot ensure that our compliance controls, policies and procedures will be sufficient to protect against acts of our employees, </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
business partners or vendors that may violate federal or state fraud and abuse laws or other applicable requirements. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Federal enforcement agencies and private whistleblowers recently have shown interest in pharmaceutical companies&#146; product and patient assistance
programs, including reimbursement support, <FONT STYLE="white-space:nowrap">co-pay</FONT> support, nursing, adherence and educational services, referrals to other providers, donations to independent patient assistance charities, and relationships
with specialty pharmacies. <FONT STYLE="white-space:nowrap">Co-pay</FONT> assistance programs are intended to assist qualified patients with private insurance with any
<FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">out-of-pocket</FONT></FONT> financial obligations, but must exclude any government health care program beneficiaries. A number of investigations into patient assistance practices have
resulted in significant civil and criminal settlements. We offer <FONT STYLE="white-space:nowrap">co-pay</FONT> assistance for our vitamin products, and will offer patient assistance including <FONT STYLE="white-space:nowrap">co-pay</FONT>
assistance and free drug sample starter packs for IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>, and potentially for our other drug candidates. If we fail to structure these and other support programs to comply with applicable law,
we risk becoming subject to government investigations, and potentially, facing penalties or consequences for violations under fraud and abuse laws. In addition, to the extent we, our subsidiary, VitaMed Rx, or our other contractors or agents receive
or obtain individually identifiable health information from patients, health care professionals, pharmacies, or other individuals or entities, although we are not directly subject to HIPAA, we could be subject to criminal penalties if we mishandle
individually identifiable health information in a manner that is not authorized or permitted by HIPAA. Claims that we have violated individuals&#146; privacy rights or breached our contractual obligations, even if we are not found liable, could be
expensive and time-consuming to defend and could result in adverse publicity that could harm our business. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The occurrence of any of the foregoing
events or penalties may force us to expend significant amounts of time and money and may significantly inhibit our ability to bring to market or continue to market our products and generate revenue. Similar regulations apply in foreign
jurisdictions. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Any failure to adequately expand a direct sales force will impede our growth. </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We expect to be substantially dependent on a direct sales force to attract new business and to manage customer relationships. We plan to expand our
direct sales force and believe that there is significant competition for qualified, productive direct sales personnel with advanced sales skills and technical knowledge. Our ability to achieve significant growth in revenue in the future will depend,
in large part, on our success in recruiting, training, and retaining sufficient direct sales personnel. New and future hires may not become as productive as expected, and we may be unable to hire sufficient numbers of qualified individuals in the
future in the markets in which we do business. If we are unable to hire and develop sufficient numbers of productive sales personnel or are required to hire more sales personnel than we expect our business prospects could suffer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Other pharmaceutical companies with which we compete for qualified personnel may have greater financial and other resources, different risk profiles,
and longer histories than we do. They also may provide more diverse opportunities and better chances for career advancement. Some of these characteristics may be more appealing to high-quality candidates than what we offer. If we are unable to
continue to attract and retain high-quality personnel, our ability to commercialize drug candidates may be limited. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Licensing of intellectual property
involves complex legal, business and scientific issues, and disputes could jeopardize our rights under such agreements. Additionally, our current licensing agreements contain limitations and restrictions that could limit or adversely affect our
ability to develop and commercialize other products in the future. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We are currently and may in the future be a party to license agreements
of importance to our business and to our current product and product candidates, and we expect to be subject to additional </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
such agreements in the future. Disputes may arise between us and any of these counterparties regarding intellectual property subject to and each parties&#146; obligations under such agreements,
including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our diligence obligations with respect to the use of the licensed technology in relation to our development and commercialization of our product and product candidates, and what activities satisfy those diligence
obligations; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the scope of rights granted under the agreement and other interpretation-related issues; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our obligations to make milestone, royalty or other payments under those agreements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether and the extent to which our technology and processes infringe on intellectual property of the licensor that is not subject to the agreement; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our right to sublicense patent and other rights to third parties; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the ownership of inventions and <FONT STYLE="white-space:nowrap">know-how</FONT> arising under the agreement or resulting from the joint creation or use of intellectual property by our licensors and us and our partners;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our right to transfer or assign the license; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effects of termination. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">These or other disputes over our obligations or intellectual property that
we have licensed may prevent or impair our ability to maintain our current arrangements on acceptable terms, or may impair the value of the arrangement to us. Any such dispute could have an adverse effect on our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If we fail to meet our obligations under a license agreement in a material respect, the respective licensor could have the right to terminate the
respective agreement and upon the effective date of such termination, have the right to <FONT STYLE="white-space:nowrap">re-obtain</FONT> the related technology as well as, potentially, aspects of any intellectual property controlled by us and
developed during the period the agreement was in force that relate to the applicable technology. This means that the licensor to each of these agreements could effectively take control of the development and commercialization of the applicable
product or product candidate after an uncured, material breach of the agreement by us. This may also be the case if we voluntarily terminate the relevant agreement.&nbsp;Any uncured, material breach under a license agreement could result in our loss
of exclusive rights and may lead to a complete termination of our product development and any commercialization efforts for the applicable product or product candidates. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In July 2018, we entered into a license agreement with the Population Council to obtain exclusive U.S. rights to commercialize the Population
Council&#146;s investigational segesterone acetate/ethinyl estradiol <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal system for human contraceptive indications. The agreement requires us to use commercially reasonable efforts to
commercialize, if approved, this product candidate and enter into certain manufacturing agreements, make timely milestone and other payments, provide certain information regarding our activities under the agreement, and indemnify the other party
with respect to our development and commercialization activities under the terms of the agreements. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, our current licensing agreement
with the Population Council contains limitations and restrictions, including limitations that could limit or adversely affect our ability to develop and commercialize this or other product candidates including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we cannot sublicense the rights licensed to us&nbsp;without the consent of the Population Council; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">neither we nor the Population Council may develop a competitive product (as defined with respect to each party in the agreement) for six years from the date of the agreement; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">currently there are no Orange Book listable patents or patent applications covering this system; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the Population Council owns any program improvements, as defined in the agreement. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Our level of indebtedness and the terms of the Credit Agreement could adversely affect our operations and limit
our ability to plan for or respond to changes in our business. If we are unable to satisfy certain conditions in our Credit Agreement, we will be unable to draw down the remaining the facility and if we are unable to comply with restrictions in the
Credit Agreement, the repayment of our existing indebtedness could be accelerated. </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Under the Credit Agreement, we have incurred a
substantial amount of debt, which could adversely affect our business. In June 2018, we drew down the first tranche of $75.0&nbsp;million under the Credit Agreement and we currently intend to draw down up to an additional $125.0&nbsp;million in the
aggregate in two additional tranches under the terms of the Credit Agreement, when and if the conditions precedent to such tranches have been met. Our high level of indebtedness could affect our business in the following ways, among other things:
make it more difficult for us to satisfy our contractual and commercial commitments; require us to use a substantial portion of our cash flow from operations to pay interest and principal, which would reduce funds available for working capital,
capital expenditures and other general corporate purposes; limit our ability to obtain additional financing for working capital, capital expenditures, acquisitions and other investments or general corporate purposes; heighten our vulnerability to
downturns in our business, our industry or in the general economy; place us at a disadvantage compared to those of our competitors that may have proportionately less debt; limit management&#146;s discretion in operating our business; and limit our
flexibility in planning for, or reacting to, changes in our business, the industry in which we operate or the general economy. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We must satisfy
certain conditions to be eligible to draw down the second tranche of $75.0&nbsp;million and the third tranche of $50.0&nbsp;million. The second tranche may be drawn by us on or before May&nbsp;31, 2019, provided that we satisfy certain conditions
described in the Credit Agreement, including (i)&nbsp;the approval by the FDA of the NDA for our <FONT STYLE="white-space:nowrap">TX-001HR</FONT> drug candidate and (ii)&nbsp;that we have consummated our first commercial sale in the United States of
<FONT STYLE="white-space:nowrap">TX-001HR.</FONT> The third tranche of $50.0&nbsp;million may be drawn by us on or before December&nbsp;31, 2019, provided that we satisfy certain conditions described in the Credit Agreement, including that
(i)&nbsp;tranche 2 has been drawn and (ii)&nbsp;we and our subsidiaries party to the Credit Agreement have generated at least $75.0&nbsp;million of consolidated net revenue attributable to commercial sales of
<FONT STYLE="white-space:nowrap">TX-001HR</FONT> and IMVEXXY&#153; during the twelve-month period ending immediately prior to the funding of tranche 3. If we are unable to satisfy those conditions, we would not be able to draw down the respective
tranche of financing and may not be able to obtain alternative financing on commercially reasonable terms or at all. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The Credit Agreement requires
us to make certain payments of principal and interest over time and contains a number of other restrictive covenants. Among other requirements of the Credit Agreement, we and our subsidiaries party to the Credit Agreement must (i)&nbsp;maintain a
minimum cash balance of $50.0&nbsp;million and (ii)&nbsp;achieve certain minimum consolidated net revenue amounts attributable to commercial sales of our products. The Credit Agreement also contains covenants that limit, among other things, the
ability of us and our subsidiaries party to the Credit Agreement to (i)&nbsp;incur indebtedness, (ii)&nbsp;incur liens on our property, (iii)&nbsp;pay dividends or make other distributions, (iv)&nbsp;sell our assets, (v)&nbsp;make certain loans or
investments, (vi)&nbsp;merge or consolidate, (vii)&nbsp;voluntarily repay or prepay certain permitted indebtedness and (viii)&nbsp;enter into transactions with affiliates, in each case subject to certain exceptions. These and other terms in the
Credit Agreement have to be monitored closely for compliance and could restrict our ability to grow our business or enter into transactions that we believe would be beneficial to our business. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As part of an amendment to the Credit Agreement entered in connection with entering into the Council License Agreement, we are required to receive
aggregate net cash proceeds of at least $75&nbsp;million from the issuance of our equity securities within thirty days of entering into the Council License Agreement.&nbsp;Failure to complete this obligation will constitute an automatic event of
default under the Credit Agreement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our business may not generate cash flow from operations in the future sufficient to service our debt
and support our growth strategies. If we are unable to generate such cash flow, we may be required to adopt one or more alternatives, such as selling assets, restructuring debt or obtaining additional equity capital on terms that may be onerous or
highly dilutive. Our ability to refinance our indebtedness will depend on the capital markets and our financial condition at such time. We may not be able to engage in any of these activities or engage in these activities on desirable terms, which
could result in a default on our debt obligations, including under our current debt obligations. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="supprom554088_4"></A>CAUTIONARY STATEMENT ABOUT FORWARD-LOOKING INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This prospectus supplement, the accompanying prospectus and the documents and information incorporated by reference herein and therein may contain
&#147;forward-looking statements&#148; within the meaning of Section&nbsp;27A of the Securities Act of 1933, as amended, or the Securities Act, and Section&nbsp;21E of the Exchange Act. Forward-looking statements may include, but are not limited to,
statements relating to our objectives, plans and strategies as well as statements, other than historical facts, that address activities, events, or developments that we intend, expect, project, believe or anticipate will or may occur in the future.
These statements are often characterized by terminology such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;could,&#148; &#147;intends,&#148; &#147;target,&#148;
&#147;projects,&#148; &#147;contemplates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;potential,&#148; or &#147;continue&#148; or the negative of these terms or other similar expressions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Forward-looking statements are based on assumptions and assessments made in light of our experience and perception of historical trends, current
conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of our control. You
should not place undue reliance on these forward-looking statements, which reflect our view only as of the date of this prospectus supplement, and we undertake no obligation to update these forward-looking statements in the future, except as
required by applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">A number of important factors could cause actual results to differ materially from those indicated by the
forward-looking statements, including, without limitation, those factors described under the caption &#147;Risk Factors&#148; in our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2017,
which is incorporated by reference in this prospectus supplement and the accompanying prospectus, and under similar headings in our subsequently filed quarterly reports on Form <FONT STYLE="white-space:nowrap">10-Q,</FONT> as well as the other risks
and uncertainties described herein and in the other documents incorporated by reference in this prospectus supplement. Some of the key factors that could cause actual results to differ from our expectations include the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our operating losses incurred since inception and anticipated for the foreseeable future; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to maintain or increase sales of our products; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the ability of our products to produce the intended effects; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to develop and commercialize our hormone therapy drug product and drug candidates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to obtain additional financing necessary to complete the development and commercialization of our hormone
therapy drug product and drug candidates; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">whether the FDA will approve our NDAs for our <FONT STYLE="white-space:nowrap">TX-001HR</FONT> drug candidate and our <FONT
STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system candidate and whether such approvals will occur by their respective PDUFA target action dates; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our lack of experience in bringing a drug to regulatory approval or marketing and selling a drug after regulatory approval;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the length, cost and uncertain results of our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">delays, suspensions, or discontinuation of our clinical trials; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the potential of adverse side effects or other safety risks that could preclude the approval of our drug candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our reliance on third parties to conduct our clinical trials, research and development and manufacturing;
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the effects of laws, regulations and enforcement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our ability to gain and retain market acceptance for our hormone therapy drug product or drug candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the competitive nature of the industries in which we conduct our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the availability of reimbursement from government authorities and health insurance companies for our products;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the impact of product liability lawsuits; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the influence of extensive and costly government regulation; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the effect of governmental regulations on our business; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">whether we will be able to comply with the covenants and conditions under our credit agreement; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the ability of our partners and third-party manufacturers to manufacture and distribute sufficient amounts of our hormone
therapy drug product; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the ability of our licensees to commercialize and distribute our hormone therapy drug product and drug candidates;
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the volatility of the trading price of our common stock; and </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the concentration of power in our stock ownership. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="supprom554088_5"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We estimate that the net proceeds from the sale of the shares of common stock in this offering and the concurrent offering will be approximately $
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million, or approximately $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; million if the underwriters exercise in full their option to purchase
additional shares, based on the public offering price of $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share, after deducting underwriting discounts and commissions and estimated offering and concurrent offering
expenses payable by us. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We intend to use the net proceeds from this offering and the concurrent offering to fund a portion of the costs for the
commercial launch of our recently approved product, IMVEXXY&#153; (estradiol vaginal inserts) for the treatment of <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">moderate-to-severe</FONT></FONT> dyspareunia (vaginal pain
associated with sexual activity), a symptom of VVA, due to menopause, and to fund a portion of the costs for <FONT STYLE="white-space:nowrap">pre-commercialization</FONT> and commercialization activities for
<FONT STYLE="white-space:nowrap">TX-001HR,</FONT> our <FONT STYLE="white-space:nowrap">bio-identical</FONT> hormone therapy combination of 17&szlig;- estradiol and progesterone in a single, oral softgel drug candidate, for the treatment of moderate
to severe VMS due to menopause in menopausal women with an intact uterus, and our <FONT STYLE="white-space:nowrap">one-year</FONT> vaginal contraceptive system candidate. We additionally intend to use a portion of the net proceeds from this offering
and the concurrent offering for working capital and general corporate purposes. We may also use a portion of the net proceeds from this offering and the concurrent offering to acquire or invest in businesses and products that we believe would
complement our women&#146;s health products and drug candidates. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">As of the date of this prospectus supplement, we cannot specify with certainty all
of the particular uses of the proceeds from this offering and the concurrent offering. The amounts and timing of our actual expenditures will depend on numerous factors, including the progress of regulatory approvals, commercialization activities,
the timing of our revenue and the amount of cash used by our operations. Accordingly, we will retain broad discretion over the use of such proceeds. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We can offer no assurance that the concurrent offering will close, and if it does not close, the amount of our net proceeds will be limited to the net
proceeds from this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pending use of the proceeds as described above or otherwise, we intend to invest the net proceeds in short-term
interest-bearing, investment-grade securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="supprom554088_6"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Our net tangible book value as of June&nbsp;30, 2018 was approximately $74.1&nbsp;million, or $0.34 per share. Net tangible book value per share is
determined by dividing our total tangible assets, less total liabilities, by the number of shares of our common stock outstanding as of June&nbsp;30, 2018. Dilution in net tangible book value per share represents the difference between the amount
per share paid by purchasers of shares of common stock in this offering and the net tangible book value per share of our common stock immediately after this offering and the concurrent offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">After giving effect to the sale of $85&nbsp;million of shares of our common stock in this offering and the concurrent offering at an assumed public
offering price of $5.52&nbsp;per share, which was the last reported sale price of our common stock on the Nasdaq Global Select Market on July&nbsp;30, 2018, and after deducting the underwriting discounts and commissions and estimated offering and
concurrent offering expenses we must pay, our as adjusted net tangible book value as of June&nbsp;30, 2018 would have been approximately $154.9&nbsp;million, or $0.67 per share. This would represent an immediate increase in net tangible book value
of $0.33 per share to existing stockholders and immediate dilution in net tangible book value of $4.85 per share to new investors purchasing our common stock in this offering. The following table illustrates this dilution on a per share basis. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="86%"></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="3%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Assumed public offering price per share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">5.52</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Net tangible book value per share as of June&nbsp;30, 2018</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Increase per share attributable to new investors</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">As adjusted net tangible book value per share after this offering and the concurrent offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">0.67</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Dilution per share to new investors in this offering</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">$</TD>
<TD VALIGN="bottom" ALIGN="right">4.85</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">If the underwriters exercises in full their option to purchase 1,766,304 additional shares of common stock at the public
offering price of $5.52 per share, the as adjusted net tangible book value after this offering and the concurrent offering would be $0.70 per share, representing an increase in net tangible book value of $0.36 per share to existing stockholders and
immediate dilution in net tangible book value of $4.82 per share to new investors purchasing our common stock in this offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The above
discussion and table are based on 216,834,059 shares outstanding on June&nbsp;30, 2018 and exclude the following as of that date: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">outstanding options representing the right to purchase a total of 25,210,899 shares of common stock at a weighted average exercise price of $3.92 per share; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">outstanding warrants representing the right to purchase a total of 3,007,571 shares of common stock at a weighted-average exercise price of $2.78 per share; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">5,052,120 shares of common stock reserved for future issuance under our <FONT STYLE="white-space:nowrap">non-qualified</FONT> stock option plans. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">To the extent that outstanding options or warrants are exercised or we issue shares of common stock under our stock incentive plans, investors
purchasing our common stock in this offering will experience further dilution. In addition, we may choose to raise additional capital due to market conditions or strategic considerations even if we believe we have sufficient funds for our current or
future operating plans. To the extent that additional capital is raised through the sale of equity or convertible debt securities, the issuance of these securities could result in further dilution to our stockholders. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="supprom554088_7"></A>UNDERWRITING </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We and the underwriters named below have entered into an underwriting agreement with respect to the shares being offered. Subject to certain conditions,
each underwriter has severally agreed to purchase the number of shares indicated in the following table. Goldman Sachs&nbsp;&amp; Co. LLC is the representative of the underwriters. </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="83%"></TD>
<TD VALIGN="bottom" WIDTH="11%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom" NOWRAP> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-bottom:1.00pt solid #000000; display:table-cell; font-size:8pt; font-family:ARIAL; "><B>Underwriters</B></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Number&nbsp;of&nbsp;Shares</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Goldman Sachs&nbsp;&amp; Co. LLC</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Cantor Fitzgerald&nbsp;&amp; Co.</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:1.00px solid #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:3.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom"></TD></TR>
<TR STYLE="font-size:1px; ">
<TD VALIGN="bottom"></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD VALIGN="bottom"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; border-top:3.00px double #000000">&nbsp;</P></TD>
<TD>&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters are committed to take and pay for all of the shares being offered, if any are taken, other than the
shares covered by the option described below unless and until this option is exercised. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters have an option to buy up to an additional
&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;shares from us to cover sales by the underwriters of a greater number of shares than the total number set forth in the table above. They may exercise that option for 30
days. If any shares are purchased pursuant to this option, the underwriters will severally purchase shares in approximately the same proportion as set forth in the table above. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The closing of the concurrent offering is contingent upon the closing of this offering, but the closing of this offering is not contingent upon the
closing of the concurrent offering. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The following table shows the per share and total underwriting discounts and commissions to be paid to the
underwriters by us. Such amounts are shown assuming both no exercise and full exercise of the underwriters&#146; option to purchase &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; additional shares. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Paid by Us </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="76%"></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD>
<TD VALIGN="bottom" WIDTH="6%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:8pt">
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>No&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom" COLSPAN="2" ALIGN="center" STYLE="border-bottom:1.00pt solid #000000"><B>Full&nbsp;Exercise</B></TD>
<TD VALIGN="bottom">&nbsp;</TD></TR>


<TR BGCOLOR="#cceeff" STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Per Share</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:ARIAL; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:ARIAL">Total</P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">$</TD>
<TD NOWRAP VALIGN="bottom" ALIGN="right">&nbsp;</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Shares sold by the underwriters to the public will initially be offered at the public offering price set forth on the
cover of this prospectus supplement. Any shares sold by the underwriters to securities dealers may be sold at a discount of up to $ &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; per share from the public offering price.
After the initial offering of the shares, the representative may change the offering price and the other selling terms. The offering of the shares by the underwriters is subject to receipt and acceptance and subject to the underwriters&#146; right
to reject any order in whole or in part. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have agreed that we will not, for a period of 90 days after the date of this prospectus supplement, and
its directors and executive officers will not, for a period of 90 days after the date of this prospectus supplement: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">offer, sell, contract to sell, pledge, grant any option to purchase, make any short sale or otherwise transfer or dispose
of, directly or indirectly, or, in our case, file with the Commission a registration statement under the Securities Act relating to, any securities of our company that are substantially similar to the common stock, including but not limited to any
options or warrants to purchase shares of common stock or any securities that are convertible into or </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="7%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">
exchangeable for, or that represent the right to receive, common stock or any such substantially similar securities, or publicly disclose the intention to effect any of the foregoing; or
</P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">in our case, enter into any swap or other agreement that transfers, in whole or in part, any of the economic consequences
of ownership of our common stock or any such other securities, </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">whether any such transaction described above is to be settled by delivery of
common stock or such other securities, in cash or otherwise (other than the shares to be issued hereunder or pursuant to employee stock option plans existing on, or upon the conversion or exchange of convertible or exchangeable securities
outstanding as of, the date of this prospectus supplement), without the consent of Goldman Sachs&nbsp;&amp; Co. LLC. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The restrictions in the
immediately preceding paragraph shall not apply to: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">with respect to our directors or officers, a transfer as any bona fide gift or gifts, provided that any donee agrees to be
bound in writing by the restrictions, that any such transfer shall not involve a disposition for value and that no public disclosure or filing under the Exchange Act by any party to the transfer shall be required, or made voluntarily, with respect
to such transfer prior to the expiration of the restricted period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">with respect to our directors or officers, a transfer to any trust for the direct or indirect benefit of the undersigned or
the immediate family of the undersigned, or if the undersigned is a trust, to any beneficiary (including such beneficiary&#146;s estate) of the undersigned, provided that the trustee of the trust or such beneficiary or estate agrees to be bound in
writing by the restrictions, that any such transfer shall not involve a disposition for value and that no public disclosure or filing under the Exchange Act by any party to the transfer shall be required, or made voluntarily, with respect to such
transfer prior to the expiration of the restricted period; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">with respect to our directors or officers, a transfer by will or under the laws of descent, provided that the recipient
agrees to be bound in writing by the restrictions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">with respect to our directors or officers, a transfer pursuant to a bona fide third-party tender offer, merger,
consolidation or other similar transaction made to all holders of our capital stock involving a change of control of our company that is recommended or approved by the board of directors of our company, provided that in the event that such tender
offer, merger, consolidation or other such transaction is not completed, such shares shall remain subject to the restrictions; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">with respect to us, transfers pursuant to employee stock option plans existing on, or upon the conversion or exchange of
convertible or exchangeable securities outstanding as of, the date of this prospectus supplement; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">with respect to us, the concurrent offering. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with the concurrent offering, Knight has agreed that, without our prior written consent, which may not be given without Goldman
Sachs&nbsp;&amp; Co. LLC&#146;s prior written consent, subject to certain exceptions, Knight will not offer or contract to sell any of the shares of our common stock for a period of up to 90 days following the date of this prospectus supplement.
Knight&#146;s agreement is subject to certain customary exceptions, including in respect of bona fide gifts of shares.&nbsp;Additionally, provided that no public disclosure is required pursuant to the Exchange Act, Knight may, immediately and
without restriction, sell or contract to sell up to 50% of the shares of common stock acquired by Knight in the concurrent offering, as well as up to an additional 16.67% of such shares on or after each of the 30<SUP
STYLE="font-size:85%; vertical-align:top">th</SUP> day and the 60<SUP STYLE="font-size:85%; vertical-align:top">th</SUP> day following the date of the prospectus supplement of the concurrent offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In connection with the offering, the underwriters may purchase and sell shares of common stock in the open market. These transactions may include short
sales, stabilizing transactions and purchases </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
to cover positions created by short sales. Short sales involve the sale by the underwriters of a greater number of shares than they are required to purchase in the offering, and a short position
represents the amount of such sales that have not been covered by subsequent purchases. A &#147;covered short position&#148; is a short position that is not greater than the amount of additional shares for which the underwriters&#146; option
described above may be exercised. The underwriters may cover any covered short position by either exercising their option to purchase additional shares or purchasing shares in the open market. In determining the source of shares to cover the covered
short position, the underwriters will consider, among other things, the price of shares available for purchase in the open market as compared to the price at which they may purchase additional shares pursuant to the option described above.
&#147;Naked&#148; short sales are any short sales that create a short position greater than the amount of additional shares for which the option described above may be exercised. The underwriters must cover any such naked short position by
purchasing shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there may be downward pressure on the price of the common stock in the open market after pricing that could adversely
affect investors who purchase in the offering. Stabilizing transactions consist of various bids for or purchases of common stock made by the underwriters in the open market prior to the completion of the offering. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters may also impose a penalty bid. This occurs when a particular underwriter repays to the underwriters a portion of the underwriting
discount received by it because the representative has repurchased shares sold by or for the account of such underwriter in stabilizing or short covering transactions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Purchases to cover a short position and stabilizing transactions, as well as other purchases by the underwriters for their own accounts, may have the
effect of preventing or retarding a decline in the market price of our stock, and together with the imposition of the penalty bid, may stabilize, maintain or otherwise affect the market price of the common stock. As a result, the price of the common
stock may be higher than the price that otherwise might exist in the open market. The underwriters are not required to engage in these activities and may end any of these activities at any time. These transactions may be effected on the Nasdaq
Global Select Market, in the <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">over-the-counter</FONT></FONT> market or otherwise. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>European
Economic Area </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In relation to each Member State of the European Economic Area which has implemented the Prospectus Directive (each, a
&#147;Relevant Member State&#148;) an offer to the public of our common shares may not be made in that Relevant Member State, except that an offer to the public in that Relevant Member State of our common shares may be made at any time under the
following exemptions under the Prospectus Directive: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">to any legal entity which is a qualified investor as defined in the Prospectus Directive; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">To fewer than 150 natural or legal persons (other than qualified investors as defined in the Prospectus Directive), subject
to obtaining the prior consent of the representative for any such offer; or </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">in any other circumstances falling within Article 3(2) of the Prospectus Directive, </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">provided that no such offer or shares of our common stock shall result in a requirement for the publication by us or any underwriter of a prospectus pursuant to Article
3 of the Prospectus Directive. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">For the purposes of this provision, the expression an &#147;offer to public&#148; in relation to our common shares
in any Relevant Member State means the communication in any form and by any means of sufficient information on the terms of the offer and our common shares to be offered so as to enable an </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
investor to decide to purchase our common shares, as the same may be varied in that Member State by any measure implementing the Prospectus Directive in that Member State, the expression
&#147;Prospectus Directive&#148; means Directive 2003/71/EC (as amended), including by Directive 2010/73/EU and includes any relevant implementing measure in the Relevant Member State. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This European Economic Area selling restriction is in addition to any other selling restrictions set out below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>United Kingdom </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the United Kingdom, this prospectus
is only addressed to and directed as qualified investors who are (i)&nbsp;investment professionals falling within Article 19(5) of the Financial Services and Markets Act 2000 (Financial Promotion) Order 2005 (the Order); or (ii)&nbsp;high net worth
entities and other persons to whom it may lawfully be communicated, falling within Article 49(2)(a) to (d)&nbsp;of the Order (all such persons together being referred to as &#147;relevant persons&#148;). Any investment or investment activity to
which this prospectus relates is available only to relevant persons and will only be engaged with relevant persons. Any person who is not a relevant person should not act or relay on this prospectus or any of its contents. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Canada </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The securities may be sold in Canada only to
purchasers purchasing, or deemed to be purchasing, as principal that are accredited investors, as defined in National Instrument <FONT STYLE="white-space:nowrap">45-106</FONT> Prospectus Exemptions or subsection 73.3(1) of the Securities Act
(Ontario), and are permitted clients, as defined in National Instrument <FONT STYLE="white-space:nowrap">31-103</FONT> Registration Requirements, Exemptions, and Ongoing Registrant Obligations. Any resale of the securities must be made in accordance
with an exemption from, or in a transaction not subject to, the prospectus requirements of applicable securities laws. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Securities legislation in
certain provinces or territories of Canada may provide a purchaser with remedies for rescission or damages if this prospectus supplement (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or
damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser&#146;s province or territory. The purchaser should refer to any applicable provisions of the securities legislation of the
purchaser&#146;s province or territory for more information about these rights or consult with a legal advisor. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Pursuant to section 3A.3 of
National Instrument <FONT STYLE="white-space:nowrap">33-105</FONT> Underwriting Conflicts (NI <FONT STYLE="white-space:nowrap">33-105),</FONT> the underwriters are not required to comply with the disclosure requirements of NI <FONT
STYLE="white-space:nowrap">33-105</FONT> regarding underwriter conflicts of interest in connection with this offering. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Hong Kong </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The shares may not be offered or sold in Hong Kong by means of any document other than (i)&nbsp;in circumstances which do not constitute an offer to the
public within the meaning of the Companies (Winding Up and Miscellaneous Provisions) Ordinance (Cap. 32 of the Laws of Hong Kong) (&#147;Companies (Winding Up and Miscellaneous Provisions) Ordinance&#148;) or which do not constitute an invitation to
the public within the meaning of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong) (&#147;Securities and Futures Ordinance&#148;), or (ii)&nbsp;to &#147;professional investors&#148; as defined in the Securities and Futures
Ordinance and any rules made thereunder, or (iii)&nbsp;in other circumstances which do not result in the document being a &#147;prospectus&#148; as defined in the Companies (Winding Up and Miscellaneous Provisions) Ordinance, and no advertisement,
invitation or document relating to the shares may be issued or may be in the possession of any person for the purpose of issue (in each case whether in Hong Kong or elsewhere), which is directed at, or the contents of which are likely to be
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
accessed or read by, the public in Hong Kong (except if permitted to do so under the securities laws of Hong Kong) other than with respect to shares which are or are intended to be disposed of
only to persons outside Hong Kong or only to &#147;professional investors&#148; in Hong Kong as defined in the Securities and Futures Ordinance and any rules made thereunder. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Singapore </I></B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">This prospectus has not been registered as
a prospectus with the Monetary Authority of Singapore. Accordingly, this prospectus and any other document or material in connection with the offer or sale, or invitation for subscription or purchase, of the shares may not be circulated or
distributed, nor may the shares be offered or sold, or be made the subject of an invitation for subscription or purchase, whether directly or indirectly, to persons in Singapore other than (i)&nbsp;to an institutional investor (as defined under
Section&nbsp;4A of the Securities and Futures Act, Chapter 289 of Singapore (the &#147;SFA&#148;)) under Section&nbsp;274 of the SFA, (ii)&nbsp;to a relevant person (as defined in Section&nbsp;275(2) of the SFA) pursuant to Section&nbsp;275(1) of
the SFA, or any person pursuant to Section&nbsp;275(1A) of the SFA, and in accordance with the conditions specified in Section&nbsp;275 of the SFA or (iii)&nbsp;otherwise pursuant to, and in accordance with the conditions of, any other applicable
provision of the SFA, in each case subject to conditions set forth in the SFA. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Where the shares are subscribed or purchased under Section&nbsp;275
of the SFA by a relevant person which is a corporation (which is not an accredited investor (as defined in Section&nbsp;4A of the SFA)) the sole business of which is to hold investments and the entire share capital of which is owned by one or more
individuals, each of whom is an accredited investor, the securities (as defined in Section&nbsp;239(1) of the SFA) of that corporation shall not be transferable for 6 months after that corporation has acquired the shares under Section&nbsp;275 of
the SFA except: (1)&nbsp;to an institutional investor under Section&nbsp;274 of the SFA or to a relevant person (as defined in Section&nbsp;275(2) of the SFA), (2) where such transfer arises from an offer in that corporation&#146;s securities
pursuant to Section&nbsp;275(1A) of the SFA, (3)&nbsp;where no consideration is or will be given for the transfer, (4)&nbsp;where the transfer is by operation of law, (5)&nbsp;as specified in Section&nbsp;276(7) of the SFA, or (6)&nbsp;as specified
in Regulation 32 of the Securities and Futures (Offers of Investments) (Shares and Debentures) Regulations 2005 of Singapore (&#147;Regulation 32&#148;). </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">Where the shares are subscribed or purchased under Section&nbsp;275 of the SFA by a relevant person which is a trust (where the trustee is not an
accredited investor (as defined in Section&nbsp;4A of the SFA)) whose sole purpose is to hold investments and each beneficiary of the trust is an accredited investor, the beneficiaries&#146; rights and interest (howsoever described) in that trust
shall not be transferable for 6 months after that trust has acquired the shares under Section&nbsp;275 of the SFA except: (1)&nbsp;to an institutional investor under Section&nbsp;274 of the SFA or to a relevant person (as defined in
Section&nbsp;275(2) of the SFA), (2) where such transfer arises from an offer that is made on terms that such rights or interest are acquired at a consideration of not less than S$200,000 (or its equivalent in a foreign currency) for each
transaction (whether such amount is to be paid for in cash or by exchange of securities or other assets), (3) where no consideration is or will be given for the transfer, (4)&nbsp;where the transfer is by operation of law, (5)&nbsp;as specified in
Section&nbsp;276(7) of the SFA, or (6)&nbsp;as specified in Regulation 32. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL"><B><I>Japan </I></B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The securities have not been and will not be registered under the Financial Instruments and Exchange Act of Japan (Act No.&nbsp;25 of 1948, as amended),
or the FIEA. The securities may not be offered or sold, directly or indirectly, in Japan or to or for the benefit of any resident of Japan (including any person resident in Japan or any corporation or other entity organized under the laws of Japan)
or to others for reoffering or resale, directly or indirectly, in Japan or to or for the benefit of any resident of </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL">
Japan, except pursuant to an exemption from the registration requirements of the FIEA and otherwise in compliance with any relevant laws and regulations of Japan. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We estimate that our share of the total expenses of the offering and the concurrent offering, excluding underwriting discounts and commissions, will be
approximately $265,000. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We have agreed to indemnify the several underwriters against certain liabilities, including liabilities under the
Securities Act. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The underwriters and their respective affiliates are full service financial institutions engaged in various activities, which may
include sales and trading, commercial and investment banking, advisory, investment management, investment research, principal investment, hedging, market making, brokerage and other financial and <FONT STYLE="white-space:nowrap">non-financial</FONT>
activities and services. Certain of the underwriters and their respective affiliates have provided, and may in the future provide, a variety of these services to our company and to persons and entities with relationships with our company, for which
they received or will receive customary fees and expenses. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In the ordinary course of their various business activities, the underwriters and their
respective affiliates, officers, directors and employees may purchase, sell or hold a broad array of investments and actively trade securities, derivatives, loans, commodities, currencies, credit default swaps and other financial instruments for
their own account and for the accounts of their customers, and such investment and trading activities may involve or relate to assets, securities and/or instruments of our company (directly, as collateral securing other obligations or otherwise)
and/or persons and entities with relationships with our company. The underwriters and their respective affiliates may also communicate independent investment recommendations, market color or trading ideas and/or publish or express independent
research views in respect of such assets, securities or instruments and may at any time hold, or recommend to clients that they should acquire, long and/or short positions in such assets, securities and instruments. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="supprom554088_8"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The validity of the shares of common stock offered hereby will be passed upon for us by Greenberg Traurig, LLP, Las Vegas, Nevada. Certain legal matters
relating to this offering will be passed upon for the underwriters by Ropes&nbsp;
&amp; Gray LLP, Boston, Massachusetts. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="supprom554088_9"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The audited financial statements and management&#146;s assessment of the effectiveness of internal control over financial reporting incorporated by
reference in this prospectus supplement and elsewhere in the registration statement have been incorporated by reference in reliance upon the reports of Grant Thornton LLP, independent registered public accountants, upon the authority of said firm as
experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="supprom554088_10"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Through our website at
<I>www.therapeuticsmd.com</I>, you may access, free of charge, our filings, as soon as reasonably practical after we electronically file them with or furnish them to the SEC. The information contained in, or available through, our website is not
incorporated by reference in, and should not be considered a part of, this prospectus supplement or the accompanying prospectus. You also may read and copy any document we file with the SEC at the SEC&#146;s Public Reference Room at 100 F Street,
N.E., Washington, D.C. 20549. Please call the SEC at <FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap"><FONT STYLE="white-space:nowrap">1-800-SEC-0330</FONT></FONT></FONT> for further information. Our SEC filings are also available
to the public at the SEC&#146;s website at <I>www.sec.gov</I>. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The accompanying prospectus is part of a registration statement on Form <FONT
STYLE="white-space:nowrap">S-3</FONT> that we filed with the SEC to register the securities offered hereby under the Securities Act. The accompanying prospectus does not contain all of the information included in the registration statement,
including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the address listed above or from the SEC&#146;s website listed above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B><A NAME="supprom554088_11"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">The SEC allows us to incorporate by reference the information we file with the SEC, which means that we can disclose important information to you by
referring you to those documents. The information that we incorporate by reference is considered to be part of this prospectus supplement and the accompanying prospectus. Information that we file with the SEC in the future and incorporate by
reference in this prospectus supplement and the accompanying prospectus automatically updates and supersedes previously filed information as applicable. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We incorporate by reference into this prospectus supplement and the accompanying prospectus the following documents filed by us with the SEC, other than
any portion of any such documents that is not deemed &#147;filed&#148; under the Exchange Act in accordance with the Exchange Act and applicable SEC rules: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our Annual Report on Form <FONT STYLE="white-space:nowrap">10-K</FONT> for the fiscal year ended December&nbsp;31, 2017,
filed with the SEC on February&nbsp;23, 2018; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our Quarterly Reports on Form <FONT STYLE="white-space:nowrap">10-Q</FONT> for the quarters ended March&nbsp;31, 2018 and
June&nbsp;30, 2018, filed with the SEC on May&nbsp;7, 2018 and July&nbsp;30, 2018; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our Definitive Proxy Statement on Schedule 14A, filed with the SEC on April&nbsp;27, 2018; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">our Current Reports on Form <FONT STYLE="white-space:nowrap">8-K</FONT> filed with the SEC on April&nbsp;2, 2018,
May&nbsp;3, 2018, June&nbsp;7, 2018 and June&nbsp;26, 2018; and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:ARIAL; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="1%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:ARIAL; font-size:10pt">the description of our common stock included under the heading &#147;Description of Common Stock&#148; in the prospectus
forming a part of the Registration Statement on Form <FONT STYLE="white-space:nowrap">S-3</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;333-207837),</FONT> as filed with the SEC on November&nbsp;5, 2015, which description has been
incorporated by reference in Item 1 of our Form <FONT STYLE="white-space:nowrap">8-A</FONT> (File <FONT STYLE="white-space:nowrap">No.&nbsp;001-00100),</FONT> as filed with the SEC on October&nbsp;6, 2017, including any amendment or report filed
with the SEC for the purpose of updating such description. </P></TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">In addition, all documents subsequently filed by us pursuant to
Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (not including any information furnished under Item 2.02, 7.01 or 9.01 of Form <FONT STYLE="white-space:nowrap">8-K</FONT> and any other information that is identified as &#147;furnished&#148;
rather than filed, which information is not incorporated by reference herein) prior to the termination of this offering, will be deemed to be incorporated herein by reference and to be a part of this prospectus supplement and the accompanying
prospectus from the date of filing of such documents. Any statement contained in a document incorporated herein by reference will be deemed to be modified or superseded for purposes of this prospectus supplement and the accompanying prospectus to
the extent that a statement contained herein, or in a subsequently filed document incorporated herein by reference, modifies or supersedes the statement. Any statement modified or superseded will not be deemed, except as modified or superseded, to
constitute a part of this prospectus supplement and the accompanying prospectus. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:5%; font-size:10pt; font-family:ARIAL">We will provide without charge to each person, including any
beneficial owner, to whom a prospectus supplement is delivered, upon written or oral request of that person, a copy of any and all of the information that has been incorporated by reference in this prospectus supplement and the accompanying
prospectus but not delivered with this prospectus supplement (excluding exhibits unless specifically incorporated by reference into those documents). Please direct requests to us at the following address: </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>TherapeuticsMD, Inc. </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Attention: Corporate
Secretary </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>6800 Broken Sound Parkway NW, Third Floor </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>Boca Raton, Florida 33487 </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center"><B>(561) <FONT
STYLE="white-space:nowrap">961-1900</FONT> </B></P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:ARIAL" ALIGN="center">S-40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>PROSPECTUS </B></P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g368527g96q94.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Common Stock </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Preferred Stock </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Debt
Securities </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Depositary Shares </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Warrants </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Purchase
Contracts </B></P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:14pt; font-family:Times New Roman" ALIGN="center"><B>Units </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We or any
selling stockholder may offer and sell from time to time, in one or more series or issuances and on terms that we will determine at the time of the offering, any combination of the securities described in this prospectus. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus provides you with a general description of the securities we or any selling stockholder may offer and sell. We will provide
specific terms of any offering in a supplement to this prospectus. Any prospectus supplement may also add, update, or change information contained in this prospectus. You should carefully read this prospectus and the applicable prospectus supplement
as well as the documents incorporated or deemed to be incorporated by reference in this prospectus before you invest in any of our securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We or any selling stockholder may offer and sell in the same offering or in separate offerings; to or through underwriters, dealers and
agents; or directly to purchasers. The names of any underwriters, dealers, or agents involved in the sale of our securities and any applicable fees, commissions, or discounts will be described in the applicable prospectus supplement. Our net
proceeds from the sale of securities will also be set forth in the applicable prospectus supplement. We will not receive any proceeds from the sale of securities by selling stockholders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus may not be used to consummate a sale of our securities unless accompanied by the applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Select Market of The Nasdaq Stock Market LLC under the symbol &#147;TXMD.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:12pt; font-family:Times New Roman"><B>Investing in our securities involves a high degree of risk. See the &#147;<A HREF="#rom368527_2">Risk Factors</A>&#148; section beginning
on page&nbsp;1 of this prospectus for a discussion of information that should be considered in connection with an investment in our securities. </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:18pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><B>Neither the
Securities and Exchange Commission nor any state securities commission has approved or disapproved of these securities or passed upon the adequacy or accuracy of this prospectus. Any representation to the contrary is a criminal offense. </B></P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>The date of this prospectus is July 31, 2018. </B></P>
</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="toc"></A>TABLE OF CONTENTS </B></P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE CELLSPACING="0" CELLPADDING="0" WIDTH="100%" BORDER="0" STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" ALIGN="center">


<TR>
<TD WIDTH="96%"></TD>
<TD VALIGN="bottom" WIDTH="2%"></TD>
<TD></TD>
<TD></TD>
<TD></TD></TR>


<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom368527_1">ABOUT THIS PROSPECTUS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">ii</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom368527_2">RISK FACTORS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">1</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom368527_3">FORWARD-LOOKING STATEMENTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">2</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom368527_4">OUR COMPANY</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">4</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom368527_5">RATIO OF EARNINGS TO FIXED CHARGES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">5</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom368527_7">USE OF PROCEEDS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">6</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom368527_7a">SELLING STOCKHOLDERS </A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">7</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom368527_6">DILUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">8</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom368527_8">DESCRIPTION OF COMMON STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">9</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom368527_9">DESCRIPTION OF PREFERRED STOCK</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">11</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom368527_10">DESCRIPTION OF DEBT SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">15</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom368527_11">DESCRIPTION OF DEPOSITARY SHARES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">27</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom368527_12">DESCRIPTION OF WARRANTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">30</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom368527_13">DESCRIPTION OF PURCHASE CONTRACTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">33</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom368527_14">DESCRIPTION OF UNITS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">34</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom368527_15">CERTAIN PROVISIONS OF NEVADA LAW AND OUR CHARTER AND BYLAWS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">36</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom368527_16">LEGAL OWNERSHIP OF SECURITIES</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">40</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom368527_17">PLAN OF DISTRIBUTION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">44</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom368527_18">LEGAL MATTERS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom368527_19">EXPERTS</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom368527_20">WHERE YOU CAN FIND MORE INFORMATION</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">47</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
<TR STYLE="page-break-inside:avoid ; font-family:Times New Roman; font-size:10pt">
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; margin-left:1.00em; text-indent:-1.00em; font-size:10pt; font-family:Times New Roman"><A HREF="#rom368527_21">INCORPORATION OF CERTAIN INFORMATION BY REFERENCE</A></P></TD>
<TD VALIGN="bottom">&nbsp;&nbsp;</TD>
<TD VALIGN="bottom">&nbsp;</TD>
<TD VALIGN="bottom" ALIGN="right">48</TD>
<TD NOWRAP VALIGN="bottom">&nbsp;</TD></TR>
</TABLE> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">i </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom368527_1"></A>ABOUT THIS PROSPECTUS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement that we filed with the Securities and Exchange Commission, or the SEC, utilizing a
&#147;shelf&#148; registration process. Under this shelf registration process, we and/or selling stockholders may sell, from time to time, any combination of the securities described in this prospectus in one or more offerings. This prospectus
provides you with general information regarding the securities we and/or selling stockholders may offer. We will provide a prospectus supplement that contains specific information about any offering by us and/or selling stockholders. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement also may add, update, or change information contained in the prospectus. You should read both this prospectus and
the prospectus supplement related to any offering as well as additional information described under the headings &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain Information by Reference.&#148; </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor any selling stockholder has authorized anyone to provide you with information different from that contained or incorporated by
reference in this prospectus or any accompanying prospectus supplement or any &#147;free writing prospectus.&#148; We and/or selling stockholders are offering to sell, and seeking offers to buy, securities only in jurisdictions where offers and
sales are permitted. The information contained in this prospectus and in any accompanying prospectus supplement is accurate only as of the dates of their covers, regardless of the time of delivery of this prospectus or any prospectus supplement or
of any sale of our securities. Our business, financial condition, results of operations, and prospects may have changed since those dates. You should rely only on the information contained or incorporated by reference in this prospectus or any
accompanying prospectus supplement. To the extent there is a conflict between the information contained in this prospectus and the prospectus supplement, you should rely on the information in the prospectus supplement, provided that if any statement
in one of these documents is inconsistent with a statement in another document having a later date &#151; for example, a document incorporated by reference into this prospectus or any prospectus supplement &#151; the statement in the document having
the later date modifies or supersedes the earlier statement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the context otherwise requires, the terms &#147;Therapeutics,&#148;
&#147;TXMD,&#148; &#147;Company,&#148; &#147;we,&#148; &#147;us,&#148; or &#147;our&#148; refer to TherapeuticsMD, Inc., a Nevada corporation, and its subsidiaries, vitaMedMD, LLC, a Delaware limited liability company, BocagreenMD, Inc., a Nevada
corporation, and VitaCare Prescription Services, Inc., a Florida corporation. </P> <P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">ii </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom368527_2"></A>RISK FACTORS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Investing in our securities involves a high degree of risk. Before making an investment decision, you should carefully consider the discussion
of risks and uncertainties under the heading &#147;Risk Factors&#148; contained in our Annual Report on Form 10-K for the fiscal year ended December 31, 2017, which is incorporated by reference in this prospectus, and under similar headings in our
subsequently filed quarterly reports on Form 10-Q and annual reports on Form 10-K, as well as the other risks and uncertainties described in any applicable prospectus supplement or free writing prospectus and in the other documents incorporated by
reference in this prospectus. See the sections entitled &#147;Where You Can Find More Information&#148; and &#147;Incorporation of Certain Information by Reference&#148; in this prospectus. The risks and uncertainties we discuss in this prospectus,
in any applicable prospectus supplement or free writing prospectus and in the other documents incorporated by reference in this prospectus are not the only ones facing our company. Additional risks and uncertainties not presently known to us or that
we currently believe are immaterial also may materially and adversely affect our business, financial condition and results of operations. Please also refer to the section of this prospectus titled &#147;Cautionary Statement About Forward Looking
Statements.&#148; </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">1 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom368527_3"></A>CAUTIONARY STATEMENT ABOUT FORWARD-LOOKING STATEMENTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus, any applicable prospectus supplement and the documents and information incorporated by reference herein and therein may
contain &#147;forward-looking statements&#148; within the meaning of Section 27A of the Securities Act and Section 21E of the Securities Exchange Act of 1934, as amended, or the Exchange Act. Forward-looking statements may include, but are not
limited to, statements relating to our objectives, plans and strategies as well as statements, other than historical facts, that address activities, events, or developments that we intend, expect, project, believe or anticipate will or may occur in
the future. These statements are often characterized by terminology such as &#147;may,&#148; &#147;will,&#148; &#147;should,&#148; &#147;expects,&#148; &#147;plans,&#148; &#147;anticipates,&#148; &#147;could,&#148; &#147;intends,&#148;
&#147;target,&#148; &#147;projects,&#148; &#147;contemplates,&#148; &#147;believes,&#148; &#147;estimates,&#148; &#147;predicts,&#148; &#147;potential,&#148; or &#147;continue&#148; or the negative of these terms or other similar expressions. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Forward-looking statements are based on assumptions and assessments made in light of our experience and perception of historical trends,
current conditions, expected future developments and other factors believed to be appropriate. Forward-looking statements are not guarantees of future performance and are subject to risks and uncertainties, many of which are outside of our control.
You should not place undue reliance on these&nbsp;forward-looking&nbsp;statements, which reflect our view only as of the date of this prospectus, and we undertake no obligation to update these forward-looking statements in the future, except as
required by applicable law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A number of important factors could cause actual results to differ materially from those indicated by the
forward-looking statements, including, without limitation, those factors described under the heading &#147;Risk Factors&#148; in our Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2017, which is incorporated by reference in
this prospectus, and under similar headings in our subsequently filed quarterly reports on Form 10-Q and annual reports on Form 10-K, as well as the other risks and uncertainties described in any applicable prospectus supplement or free writing
prospectus and in the other documents incorporated by reference in this prospectus. Some of the key factors that could cause actual results to differ from our expectations include the following: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our operating losses incurred since inception and anticipated for the foreseeable future; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to maintain or increase sales of our products; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our products to produce the intended effects; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to develop and commercialize our hormone therapy drug product and drug candidates;
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to obtain additional financing necessary to complete the development and commercialization of our
hormone therapy drug product and drug candidates; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether the U.S. Food and Drug Administration, or FDA, will approve our new drug application, or NDA, for our
TX-001HR product candidate and whether such approval will occur by the Prescription Drug User Fee Act, or PDUFA, target action date; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our lack of experience in bringing a drug to regulatory approval; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the length, cost and uncertain results of our clinical trials; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">delays, suspensions, or discontinuation of our clinical trials; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the potential of adverse side effects or other safety risks that could preclude the approval of our hormone
therapy drug candidates; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our reliance on third parties to conduct our clinical trials, research and development; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effects of laws, regulations and enforcement; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our ability to gain and retain market acceptance for our hormone therapy drug product or drug candidates;
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the competitive nature of the industries in which we conduct our business; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the availability of reimbursement from government authorities and health insurance companies for our products;
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the impact of product liability lawsuits; </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">2 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the influence of extensive and costly government regulation; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the effect of governmental regulations on our business; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">whether we will be able to comply with the covenants and conditions under our credit agreement;
</P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the ability of our licensees to commercialize and distribute our hormone therapy drug product and drug
candidates; </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the volatility of the trading price of our common stock; and </P></TD></TR></TABLE>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="5%">&nbsp;</TD>
<TD WIDTH="2%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the concentration of power in our stock ownership. </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">3 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom368527_4"></A>OUR COMPANY </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a women&#146;s health care company focused on creating and commercializing products targeted exclusively for women. Currently, we are
focused on commercializing our recently FDA approved product, IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> (estradiol vaginal inserts) for the treatment of moderate-to-severe dyspareunia (vaginal pain associated with sexual
activity), a symptom of vulvar and vaginal atrophy, or VVA, due to menopause, and pursuing the regulatory approvals and precommercialization activities necessary for commercialization of <FONT STYLE="white-space:nowrap">TX-001HR,</FONT> our
bio-identical hormone therapy combination of 17&szlig;- estradiol and progesterone in a single, oral softgel drug candidate, for the treatment of moderate to severe vasomotor symptoms, or VMS, due to menopause in menopausal women with an intact
uterus. The new drug application, or NDA, for TX-001HR has a PDUFA target action date for the completion of the FDA&#146;s review of October 28, 2018. IMVEXXY<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP> and TX-001HR are designed to
alleviate the symptoms of and reduce the health risks resulting from menopause-related hormone deficiencies, including hot flashes, osteoporosis and vaginal discomfort. With our SYMBODA<SUP STYLE="font-size:85%; vertical-align:top">TM</SUP>
technology, we are developing advanced hormone therapy pharmaceutical products to enable delivery of bio-identical hormones through a variety of dosage forms and administration routes. In addition, we manufacture and distribute branded and generic
prescription prenatal vitamins. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a Nevada corporation. We maintain our principal executive offices at 6800 Broken Sound Parkway NW,
Third Floor, Boca Raton, Florida 33487. Our telephone number is (561) 961-1900. We maintain websites at <I>www.therapeuticsmd.com</I>, <I>www.vitamedmdrx.com</I> and <I>www.bocagreenmd.com</I>. The information contained on our websites or that can
be accessed through our websites does not constitute part of this prospectus supplement or the accompanying prospectus. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">4 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom368527_5"></A>RATIO OF EARNINGS TO FIXED CHARGES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our ratio of earnings to fixed charges for each of the five most recently completed fiscal years and any required interim periods will each be
specified in a prospectus supplement or in a document that we file with the SEC and incorporate by reference into this prospectus, pertaining to the issuance, if any, by us of debt securities in the future. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">5 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom368527_7"></A>USE OF PROCEEDS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as may be otherwise set forth in any prospectus supplement accompanying this prospectus, we will use the net proceeds we receive from
sales of securities offered hereby to fund the commercialization activities of our advanced hormone therapy pharmaceutical products for women and for general corporate purposes, which may include the repayment of indebtedness outstanding from time
to time and for working capital, capital expenditures, acquisitions and repurchases of our common stock or other securities. Pending these uses, the net proceeds may also be temporarily invested in cash equivalents or short-term securities. When
specific securities are offered, the prospectus supplement relating thereto will set forth our intended use of the net proceeds that we receive from the sale of such securities. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom368527_7a"></A>SELLING STOCKHOLDERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Selling stockholders are persons or entities that, directly or indirectly, have acquired or will from time to time acquire from us, our
securities. Such selling stockholders may be parties to registration rights agreements with us, or we otherwise may have agreed or will agree to register their securities for resale. The initial purchasers of our securities, as well as their
transferees, pledges, donees or successors, all of whom we refer to as &#147;selling stockholders,&#148; may from time to time offer and sell our securities pursuant to this prospectus and any applicable prospectus supplement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement will set forth the name of each of the selling stockholders and the number of securities beneficially
owned by such selling stockholder that are covered by such prospectus supplement. The applicable prospectus supplement will also disclose whether any of the selling stockholders has held any position or office with, has been employed by or otherwise
has had a material relationship with us during the three years prior to the date of the applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">7 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom368527_6"></A>DILUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will set forth in a prospectus supplement the following information regarding any material dilution of the equity interests of investors
purchasing securities in an offering under this prospectus: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the net tangible book value per share of our equity securities before and after the offering; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the amount of the increase in such net tangible book value per share attributable to the cash payments made by purchasers of the equity interests being offered; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the amount of the immediate dilution from the public offering price which will be absorbed by such purchasers.
</P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">8 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom368527_7"></A><A NAME="rom368527_8"></A>DESCRIPTION OF COMMON STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section describes the general terms of our common stock. A prospectus supplement may provide information that is different from this
prospectus. If the information in the prospectus supplement with respect to our common stock being offered differs from this prospectus, you should rely on the information in the prospectus supplement. A copy of our amended and restated articles of
incorporation, as amended, has been incorporated by reference from our filings with the SEC as an exhibit to the registration statement of which this prospectus forms a part. Our common stock and the rights of the holders of our common stock are
subject to the applicable provisions of the Nevada Private Corporation Code, which we refer to as &#147;Nevada law,&#148; our amended and restated articles of incorporation, as amended, our bylaws, as amended, and the rights of the holders of our
preferred stock, if any, as well as some of the terms of our outstanding indebtedness. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our amended and restated articles of
incorporation, as amended, we have the authority to issue 350,000,000 shares of common stock, par value $0.001 per share. As of June 30, 2018, there were 216,834,059 shares of our common stock outstanding. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description of our common stock, and any description of our common stock in a prospectus supplement, may not be complete and is
subject to, and qualified in its entirety by reference to, Nevada law and the actual terms and provisions contained in our amended and restated articles of incorporation and our bylaws, each as amended from time to time. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each outstanding share of
our common stock is entitled to one vote per share of record on all matters submitted to a vote of stockholders and to vote together as a single class for the election of directors and in respect of other corporate matters. At a meeting of
stockholders at which a quorum is present, for all matters other than the election of directors, an affirmative vote of the majority of shares entitled to vote on a matter and that are represented either in person or by proxy at a meeting of
stockholders decides all questions, unless the matter is one upon which a different vote is required by express provision of law or our amended and restated articles incorporation or our bylaws, each as may be amended from time to time. Directors
will be elected by a plurality of the votes of the shares present at a meeting. Holders of shares of common stock do not have cumulative voting rights with respect to the election of directors or any other matter. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of our common stock
are entitled to receive dividends or other distributions when, as and if declared by our board of directors. The right of our board of directors to declare dividends, however, is subject to any rights of the holders of other classes of our capital
stock, any indebtedness outstanding from time to time and the availability of sufficient funds, as determined under Nevada law, to pay dividends. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Preemptive Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The holders of our
common stock do not have preemptive rights to purchase or subscribe for any of our capital stock or other securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Redemption </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Shares of our common stock are not subject to redemption by operation of a sinking fund or otherwise. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidation Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In the event of any
liquidation, dissolution, or winding up of our company, subject to the rights, if any, of the holders of other classes of our capital stock, the holders of shares of our common stock are entitled to receive any of our assets available for
distribution to our stockholders ratably in proportion to the number of shares held by them. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">9 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Options and Other Stock-Based Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">From time to time, we have issued and expect to continue to issue options and other stock-based rights to various lenders, investors,
consultants, employees, officers and directors of our company. As of June 30, 2018, we had outstanding (i)&nbsp;stock options to purchase 25,210,899 shares of our common stock, of which 20,565,025 shares of common stock were issuable upon exercise
of vested stock options as of that date, and (ii)&nbsp;warrants for the purchase of 3,007,571 shares of our common stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Listing </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our common stock is listed on the Nasdaq Global Select Market of the Nasdaq Stock Market LLC under the symbol &#147;TXMD.&#148; </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Transfer Agent and Registrar </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
transfer agent and registrar for our common stock is Computershare Trust Company, N.A., 350 Indiana Street, Suite 800, Golden, Colorado 80401. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">10 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom368527_9"></A>DESCRIPTION OF PREFERRED STOCK </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This section describes the general terms of our preferred stock to which any prospectus supplement may relate. A prospectus supplement will
describe the terms relating to any preferred stock to be offered by us in greater detail and may provide information that is different from terms described in this prospectus. If the information in the prospectus supplement with respect to the
particular preferred stock being offered differs from this prospectus, you should rely on the information in the prospectus supplement. A copy of our amended and restated articles of incorporation, as amended, has been incorporated by reference from
our filings with the SEC as an exhibit to the registration statement of which this prospectus forms a part. A certificate of designation or amendment to the amended and restated articles of incorporation, as amended, will specify the terms of the
preferred stock being offered, and will be filed or incorporated by reference as an exhibit to the registration statement before the preferred stock is issued. The following description of our preferred stock, and any description of the preferred
stock in a prospectus supplement may not be complete and is subject to, and qualified in its entirety by reference to, Nevada law and the actual terms and provisions contained in our amended and restated articles of incorporation, as amended, and
bylaws, each as amended from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Under our amended and restated articles of incorporation, as amended, we have the authority to
issue 10,000,000 shares of preferred stock, par value $0.001 per share, which are issuable in series on terms to be determined by our board of directors. Accordingly, our board of directors is authorized, without action by the stockholders, to issue
preferred stock from time to time with such dividend, liquidation, conversion, voting, redemption, sinking fund and other rights, preferences, privileges and restrictions as it may determine. All shares of any one series of our preferred stock will
be identical, except that shares of any one series issued at different times may differ as to the dates from which dividends may be cumulative. All series will rank equally and will provide for other terms as described in the applicable prospectus
supplement. As of the date of this prospectus, there were no outstanding shares of our preferred stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Terms of Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless provided in a prospectus supplement, the shares of our preferred stock to be issued will have no preemptive rights. Any prospectus
supplement offering our preferred stock will furnish the following information with respect to the preferred stock offered by that prospectus supplement: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the title and stated value of the preferred stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the number of shares of preferred stock to be issued and the offering price of the preferred stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any dividend rights; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any dividend rates, periods, or payment dates, or methods of calculating dividends applicable to the preferred stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the date from which distributions on the preferred stock will accumulate, if applicable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms and conditions, if applicable, upon which the preferred stock will be convertible into our common stock, including the conversion price (or manner of calculation thereof); </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any right to convert the preferred stock into a different type of security; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any voting rights attributable to the preferred stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any rights and preferences upon our liquidation, dissolution, or winding up of our affairs; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any terms of redemption; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any procedures for any auction and remarketing for the preferred stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any provisions for a sinking fund for the preferred stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any listing of the preferred stock on any securities exchange; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">11 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a discussion of material U.S. federal income tax considerations applicable to the preferred stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the relative ranking and preferences of the preferred stock as to distribution rights (including whether any liquidation preference as to the preferred stock will be treated as a liability for purposes of determining
the availability of assets for distributions to holders of stock ranking junior to the shares of preferred stock as to distribution rights); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any limitations on issuance of any series of preferred stock ranking senior to or on a parity with the series of preferred stock being offered as to distribution rights and rights upon the liquidation, dissolution, or
winding up or our affairs; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other specific terms, preferences, rights, limitations, or restrictions of the preferred stock. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Rank
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in the applicable prospectus supplement, shares of our preferred stock will rank, with respect to payment
of distributions and rights upon our liquidation, dissolution, or winding up, and allocation of our earnings and losses as follows: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">senior to all classes or series of our common stock and to all of our equity securities ranking junior to the preferred stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">on a parity with all equity securities issued by us, the terms of which specifically provide that such equity securities rank on a parity with the preferred stock; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">junior to all equity securities issued by us, the terms of which specifically provide that such equity securities rank senior to the preferred stock. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Distributions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Subject to any
preferential rights of any outstanding stock or series of stock, our preferred stockholders will be entitled to receive distributions, in accordance with the applicable terms of each series of preferred stock, when, as, and if declared by our board
of directors, out of legally available funds, and to share pro rata based on the number of preferred shares, common stock, and other parity equity securities outstanding. The rates and dates of payment of dividends, if any, will be set forth in the
prospectus supplement relating to the applicable series of preferred stock. Dividends, if any, will be payable to holders of record of preferred stock as they appear on our books or, if applicable, the records of the depositary, if any, referred to
below on the record dates fixed by our board of directors. Dividends on a series of preferred stock may be cumulative or noncumulative. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may not declare, pay, or set apart for payment dividends on the preferred stock unless full dividends on other series of preferred stock
that rank on an equal or senior basis have been paid or sufficient funds have been set apart for payment for: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all prior dividend periods of other series of preferred stock that pay dividends on a cumulative basis; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the immediately preceding dividend period of other series of preferred stock that pay dividends on a noncumulative basis. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Partial dividends declared on shares of preferred stock and each other series of preferred stock ranking on an equal basis as to dividends
will be declared pro rata. A pro rata declaration means that the ratio of dividends declared per share to accrued dividends per share will be the same for each series of preferred stock. Similarly, we may not declare, pay, or set apart for payment
non-stock dividends or make other payments on the common stock or any other of our stock ranking junior to the preferred stock until full dividends on the preferred stock have been paid or set apart for payment for: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">all prior dividend periods if the preferred stock pays dividends on a cumulative basis; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the immediately preceding dividend period if the preferred stock pays dividends on a noncumulative basis. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">12 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in the applicable prospectus supplement, or as required by Nevada law, holders of our preferred stock will not have
any voting rights. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidation Preference </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon the voluntary or involuntary liquidation, dissolution, or winding up of our affairs, then, before any distribution or payment will be made
to the holders of any common stock or any other class or series of stock ranking junior to the preferred stock in our distribution of assets upon any liquidation, dissolution, or winding up, the holders of each series of our preferred stock will be
entitled to receive, after payment or provision for payment of our debts and other liabilities, out of our assets legally available for distribution to stockholders, liquidating distributions in the amount of the liquidation preference per share
(set forth in the applicable prospectus supplement), plus an amount, if applicable, equal to all distributions accrued and unpaid thereon (which will not include any accumulation in respect of unpaid distributions for prior distribution periods if
the preferred stock is not entitled to a cumulative distribution). Unless otherwise specified in the applicable prospectus supplement, after payment of the full amount of the liquidating distributions to which they are entitled, the holders of
preferred stock will have no right or claim to any of our remaining assets. In the event that, upon our voluntary or involuntary liquidation, dissolution, or winding up, the legally available assets are insufficient to pay the amount of the
liquidating distributions on all of our outstanding preferred stock and the corresponding amounts payable on all of our other classes or series of equity securities ranking on a parity with the preferred stock in the distribution of assets upon
liquidation, dissolution, or winding up, then the holders of our preferred stock and all other such classes or series of equity securities will share ratably in the distribution of assets in proportion to the full liquidating distributions to which
they would otherwise be respectively entitled. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the liquidating distributions are made in full to all holders of preferred stock, our
remaining assets will be distributed among the holders of any other classes or series of equity securities ranking junior to the preferred stock upon our liquidation, dissolution, or winding up, according to their respective rights and preferences
and in each case according to their respective number of shares of stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conversion Rights </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms and conditions, if any, upon which shares of any series of preferred stock are to be convertible into other securities will be set
forth in the applicable prospectus supplement. These terms will include the amount and type of security into which the shares of preferred stock are convertible, the conversion price (or manner of calculation thereof), the conversion period,
provisions as to whether conversion will be at the option of the holders of the preferred stock or us, the events requiring an adjustment of the conversion price, and provisions affecting conversion in the event of the redemption of that preferred
stock. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Redemption </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If so provided in
the applicable prospectus supplement, our preferred stock will be subject to mandatory redemption or redemption at our option, in whole or in part, in each case upon the terms, at the times and at the redemption prices set forth in such prospectus
supplement. Unless we default in the payment of the redemption price, dividends will cease to accrue after the redemption date on shares of preferred stock called for redemption and all rights of holders of such shares will terminate, except for the
right to receive the redemption price. No series of preferred stock will receive the benefit of a sinking fund except as set forth in the applicable prospectus supplement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Registrar and Transfer Agent </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
registrar and transfer agent for our preferred stock will be set forth in the applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">13 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If our board of directors decides to issue any shares of preferred stock, it may discourage
or make more difficult a merger, tender offer, business combination or proxy contest, assumption of control by a holder of a large block of our securities, or the removal of incumbent management, even if these events were favorable to the interests
of stockholders. Our board of directors, without stockholder approval, may issue preferred stock with voting and conversion rights and dividend and liquidation preferences that may adversely affect the holders of our other equity or debt securities.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">14 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom368527_10"></A>DESCRIPTION OF DEBT SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus describes certain general terms and provisions of the debt securities that we may offer under this prospectus and one or more
prospectus supplements. When we offer to sell a particular series of debt securities, we will describe the specific terms of the series in a prospectus supplement. The following description of debt securities will apply to the debt securities
offered by this prospectus unless we provide otherwise in the applicable prospectus supplement. The applicable prospectus supplement for a particular series of debt securities may specify different or additional terms. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue &#147;senior,&#148; &#147;senior subordinated,&#148; or &#147;subordinated&#148; debt securities. &#147;Senior securities&#148;
will be direct obligations of ours and will rank equally and ratably in right of payment with other indebtedness of ours that is not subordinated. &#147;Senior subordinated securities&#148; will be subordinated in right of payment to the prior
payment in full of senior indebtedness, as defined in the applicable prospectus supplement, and may rank equally and ratably with any other senior subordinated indebtedness. &#147;Subordinated securities&#148; will be subordinated in right of
payment to senior subordinated securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We need not issue all debt securities of one series at the same time. Unless we provide
otherwise, we may reopen a series, without the consent of the holders of such series, for issuances of additional securities of that series. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will issue the senior debt securities and senior subordinated debt securities under a senior indenture, which we will enter into with a
trustee to be named in the senior indenture, and we will issue the subordinated debt securities under a subordinated indenture, which we will enter into with a trustee to be named in the subordinated indenture. We use the term &#147;indenture&#148;
or &#147;indentures&#148; to refer to both the senior indenture and the subordinated indenture. Each indenture will be subject to and governed by the Trust Indenture Act of 1939, as amended, or the Trust Indenture Act, and we may supplement the
indenture from time to time. Any trustee under any indenture may resign or be removed with respect to one or more series of debt securities, and we may appoint a successor trustee to act with respect to that series. We have filed a form of indenture
as an exhibit to this registration statement, of which this prospectus forms a part. The terms of the senior indenture and subordinated indenture will be substantially similar, except that the subordinated indenture will include provisions
pertaining to the subordination of the subordinated debt securities and senior subordinated debt securities to the senior debt securities and any other of our senior securities. The following statements relating to the debt securities and the
indenture are summaries only, are subject to change, and are qualified in their entirety to the detailed provisions of the indenture, any supplemental indenture, and the discussion contained in any prospectus supplements. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The debt securities will be our
direct obligations. We may issue debt securities from time to time and in one or more series as our board of directors may establish by resolution or as we may establish in one or more supplemental indentures. The particular terms of each series of
debt securities will be described in a prospectus supplement relating to the series. We may issue debt securities with terms different from those of debt securities that we previously issued. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue debt securities from time to time and in one or more series with the same or various maturities, at par, at a premium, or at a
discount. We will set forth in a prospectus supplement, relating to any series of debt securities being offered, the initial offering price, and the following terms of the debt securities: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the title of the debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the series designation and whether they are senior securities, senior subordinated securities, or subordinated securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the aggregate principal amount of the debt securities and any limit on the aggregate amount of the series of debt securities; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">15 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the price or prices (expressed as a percentage of the aggregate principal amount) at which we will issue the debt securities and, if other than the principal amount of the debt securities, the portion of the principal
amount of the debt securities payable upon the maturity of the debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the date or dates on which we will pay the principal on the debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the rate or rates (which may be fixed or variable) or the method used to determine the rate or rates (including any commodity, commodity index, stock exchange index, or financial index) at which the debt securities will
bear interest, the date or dates from which interest will accrue, the date or dates on which interest will commence and be payable, and any regular record date for the interest payable on any interest payment date; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the place or places where principal, premium, if any, and any interest will be payable or the method of such payment and where the debt securities can be surrendered for transfer, exchange, or conversion;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms, if any, by which holders of the debt securities may convert or exchange the debt securities for our common stock, preferred stock, or any other security or property; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if convertible, the initial conversion price, the conversion period, and any other terms governing such conversion; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any subordination provisions or limitations relating to the debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any sinking fund requirements; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any obligation we have to redeem, purchase or repay the debt securities pursuant to any sinking fund or analogous provisions or at the option of a holder of debt securities and the price or prices at which and the
period and periods within which and the terms and conditions upon which debt securities of the series shall be redeemed, purchased, or repaid pursuant to such obligation; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the dates on which and the price or prices at which we will repurchase the debt securities at the option of the holders of debt securities and other detailed terms and provisions of these repurchase obligations;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the denominations in which the debt securities will be issued, if other than denominations of $1,000 and any integral multiple thereof; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the portion of principal amount of the debt securities payable upon declaration of acceleration of the maturity date, if other than the principal amount; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether we will issue the debt securities in certificated or book-entry form; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the price or prices at which (if any), the period or periods within which (if any), and the terms and conditions upon which (if other than as provided herein) the debt securities may be redeemed, in whole or in part, at
the option, or as an obligation, of the Company; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the debt securities shall be issued in whole or in part in the form of a global security or securities; the terms and conditions, if any, upon which such global security or securities may be exchanged in whole
or in part for other individual debt securities, and the depositary for such global security and securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the debt securities will be in registered or bearer form and, if in registered form, whether the securities will be issuable, in whole or in part, in the form of a global security; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the currency of denomination of the debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the designation of the currency, currencies, or currency units in which payment of principal of, premium, and interest on the debt securities will be made; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">if payments of principal of, and interest and any additional amounts on the debt securities will be made in one
or more currencies or currency units other than that or those in which the debt securities are </P></TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">16 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="8%">&nbsp;</TD>
<TD VALIGN="top"> <P STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">
denominated, the manner in which the exchange rate with respect to these payments will be determined; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the manner in which the amounts of payment of principal of, premium or interest on the debt securities will be determined, if these amounts may be determined by reference to an index based on a currency or currencies
other than that in which the debt securities are denominated or designated to be payable or by reference to a commodity, commodity index, stock exchange index, or financial index; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any applicability of the defeasance provisions described in this prospectus or any prospectus supplement; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the trustee for the debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether and under what circumstances, if any, we will pay additional amounts on any debt securities in respect of any tax, assessment, or governmental charge and, if so, whether we will have the option to redeem the
debt securities instead of making this payment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any addition to or change in the events of default described in this prospectus or in the indenture with respect to the debt securities and any change in the acceleration provisions described in this prospectus or in
the indenture with respect to the debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any addition to or change in the covenants described in this prospectus or in the indenture with respect to the debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if the debt securities are to be issued upon the exercise of debt warrants, the time, manner, and place for them to be authenticated and delivered; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any securities exchange on which we will list the debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any restrictions on transfer, sale, or other assignment; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any provisions relating to any security provided for the debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any provisions relating to any guarantee of the debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other terms of the debt securities, which may modify or delete any provision of the indenture as it applies to that series; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any depositaries, interest rate calculation agents, exchange rate calculation agents, or other agents with respect to the debt securities. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue debt securities that are exchangeable for or convertible into shares of our common stock or other securities or property. The
terms, if any, on which the debt securities may be exchanged for or converted into shares of our common stock or other securities or property will be set forth in the applicable prospectus supplement. Such terms may include provisions for
conversion, either mandatory, at the option of the holder or at our option, in which case the number of shares of common stock or other securities or property to be received by the holders of debt securities would be calculated as of a time and in
the manner stated in the prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue debt securities at less than the principal amount payable upon maturity. We
refer to these securities as &#147;original issue discount securities.&#148; If material or applicable, we will describe in the applicable prospectus supplement special U.S. federal income tax, accounting, and other considerations applicable to
original issue discount securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we denominate the purchase price of any of the debt securities in a foreign currency or currencies
or a foreign currency unit or units, or if the principal of and interest and any additional amounts on any series of debt securities is payable in a foreign currency or currencies or a foreign currency unit or units, we will describe the
restrictions, elections, general tax considerations, specific terms, and provide other information with respect to that issue of debt securities and such foreign currency or currencies or foreign currency unit or units in the applicable prospectus
supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">17 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as may be set forth in any prospectus supplement relating to the debt securities, no
indenture will contain any other provisions that would limit our ability to incur indebtedness or that would afford holders of the debt securities protection in the event of a highly leveraged or similar transaction involving us or in the event of a
change in control. You should review carefully the applicable prospectus supplement for information with respect to events of default and any covenants applicable to the debt securities being offered. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Payments and Paying Agents </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we
otherwise indicate in the applicable prospectus supplement, we will make payment of the interest on any debt securities on any interest payment date to the person in whose name the debt securities, or one or more predecessor securities, are
registered at the close of business on the regular record date for the interest. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay principal of, and interest and any
additional amounts on, the debt securities of a particular series at the office of the paying agents designated by us, except that, unless we otherwise indicate in the applicable prospectus supplement, we may make interest payments by check, which
we will mail to the holder, or by wire transfer to certain holders. Unless we otherwise indicate in a prospectus supplement, we will designate the corporate trust office of the trustee as our sole paying agent for payments with respect to debt
securities of each series. We will name in the applicable prospectus supplement any other paying agents that we initially designate for the debt securities of a particular series.</P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form, Transfer, and Exchange </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each debt
security will be represented by either one or more global securities registered in the name of The Depository Trust Company, as depositary, or a nominee of the depositary (as a &#147;book-entry debt security&#148;), or a certificate issued in
definitive registered form (as a &#147;certificated debt security&#148;), as described in the applicable prospectus supplement. Except as described under &#147;Global Debt Securities and Book-Entry System&#148; below, book-entry debt securities will
not be issuable in certificated form. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Certificated Debt Securities </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of our debt securities may transfer or exchange certificated debt securities at the trustee&#146;s office or paying agencies in
accordance with the terms of the indenture. No service charge will be made for any transfer or exchange of certificated debt securities, but we may require payment of a sum sufficient to cover any tax or other governmental charge payable in
connection with a transfer or exchange. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of our debt securities may transfer certificated debt securities and the right to
receive the principal of, and interest and any additional amounts on, certificated debt securities only by surrendering the old certificate representing those certificated debt securities and either we or the trustee will reissue the old certificate
to the new holder, or we or the trustee will issue a new certificate to the new holder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Global Debt Securities and Book-Entry System
</I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each global debt security representing book-entry debt securities will be deposited with, or on behalf of, the depositary, and
registered in the name of the depositary or a nominee of the depositary. Ownership of beneficial interests in book-entry debt securities will be limited to persons that have accounts with the depositary for the related global debt security, whom we
refer to as participants, or persons that may hold interests through participants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as described in this prospectus or any
applicable prospectus supplement, beneficial owners of <FONT STYLE="white-space:nowrap">book-entry</FONT> debt securities will not be entitled to have securities registered in their names, will not receive or be entitled to receive physical delivery
of a certificate in definitive form representing securities, and will not be considered the owners or holders of those securities under the indenture. Accordingly, to exercise any rights of a holder under the indenture, each person beneficially
owning book-entry debt securities must rely on the procedures of the depositary for the related global debt security and, if that person is not a participant, on the procedures of the participant through which that person owns its interest. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">18 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We understand, however, that under existing industry practice, the depositary will authorize
the persons on whose behalf it holds a global debt security to exercise certain rights of holders of debt securities, and the indenture provides that we, the trustee, and our respective agents will treat as the holder of a debt security the persons
specified in a written statement of the depositary with respect to that global debt security for purposes of obtaining any consents or directions required to be given by holders of the debt securities pursuant to the indenture. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will make payments of principal of, and interest and any additional amounts on, book-entry debt securities to the depositary or its
nominee, as the case may be, as the registered holder of the related global debt security. We, the trustee, and any other agent of ours or agent of the trustee will not have any responsibility or liability for any aspect of the records relating to
or payments made on account of beneficial ownership interests in a global debt security or for maintaining, supervising, or reviewing any records relating to such beneficial ownership interests. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Any certificated debt securities issued in exchange for a global debt security will be registered in such name or names as the depositary
shall instruct the trustee. We expect that such instructions will be based upon directions received by the depositary from participants with respect to ownership of book-entry debt securities relating to such global debt security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For additional discussion of book entry and certificated securities, see the section entitled &#147;Legal Ownership of Securities&#148;
included in this prospectus. We have obtained the foregoing information in this section and the &#147;Legal Ownership of Securities&#148; section concerning the depositary and the depositary&#146;s book-entry system from sources we believe to be
reliable. We take no responsibility for the depositary&#146;s performance of its obligations under the rules and regulations governing its operations. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>No Protection in the Event of a Change in Control </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the applicable prospectus supplement, the debt securities will not contain any provisions that may afford
holders of the debt securities protection in the event we have a change in control or in the event of a highly leveraged transaction (whether or not such transaction results in a change in control). </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Covenants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in
the applicable prospectus supplement, the debt securities will not contain any restrictive covenants, including covenants restricting us or any of our subsidiaries from incurring, issuing, assuming, or guaranteeing any indebtedness secured by a lien
on any of our or our subsidiaries&#146; property or capital stock or restricting us or any of our subsidiaries from entering into any sale and leaseback transactions. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Merger, Consolidation, and Sale of Assets </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the applicable prospectus supplement, we may not merge with or into or consolidate with, or convey, transfer, or
lease all or substantially all of our properties and assets to, any person (a &#147;successor person&#148;), unless the following applies: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">either (a)&nbsp;the company is the surviving entity or (b)&nbsp;the successor person is a corporation, partnership, trust, or other entity organized and validly existing under the laws of any U.S. domestic jurisdiction
and expressly assumes our obligations on the debt securities and under the indenture; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">immediately after giving effect to the transaction, no event of default, and no event that, after notice or lapse of time, or both, would become an event of default, will have occurred and be continuing under the
indenture; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">certain other conditions that may be set forth in the applicable prospectus supplement are met. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">19 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This covenant would not apply to any recapitalization transaction, a change in control of
us, or a transaction in which we incur a large amount of additional debt unless the transactions or change in control included a merger, consolidation, or transfer or lease of substantially all of our assets. Except as may be described in the
applicable prospectus supplement, there are no covenants or other provisions in the indenture providing for a &#147;put&#148; right or increased interest or that would otherwise afford holders of debt securities additional protection in the event of
a recapitalization transaction, a change in control of us, or a transaction in which we incur a large amount of additional debt. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Events of Default
Under the Indenture </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the applicable prospectus supplement, an &#147;event of default&#148; will mean,
with respect to any series of debt securities, any of the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">default in the payment of any interest upon any debt security of that series when it becomes due and payable and continuance of that default for a period of 30 days (unless the entire amount of such payment is deposited
by us with the trustee or with a paying agent before the expiration of the 30-day period); </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">default in the payment of principal of, and any other amounts due on, any debt security of that series when due and payable either at maturity, redemption, or otherwise; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">default in the deposit of any sinking fund payment, when and as due in respect of any debt security of that series; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">default in the performance or breach of any other covenant or warranty by us in the indenture (other than a covenant or warranty that has been included in the indenture solely for the benefit of a series of debt
securities other than that series) or in the debt security, which default continues uncured for a period of 60 days after we receive written notice from the trustee or we and the trustee receive written notice from the holders of not less than a
majority in principal amount of the outstanding debt securities of that series as provided in the indenture; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we, pursuant to or within the meaning of any applicable bankruptcy law, commence a voluntary case, consent to the entry of an order for relief against us in an involuntary case, consent to the appointment of a custodian
for all or substantially all of our property, make a general assignment for the benefit of our creditors, or admit in writing our inability generally to pay our debts as they become due; or, similarly, a court enters an order or decree under any
applicable bankruptcy law that provides for relief against us in an involuntary case, appoints a custodian for all or substantially all of our properties, or orders our liquidation (and the order remains in effect for 60 days); and
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other event of default provided with respect to debt securities of that series that is included in any supplemental indenture or is described in the applicable prospectus supplement accompanying this prospectus.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">No event of default with respect to a particular series of debt securities (except as to certain events of bankruptcy,
insolvency, or reorganization) necessarily will constitute an event of default with respect to any other series of debt securities. An event of default may also be an event of default under our bank credit agreements or other debt securities in
existence from time to time and under certain guaranties by us of any subsidiary indebtedness. In addition, certain events of default or an acceleration under the indenture may also be an event of default under some of our other indebtedness
outstanding from time to time. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the applicable prospectus supplement, if an event of default with respect
to debt securities of any series at the time outstanding occurs and is continuing (other than certain events of our bankruptcy, insolvency, or reorganization), then the trustee or the holders of not less than a majority in principal amount of the
outstanding debt securities of that series may, by written notice to us (and to the trustee if given by the holders), declare to be due and payable immediately the principal (or, if the debt securities of that series are
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">20 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
discount securities, that portion of the principal amount as may be specified in the terms of that series) of and accrued and unpaid interest, if any, of all debt securities of that series. In
the case of an event of default resulting from certain events of bankruptcy, insolvency, or reorganization, the principal (or such specified amount) of and accrued and unpaid interest, if any, of all outstanding debt securities will become and be
immediately due and payable without any declaration or other act by the trustee or any holder of outstanding debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">At any time
after an acceleration with respect to debt securities of a series has been made, but before a judgment or decree for payment of the money due has been obtained by the trustee, the holders of not less than a majority in principal amount of the
outstanding debt securities of that series may cancel the acceleration and annul its consequences if the rescission would not conflict with any judgment or decree and if all existing events of default with respect to that series have been cured or
waived except nonpayment of principal (or such lesser amount) or interest that has become due solely because of the acceleration. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
indenture also provides that the holders of not less than a majority in principal amount of the outstanding debt securities of any series may waive any past default with respect to that series and its consequences, except a default involving the
following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">our failure to pay the principal of, and interest and any additional amounts on, any debt security; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">a covenant or provision contained in the indenture that cannot be modified or amended without the consent of the holders of each outstanding debt security affected by the default. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The trustee is generally required to give notice to the holders of debt securities of each affected series within 90 days of a default
actually known to a responsible officer of the trustee unless the default has been cured or waived. The indenture provides that the trustee may withhold notice to the holders of debt securities of any series of any default or event of default
(except in payment on any debt securities of that series) with respect to debt securities of that series if it in good faith determines that withholding notice is in the interest of the holders of those debt securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the applicable prospectus supplement, the indenture will provide that the trustee will be under no obligation
to exercise any of its rights or powers under the indenture at the request or discretion of any holder of any such outstanding debt securities unless the trustee receives indemnity satisfactory to it against any loss, liability, or expense. Subject
to certain rights of the trustee, the holders of a majority in principal amount of the outstanding debt securities of any series will have the right to direct the time, method, and place of conducting any proceeding for any remedy available to the
trustee or exercising any trust or power conferred on the trustee with respect to the debt securities of that series. The trustee may, however, refuse to follow any discretion that conflicts with the indenture or any law or which may be unduly
prejudicial to the holders of the debt securities of the applicable series not joining in the discretion. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in
the applicable prospectus supplement, no holder of any debt security of any series will have any right to institute any proceeding, judicial or otherwise, with respect to the indenture or for the appointment of a receiver or trustee, or for any
remedy under the indenture, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">that holder has previously given to the trustee written notice of a continuing event of default with respect to debt securities of that series; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the holders of at least 25% in principal amount of the outstanding debt securities of that series have made written request, and offered reasonable indemnity, to the trustee to institute such proceeding as trustee, and
the trustee will not have received from the holders of a majority in principal amount of the outstanding debt securities of that series a direction inconsistent with that request and has failed to institute the proceeding within 60 days.
</TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, except as provided in the subordination provisions, if any, the holder of any debt security
will have an absolute and unconditional right to receive payment of the principal of, and any interest or additional amounts on, that debt security on or after the due dates expressed in that debt security and to institute suit for the enforcement
of payment. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">21 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indenture requires us, within 120 days after the end of our fiscal year, to furnish to
the trustee a certificate as to compliance with the indenture, or, in the event of noncompliance, specify the noncompliance and the nature and status of the noncompliance. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Modification of Indenture and Waiver </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as specified below, modifications and amendments to the indenture require the approval of not less than a majority in principal amount
of our outstanding debt securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Changes Requiring the Unanimous Approval </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the trustee may not make any modification or amendment to the indenture without the consent of the holder of each affected debt security
then outstanding if that amendment will have any of the following results: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduce the rate of or extend the time for payment of interest on any debt security; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduce the principal of or change the fixed maturity of any debt security or waive a redemption payment or alter the redemption provisions on any debt security; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduce the amount of, or postpone the date fixed for, the payment of any sinking fund or analogous obligation with respect to any series of debt securities; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduce the principal amount of discount securities payable upon acceleration of maturity; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">waive a default in the payment of the principal, interest, or any additional amounts on any debt security, except a rescission of acceleration of the debt securities of any series by the holders of at least a majority
in aggregate principal amount of the then outstanding debt securities of that series and a waiver of the payment default that resulted from that acceleration; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">make the principal of, or interest or any additional amounts on, any debt security payable in currency other than that stated in the debt security; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">change the place of payment on a debt security; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">change the currency or currencies of payment of the principal of, and any premium, make-whole payment, interest, or additional amounts on, any debt security; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">impair the right to initiate suit for the enforcement of any payment on or with respect to any debt security; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduce the percentage of holders of debt securities whose consent is needed to modify or amend an indenture; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">reduce the percentage of the holders of outstanding debt securities of any series necessary to modify or amend the indenture, to waive compliance with provisions of the indenture or defaults and their consequences under
the indenture, or to reduce the quorum or voting requirements contained in the indenture; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">make any change that adversely affects the right to convert or exchange any debt security other than as permitted by the indenture or decrease the conversion or exchange rate or increase the conversion or exchange price
of any such debt security; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">waive a redemption payment with respect to any debt security; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">make any change to certain provisions of the indenture relating to, among other things, the right of holders of debt securities to receive payment of the principal of, and interest and any additional amount on, those
debt securities, the right of holders to institute suit for the enforcement of any payment or the right of holders to waive past defaults. </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">22 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Changes Not Requiring Approval of Debt Holders </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and the trustee may modify or amend an indenture, without the consent of any holder of debt securities, for any of the following purposes:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to evidence the succession of another person to us as obligor under the indenture; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to add to our existing covenants additional covenants for the benefit of the holders of all or any series of debt securities, or to surrender any right or power conferred upon us in the indenture; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to add events of default for the benefit of the holders of all or any series of debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to add or change any provisions of the indenture to facilitate the issuance of, or to liberalize the terms of, debt securities in bearer form, or to permit or facilitate the issuance of debt securities in uncertificated
form, provided that this action will not adversely affect the interests of the holders of the debt securities of any series in any material respect; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to add, change, or eliminate any provisions of the indenture, provided that any addition, change, or elimination (a)&nbsp;shall neither (i)&nbsp;apply to any debt security of any series created prior to the execution of
such supplemental indenture and entitled to the benefit of such provision nor (ii)&nbsp;modify the rights of the holder of any debt security with respect to such provision, or (b) shall become effective only when there are no outstanding debt
securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to establish additional series of debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to secure previously unsecured debt securities; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to establish the form or terms of debt securities of any series, including the provisions and procedures, if applicable, for the conversion or exchange of the debt securities into our common stock, preferred stock, or
other securities or property; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to evidence and provide for the acceptance or appointment of a successor trustee or facilitate the administration of the trusts under the indenture by more than one trustee; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to make any provision with respect to the conversion or exchange of rights of holders pursuant to the requirements of the indenture; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to cure any ambiguity, defect, or inconsistency in the indenture, provided that the action does not adversely affect the interests of holders of debt securities of any series issued under the indenture;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to close the indenture with respect to the authentication and delivery of additional series of debt securities or to qualify, or maintain qualification of, the indenture under the Trust Indenture Act; or
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to supplement any of the provisions of the indenture to the extent necessary to permit or facilitate defeasance and discharge of any series of debt securities, provided that the action shall not adversely affect the
interests of the holders of the debt securities of any series in any material respect. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A vote by holders of debt securities
will not be required for clarifications and certain other changes that would not adversely affect holders of the debt securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Defeasance of Debt
Securities and Certain Covenants in Certain Circumstances </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Legal Defeasance </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the terms of the applicable series of debt securities provide otherwise, we may be discharged from any and all obligations in respect of
the debt securities of any series (except for certain obligations to register the transfer or exchange of debt securities of the series; to replace stolen, lost, or mutilated debt securities of the series; and to maintain paying agencies and certain
provisions relating to the treatment of funds held by paying agents). We will be so discharged upon the deposit with the trustee, in trust, of money and/or U.S. government obligations or, in the case of debt securities denominated in a single
currency other than U.S. dollars, foreign </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">23 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
government obligations (as described at the end of this section), that, through the payment of interest and principal in accordance with their terms, will provide money in an amount sufficient to
pay and discharge each installment of principal, interest, and any additional amounts on and any mandatory sinking fund payments in respect of the debt securities of that series on the stated maturity of such payments in accordance with the terms of
the indenture and those debt securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This discharge may occur only if, among other things, we have delivered to the trustee an
officers&#146; certificate and an opinion of counsel stating that we have received from, or there has been published by, the U.S.&nbsp;Internal Revenue Service a ruling or, since the date of execution of the indenture, there has been a change in the
applicable U.S. federal income tax law, in either case to the effect that holders of the debt securities of such series will not recognize income, gain, or loss for U.S. federal income tax purposes as a result of the deposit, defeasance, and
discharge and will be subject to U.S. federal income tax on the same amount and in the same manner and at the same times as would have been the case if the deposit, defeasance, and discharge had not occurred. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Defeasance of Certain Covenants </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the terms of the applicable series of debt securities provide otherwise, upon compliance with certain conditions, we may omit to comply
with the restrictive covenants contained in the indenture (except for certain obligations to maintain paying agencies and certain provisions relating to the treatment of funds held by paying agents), as well as any additional covenants contained in
the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The conditions include, among others, the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">depositing with the trustee money and/or U.S. government obligations or, in the case of debt securities denominated in a single currency other than U.S. dollars, foreign government obligations, that, through the payment
of interest and principal in accordance with their terms, will provide money in an amount sufficient, in the opinion of a nationally recognized firm of independent public accountants, to pay principal, interest, and any additional amounts on and any
mandatory sinking fund payments in respect of the debt securities of that series on the stated maturity of those payments in accordance with the terms of the indenture and those debt securities; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">delivering to the trustee an opinion of counsel to the effect that the holders of the debt securities of that series will not recognize income, gain, or loss for U.S. federal income tax purposes as a result of the
deposit and related covenant defeasance and will be subject to U.S. federal income tax in the same amount and in the same manner and at the same times as would have been the case if the deposit and related covenant defeasance had not occurred.
</TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; margin-left:4%; font-size:10pt; font-family:Times New Roman"><I>Covenant Defeasance and Events of Default </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If we exercise our option, as described above, not to comply with certain covenants of the indenture with respect to any series of debt
securities, and the debt securities of that series are declared due and payable because of the occurrence of any event of default, the amount of money and/or U.S. government obligations or foreign government obligations on deposit with the trustee
will be sufficient to pay amounts due on the debt securities of that series at the time of their stated maturity but may not be sufficient to pay amounts due on the debt securities of that series at the time of the acceleration resulting from the
event of default. However, we will remain liable for those payments. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">&#147;Foreign government obligations&#148; means, with respect to
debt securities of any series that are denominated in a currency other than U.S. dollars: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">direct obligations of the government that issued or caused to be issued such currency for the payment of which obligations its full faith and credit is pledged, which are not callable or redeemable at the option of the
issuer thereof; or </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">24 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">obligations of a person controlled or supervised by or acting as an agency or instrumentality of that government, the timely payment of which is unconditionally guaranteed as a full faith and credit obligation by that
government, which are not callable or redeemable at the option of the issuer thereof. </TD></TR></TABLE> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Guarantees </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our payment obligations under any series of debt securities may be guaranteed by us or one or more of our subsidiaries. The terms of any such
guarantee will be set forth in the applicable prospectus supplement. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Subordination </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will set forth in the applicable prospectus supplement the terms and conditions, if any, upon which any series of senior subordinated
securities or subordinated securities is subordinated to debt securities of another series or to other indebtedness of ours. The terms will include a description of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the indebtedness ranking senior to the debt securities being offered; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any restrictions on payments to the holders of the debt securities being offered while a default with respect to the senior indebtedness is continuing; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any restrictions on payments to the holders of the debt securities being offered following an event of default; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">provisions requiring holders of the debt securities being offered to remit some payments to holders of senior indebtedness. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conversion and Exchange Rights </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The terms
on which debt securities of any series may be convertible into or exchangeable for our common stock, preferred stock, or other securities or property of our company will be described in the applicable prospectus supplement. These terms will include
the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the conversion or exchange price, or the manner of calculating the price; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the exchange or conversion period; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the conversion or exchange is mandatory, or voluntary at the option of the holder, or at our option; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any restrictions on conversion or exchange in the event of redemption of the debt securities and any restrictions on conversion or exchange; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the means of calculating the number of shares of our common stock, preferred stock, or other securities or property of our company to be received by the holders of debt securities. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The conversion or exchange price of any debt securities of any series that are convertible into our common stock or preferred stock may be
adjusted for any stock dividends, stock splits, reclassification, combinations, or similar transactions, as set forth in the applicable prospectus supplement. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Redemption of Debt Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The debt
securities may be subject to optional or mandatory redemption on terms and conditions described in the applicable prospectus supplement. Subject to such terms, we may opt at any time to redeem the debt securities in whole or in part. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If less than all the debt securities of any series are to be redeemed or purchased in an offer to purchase at any time, the trustee will
select the debt securities of that series to be redeemed or purchased as follows: (1)&nbsp;if the securities of such series are listed on any national securities exchange, in compliance with the requirements of the
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">25 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
principal national securities exchange on which the debt securities of that series are listed, or, (2)&nbsp;if the debt securities of that series are not listed on a national securities exchange,
on a pro rata basis, by lot, or by such other method as the trustee deems fair and appropriate. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided as to any
particular series of debt securities, at least 30&nbsp;days but not more than 60 days before a redemption date, we or the trustee will mail a notice of redemption to each holder whose debt securities are to be redeemed. From and after notice has
been given as provided in the applicable indenture, if funds for the redemption of any debt securities called for redemption shall have been made available on the redemption date, the debt securities will cease to bear interest on the date fixed for
the redemption specified in the notice, and the only right of the holders of the debt securities will be to receive payment of the redemption price. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Governing Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The indentures and the
debt securities will be governed by and construed in accordance with the laws of the state of New York, except to the extent that the Trust Indenture Act is applicable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">26 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom368527_11"></A>DESCRIPTION OF DEPOSITARY SHARES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue receipts for depositary shares representing fractional shares of preferred stock. The fractional share of the applicable series
of preferred stock represented by each depositary share will be set forth in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The shares of any
series of preferred stock underlying any depositary shares that we may sell under this prospectus will be deposited under a deposit agreement between us and a depositary selected by us. Subject to the terms of the deposit agreement, each holder of a
depositary share will be entitled, in proportion to the applicable fraction of a share of the preferred stock underlying the depositary share, to all of the rights, preferences, and privileges, and will be subject to the qualifications and
restrictions, of the preferred stock underlying that depositary share. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary shares will be evidenced by depositary receipts
issued under the deposit agreement. Depositary receipts will be distributed to the holders of the depositary shares that are sold in the applicable offering. We will incorporate by reference into the registration statement of which this prospectus
forms a part the form of any deposit agreement, including a form of depositary receipt, that describes the terms of any depositary shares we are offering before the issuance of the related depositary shares. The following summaries of material
provisions of the deposit agreement, the depositary shares and the depositary receipts are subject to, and qualified in their entirety by reference to, all of the provisions of the deposit agreement applicable to a particular offering of depositary
shares. We urge you to read the prospectus supplements relating to any depositary shares that are sold under this prospectus, as well as the complete deposit agreement and depositary receipt. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Form </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Pending the preparation of
definitive depositary receipts, the depositary may, upon our written order, issue temporary depositary receipts substantially identical to the definitive depositary receipts but not in definitive form. These temporary depositary receipts will
entitle their holders to all of the rights of definitive depositary receipts. Temporary depositary receipts will then be exchangeable for definitive depositary receipts at our expense. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Dividends and Other Distributions </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The
depositary will distribute all cash dividends or other cash distributions received with respect to the underlying preferred stock to the record holders of depositary shares in proportion to the number of depositary shares owned by those holders.
</P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If there is a distribution other than in cash, the depositary will distribute property received by it to the record holders of depositary
shares in proportion to the number of depositary shares owned by those holders, unless the depositary determines that it is not feasible to do so. If this occurs, the depositary may, with our approval, sell the property and distribute the net
proceeds from the sale to those holders in proportion to the number of depositary shares owned by them. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The amount distributed to holders
of depositary shares will be reduced by any amounts required to be withheld by us or the preferred stock depositary on account of taxes or other governmental charges. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Liquidation Preference </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If a series of
preferred stock underlying the depositary shares has a liquidation preference, in the event of our voluntary or involuntary liquidation, dissolution, or winding up, holders of depositary shares will be entitled to receive the fraction of the
liquidation preference accorded each share of the applicable series of preferred stock, as set forth in the applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">27 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Withdrawal of Underlying Preferred Stock </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as otherwise provided in a prospectus supplement, holders may surrender depositary receipts at the principal office of the depositary
and, upon payment of any unpaid amount due to the depositary, be entitled to receive the number of whole shares of underlying preferred stock and all money and other property represented by the related depositary shares. We will not issue any
partial shares of preferred stock. If the holder delivers depositary receipts evidencing a number of depositary shares that represent more than a whole number of shares of preferred stock, the depositary will issue a new depositary receipt
evidencing the excess number of depositary shares to the holder. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Redemption of Depositary Shares </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the preferred stock underlying any depositary shares we may sell under this prospectus is subject to redemption, the depositary shares will
be redeemed from the proceeds received by the depositary resulting from any such redemption, in whole or in part, of that underlying preferred stock. The redemption price per depositary share will be equal to the applicable fraction of the
redemption price per share payable with respect to the underlying preferred stock. Whenever we redeem shares of underlying preferred stock that are held by the depositary, the depositary will redeem, as of the same redemption date, the number of
depositary shares representing the shares of underlying preferred stock so redeemed. If fewer than all of the depositary shares are to be redeemed, the depositary shares to be redeemed will be selected by lot or proportionately, as may be determined
by the depositary. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">After the date fixed for redemption, the depositary shares called for redemption will no longer be deemed to be
outstanding, and all rights of the holders of the depositary shares will cease, except the right to receive the monies payable and any other property to which the holders were entitled upon the redemption upon surrender to the preferred stock
depositary of the depositary receipts evidencing the depositary shares. Any funds deposited by us with the preferred stock depositary for any depositary shares that the holders fail to redeem will be returned to us after a period of two years from
the date the funds are deposited. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Voting </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Upon receipt of notice of any meeting at which holders of the preferred stock underlying any depositary shares that we may sell under this
prospectus are entitled to vote, the depositary will mail the information contained in the notice to the record holders of the depositary shares. Each record holder of the depositary shares on the record date, which will be the same date as the
record date for the underlying preferred stock, will be entitled to instruct the depositary as to the exercise of the voting rights pertaining to the amount of the underlying preferred stock represented by the holder&#146;s depositary shares. The
depositary will then try, as far as practicable, to vote the number of shares of preferred stock underlying those depositary shares in accordance with those instructions, and we will agree to take all reasonable actions which may be deemed necessary
by the depositary to enable the depositary to do so. The depositary will not vote the underlying preferred stock to the extent it does not receive specific instructions with respect to the depositary shares representing such preferred stock. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Conversion of Preferred Stock </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the
prospectus supplement relating to any depositary shares that we may sell under this prospectus states that the underlying preferred stock is convertible into our common stock or other securities, the following will apply. The depositary shares, as
such, will not be convertible into any of our securities. Rather, any holder of the depositary shares may surrender the related depositary receipts to the depositary with written instructions that direct us to cause conversion of the preferred stock
represented by the depositary shares into or for whole shares of our common stock or other securities, as applicable. Upon receipt of those instructions and any amounts payable by the holder in connection with the conversion, we will cause the
conversion using the same procedures as those provided for conversion of the underlying preferred stock. If only some of a holder&#146;s depositary shares are converted, a new depositary receipt or receipts will be issued to the holder for any
depositary shares not converted. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">28 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendment and Termination of the Deposit Agreement </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The form of depositary receipt evidencing the depositary shares and any provision of the deposit agreement may at any time be amended by
agreement between us and the depositary. However, any amendment which materially and adversely alters the rights of the holders of depositary shares will not be effective until 90 days after notice of that amendment has been given to the holders.
Each holder of depositary shares at the time any amendment becomes effective shall be deemed to consent and agree to that amendment and to be bound by the deposit agreement as so amended. The deposit agreement may be terminated by us or by the
depositary only if all outstanding depositary shares have been redeemed or converted into any other securities into which the underlying preferred stock is convertible or there has been a final distribution, including to holders of depositary
receipts, of the underlying preferred stock in connection with our liquidation, dissolution, or winding up. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Charges of Depositary </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will pay all transfer and other taxes and governmental charges arising solely from the existence of the depositary arrangement. We will also
pay charges of the depositary in connection with the initial deposit of the preferred stock, the initial issuance of the depositary shares, any redemption of the preferred stock, and all withdrawals of preferred stock by owners of depositary shares.
Holders of depositary receipts will pay transfer, income, and other taxes and governmental charges and other specified charges as provided in the deposit arrangement for their accounts. If these charges have not been paid, the depositary may refuse
to transfer depositary shares, withhold dividends and distributions, and sell the depositary shares evidenced by the depositary receipt. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitation on
Liability </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Neither we nor the depositary will be liable if either of us is prevented or delayed by law or any circumstance beyond our
control in performing our respective obligations under the deposit agreement. Our obligations and those of the depositary will be limited to performance of our respective duties under the deposit agreement without, in our case, negligence or bad
faith or, in the case of the depositary, negligence or willful misconduct. We and the depositary may rely upon advice of counsel or accountants, or upon information provided by persons presenting the underlying preferred stock for deposit, holders
of depositary receipts, or other persons believed by us in good faith to be competent and on documents believed to be genuine. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Corporate Trust Office
of Preferred Stock Depositary </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The preferred stock depositary&#146;s corporate trust office will be set forth in the applicable
prospectus supplement relating to a series of depositary shares. The preferred stock depositary will act as transfer agent and registrar for depositary receipts, and, if shares of a series of preferred stock are redeemable, the preferred stock
depositary will act as redemption agent for the corresponding depositary receipts. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Resignation and Removal of Depositary </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The depositary may resign at any time by delivering notice to us of its election to resign. We may remove the depositary at any time. Any
resignation or removal will take effect upon the appointment of a successor depositary and its acceptance of the appointment. The successor depositary must be appointed within 60 days after delivery of the notice of resignation or removal and must
be a bank or trust company having its principal office in the United States and having a combined capital and surplus of at least $50,000,000. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Reports
to Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will deliver all required reports and communications to holders of the preferred stock to the preferred stock
depositary, and it will forward those reports and communications to the holders of depositary shares. Upon request, the preferred stock depositary will provide for inspection to the holders of depositary shares the transfer books of the depositary
and the list of holders of receipts; provided that any requesting holder certifies to the preferred stock depositary that such inspection is for a proper purpose reasonably related to such person&#146;s interest as an owner of depositary shares
evidenced by the receipts. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">29 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom368527_12"></A>DESCRIPTION OF WARRANTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue warrants to
purchase common stock, which we refer to as common stock warrants, preferred stock, which we refer to as preferred stock warrants, debt securities, which we refer to as debt security warrants, or depositary shares, which we refer to as depositary
share warrants. Any of these warrants may be issued independently or together with any other securities offered by this prospectus and may be attached to or separate from those securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">While the terms we have summarized below will generally apply to any future warrants we may offer under this prospectus, we will describe the
particular terms of any warrants that we may offer in more detail in the applicable prospectus supplement. The terms of any warrants we offer under a prospectus supplement may differ from the terms we describe below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue the warrants under a warrant agreement, which we will enter into with a warrant agent to be selected by us. Each warrant agent
will act solely as our agent under the applicable warrant agreement and will not assume any obligation or relationship of agency or trust with any holder of any warrant. A single bank or trust company may act as warrant agent for more than one issue
of warrants. A warrant agent will have no duty or responsibility in case of any default by us under the applicable warrant agreement or warrant, including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any
demand upon us. Any holder of a warrant may, without the consent of the related warrant agent or the holder of any other warrant, enforce by appropriate legal action its right to exercise, and receive the securities purchasable upon exercise of, its
warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will incorporate by reference into the registration statement of which this prospectus forms a part the form of warrant
agreement, including a form of warrant certificate, that describes the terms of the series of warrants we are offering before the issuance of the related series of warrants. The following summaries of material provisions of the warrants and the
warrant agreements are subject to, and qualified in their entirety by reference to, all the provisions of the warrant agreement applicable to a particular series of warrants. We urge you to read the applicable prospectus supplements related to the
warrants that we sell under this prospectus, as well as the complete warrant agreements that contain the terms of the warrants. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will
set forth in the applicable prospectus supplement the terms of the warrants in respect of which this prospectus is being delivered, including, when applicable, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the title of the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the aggregate number of the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the price or prices at which the warrants will be issued; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the designation, number, and terms of the securities purchasable upon exercise of the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the designation and terms of the other securities, if any, with which the warrants are issued and the number of warrants issued with each such security; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the date, if any, on and after which the warrants and the related underlying securities will be separately transferable; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the price at which each underlying security purchasable upon exercise of the warrants may be purchased; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the date on which the right to exercise the warrants will commence and the date on which such right will expire; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the minimum amount of the warrants that may be exercised at any one time; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any information with respect to book-entry procedures; </TD></TR></TABLE>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">30 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">

<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the effect of any merger, consolidation, sale, or other disposition of our business on the warrant agreement and the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other terms of the warrants, including terms, procedures, and limitations relating to the transferability, exchange, and exercise of such warrants; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the terms of any rights to redeem or call, or accelerate the expiration of, the warrants; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the date on which the right to exercise the warrants begins and the date on which that right expires; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the U.S. federal income tax consequences of holding or exercising the warrants; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any other specific terms, preferences, rights, or limitations of, or restrictions on, the warrants. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless specified in an applicable prospectus supplement, common stock warrants, preferred stock warrants, debt security warrants, or
depositary shares warrants will be in registered form only. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A holder of warrant certificates may exchange them for new certificates of
different denominations, present them for registration of transfer, and exercise them at the corporate trust office of the warrant agent or any other office indicated in the applicable prospectus supplement. Until any common stock warrants,
preferred stock warrants, debt security warrants, or depositary shares warrants are exercised, holders of the warrants will not have any rights of holders of the underlying common stock, preferred stock, debt securities, or depositary shares,
including any rights to receive dividends or to exercise any voting rights, except to the extent set forth under the heading &#147;Warrant Adjustments&#148; below. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Exercise of Warrants </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each warrant will
entitle the holder to purchase for cash shares of common stock, preferred stock, debt securities, or depositary shares at the applicable exercise price set forth in, or determined as described in, the applicable prospectus supplement. Warrants may
be exercised at any time up to the close of business on the expiration date set forth in the applicable prospectus supplement. After the close of business on the expiration date, unexercised warrants will become void. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Warrants may be exercised by delivering to the corporation trust office of the warrant agent or any other officer indicated in the applicable
prospectus supplement (a)&nbsp;the warrant certificate properly completed and duly executed and (b)&nbsp;payment of the amount due upon exercise. As soon as practicable following exercise, we will forward the shares of common stock, preferred stock,
debt securities, or depositary shares. If less than all of the warrants represented by a warrant certificate are exercised, a new warrant certificate will be issued for the remaining warrants. If we so indicate in the applicable prospectus
supplement, holders of the warrants may surrender securities as all or a part of the exercise price for the warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Amendments and Supplements to
the Warrant Agreements </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may amend or supplement a warrant agreement without the consent of the holders of the applicable warrants to
cure ambiguities in the warrant agreement, to cure or correct a defective provision in the warrant agreement, or to provide for other matters under the warrant agreement that we and the warrant agent deem necessary or desirable, so long as, in each
case, such amendments or supplements do not materially and adversely affect the interests of the holders of the warrants. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Warrant Adjustments </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless the applicable prospectus supplement states otherwise, the exercise price of, and the number of securities covered by, a common stock
warrant, preferred stock warrant, debt security warrant, or depositary </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">31 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
share warrant will be adjusted proportionately if we subdivide or combine our common stock, preferred stock, debt securities, or depositary shares, as applicable. In addition, unless the
prospectus supplement states otherwise, if we, without payment: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issue capital stock or other securities convertible into or exchangeable for common stock or preferred stock, or any rights to subscribe for, purchase, or otherwise acquire any of the foregoing, as a dividend or
distribution to holders of our common stock or preferred stock; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">pay any cash to holders of our common stock or preferred stock other than a cash dividend paid out of our current or retained earnings or other than in accordance with the terms of the preferred stock;
</TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issue any evidence of our indebtedness or rights to subscribe for or purchase our indebtedness to holders of our common stock or preferred stock; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">issue common stock or preferred stock or additional stock or other securities or property to holders of our common stock or preferred stock by way of spinoff, split-up, reclassification, combination of shares, or
similar corporate rearrangement, </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">then the holders of common stock warrants, preferred stock warrants, debt security warrants, and
depositary share warrants, as applicable, will be entitled to receive upon exercise of the warrants, in addition to the securities otherwise receivable upon exercise of the warrants and without paying any additional consideration, the amount of
stock and other securities and property such holders would have been entitled to receive had they held the common stock, preferred stock, debt securities, or depositary shares, as applicable, issuable under the warrants on the dates on which holders
of those securities received or became entitled to receive such additional stock and other securities and property. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Except as stated
above, the exercise price and number of securities covered by a common stock warrant, preferred stock warrant, debt security warrant, and depositary share warrant, and the amounts of other securities or property to be received, if any, upon exercise
of those warrants, will not be adjusted or provided for if we issue those securities or any securities convertible into or exchangeable for those securities, or securities carrying the right to purchase those securities or securities convertible
into or exchangeable for those securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Holders of common stock warrants, preferred stock warrants, debt security warrants, and
depositary share warrants may have additional rights under the following circumstances: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">certain reclassifications, capital reorganizations, or changes of the common stock, preferred stock, or depositary shares, as applicable; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">certain share exchanges, mergers, or similar transactions involving us and which result in changes of the common stock, preferred stock, or depositary shares, as applicable; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">certain sales or dispositions to another entity of all or substantially all of our property and assets. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If one of the above transactions occurs and holders of our common stock, preferred stock, debt securities, or depositary shares are entitled
to receive stock, securities, or other property with respect to or in exchange for their securities, the holders of the common stock warrants, preferred stock warrants, debt security warrants, and depositary share warrants then outstanding, as
applicable, will be entitled to receive upon exercise of their warrants the kind and amount of shares of stock and other securities or property that they would have received upon the applicable transaction if they had exercised their warrants
immediately before the transaction. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">32 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom368527_13"></A>DESCRIPTION OF PURCHASE CONTRACTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue purchase contracts, including contracts obligating holders to purchase from us, and for us to sell to holders, a specific or
varying number of debt securities, shares of common stock or preferred stock, depositary shares, warrants, or any combination of the above, at a future date or dates. Alternatively, the purchase contracts may obligate us to purchase from holders,
and obligate holders to sell to us, a specific or varying number of debt securities, shares of common stock or preferred stock, depositary shares, warrants, or any combination of the above. The price of the securities subject to the purchase
contracts may be fixed at the time the purchase contracts are issued or may be determined by reference to a specific formula described in the purchase contracts. We may issue purchase contracts separately or as a part of units each consisting of a
purchase contract and one or more of the other securities described in this prospectus or securities of third parties, including U.S.&nbsp;Treasury securities, securing the holder&#146;s obligations under the purchase contract. If we issue a
purchase contract as part of a unit, the applicable prospectus supplement will state whether the purchase contract will be separable from the other securities in the unit before the purchase contract settlement date. The purchase contracts may
require us to make periodic payments to holders or vice versa and the payments may be unsecured or pre-funded on some basis. The purchase contracts may require holders to secure the holder&#146;s obligations in a manner specified in the applicable
prospectus supplement, and in certain circumstances, we may deliver newly issued prepaid purchase contracts, often known as prepaid securities, upon release to a holder of any collateral securing such holder&#146;s obligations under the original
purchase contract. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will incorporate by reference into the registration statement of which this prospectus forms a part the form of
purchase contract we are offering before the issuance of the purchase contract. The following summaries of material provisions of the purchase contract are subject to, and qualified in their entirety by reference to, all the provisions of the
purchase contract. We urge you to read the applicable prospectus supplements related to the purchase contracts that we sell under this prospectus, as well as the complete purchase contract. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The applicable prospectus supplement will describe the terms of any purchase contracts in respect of which this prospectus is being delivered,
including, to the extent applicable, the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the purchase contracts obligate the holder or us to purchase or sell, or both purchase and sell, the securities subject to purchase under the purchase contract, and the nature and amount of each of those
securities, or the method of determining those amounts; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the purchase contracts are to be prepaid or not; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the purchase contracts will be issued as part of a unit and, if so, the other securities comprising the unit; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the purchase contracts are to be settled by delivery, or by reference or linkage to the value, performance, or level of the securities subject to purchase under the purchase contract; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any acceleration, cancellation, termination, or other provisions relating to the settlement of the purchase contracts; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether the purchase contracts will be issued in fully registered or global form. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Material
U.S. federal income tax consideration applicable to the purchase contracts and the purchase units will also be discussed in the applicable prospectus supplement. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">33 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom368527_14"></A>DESCRIPTION OF UNITS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following description, together with the additional information we include in any applicable prospectus supplement, summarizes the
material terms and provisions of the units that we may offer under this prospectus. Units may be offered independently or together with common stock, preferred stock, debt securities, depositary shares, and warrants offered by any prospectus
supplement, and may be attached to or separate from those securities. While the terms we have summarized below will generally apply to any future units that we may offer under this prospectus, we will describe the particular terms of any series of
units that we may offer in more detail in the applicable prospectus supplement. The terms of any units offered under a prospectus supplement may differ from the terms described below. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will incorporate by reference into the registration statement of which this prospectus forms a part the form of unit agreement, including a
form of unit certificate, if any, that describes the terms of the series of units we are offering before the issuance of the related series of units. The following summaries of material provisions of the units and the unit agreements are subject to,
and qualified in their entirety by reference to, all the provisions of the unit agreement applicable to a particular series of units. We urge you to read the applicable prospectus supplements related to the units that we sell under this prospectus,
as well as the complete unit agreements that contain the terms of the units. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue units consisting of common stock, preferred stock, debt securities, depositary shares, and warrants in any combination. Each unit
will be issued so that the holder of the unit is also the holder of each security included in the unit. Thus, the holder of a unit will have the rights and obligations of a holder of each included security. The unit agreement under which a unit is
issued may provide that the securities included in the unit may not be held or transferred separately, at any time, or at any time before a specified date. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will describe in the applicable prospectus supplement the terms of the series of units, including the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the designation and terms of the units and of the securities comprising the units, including whether and under what circumstances those securities may be held or transferred separately; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any provisions of the governing unit agreement that differ from those described below; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any provisions for the issuance, payment, settlement, transfer, or exchange of the units or of the securities comprising the units. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The provisions described in this section, as well as those described under &#147;Description of Common Stock,&#148; &#147;Description of
Preferred Stock,&#148; &#147;Description of Debt Securities,&#148; &#147;Description of Depositary Shares,&#148; and &#147;Description of Warrants,&#148; will apply to each unit and to any common stock, preferred stock, debt security, depositary
share, or warrant included in each unit, respectively. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Issuance in Series </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue units in such amounts and in such numerous distinct series as we determine. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Enforceability of Rights by Holders of Units </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Each unit agent will act solely as our agent under the applicable unit agreement and will not assume any obligation or relationship of agency
or trust with any holder of any unit. A single bank or trust company may act as unit agent for more than one series of units. A unit agent will have no duty or responsibility in case of any default by us under the applicable unit agreement or unit,
including any duty or responsibility to initiate any proceedings at law or otherwise, or to make any demand upon us. Any holder of a unit, without the consent of the related unit agent or the holder of any other unit, may enforce by appropriate
legal action its rights as holder under any security included in the unit. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">34 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Title </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We, the unit agent, and any of their agents may treat the registered holder of any unit certificate as an absolute owner of the units evidenced
by that certificate for any purposes and as the person entitled to exercise the rights attaching to the units so requested, despite any notice to the contrary. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">35 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom368527_15"></A>CERTAIN PROVISIONS OF NEVADA LAW AND </B></P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B>OUR CHARTER AND BYLAWS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The following paragraphs summarize certain provisions of Nevada law and our amended and restated articles of incorporation, as amended, and
bylaws. The summary does not purport to be complete and is subject to and qualified in its entirety by reference to Nevada law and to our amended and restated articles of incorporation, as amended, and bylaws, as amended, copies of which are on file
with the SEC as exhibits to reports previously filed by us. See &#147;Where You Can Find More Information.&#148; </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>General </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Certain provisions of our amended and restated articles of incorporation, as amended, and bylaws and Nevada law could make our acquisition by a
third party, a change in our incumbent management, or a similar change in control more difficult, including: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an acquisition of us by means of a tender or exchange offer; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an acquisition of us by means of a proxy contest or otherwise; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the removal of a majority or all of our incumbent officers and directors. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">These provisions, which are
summarized below, are likely to discourage certain types of coercive takeover practices and inadequate takeover bids. These provisions are also designed to encourage persons seeking to acquire control of us to first negotiate with our board of
directors. We believe that these provisions help to protect our potential ability to negotiate with the proponent of an unfriendly or unsolicited proposal to acquire or restructure us, and that this benefit outweighs the potential disadvantages of
discouraging such a proposal because our ability to negotiate with the proponent could result in an improvement of the terms of the proposal. The existence of these provisions which are described below could limit the price that investors might
otherwise pay in the future for our securities. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Articles of Incorporation and Bylaws </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Authorized But Unissued Capital Stock. </I>We have shares of common stock and preferred stock available for future issuance without
stockholder approval, subject to any limitations imposed by the listing standards of any securities exchange on which our stock may be listed. We may utilize these additional shares for a variety of corporate purposes, including for future public
offerings to raise additional capital or facilitate corporate acquisitions or for payment as a dividend on our capital stock. The existence of unissued and unreserved common stock and preferred stock may enable our board of directors to issue shares
to persons friendly to current management or to issue preferred stock with terms that could have the effect of making it more difficult for a third party to acquire, or could discourage a third party from seeking to acquire, a controlling interest
in our company by means of a merger, tender offer, proxy contest, or otherwise. In addition, if we issue preferred stock, the issuance could adversely affect the voting power of holders of common stock and the likelihood that such holders will
receive dividend payments and payments upon liquidation. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Blank Check Preferred Stock</I>. Our board of directors, without stockholder
approval, has the authority under our amended and restated articles of incorporation, as amended, to issue preferred stock with rights superior to the rights of the holders of common stock. As a result, preferred stock could be issued quickly and
easily, could impair the rights of holders of common stock, and could be issued with terms calculated to delay or prevent a change in control or make removal of management more difficult. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Election of Directors</I>. Our bylaws provide that a majority of directors then in office may fill any vacancy occurring on our board of
directors, even though less than a quorum may then be in office. These provisions may discourage a third party from voting to remove incumbent directors and simultaneously gaining control of our board of directors by filling the vacancies created by
that removal with its own nominees. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">36 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Removal of Directors</I>. Except in certain cases for directors elected by the holders of
any series of preferred stock, a director may be removed only by the affirmative vote of two-thirds or more of the combined voting power of the then issued and outstanding shares of our capital stock entitled to vote in the election of directors,
voting together as a single class. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I>Stockholder Meetings</I>. Our bylaws do not permit stockholders to call a special meeting of
stockholders. Rather, only our board of directors or such person or persons authorized by our board of directors will be able to call special meetings of stockholders. This provision may discourage another person or entity from making a tender
offer, even if it acquired a majority of our outstanding voting stock, because the person or entity could only take action at a duly called stockholders&#146; meeting. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Anti-takeover Effects of Nevada Law </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Business
Combinations with Interested Stockholders </I></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The &#147;business combination with interested stockholders&#148; provisions of Sections
78.411 to 78.444, inclusive, of the Nevada Revised Statutes, or NRS, generally prohibit a Nevada corporation with at least 200 stockholders of record from engaging in various &#147;combination&#148; transactions with any interested stockholder for a
period of two years after the date of the transaction in which the person became an interested stockholder, unless the combination is approved by our board of directors prior to the date the interested stockholder obtained such status or the
combination is approved by our board of directors and at such time or thereafter is approved at a meeting of the stockholders by the affirmative vote of stockholders representing at least 60% of the outstanding voting power held by disinterested
stockholders, and extends beyond the expiration of the two-year period, unless: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the combination was approved by our board of directors prior to the person becoming an interested stockholder or the transaction by which the person first became an interested stockholder was approved by our board of
directors before the person became an interested stockholder or the combination is later approved by a majority of the voting power held by disinterested stockholders; or </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if the consideration to be paid by the interested stockholder is at least equal to the highest of: (a)&nbsp;the highest price per share paid by the interested stockholder within the two years immediately preceding the
date of the announcement of the combination or in the transaction in which it became an interested stockholder, whichever is higher; (b)&nbsp;the market value per share of common stock on the date of announcement of the combination and the date the
interested stockholder acquired the shares, whichever is higher; or (c)&nbsp;for holders of preferred stock, the highest liquidation value of the preferred stock, if it is higher. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Notwithstanding the foregoing, NRS 78.411 to 78.444, inclusive, do not apply to any combination of a resident domestic corporation with an
interested stockholder after the expiration of four years after the person first became an interested stockholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A
&#147;combination&#148; is generally defined to include mergers or consolidations or any sale, lease exchange, mortgage, pledge, transfer, or other disposition, in one transaction or a series of transactions, with an &#147;interested
stockholder&#148; having: (a)&nbsp;an aggregate market value equal to more than 5% of the aggregate market value of the assets of the corporation, (b)&nbsp;an aggregate market value equal to more than 5% of the aggregate market value of all
outstanding voting shares of the corporation, (c)&nbsp;more than 10% of the earning power or net income of the corporation, and (d)&nbsp;certain other transactions with an interested stockholder or an affiliate or associate of an interested
stockholder. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In general, an &#147;interested stockholder&#148; is a person who, together with affiliates and associates, owns (or within
two years, did own) 10% or more of a corporation&#146;s voting stock. The statute could prohibit or delay mergers or other takeover or change in control attempts and, accordingly, may discourage attempts to acquire our company even though such a
transaction may offer our stockholders the opportunity to sell their stock at a price above the prevailing market price. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">37 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><I>Control Share Acquisitions </I></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The &#147;control share&#148; provisions of Sections 78.378 to 78.3793, inclusive, of the NRS apply to &#147;issuing corporations&#148; that
are Nevada corporations with at least 200 stockholders of record, including at least 100 stockholders of record who are Nevada residents, and that conduct business directly or indirectly in Nevada. The control share statute prohibits an acquirer,
under certain circumstances, from voting its shares of a target corporation&#146;s stock after crossing certain ownership threshold percentages, unless the acquirer obtains approval of the target corporation&#146;s disinterested stockholders. The
statute specifies three thresholds: one-fifth or more but less than one-third, one-third but less than a majority, and a majority or more, of the outstanding voting power. Generally, once an acquirer crosses one of the above thresholds, those shares
in an offer or acquisition and acquired within 90 days thereof become &#147;control shares&#148; and such control shares are deprived of the right to vote until disinterested stockholders restore the right. These provisions also provide that if
control shares are accorded full voting rights and the acquiring person has acquired a majority or more of all voting power, all other stockholders who do not vote in favor of authorizing voting rights to the control shares are entitled to demand
payment for the fair value of their shares in accordance with statutory procedures established for dissenters&#146; rights. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A corporation
may elect to not be governed by, or &#147;opt out&#148; of, the control share provisions by making an election in its articles of incorporation or bylaws, provided that the opt-out election must be in place on the 10th&nbsp;day following the date an
acquiring person has acquired a controlling interest, that is, crossing any of the three thresholds described above. We have not opted out of the control share statutes, and will be subject to these statutes if we are an &#147;issuing
corporation&#148; as defined in such statutes. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The effect of the Nevada control share statutes is that the acquiring person, and those
acting in association with the acquiring person, will obtain only such voting rights in the control shares as are conferred by a resolution of the stockholders at an annual or special meeting. The Nevada control share law, if applicable, could have
the effect of discouraging takeovers of our company. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Limitations of Liability and Indemnification of Officers and Directors </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated articles of incorporation, as amended, limit the liability of directors to the fullest extent permitted by Nevada law
and provides that no director or officer of ours will be personally liable to us or any of our stockholders for damages for breach of fiduciary duty as a director or officer involving any act or omission of any act by such director or officer, other
than (i)&nbsp;for acts or omissions which involve intentional misconduct, fraud, or a known violation of the law, or (ii)&nbsp;the payment of dividends in violation of Section&nbsp;78.300 of the NRS. In addition, our amended and restated articles of
incorporation, as amended, provide that we will indemnify our directors and officers to the fullest extent permitted by law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We are a
Nevada corporation and generally governed by the Nevada Private Corporations Code, Chapter 78 of the Nevada Revised Statutes, or NRS. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;78.138 of the NRS provides that, unless the corporation&#146;s articles of incorporation provide otherwise, a director or officer
is not individually liable to the corporation or its stockholders or creditors for damages as a result of any action or omission to act as a director or officer unless the trier of fact determines that the presumption that the director or officer
acted in good faith, on an informed basis and with a view to the interests to the corporation is rebutted and it is proven that (i)&nbsp;the director&#146;s or officer&#146;s acts or omissions constituted a breach of his or her fiduciary duties, and
(ii)&nbsp;such breach involved intentional misconduct, fraud, or a knowing violation of the law. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;78.7502 of the NRS permits
a company to indemnify its directors and officers against expenses, judgments, fines, and amounts paid in settlement actually and reasonably incurred in connection with a threatened, pending, or completed action, suit, or proceeding, if the officer
or director (i)&nbsp;is not liable pursuant to Section&nbsp;78.138 of the NRS, or (ii)&nbsp;acted in good faith and in a manner the officer or director reasonably believed </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">38 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
to be in or not opposed to the best interests of the corporation and, if a criminal action or proceeding, had no reasonable cause to believe the conduct of the officer or director was unlawful.
Section&nbsp;78.7502 of the NRS precludes indemnification by the corporation if the officer or director has been adjudged by a court of competent jurisdiction, after exhaustion of all appeals, to be liable to the corporation or for amounts paid in
settlement to the corporation, unless and only to the extent that the court determines that in view of all the circumstances, the person is fairly and reasonably entitled to indemnity for such expenses and Section 78.7502 requires a corporation to
indemnify its officers and directors if they have been successful on the merits of the action or otherwise in defense of any claim, issue, or matter resulting from their service as a director or officer. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;78.751 of the NRS permits a Nevada corporation to indemnify its officers and directors against expenses incurred by them in
defending a civil or criminal action, suit, or proceeding as they are incurred and in advance of final disposition thereof, upon determination by the stockholders, the disinterested board members, or by independent legal counsel. Section&nbsp;78.751
of the NRS provides that the articles of incorporation, the bylaws or an agreement may require a corporation to advance expenses as incurred upon receipt of an undertaking by or on behalf of the officer or director to repay the amount if it is
ultimately determined by a court of competent jurisdiction that such officer or director is not entitled to be indemnified by the corporation if so provided in the corporation&#146;s articles of incorporation, bylaws, or other agreement.
Section&nbsp;78.751 of the NRS further permits the corporation to grant its directors and officers additional rights of indemnification under its articles of incorporation, bylaws, or other agreement. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Section&nbsp;78.752 of the NRS provides that a Nevada corporation may purchase and maintain insurance or make other financial arrangements on
behalf of any person who is or was a director, officer, employee, or agent of the corporation, or is or was serving at the request of the corporation as a director, officer, employee, or agent of another company, partnership, joint venture, trust,
or other enterprise, for any liability asserted against him and liability and expenses incurred by him in his capacity as a director, officer, employee, or agent, or arising out of his status as such, whether or not the corporation has the authority
to indemnify him against such liability and expenses. We have obtained primary and excess insurance policies insuring our directors and officers and our subsidiaries against certain liabilities they may incur in their capacity as directors and
officers. Under such policies, the insurer, on our behalf, may also pay amounts for which we have granted indemnification to the directors or officers. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The foregoing discussion of indemnification merely summarizes certain aspects of indemnification provisions and is limited by reference to the
above discussed sections of the Nevada Private Corporations Code. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our amended and restated articles of incorporation, as amended, provide
that we may indemnify to the full extent of its power to do so, all directors, officers, employees, and/or agents. Insofar as indemnification by our company for liabilities arising under the Securities Act may be permitted to officers and directors
of our company pursuant to the foregoing provisions or otherwise, we are aware that in the opinion of the SEC, such indemnification is against public policy as expressed in the Securities Act and is, therefore, unenforceable. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Indemnification for Securities Act Liabilities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Insofar as indemnification for liabilities arising under the Securities Act, may be permitted for directors, officers, or controlling persons
pursuant to the provisions described in the preceding paragraph, we have been informed that in the opinion of the SEC such indemnification is against public policy as expressed in the Securities Act and is therefore unenforceable. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">39 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom368527_16"></A>LEGAL OWNERSHIP OF SECURITIES </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We can issue securities in registered form or in the form of one or more global securities. We refer to those persons who have securities
registered in their own names on the books that we or any applicable trustee, depositary or warrant agent maintain for this purpose as the &#147;holders&#148; of those securities. These persons are the legal holders of the securities. We refer to
those persons who, indirectly through others, own beneficial interests in securities that are not registered in their own names, as &#147;indirect holders&#148; of those securities. As we discuss below, indirect holders are not legal holders, and
investors in securities issued in book-entry form or in street name will be indirect holders. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">See also the section entitled
&#147;Description of Debt Securities &#151; Form, Transfer, and Exchange&#148; above for additional discussion of book entry and certificated form of ownership as such forms of ownership impact the rights and obligations of purchasers of debt
securities to be issued under this prospectus. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Book-Entry Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may issue securities in book-entry form only, as we will specify in the applicable prospectus supplement. This means securities may be
represented by one or more global securities registered in the name of a financial institution that holds them as depositary on behalf of other financial institutions that participate in the depositary&#146;s book-entry system. These participating
institutions, which are referred to as participants, in turn, hold beneficial interests in the securities on behalf of themselves or their customers. Upon the issuance of a global security, the depositary will credit, on its book-entry registration
and transfer system, the participants&#146; accounts with the respective principal amounts of the book-entry securities represented by the global security beneficially owned by such participants. The accounts to be credited will be designated by any
dealers, underwriters, or agents participating in the distribution of the book-entry securities. Ownership of book-entry securities will be shown on, and the transfer of the ownership interests will be effected only through, records maintained by
the depositary for the related global security (with respect to interests of participants) and on the records of participants (with respect to interests of persons holding through participants). The laws of some states may require that certain
purchasers of securities take physical delivery of such securities in definitive form. These laws may impair the ability to own, transfer, or pledge beneficial interests in book-entry securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Only the person in whose name a security is registered is recognized as the holder of that security. Securities issued in global form will be
registered in the name of the depositary or its participants. Consequently, for securities issued in global form, we will recognize only the depositary as the holder of the securities, and we will make all payments on the securities to the
depositary. The depositary passes along the payments it receives to its participants, which in turn pass the payments along to their customers who are the beneficial owners. The depositary and its participants do so under agreements they have made
with one another or with their customers; they are not obligated to do so under the terms of the securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">As a result, investors in a
book-entry security will not own securities directly. Instead, they will own beneficial interests in a global security, through a bank, broker, or other financial institution that participates in the depositary&#146;s book-entry system or holds an
interest through a participant. As long as the securities are issued in global form, investors will be indirect holders, and not holders, of the securities. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Street Name Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may terminate a
global security or issue securities in non-global form. In these cases, investors may choose to hold their securities in their own names or in &#147;street name.&#148; Securities held by an investor in street name would be registered in the name of
a bank, broker, or other financial institution that the investor chooses, and the investor would hold only a beneficial interest in those securities through an account he, she, or it maintains at that institution. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">40 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For securities held in street name, we will recognize only the intermediary banks, brokers,
and other financial institutions in whose names the securities are registered as the holders of those securities, and we will make all payments on those securities to them. These institutions pass along the payments they receive to their customers
who are the beneficial owners, but only because they agree to do so in their customer agreements or because they are legally required to do so. Investors who hold securities in street name will be indirect holders, not holders, of those securities.
</P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Legal Holders </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Our obligations, as
well as the obligations of any applicable trustee and of any third parties employed by us or a trustee, run only to the legal holders of the securities. We do not have obligations to investors who hold beneficial interests in global securities, in
street name, or by any other indirect means. This will be the case whether an investor chooses to be an indirect holder of a security or has no choice because we are issuing the securities only in global form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">For example, once we make a payment or give a notice to the holder, we have no further responsibility for the payment or notice even if that
holder is required, under agreements with depositary participants or customers or by law, to pass it along to the indirect holders but does not do so. Whether and how the holders contact the indirect holders is up to the holders. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Considerations For Indirect Holders </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If you hold securities through a bank, broker, or other financial institution, either in book-entry form or in street name, you should check
with your own institution to determine the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">how it handles securities payments and notices; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether it imposes fees or charges; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">how it would handle a request for the holders&#146; consent, if ever required; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">whether and how you can instruct it to send you securities registered in your own name so you can be a holder, if that is permitted in the future; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">how it would exercise rights under the securities if there were a default or other event triggering the need for holders to act to protect their interests; and </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if the securities are in book-entry form, how the depositary&#146;s rules and procedures will affect these matters. </TD></TR></TABLE>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Global Securities </B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A global security is a
security that represents one or any other number of individual securities held by a depositary. Generally, all securities represented by the same global securities will have the same terms. Each security issued in book-entry form will be represented
by a global security that we deposit with and register in the name of a financial institution or its nominee that we select. The financial institution that we select for this purpose is called the depositary. Unless we specify otherwise in the
applicable prospectus supplement, The Depository Trust Company, New York, New York, known as DTC, will be the depositary for all securities issued in book-entry form. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">A global security may not be transferred to or registered in the name of anyone other than the depositary, its nominee, or a successor
depositary, unless special termination situations arise. We describe those situations below under &#147;Special Situations When a Global Security Will Be Terminated.&#148; As a result of these arrangements, the depositary, or its nominee, will be
the sole registered owner and holder of all securities represented by a global security, and investors will be permitted to own only beneficial interests in a global security. Beneficial interests must be held by means of an account with a broker,
bank, or other financial institution that in turn has an account with the depositary or with another institution that does. Thus, an investor whose security is represented by a global security will not be a holder of the security, but only an
indirect holder of a beneficial interest in the global security. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">41 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If the prospectus supplement for a particular security indicates that the security will be
issued in global form only, then the security will be represented by a global security at all times unless and until the global security is terminated. If termination occurs, we may issue the securities through another book-entry clearing system or
decide that the securities may no longer be held through any book-entry clearing system. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We may at any time and in our sole discretion
determine not to have any of the book-entry securities of any series represented by one or more global securities and, in that event, we will issue certificated securities in exchange for the global securities of that series. </P>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B></B><B>Special Considerations For Global Securities </B></P>
<P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The rights of an indirect holder relating to a global security will be governed by the account rules of the investor&#146;s financial
institution and of the depositary, as well as general laws relating to securities transfers. We do not recognize an indirect holder as a holder of securities and instead deal only with the depositary that holds the global security. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">If securities are issued only in the form of a global security, an investor should be aware of the following: </P>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an investor cannot cause the securities to be registered in his, her, or its name, and cannot obtain <FONT STYLE="white-space:nowrap">non-global</FONT> certificates for his, her, or its interest in the securities,
except in the special situations we describe below; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an investor will be an indirect holder and must look to his, her, or its own bank or broker for payments on the securities and protection of his, her, or its legal rights relating to the securities, as we describe
above; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an investor may not be able to sell interests in the securities to some insurance companies and to other institutions that are required by law to own their securities in non-book-entry form; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">an investor may not be able to pledge his, her, or its interest in a global security in circumstances where certificates representing the securities must be delivered to the lender or other beneficiary of the pledge in
order for the pledge to be effective; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the depositary&#146;s policies, which may change from time to time, will govern payments, transfers, exchanges, and other matters relating to an investor&#146;s interest in a global security; </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">we and any applicable trustee have no responsibility for any aspect of the depositary&#146;s actions or for its records of ownership interests in a global security, nor do we or any applicable trustee supervise the
depositary in any way; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the depositary may, and we understand that DTC will, require that those who purchase and sell interests in a global security within its book-entry system use immediately available funds, and your broker or bank may
require you to do so as well; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">financial institutions that participate in the depositary&#146;s book-entry system, and through which an investor holds its interest in a global security, may also have their own policies affecting payments, notices,
and other matters relating to the securities. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">There may be more than one financial intermediary in the chain of ownership for an investor.
We do not monitor and are not responsible for the actions of any of those intermediaries. </P> <P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman"><B>Special Situations When a Global Security Will Be Terminated
</B></P> <P STYLE="margin-top:6pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In a few special situations described below, the global security will terminate and interests in it will be exchanged for physical
certificates representing those interests. After that exchange, the choice of whether to hold securities directly or in street name will be up to the investor. Investors must consult their own banks or brokers to find out how to have their interests
in securities transferred to their own name, so that they will be direct holders. We have described the rights of holders and street name investors above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">42 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless we provide otherwise in the applicable prospectus supplement, the global security
will terminate when the following special situations occur: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if the depositary notifies us that it is unwilling, unable, or no longer qualified under the Exchange Act to continue as depositary for that global security and we do not appoint another institution to act as depositary
within 90 days; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if we notify any applicable trustee that we wish to terminate that global security; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">if an event of default has occurred with regard to securities represented by that global security and has not been cured or waived. </TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">The prospectus supplement may also list additional situations for terminating a global security that would apply only to the particular types and series of
securities covered by the applicable prospectus supplement. When a global security terminates, the depositary, and not we or any applicable trustee, is responsible for deciding the names of the institutions that will be the initial direct holders.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">43 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom368527_17"></A>PLAN OF DISTRIBUTION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and/or any selling stockholder may sell the securities described in this prospectus from time to time in one or more of the following ways:
</P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">to or through underwriters or dealers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">directly to one or more purchasers; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">through agents; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">through a combination of any of those methods of sale. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The prospectus supplement with respect
to the offered securities will describe the terms of the offering, including the following: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the name or names of any underwriters or agents; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any public offering price; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">the proceeds from such sale; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any underwriting discounts or agency fees and other items constituting underwriters&#146; or agents&#146; compensation; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any over-allotment options under which underwriters may purchase additional securities from us and/or any selling stockholder; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any discounts or concessions allowed or reallowed or paid to dealers; and </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">any securities exchanges on which the securities may be listed. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and/or any selling
stockholder may distribute the securities from time to time in one or more of the following ways: </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at a fixed public offering price or prices, which may be changed; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at prices relating to prevailing market prices at the time of sale; </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at varying prices determined at the time of sale; or </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">at negotiated prices. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise indicated in the applicable prospectus supplement, if
we and/or any selling stockholder use underwriters for a sale of securities, the underwriters will acquire the securities for their own account. The underwriters may resell the securities in one or more transactions, including negotiated
transactions, at a fixed public offering price, or at varying prices determined at the time of sale. The obligations of the underwriters to purchase the securities will be subject to the conditions set forth in the applicable underwriting agreement.
Unless otherwise indicated in a prospectus supplement, the underwriters will be obligated to purchase all the securities of the series offered if they purchase any of the securities of that series. We and/or any selling stockholder may change from
time to time any initial public offering price and any discounts or concessions the underwriters allow or reallow or pay to dealers. We and/or any selling stockholder may use underwriters with whom we or they have a material relationship. We will
describe in the prospectus supplement naming the underwriter the nature of any such relationship. We and/or any selling stockholder may designate agents who agree to use their reasonable efforts to solicit purchases for the period of their
appointment or to sell securities on a continuing basis. We and/or any selling stockholder may also sell securities directly to one or more purchasers without using underwriters or agents. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Underwriters, dealers, or agents may receive compensation in the form of discounts, concessions, or commissions from us and/or any selling
stockholder or from purchasers of the securities as their agents in connection with the sale of the securities. These underwriters, dealers, or agents may be considered to be underwriters under the Securities Act. As a result, discounts,
commissions, or profits on resale received by underwriters, dealers, or agents may be treated as underwriting discounts and commissions. Each prospectus supplement will identify any underwriter, dealer, or agent and describe any compensation
received by them from us and/or any selling stockholder. Any initial public offering price and any discounts or concessions allowed or reallowed or paid to dealers may be changed from time to time. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">44 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Unless otherwise specified in the applicable prospectus supplement, each class or series of
securities will be a new issue with no established trading market, other than our common stock, which is listed on the Nasdaq Global Select Market. We may elect to apply for listing of our common stock on another securities exchange or to list any
other class or series of securities on any exchange, but we are not obligated to do so. It is possible that one or more underwriters may make a market in a class or series of securities, but the underwriters will not be obligated to do so and may
discontinue any market making at any time without notice. We cannot give any assurance as to the liquidity of the trading market for any of the securities. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In connection with any offering, the underwriters may engage in stabilizing transactions, over-allotment transactions, syndicate covering
transactions, and penalty bids in accordance with Regulation M under the Exchange Act. </P> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Stabilizing transactions permit bids to purchase the underlying security so long as the stabilizing bids do not exceed a specified maximum. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Over-allotment involves sales by the underwriters of shares of our common stock in excess of the number of shares the underwriters are obligated to purchase, which creates a syndicate short position. The short position
may be either a covered short position or a naked short position. In a covered short position, the number of shares of our common stock over-allotted by the underwriters is not greater than the number of shares that they may purchase in the
over-allotment option. In a naked short position, the number of shares of our common stock involved is greater than the number of shares in the over-allotment option. The underwriters may close out any covered short position by either exercising
their over-allotment option or purchasing shares of our common stock in the open market. </TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Syndicate covering transactions involve purchases of our common stock in the open market after the distribution has been completed in order to cover syndicate short positions. In determining the source of shares to
close out the short position, the underwriters will consider, among other things, the price of shares of our common stock available for purchase in the open market as compared to the price at which they may purchase shares through the over-allotment
option so that if there is a naked short position, the position can only be closed out by buying shares in the open market. A naked short position is more likely to be created if the underwriters are concerned that there could be downward pressure
on the price of the shares of our common stock in the open market after the pricing of any offering that could adversely affect investors who purchase in that offering. </TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top">Penalty bids permit the representatives of the underwriters to reclaim a selling concession from a syndicate member when the common stock originally sold by the syndicate member is purchased in a stabilizing or
syndicate covering transaction to cover syndicate short positions. </TD></TR></TABLE> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">These stabilizing transactions, over-allotments,
syndicate covering transactions, and penalty bids may have the effect of raising or maintaining the market price of our common stock or preventing or retarding a decline in the market price of our common stock. As a result, the price of our common
stock may be higher than the price that might otherwise exist in the open market. These transactions may be effected on the Nasdaq Global Select Market or otherwise and, if commenced, may be discontinued at any time. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We and/or any selling stockholder may engage in at the market offerings into an existing trading market in accordance with Rule 415(a)(4)
under the Securities Act. In addition, we and/or any selling stockholder may enter into derivative transactions with third parties, or sell securities not covered by this prospectus to third parties in privately negotiated transactions. If the
applicable prospectus supplement so indicates, in connection with those derivatives, the third parties may sell securities covered by this prospectus and the applicable prospectus supplement, including in short sale transactions. If so, the third
party may use securities pledged by us and/or any selling stockholder or borrowed from us and/or any selling stockholder or others to settle those sales or to close out any related open borrowings of stock, and may use securities received from us in
settlement of those derivatives to close out any related open borrowings of stock. The third party in such sale transactions will be an underwriter and, if not identified in this prospectus, will be named in the applicable prospectus supplement. In
addition, we and/or any selling stockholder may otherwise loan or pledge securities to a financial institution or </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">45 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman">
other third party that in turn may sell the securities short using this prospectus and an applicable prospectus supplement. Such financial institution or other third party may transfer its
economic short position to investors in our securities or in connection with a concurrent offering of other securities. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The specific
terms of any lock-up provisions in respect of any given offering will be described in the applicable prospectus supplement. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">Underwriters,
dealers, and agents may be entitled under agreements entered into with us to indemnification against certain civil liabilities, including liabilities under the Securities Act, or to contribution with respect to payments they may be required to make
in respect of these liabilities thereof. Underwriters, dealers, and agents and their affiliates may be customers of, may engage in transactions with, or perform services for us in the ordinary course of business for which they receive compensation.
</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">46 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom368527_18"></A>LEGAL MATTERS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The validity of the securities offered hereby will be passed upon by Greenberg Traurig, LLP, Las Vegas, Nevada. </P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom368527_19"></A>EXPERTS </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The audited financial statements and management&#146;s assessment of the effectiveness of internal control over financial reporting
incorporated by reference in this prospectus and elsewhere in the registration statement have been incorporated by reference in reliance upon the reports of Grant Thornton LLP, independent registered public accountants, upon the authority of said
firm as experts in accounting and auditing. </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom368527_20"></A>WHERE YOU CAN FIND MORE INFORMATION </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We file annual, quarterly and current reports, proxy statements and other information with the SEC. Through our website at
<I>www.therapeuticsmd.com</I>, you may access, free of charge, our filings, as soon as reasonably practical after we electronically file them with or furnish them to the SEC. The information contained in our website is not incorporated by reference
in, and should not be considered a part of, this prospectus or any accompanying prospectus supplement. You also may read and copy any document we file with the SEC at the SEC&#146;s Public Reference Room at 100 F Street, N.E., Washington, D.C.
20549. Please call the SEC at 1-800-SEC-0330 for further information on the Public Reference Room. Our SEC filings are also available to the public at the SEC&#146;s website at <I>www.sec.gov</I>. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">This prospectus is part of a registration statement on Form S-3 that we filed with the SEC to register the securities to be offered hereby.
This prospectus does not contain all of the information included in the registration statement, including certain exhibits and schedules. You may obtain the registration statement and exhibits to the registration statement from the SEC at the
address listed above or from the SEC&#146;s website listed above. </P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">47 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center"><B><A NAME="rom368527_21"></A>INCORPORATION OF CERTAIN INFORMATION BY REFERENCE </B></P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">The SEC allows us to incorporate by reference the information we file with the SEC, which means that we can disclose important information to
you by referring you to those documents. The information that we incorporate by reference is considered to be part of this prospectus. Information that we file with the SEC in the future and incorporate by reference in this prospectus automatically
updates and supersedes previously filed information as applicable. </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman"><I></I>We incorporate by reference into this prospectus the following
documents filed by us with the SEC, other than any portion of any such documents that is not deemed &#147;filed&#148; under the Exchange Act in accordance with the Exchange Act and applicable SEC rules: </P>
<P STYLE="font-size:12pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Annual Report on Form 10-K for the fiscal year ended December&nbsp;31, 2017, filed with the SEC on February
23, 2018; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Quarterly Reports on Form 10-Q for the quarters ended March&nbsp;31, 2018 and June 30, 2018, filed with the
SEC on May&nbsp;7, 2018 and July 30, 2018; </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Definitive Proxy Statement on Schedule 14A, filed with the SEC on April&nbsp;27, 2018; </P></TD></TR></TABLE>
<P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">our Current Reports on Form 8-K filed with the SEC on April 2, 2018, May 3, 2018, June 7, 2018 and June 26, 2018;
and </P></TD></TR></TABLE> <P STYLE="font-size:6pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<TABLE STYLE="BORDER-COLLAPSE:COLLAPSE; font-family:Times New Roman; font-size:10pt" BORDER="0" CELLPADDING="0" CELLSPACING="0" WIDTH="100%">
<TR style = "page-break-inside:avoid">
<TD WIDTH="4%">&nbsp;</TD>
<TD WIDTH="3%" VALIGN="top" ALIGN="left">&#149;</TD>
<TD WIDTH="1%" VALIGN="top">&nbsp;</TD>
<TD ALIGN="left" VALIGN="top"> <P ALIGN="left" STYLE=" margin-top:0pt ; margin-bottom:0pt; font-family:Times New Roman; font-size:10pt">the description of our common stock included under the heading &#147;Description of Common Stock&#148; in the
prospectus forming a part of the Registration Statement on Form S-3 (File No. 333-207837), as filed with the SEC on November 5, 2015, which description has been incorporated by reference in Item 1 of the Registrant&#146;s Form 8-A (File No.
001-00100), as filed with the SEC on October 6, 2017, including any amendment or report filed with the SEC for the purpose of updating such description. </P></TD></TR></TABLE>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">In addition, all documents subsequently filed by us pursuant to Sections 13(a), 13(c), 14 or 15(d) of the Exchange Act (not including any
information furnished under Item 2.02, 7.01 or 9.01 of Form 8-K and any other information that is identified as &#147;furnished&#148; rather than filed, which information is not incorporated by reference herein), including those filings made after
the date of the initial filing of the registration statement of which this prospectus forms a part, prior to the termination of the offering, will be deemed to be incorporated herein by reference and to be a part of this prospectus from the date of
filing of such documents. Any statement contained in a document incorporated herein by reference will be deemed to be modified or superseded for purposes of this prospectus to the extent that a statement contained herein, or in a subsequently filed
document incorporated herein by reference, modifies or supersedes the statement. Any statement modified or superseded will not be deemed, except as modified or superseded, to constitute a part of this prospectus. </P>
<P STYLE="margin-top:12pt; margin-bottom:0pt; text-indent:4%; font-size:10pt; font-family:Times New Roman">We will provide without charge to each person, including any beneficial owner, to whom a prospectus is delivered, upon written or oral request
of that person, a copy of any and all of the information that has been incorporated by reference in this prospectus but not delivered with this prospectus (excluding exhibits unless specifically incorporated by reference into those documents).
Please direct requests to us at the following address: </P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">TherapeuticsMD, Inc. </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Attention: Corporate Secretary </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">6800 Broken Sound Parkway NW, Third Floor </P>
<P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">Boca Raton, Florida 33487 </P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">(561)
961-1900 </P> <P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
 <p STYLE="margin-top:0pt;margin-bottom:0pt ; font-size:8pt">&nbsp;</P> <P STYLE="margin-top:0pt; margin-bottom:0pt; font-size:10pt; font-family:Times New Roman" ALIGN="center">48 </P>

</DIV></Center>


<p Style='page-break-before:always'>
<HR  SIZE="3" style="COLOR:#999999" WIDTH="100%" ALIGN="CENTER">
<h5 align="left"><a href="#toc">Table of Contents</a></h5>


<Center><DIV STYLE="width:8.5in" align="left">
 <P STYLE="line-height:2.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
<P STYLE="line-height:3.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="margin-top:96pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center">$65,000,000 </P>
<P STYLE="font-size:24pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="font-size:0pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P> <P STYLE="margin-top:0pt;margin-bottom:0pt" ALIGN="center">


<IMG SRC="g554088g96q94.jpg" ALT="LOGO">
 </P> <P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:18pt; font-family:ARIAL" ALIGN="center"><B>TherapeuticsMD, Inc. </B></P>
<P STYLE="margin-top:24pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center">Common Stock </P> <P STYLE="font-size:36pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center> <P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center>
<P STYLE="margin-top:18pt; margin-bottom:0pt; font-size:14pt; font-family:ARIAL" ALIGN="center"><B>PROSPECTUS SUPPLEMENT </B></P> <P STYLE="font-size:18pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P><center>
<P STYLE="line-height:6.0pt;margin-top:0pt;margin-bottom:2pt;border-bottom:1.00pt solid #000000;width:21%">&nbsp;</P></center> <P STYLE="margin-top:96pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Goldman
Sachs&nbsp;&amp; Co. LLC </B></P> <P STYLE="margin-top:12pt; margin-bottom:0pt; font-size:16pt; font-family:ARIAL" ALIGN="center"><B>Cantor </B></P> <P STYLE="font-size:96pt;margin-top:0pt;margin-bottom:0pt">&nbsp;</P>
<P STYLE="line-height:1.0pt;margin-top:0pt;margin-bottom:0pt;border-bottom:1px solid #000000">&nbsp;</P> <P STYLE="line-height:4.5pt;margin-top:0pt;margin-bottom:2pt;border-bottom:2.00pt solid #000000">&nbsp;</P>
</DIV></Center>

</BODY></HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>2
<FILENAME>g368527g96q94.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g368527g96q94.jpg
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M 0$! 0$! 0'_P  1"  Q :(# 1$  A$! Q$!_\0 '@   @(# 0$! 0
M      D("@8'"P4$ P'_Q !,$  !! (! @0"!08&$ <!   % @,$!@$'"  )
M"A$2$Q05(3EXMK<6(CAV=[47&B,Q.M<8)"4T-T%76')SD9:7L[35)C(V5F*!
MF,'_Q  = 0 " @,! 0$             !P4& P0( @$)_\0 4Q$  @(! P(#
M P0+"@H+ 0$  0(#! 4 $1(&$P<A,10B0391=;0(%2,R-V%Q<W2!LQ<S-4)2
MH;&RM=06)#1#4U5B=I25.%16<H*2HK;$TM.1P?_:  P# 0 "$0,1 #\ _?\
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M1NT['X*Z1*?@^Y U(8;Q:@FL+6SN/]@#-P-RL[R0Q,3M]WK2+WHT7^,\<DS
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MMN05E5KX2K<EFC[4Y7\?'I\F13C&OZKN0>+==6N&*LU:L<6DEY\%G.?;8DV
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MS-D-./UT+6A$V$/L3 MYO\I+,P2)D9$N$V$ABZ]UAU%9S&2L5UE=<=4F>"O
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M\I!]KLQ//2?R\RRRV9^!]?=V!\AM;+94M;32W$>VXMM"EMY^GT+4G&5(\_\
MXJSE/_UTCCZG;S&^OT<4DJI8<6*@D?,2/,?J/EK].OFO6CHT:J<>+3_1<XK_
M +?3_P"'9?IG>%_\)9+]!3ZPFE!XP_P3B?I&3ZL^FH=AKZI3AO\ JIL+\:-D
M]5GK3Y3Y;\]#]5@U;?#[Y'X3\S9^O6M-WZJ^KEKGP>*-^LXU7]ES4OXK;EZ>
M?AS\F[?TC;^JU-<X^+'RIJ_1-/ZW=UT'^D9KH[4*^Y+]79SU^QCR@_!*[]2_
M3_\ #V$^E\;]<AU!]3_)KJ'Z#RWU"QJL1X0W^^>X#_J.+7_,Y#],;Q3],'^7
M)?T4-*KP:]>H_P F(_IR>DN<Y.,KVQ^^%OOC?>[U%U+_  V\O2D2#?3PATT-
MK\;>)5BV:_(3!J2094@;/9N%<A^]\SB,Q(TW$MQ[V8RTJMN&R/L_1M'(0P&U
M['BU)@1PC2&F#%.H;B^S+VI#MQ))7;;<ZH^>Q1M=>9#&6+ I>WYEPMB1"ZQB
M^XFK,R<DW5N]$N_, !N6^PTW;^*,;$_SX:7_ ,"CG]9_57_=2K_ZFF_XU/[O
MJY?N-V?]?0?\OD_O6C^*,;$_SX:7_P "CG]9_1^ZE7_U--_QJ?W?1^XW9_U]
M!_R^3^]:=#V=.SK9NUI8]\'3V^@VXVMRA* )CP@]"GTO -RE3K7,7*DKF6JQ
MX(YFILF&F$-HB9C88>RI3N'\8;J/5G5<?4D=)$I/4-1YV+/.LW/O+$-AM%'Q
MV[>Y\SON/FU>.BNBI>DY<A))D$NB['70*E=H.V8&F;<\II>7+N[#TX['UW\J
MS-]K@RU>)[CB"\=N5!3SQH)A4=U.%M.2:VFMV,?AQ"L92MO! 5%4M"L90M*<
MI5C*<YQEA02-'X<%D.S?::PFX^:1I(V_]+'2ML1)-XJA'&Z_X05GV/H3$(I5
MW_%R0;ZZ'O2)UTCJJ;XG_GCM/0>KM/<5]/68M2IG(&'<+)M:S )CXL\[KFM/
M"@P^E0"<5:)409<RY0HY9UPW8LJ4+KC(-UYX.>,PI+,\.<+6O6;>2MQK,*)B
MCK1. R"Q(&<S,I\BT*JO;W! :3F '12%'XK=06\=4I8BE*\#9%9I;DL;%)#5
MB*QK75@>2I.[OW=B"R1",DI)(ITSV[_#)\?KMH#66Y^8=[V58[SM*FUZ^QM:
M:Z-C*=4J4$MHJ*;#A3A=P*7L=DLS R9#<+RAI*O"!Y!Z8)C1##,)DW,V\]XB
M7H;UFIBH:\<-::2 V)T::69XG*.Z+S6..,L#Q#+(S* Q*[\1H]-^%F.GQU6]
MFK%J6Q;@CL"K6D6"&".9%D1)',;RRRA2.95HT5BR!7"B1I6;G\,#VXG*79CM
M4N'(75DT  +FFR4785:L(-C L?(FK=,P+9224I^ TAA3DA,,T)>PA.58EH3C
M.,QE3Q&Z@$L:2Q4;(=U3B8)(W/)@!Q:*90#Y[#=6'XM2][PIZ9,$LD,V2J-'
M&[AELQ2QCBI;=UF@=BHVW/&1#M_&&E!>$W_38Y$?9:(?BSK'JT^)_P#!./\
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MBM6?09VDC).4J^'4=HNPS)TZPE?EZ?>1 V+77'$^?J]#C>?+RZT/"^5#C<E
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M+^'G6&5LY*3IO./)/.J3BM/8!%R.:IN9ZEECLTI")(P>3>9'C='9PR]MGGB
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M6<3)[-HLHVX3,60K?+G,66-5UF_&R#!210YL$R3J\M) U+C"SIHR 54.M+F
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M_I5=5GJWY39OZ0G_ *VG!X&_@@\._P#=?&_LSJ;'5=TUM'1HTH?OB?5^7O\
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M1?O410BKN23LJ@ ;DD^0]23KU.O.O6L'L>L=;7 @V7MVO:/:2S,9J&R3L=3
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MVTRRTWA+;333:4H;;0E*$(3A*<83C&.M$DDDDDDG<D^9)/J2?B3J2
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!V0$!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>g554088g47b56.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g554088g47b56.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[2'P4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $X< 5H  QLE1QP!6@ #&R5'' (   ( /QP"4  (<G(R.30V,3@< @4
M)4UI8W)O<V]F="!7;W)D("T@-34T,#@X(%!R;R!3=7!P+F1O8W@X0DE-!"4
M     !!'>6/L4JK'-2N^HW6R\%@U.$))300Z      #E    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0&<8
M08         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $  @/
M     0 ".$))300F       .             #^    X0DE- _(       H
M /_______P  .$))300-       $    >#A"24T$&0      !    !XX0DE-
M _,       D           $ .$))32<0       *  $          CA"24T#
M]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M     0!:    !@       0 U     0 M    !@       3A"24T#^
M<   _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H   X0DE-! @      !     !   "0
M D      .$))300>       $     #A"24T$&@     #-0    8
M     G8   2-          $                          0
M   $C0   G8                      0                         0
M     0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T
M,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M
M;&]N9P   G8     4F=H=&QO;F<   2-    !G-L:6-E<U9L3',    !3V)J
M8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R
M;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
M  UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   )V     %)G
M:'1L;VYG   $C0    -U<FQ415A4     0       &YU;&Q415A4     0
M     $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L
M;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R
M>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV
M97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M"V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M  QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
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MN=_+>QK7N5?(>*\\V3^CM8V[=.D >YT_U6H?U!K<WZOBPB&WWVV,_J[O3_\
M1:<-B.Q6[XSX$5]=W__1WOK=B9?3,S(ZCB>RGJ57I66#3TL@#;3<=H]N_P#>
M_P"._/\ 27"_\Y^OX-=G3<U^YSW-<+7^]Y )#/3LG])4[_![MZ]NNIIOJ=3>
MQME3Q#V. ((/[S2N:O\ J+B;R[ S;L-A,^G.]H_J266?Y]EBD$HD#B-$=6$Q
MR8S(P''"6O#?"8R/S?-Z91D^>NP<Z][,KJH%.$'-N-?JL?9?)#_3J%3G>DVW
M9^FO?L]B]!Z9A=0P,%G4,LEN1DVOR,AID"IUAW5[F_2;7M]F3^YZO_!JWTOZ
MH],P+VY=KWYN4T@MMO((:1PZNO\ >_K^HMPEA!#H(.A!2G($4->Y_@F$)F7'
M(<-"HP!XM]Y3E^E)R*<6K(86?M'+JL,[JW6M#A/[IV;G-_<?6Y*ZJO&>'5Y^
M3=<T@BDV-+2&G=%WL_1U._PEGT]B/;T>@Z46^DW_ $9 >P?U&O\ <S_/4J.D
M4-@W/-P&H9 97\ZV?3_MIEEEIY+ZX='S\KI5'6\4>ID=.M=<6D:V4OVF^W8/
M=MWLW>G_ -Q-ZPW?6CH^1CTLS;'AE;9ILU-C [Z=-SMOIV^FYO\ .M_GZOT_
M\YZM:]8D>*Y'K7^+?H?4+G9.)8[IMS]7BJ'5$GZ3_L[_ *#O^)?4CZ9 "1,3
M'Y91\?T2BY1),0)"7S0EX?I#^L\ODL^K5[J>H9^)]I9C[F;WAS&EOOVUV397
MOVOLWL8RK>K'U"Z#=F9=_6\:I^)@U5NKPZWV.L]6TAK+ILM]UF.S9M_<]7_P
MO<M?IW^*[HU%K;.HY=F>&&6U:55G^N&.?:[^S<Q=G4,>FME-6RNJMH:QC8:U
MK6C:UC&M]K6M:CI$$ F9/Z1[(-RE9 @/W8]QU<[%R\:S'.)G,!J'MBUH($'^
M9R&N]K7U_O.]CT<CHM!%K68X>W5A8UI?/\CTQO\ \U$OP<7*?ZDEEH$>I68=
M'@[EK_[:"SHU8/NNL<.X&UD_UG5L:],7( ']3RSN!;4P0X3]%OTMD_Z>YVW?
M_HZERGUL^K'5>IV[*<ME;J1 QK-S6O:06NV7,W_SS?\ 2-]B] JIJIK%=30Q
MC>&A1R,6C(:&VMF/HNX(^#D"-01N-F2$P 8ROAEO7S/CGU<<SI_0NJYF0179
M9D,P_3?'M-6VW):\?RG6U?\ ;*Z'ZI]#ZCF]6_;74 YCG^[%I?.]E;O;ZM[?
M\&[TOYNK_27?\&NU;T+#:\O!().XD!H)=^\7AF[=_*5ZFBJANVINT'4GDD^+
MG?G)O"3.4SO+3R"_BA&$8Q)EPZC^]^]+^Z\0R_(^K/5LC#RO=1D.LNZ?D6GV
M.-A#GLM?^]_I/^$_2>RK(6DS+ZVVQN+91ZV,UK!==6PAI:X>YHR [;ZC6.][
MZ/T:Z#J'3<+J6,<7-J%U1(,&00X</8]L/8_^4Q<Z?\7N #LKSLNO'[TA[8_Z
MC;_T$^0XJ]1CY*$\9UD/5UTXOJT.KY=62^GH/0HLOLK^S-<V2VJD:.<]_N_P
M7_@?_">DNQZ=@T]/P:,*G^;QV!@/<Q])Y_E/=[T#I'0NF='J+,*K:Y_\Y:X[
MK'1^_8?S?Y#?T:T$371CE(4(QV&NN\B__]+TW.HHMH=ZQ# T2+/W5R655C.;
M+[@QQY!K<1^"ZNQE.:ZRAWJ#T'!KM"UI):VP%CB/TGM?^:J=_P!7NFN:YUKK
M&M ESM\  =RGPD!O;%E@9C2CYO"9N/A2(R6F20Z:G"-)#O\ .]JS,JC$K<W[
M/<,@.$N=L+(/[NUZ[.SIGU+LK%S\RP5N <'%[@(=]%VK/Y2M?\QOJ[NV[[IF
M(]0<_P":I8<SB.TN*NW"7/R_#>8UN$(7L2<EOG>UO@%O?5G.S-YP PW8@!<?
M^!_EM<?\&]W^!_[;74?\P.@^-_\ VY_YBM'#^KG3,+&&-CM<UD[G.W>YQ_>>
M[\Y&>>$HT!?FNY3D<V+*)RF(@;\)OB_JN#;C5O'Z1@?(G2UC-"/Y?YS?SUDY
M>)B-+ ^GZ9@G[17MX+O<[_!?1_/79V_5KIUOTC9\G?[%G9GU5^K]<"U]^]WT
M6,?+C\MJC$P-RZ$HD[/$Y/3L8U./H,#XT)RJH#OY5;AZKF?^>UGV],Z?!_5O
M?,?TVB!K'T S=L_X1B[EWU'^K-K@V[[927?1WN#0?GL3N_Q5_5EQG?E?]N-_
M]))XRQ[G^7^$QG%*_EC_ "_P7S7"R\_H?4!?B/%>54=C@P[Z[ 8W4/#/;?59
M^[_VW^D7K6.]]^)5=DUG#OL8'68S_>:W$:UE[?\ SO\ TGZ14\3ZE?5OH&;5
MEUUY63?!] &;0PRQOJMV5M97;^D]CW_]:]ZZ,],QSR7_ '_[%'FF)50^K-RW
MZNP9?X(UX7&LKI_TH_S2@.KHF#> /'8[A;AZ-B'DO_SO]B@>@X1Y=9_G#_R*
M@,2WX<QC&\I?8' ].@B?7 /8%CI_!$9=9;5^D!)&@?X^7]9;/_-W _>M_P X
M?^117=%Q' -!>UHT :0(_P"BC")!LZ*S<SBE&A<CWD*X/+A>=NPG.'O9:UVL
MAM>[@_UEE9.)3N<T>N=I:'#T@2 6N=]%K_\ B?\ /77V?5G!L^E;?\GC_P @
MJ[_J9TQ\_I\D3X/:/_1:DMACEB.I^QXB[ Q28_6A)T_5C'E^>M#ZG=2ZK@]3
MJZ8RI]V/D'=9CG3T@3[\MF_^;K_TK?\ "_X/]/\ SG0/^H'27N+G9.9)Y_2M
M_P#22T/J[TKI_3\,NPV6AUQ)LLR?YX[2YC&OT;MK9_@F?^E$3(5W3/- Q,?F
MOH7_T_3Z/YW(_P",'_GNM2O<YE+G,;O=&C8F?N4*/Y[)_P",'_GNI'2*!^UQ
M\;ZM_5YK&7OZ7BU6-.X?HFC:6F6NU'M5'K_6NM]-Z@*NG]"?U"DL#_M+'&-Q
M+M[-C&/VN;_*5WZR_5NKK]-#'9-V)9BV>K4^J'-DC;^EHM#Z;?Y&[Z"M]&Z9
M3T?IF/TVJU]S,<%HLM(+W%Q-CIC;^<_V,_,8B!$#<WY?M76;U2=,R,O*P*,C
M-Q_L>38W=9CEP<6$_FEP_DJTFD>*6YLQ(D<A!"ZI83 ^Z_(?K8;',$]FM.UK
M0KDC37GA575757/MQH>UY_25$Q[OWF% I#8LK9:QU=@W,<((0<!SG8S0X[BT
MEF[Q#3M!42_-N&QM7H Z&QS@2/ZH:K%53:JVUL^BT0$E-;.^G5\_^JK5Q4\[
M^<J^?_55*XG= M&Y^CG=8ZSC=*94;W-9ZQ+6OL):P$"=7 .]W[C$W1NMX_5F
M7&@AWH.#7/82YA)&[VOAON_?8KUK*;6&NYK7UGZ37@$'XM<E5732P54M;6QO
M#& - [_1;_63?5>XIEO'[=<)]R_FOT_XJ1)-N;,2)2D>*+&NJ/2\QV5Z[B[<
MT6N%?]0$UM_ZA70YIX(T4*V8];G>D&--A+W;8&X]W:?20(-@WMNN! C($:FJ
M*1 POZ,WXN_ZIR.@87]&9\7?]4Y'HLZCR+__U/1K;<NK)M%-9L8\@DM:U\.V
MM:6NF^AS?;M_,4&YO43_ -I[!&AFIO/_ +%^Y?,Z2=]BW[7Z8^V=1T_5WZF#
M^B;II/\ W+_LK.RW81OMMR*0[((:Z]IVM@_H]C+&OS6M]NRCZ/Z-?/"2(\/P
M6RX:]7_.?H.MG38K]*J!!],APW#:3MVM^V;O=8QOI?U_]$I,_9KVU--0:T@!
MA<6B&;GG<[]=W^E_/[_^"]1B^>DD?4M'M>#](.Z?TPQOOHTK#?IO'Z,-8UO_
M &H^CZ;:O>BX^'B5Y+78]U!R6B!JYSHVCZ3?7]WZ/:OFI)-]:1[5Z5;]1[<S
M_25_]MN_]+);<S_25_\ ;;O_ $LOEQ)#[%^GC_SGZ?NIM>0;;JVD [(81K+#
M)W6G=]%$V9G^EK_[;=_Z67RXDEJK3Q_YS])96'TY^6ZS*NQADP-X=N:8 _.K
M^T_Z/^3]! _9W1(:/7Q>VR7.GD$;#]JW?37SHDG#C\5A]FS=>+](?8.F#U?T
M^/JQS+I+OH$UE^_]9]ON]#])_P 4A_L[H\?S^-&T_G/^CM;O_P"U7T/2]+?_
M "/27SFDEZ_%1]GKPOT99T[I$1;D8W(/O<[GW?\ =K^NK.%BXE=Y=AW8YN((
M=M!<8_1^I[?M'\FK>OFI)(\?6U#VKTJ_!^H]F9_I:_\ MMW_ *64L5@KH8P/
M%@'YXX)GW>*^6DDUD%7U?__9 #A"24T$(0      50    $!    #P!! &0
M;P!B &4 ( !0 &@ ;P!T &\ <P!H &\ <    !, 00!D &\ 8@!E "  4 !H
M &\ = !O ', : !O '  ( !# %, -@    $ .$))300B      %&34T *@
M  @ " $2  ,    !  $   $:  4    !    ;@$;  4    !    =@$H  ,
M   !  (   $Q  (    >    ?@$R  (    4    G $[  (    )    L(=I
M  0    !    O    .@ '#$<   G$  <,1P  "<0061O8F4@4&AO=&]S:&]P
M($-3-B H5VEN9&]W<RD ,C Q.#HP-SHS," Q-#HP.#HT-P!R<C(Y-#8Q.
M     Z !  ,    !__\  * "  0    !   $C: #  0    !   "=@
M   & 0,  P    $ !@   1H !0    $   $V 1L !0    $   $^ 2@  P
M  $  @   @$ !     $   %& @( !     $              $@    !
M2     $X0DE- _T       @          /_A 4A-30 J    "  ( 1(  P
M  $      1H !0    $   !N 1L !0    $   !V 2@  P    $  @   3$
M @   !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !     $   "\
M    Z    \     !   #P     %!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD
M;W=S*0 R,#$X.C W.C,P(#$T.C X.C0W ')R,CDT-C$X       #H $  P
M  '__P  H ( !     $   2-H , !     $   )V          8! P #
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MN$958V1E9W)VAI*4HK/%1%-F=8.$A9.CI*6RP\3&Q]/5_\0 '0$!  $$ P$
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M6.-AHD!.M5+R",BQ=O*?C*[2L9UNDVIG"9RRG$W# ;+<P^4Q'C!>VGQ]B&4
MR<+8\EF<2\0WJ!9B227AVX.G"R+-^W64EW$;&E+('M:;A+-:F26(M1TS1UQR
MY>]52Q">J6Q=*>RN9="L';2+Z3L"=L7E7QEE%+%%*J5U8LE ,R84=,93!2-<
M))4:WC$6M@5 +6N+LP!!*AVR[G+SFS?;N"J"5EDUL&LMJVTO,N,*7*0U?8NZ
M\]S"VNLK,/GKV/:*2ZTA)1[*'2>L7D]*QS!=J<D<! ,JHM3S'+8:3)*"8QJ*
MTYIFM)4RJSL'%)R%15O9=*LSD-H5B#OBIEF:3UN?9A#S'[BN5Y564L#I"IC-
M8LCNS,@9];*$#*9G0$>$=#BT/6.8RC!IA@TPP:88-,,&F&#3#!IA@TPP:88-
M,,&F&/A0!$@@'KV^8A\P^8=P_1K@]#]OQ6P^WVZ_BQ$2>O.8*Q/82@IZ4K:3
MS+%^M$%*M6]=$?P>AF$#/3\.BT64F' .Y,J$8S1DG2X&;K'5<>0U1X3$,OI\
MOR2LI\_J:>&JT9-EU)51,]7?O,SU5)3U', @33$6GD,2KN@"W9]R=2YAG_&.
M4YGP'EM?4Y4)N+>(LYH*U8<MD'<*"GRO,LSH(X&:ND$M4B4E/'532#ERL\S)
M#"- 3PY-R!G'$],C+]/&K\Q7ZW>7\?DLL/7%DWX8T<33MK#7B#2-+OBH.HN.
M6BG%BCERNTU44WSEH9F1$3F[Y1EN19S6RY=3"JAJJK+XGRDSU2&,YLD*//E]
M0W(CU1U#K*E-(IC99>6CZP;8M^*N(^.>#LCH^(<P^#J[+<LS^>GXK6@RV45*
M\+SUTT-%GU AK)Q%-04\M'-FM-(M0KPBJFA,'+L9!46;D[4+NT)R"+BG2IDS
MT],K(B2[Z+Z"&+."Z!03*L)(XG/$IF2(=6/!)^H<WM9$6^-UL"4K)3-&5K(0
M16>,D1S;@P%"-I(UL)2&(634@^22=B9+73YLLN:1U$<N3U>A\GTPA6J*72K+
M7\W5=H*HDM2*4!>G"3L3SE2-.YCR:ZH(4B"@F;5_<LEW*/I560?BK[M:*N&[
MA_+3DF1N=-PNQ@XAD[?*-$%FZCU<K=H#EL"PN$KW)LI&9?"%1-(T5%E-#)7U
MC);FNH=(8((M0*B2HGD2,.58(NIRK:=)BN,.*7X>^ *"CABJ<YXISRFR'*8I
MV<4\4CQRU=;7U(C*R24^7T%-/4-#&R/.XC@$D7-,J8BX9!G,66C&K.T/FDW4
M\CV="@C)DCR1LE 7&28/7U?5,"*ZC1Y!S*T:YB3('0(_CWSEDO[6\;'<@E5H
MLL@S>CS62E1H*O*J/X2Y)E,L=11QR1Q50!<!TG@$JS!@2DB"10B,$)M<\XCJ
M^%,UX6AS22*MRCB;-DX<-4L IJG+\ZJJ6IJ<M<JCM#+E]<U)+1-'I6>GJ):5
M^;-$9M/1CZ_V#,(WB9J\BRK]3K5NG*377*L8$J[GY2L+%9S,V^\URW33A#2@
M+L(]BS*V>KH-%'JDDF+E)LASF6609+W""LC>IK*JAILQJ$$G*2FBK%,L$$>E
M&+3" I(\KEE#/H$?AU-UX;XDK>,_A^MRJ:&@RC*\ZS'A_+97I^]39C5Y0ZT]
M?F$]YD6.B[\)Z6FIHA'.\=.:AZE3,L43;S&Y.R%P1DS(,15XP]VQ5(76KW"/
M=R"I8&+LE.710.X;@0IY&08R[=ZPEHQF!$3I-W*C5[(H+-A.O*4_"T#<1Y/E
M<]7+W#.DRZJHITC7GS4U>I;202(XS!(LM/,]R;Q\R.(AP!B]9VG9BO9_Q9Q+
M1Y52G/.#ZC/\ISFDFJ7^#Z;-,B=4,L6@=YJ*>NAFIZZD@'+<13""HJ(Y(RS+
M3(62[76K3MYC&+^*:1V5YQW#V-1U'%5.R394F3M7M,<N=TD1%9=TR2:'*Y*X
M3! YQ(3S>DY+#+<KHZJBXEGECF>3**6.>E"2$!VDKX:,K,H1BRA)2_AT^-5O
MML9[B+B?-<MS?LYHJ::CBIN+<QJ:/,VGI];0QT^05F;AZ1S,BQN\U,D1YJR@
M1LQ6SZ6'NR!DB>ALOX2I5?E896%R.\N32= 6J+]\R)5ZXK.ME&#A-VF1$SU4
M"MG'M"*Y2I!UH]"@B;7&7973U&2Y_F%3%,)\KCH'IK.8T<UE6M.XD4H=01?$
MNDH0Q&HE=L5.(N)\QR_C/@/(,OJ*)Z#B>?/8\Q+1">HA7*,J;,(332+.JH9Y
M/BY>;'* @^+"M<X2HY1NRV3]P%+&S5>!BL55>DV*!E9:$\U REIB)Z3=I6 P
MS#'SH]BK$H$3.R58N?*55%10Q^#:N?@J@3)^'J[NM543YM69A25$44]B%HY*
M2*-J<"%[2/SF+!Q(I8J%"@8BUXKSN;BOM$R(YCE67T?"64</YEE]95T3.A?.
M*/-*B=<Q(KJ<24U.U%%I,+4\N@MJD+6.,9@YG>\H#2LZSJJU62LL&60?4M5>
M? K4XK.&P(-TW$B14(]X5,LPR2<&-%E2<H\PHK@#S77B".ARBIS#(J5UK%I*
MIXHJT"*[J"&UED5EY@!$$@&]XVTNJG2*' 7P[Q9!D/'U>),G&;9;'53Y$[UX
M$#,9(Q'&LLZ/W>6PK(%E'=]$L>JBYP,V)F%] ^X/3[M8IC<&.=,,&F&#3#!I
MA@TPP:88-,,&F&#3#!IA@TPP:88-,,&F&#3##/Y]Q#$Y\PYD'#D[*R4'$9"K
M[BO/I>(*V/)1Z+A1)7VEF1VFHV.J0Z)?@5()3%$Q>2\]02&59C)E.8TF911I
M-)1RB58I+Z'(5ETMI(-B&]<8UQCPS3\9<,9UPO5U,]'39U1/12U5*(VG@5F1
MQ)$)0T98,@V8$$7&W7&NUX8MHW0TE??%0)?,./*)LFVAY9OE!93&5*K^%<O*
M>ZGT^\LI(V5:7*ELZFS]TDC9>85>NY-DG*V!%.*@@4</U2['XMERFM.25WP;
M-+GF;4E/4,*.J>)8QIBY;2(T-5SM+ZE6R1DQQG6UD6VD^ROA3/>#Z'/LB@XN
M:;A')J^MID@SS+:2JT!I96JHZ6HAJ*-X%E3XR17DEB2:=BE/J=B5!OWV@9UW
M1;"]O]WQ=F2#7P5A6CXVS17L%UNBA7Y*6K]7I3!1A[RNREKL/X2R]4@E)#I9
MH1E<9/#>VK),S2162(4^'<SRO+.):ZDS"CJ8Z^MJJBBES!JH2JDTL[!B*?NT
M7+2:339FDD* K<E=\=N.4XSF[-\OXCX7J\FS+*\IR>@SI,E>CJZ>I>AI:**1
M].81YE4)63TL E=AR:?FA'5!S6 ,_:G>,C[]M@\!G!E68>K9WJ-O>Y8Q3%5Y
MT[5CR9$PO<7ZU>B$'3U99RDSR!#1\C1+ "C@Y31%MER *:2@$)C]?14?#7$T
MN6\V6?+I8(J:K>=5#]WKZ:,RN44 :J61UJ(;"^N!"=[WRO@#BO-.T_LVH.*J
MFAI<NSLUE=/24U$[O3K4Y1F,\5.B/,S2::R"'N]0&<^&>519; (-KC'(F46N
M&-Q=PQ3<HF[YYWM8WOUQH=AKKQ:QXPV_TNAY%I% J]ZC!27]RL6,2X/9[.TD
M2I,X^SY#F&;L 74X$U53TAK<MAJX6@R[(ZFFAGCD BJLQJ*FFGJ9:>0$%VYG
MQ<#+;4E,C+OUR9:2JK5H,VGH:A:C,^(*2JFIIH6:2CRN"CJ::GAJ4 98H@A-
M1.)/"LU4ZO<FV&&QI1&^-=I-3PNPVR+5&7BMP5GKVYNRR^RVV90&KUEM<\OV
M7']\JU+;TU.-SJV Y:A#0]HJ?[84'182T(3$A'^RHF21OZJH[SF\U:<S65&R
MV"3*X8LZBHQ-*8*)*BGEG$QDH3832/'*U-)42Q,H<$WQ%45**7(X,O&4&"1,
MTGASF9^'9ZOE0K-7R4M1!!W<QYDH/=XTGA[U'313!Y$"#P^G#.WZTS\]6J-/
M8ONT[@IQX@D_-H,+-@>2PY5'6'[GX>^1J=9[&&+#LVS2C4FQ7^?=PCTBD=7V
MSFV32WM4/$SDPHR%6YA#%'-,M531UYX=CCU09@E=,M;!Q#3311&JU,9YXZ9
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MX8HYRKX ^S;+5FRE9;)?=R31#+V1IG*=NJD)E)FQIQ[=./GL@_>M(!2KN6A
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M [9:)Z=94D+=WCF$*.SD)ZVC>'9MZO>US:O1\,Y*6@7%NKTM<GT@I7'Z\I$
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M6'*2#300AG8E#8ZR[$G4;6Q+0<(4<!IG%54O)#'F@EDD$3/4S9M'RZFIE8*
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M3-5QS10SF[KH@GBAE8$G0TR.5!*;J2#S4\(4%1G!S8RR(9)HJB>FY-++'+-
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ME26L^%,DS:CS*IK\S%0B?!E-ET*5=73U4YY,FLB,TJK&M*@51'S )6NQD'B
M6^>.CH^(8,XN)8,XN,CFR#*/CHYJ@R8,6;5(J+9HS9MB)-VK9NB0B2"""9$D
MDB%33(4I0 ,(9F9BS$LS$EF8DLQ.Y))W))W).YQGZJJ*%50JJ JJH 50!8
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MB#\]XQ7B!SKI1P7-B4(FIQPT@J-1F35$ 'GA+K@'#GOP "*CE0P@(\CK)(N
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MY3@;T^7U[?4/\VL>^WV/3&S\?6F&#3#!IA@TPQUJ+)I%,=0P$(4!$QC" %*
M<B)C"(\%* !R(CP !W'T'AAB+V0=U^.*>NO&0:KF\3B(G(9E71!5B@L7L)'<
MR8#,2=!OA.5I[:J00,4R91+I]OM].%_M]OQ8C9,;HLVV,Y@KD%7ZHU4_M:BC
M=29D )SV$RKHY&@GZ0X'I8D#D1$/EPPW^V_YL)%;).X=U\:N0WB)A$!Z6L;%
M-@]3B "5-F0!*'( /P]P*'/(\B/'VZ_:_P ^&,BSS%N)BC%5+;&LN4O3U-Y2
M$C54S@ @(@)T$&ZX=7'2)BK%$ ]!+ZZYPPZ5:W?V6-.DWO\ 1P.@)B$5E:RL
M?J(!AX%4T6^,<3]//)BI/B"/'P%YX &&)=T/*U(R*T.YJTXVD#I%*9TR-UMY
M)D!N  'D>X*FZ0#J^$%#)^2<?[6J?L8S##C@(&#D/Z?/3#'.F&#3#!IA@TPP
MG[/;*S2H"6M=PGX>K5B!8KR<W8;!),XB%B8YL05'#Z1DWZR#-FU1( F47<+)
MID#U,'(:[QQ2S2)%#')++(P5(XU+NS'H%5023[ABG++%!&\TTB111J6>21U1
M$4=69F(50/4G&NON_P#V2KM&P@]D:IMZ@9K<];F1EVJLW$/CU#%[-XD/1\%I
MD8]W)V)(# )BJU^$7BW2? H3(E,!@V%E'9OFU<%FS&5,KB-CRV'/JBOG\4K"
M.,V\I'!'72<:QSOM3R;+R\66129M,MUYBDP4:L/29TUS#S+1(R&Q >_2A+,O
M[)1\1/(SATGCYYB_!D.J8X-V]/I36R3**0G Q 7G+ZI9"*JD* $,JTBX\#AU
M&\HG4!2YY1=G'#U,!WA*JN<6.J:<QH>EQRX!%87\B3;<:FV.-=UW:EQ-5$]V
MDI,OC\E@IQ*_G^R5',WMYA%'[W$*Y3QEO$]EW*CIQO)RRV.H<Q_*BW,%#M2"
M;CX4FL7"M$2$#]RF! 3*'( 7OJ9'!W#2@!<GI-OPA(QVVZO(Y^FY\R;X@VXX
MXJ<ZFSVN&]P$:- -[V(2)0?3\PPX5#\=OQ2:&[0<);H)FV(HJ H>/O=1HMI:
M.0 !#REU'U<"0!(>>_D/4%/0P* .K>?@;AF<$-E<<1-_%3S3Q,+^8"N%VZ[J
M1[#TQ<0=H/%E.P*YQ+, 0=-3!33*0#?2280Y!&UPRM^^\\6Q[=?V5'DR+=1\
M7NDV^UBVQ0G23?6[$,H]JLZ@EQTJNCU6QN9J'DUN?RHH-IN#2'D2DZ>"@.*Y
MCV74K!GRS,987MX8JM!-&Q%_V6/EO&"/,QR;]2!N,RROM=K%98\URV"H0D!I
MJ)F@D&VYY,IE1P#O8/&>N-GK9WXD&T+?-$>T8#RQ$R]H:LRO9O&T^4U;R/!)
M])3+'=U:4%)X_9-CF!%69@QE83S0Z22(CVUK/-^'<WR1K5](Z1$V2IC^,IGW
ML )5N$8^22:'Z'38@G;&2<49+Q E\NK$>8"[TDH,55'M<DPO9F4#]DCUQ^6K
M4"!.D!Y#GO\ I#@?U#WU!XR#'.F&.. ^@?J#2WV^K#'.F&#3#'@D9./B6CA_
M)O6S!DU2,LY=NUTF[9ND3\Y1998Y$TR%^9CF*4.0#GOIAB(-WWC5&,<K1M"B
MGUY>IB8AGZ)E(V (H7D/@?+HG7>%Y[]39MY!P[IN3!TF%AA@9?/VX.T*"=B\
MAZBT,(]"45%I.5P()@Z2J.I7VQ0QND0 QDBH_%W  ^3#"24LV<G!NI?*EH*<
M! 1*D\(V( AW#X$2)E$O<>P@)>  .X:8?/C*,<B[@(<2JMLA/9(I1[I2S..D
MB']0Z.7#83@41'D1(<IQ$ X-IAAU*]NUOL(9)"]TYG+-@, *R-<459.RE[ )
MQ8.C.$%C?G'$J:[8! > ] X88ESCW,U#R2B(UV:2._23ZW,,\(9E,-   ZS+
ML5^E4R93?"+AN"[;JY %N>VF&'6 0$.0'D-,,<Z88-,,&F&#3#'E>/6<>W6=
MOG3=FU;D%1=PY53002( <B9154Q2$*'S$Q@#7!(4$DV ZD[ 8JPP35,J04\4
MD\TC!8XHD:21V/0*B@L3[AB,]TW24V"54:UM!>T.B")//2.+2+*<.W)5U$S*
MN2\\?$DD"1N0Z5OF,9-FL*$B(&4C[X6"7W\SN=QT'EN,;3R/LDSW,52;-)8\
MGA:Q$4B\ZK()'RH58+";>4CZ@?E)Y8CQ-[HLE21S!''BX- 3?"FS:%75 O/(
M 9=[[083"'8PD*D'T ![ZC7S6J;Y.A![%U>OF2/9C9=!V1<,4@4U(K,P<;,T
M]08TO:UUCIQ%MY@,7/J>F$,IG++"AQ.-UEBCU<@"9T4R!]@$31*7CT["!NWK
MSJB:ZKO?O$GNLMOF\_MT],A3L_X01=/P#0D6 NPE9CY7U,Y-SZCSQF8S<3EF
M., FL82!0-R*<BR9N -SZE,8J*:@%#Y=)RC]H:[+F-4MOC2WKJ53?T\MOR==
M\6-7V8<'U0(&6=U)M9J6IJ(R+>PNRF_G=</+6-W"XG30MU<3$@\ =_"+G(8.
M_<YF+H3%-]1 CHG;D U?19ON!-'MZI^4'K\Q&,%S;L74*TF39JP;<K35Z!@;
M6 45$.FWO:%OFZXE?4,AU&]-1=5J8;OA(4#.&8CY+]KSP'#EFKTKI@!AZ?,
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M,I:&D'L3*QSI%Y'R4:Z78R#%XV4*JW=M';8Z3ALY05*51%=%0BJ9R%,0Q3%
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M%0T<>E(U&N0VYD\F^J:5EZR-_P!5;(NPQY2SO/*[/:^7,*V8O)(2%C!;E01
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M8(D86*(W8PS>%8)A&-DFD:R6;-T&8O")G]C3;Q#Y!(3(J"F!D7A$P*4A0.4
M,.M;5/?F9I)I&U.P+R-JD=M]V9[,Q-K]2;^6-B0""RI$ET16"@*%13;PK86
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M2J/.3'0YL(\NS(D(D@/ZBJF\*C0[G5#(SW'+D++>P261CI6VX!$I@$!,4Q#
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MR#UN8.Q2IFX4+DU%F]=E[*(IV>+SADU2QD @C2KNH4C?<&_L-L7&3<39QDS
MTU2[0K:]),S2TS '<:"=46K\**Q%]P3;%&.ZC9)DO;0[/,FZKEC%TZ!"-O$:
MU,G[$=41]G86B/(98\*^/^8BOYBL8].7I;._/ZFJ>>97G5/F("?K50!XXF-[
M^V-K+J7U%M0/E:QQNOAWBR@X@01 ]UKPNJ2CD:^H#9FA?82)OT #IMJ!V9HP
MX[R)<\476N9$Q]8']8N%4DF\M!S,<L9)=LY0.!A34 !Z'#-TGU-WS)<IVSUF
MJLV<IJ(JF*:6DC25&CD74C"S*1Y==@>A\P=CTWQD-91T]?32TE3#'/33QE)(
MY!=2&\[^3#8AAXD*@BQQO'^'OOAJ^]7#J-B,+&&RE4BLXK)].;F. 1TJL54&
MDY%IJF,LI7;"FW4=1Z@F4%FN1U&.%3KLQ45PFOHGHIBAWC;Q1MM\D[Z3^^'G
M?KU&V/,O%O#4W#>8F+Q24%1JDH*D@V>+8F-S8 2Q7"OY'9EN#B?FK'&*X-,,
M&F&#3#!IABC?QJ][#K!>(VNW_'TT9AD[,S%<T\]8+&3D*MC$BIVDDNFHD)3M
MGMP=)JP#,_5U#$HV)0@IKE:*EV1V=<.KF=>V:540>BRYQRD< I/6V!12#U6!
M3S3M8/RSY''E;]$_VH2<*\/1<'9-5&'/>)H7-;-"Y6?+\A#%)B&7=),UD5Z)
M//NRUI&EN6^-/ALW7>.4&K9%5TZ=K)-VS=$AUEW+A<Y4TD44T^5%5553 FF0
M@"90Y@( =0AK?C,$346 " ESL  H):]^@V)/F!N,?...-YI(X8D:225UCCC1
M2SN[L%5$479F8D*J@$DD  G;&QSL7V1QN#H-AD?(L8V?Y@F&P*H-W)4G*./H
MYR4W$9'=SI?A"X1,'OJ43Y4;]9XAB<C<CMQ):5XKXGES:9J.C=ERV%BOA.DU
M;J1\8QV)@U#XJ,@7*\UKW4#Z,]AW8G2<#T,'$7$5/#4<7UL.M$D594R"GF4_
MJ>G^4IKI(B!5U*DE-1I82J+-)464%#@@% ..2!QZ]^W #R ]@^7K^KN&L,W)
M%QT^@;;;?4 #8?B]&].A\K?-^,^TFQ/NQ#W>_E6]8DP-/S&+VAGN2[/*PE$H
M29$R.ETK#:G8-"/V;(X'*]>1C!.0D6;8R2Z1W39,[A%5JFNF-"LJ4I*:2>1@
MJ)8$V_"Z'VV_!\\7=%2/6U,5,BZF<_)Z$VW(O<#WDV]+XU*-T&R#>Y395KD*
MQVV23R9+%=S[CV7(,FYM42T$S)=D*TR+H[\TPKY:Q54&ZR2;8%#%1*B %)K!
M)N,*%*L0,TL9V^,L=3$FWRE8@+L-[;7.V-AQ<#YFU&:J..%D\0T$@>&P-A?<
MN3<6 .X^8WX^"_N2RUG3;Y9Z=G-[(RF3,)6QO3WLM,'.I-RE9D(IN_KJTNNL
M!5WL@U\J08G?+E\]P@W;^:*BI3+*9MEU4E;3B9&UKY-UVVW.V]MP?Q6&,!S&
MC>AJFAD0HVUT(((N+&P)VOL1Y>GIBY8>.H1Y$."%$/GR %$!#Y!ZF#Y#J_/M
MV)]?GO\ B]GF -\1^Y\O7[;=;7O^.XP" ]0  \B <]AX[&$1#]/81[_H^P-N
MGEN=_;;^/U]-L<^1/0[#;VB^_O\ /V^O3%8>_+9 PRU$2F7<6Q*33*,2V.\G
MX9BD"2>0H]LCRHIY).$_PM:I$$6SD"@I,I$%D[%1R5FHGG/"?$[Y?*N7ULC-
M0R'1 ['4:1W8:0MP3R&8A;7.@MKL "#Y@[>>Q*FXLI:GBWA>EC@XII8C-F-)
M A6//X(U)9RH"JN;1*!RY!_LQ+02@S")\:]:2KI@Z(LBHNS>LW!5$U4S'0<M
M7390#$.0Y1*JBN@L0#%,42G34( @(&*'&XO!(MC9E==QU5E86]S*1?U!!]#O
M\]_C(GVUQ21OY$I)&Z-ZBS(Z,OL8$>6-XOPI]Z7XVVWU!K;Y1-UF+%?L-8R
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M4SSW=Y9&"Q4\""[SRM8@(-D47!>1XXU\3#&[QM7P+MQQ-B*O5_;Y,P<]4RH
M6;NB#6"D)VZ6D6B:CF3L,BZAT9!&26%8#,V)GK5"%9'19L 9I)@H/E;B'.ZG
MB:N.9S59FC.I(HEWCIH[BT$2M"#'I%M;7+LQ+2-JZ^L,GX;I^$Z!,N2B[M*%
M#2221CF5<EO%4,^MUD!).@*=$8V0$6&+5ZK5$'5;CTP1462&.:D,B==RX3,
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M-8#"K.-KC=\G8LQ7V.Q=%M8[I-+2;%T=$;>C&HMNE911RU6;59+K\LA%)I4
M,8C=\JAK/B',GFSBERL&Z4M.V:S@MX$T$+1B0MX-+2CG:21<0@^F-F<.97RL
MMKLV*'54S+E5.VDW;F6>KY>D:KB$&(L-E,I4D;XW#7V>L%;',187V^WD[^$D
M&M1KL4^/6X=*7BH64-')-SFE&40LK-,F*[M)4B,@$(HR/Y8BFKT)+F0@*>JI
MZ>G,$TK=Z!>HG(7P:Y6+-J<"UW]7MNQ Z8R^'+ZNHJ!6PP T8*TT W#%(55
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MMA"9-C'\U1;5&1:I6TNYA7Q8AT8>GV>621,M&N ,4P&*9-XFC^4 >2!\0"
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MF]KW'G[L5H[\\4(Y;P5>(E- ',_ (&N%64!,#K)RL FHY6:I&$!. RD6+V.
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M)'$<U*D](;L(]0"LH<   #AN8 _M8\9922&',VN3IG,@/D"Q*M&W7S -O?\
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MSQJOA/BCAYW+')L[ILQA5B3H@SFD,3*HZ!5GRJ1_^',3MM?;X*4"%*4/0H
M?+L'V!Z:U;CV!B%&?]D&.]Q$UDJ=MT]:(R0R#CFCX^0<P2D:@YJ1J'8KE8(R
MS5YPX8N%"3#PMWF8>33=F<,7<*NNR%N0KMR)\AROB2MRF.DBIXH'2EJZFIM*
M'83"JBIXGAE4.H,:FFCDC*Z9%D&L/LH&K^,.RK(^-*G.ZO,JS,()\XR7*<G2
M2C:".3+6RBLS.LIZ^C=H7;O,GPK54U0LW,ADI7:$(O,D+-R'AMX?;_MBE6L4
M\M'9!KUHBU@>PM*6F*U-W"L1];E;+7;8K71L+!PDK')3K!B#[V5O+J&*<RT:
M1O'(7?W7YA^HM,,0>DGIY 5>H"3I33O,D4T(EY3@B0Q,^@.R#J&9F:%'8APR
M%SQ&K:QH,YH\PA/,ILK-5E]7F>7PT%57T.8&B[Y#(&A2MAB$NB.I)%VIU2!%
MWMQV0XXVVW*QWBK6FW622L]-A:HX3LCF-7:-7K9M%_A?;&16+%J)+#DF7AHV
MQ7%R!O*>S#<%4DTB""9+3-N)JS.*>&EG@IX4@J)9@85D#.I9S34[ZV93%1I)
M+% !8JC$,6/BQ+<#=D^1\"YG79OE^89E73U^5T>7N*YZ=HXY(XJ<9IF4?)AB
M/?L^J:2"NS25BRR52:U55LH\=2V,X6IE%QCC:OJI1\ECG*5:S,[L[&'JK&ZW
MV5J=EL,[$I75XRBFR\M&H.+$O&I.E0,X;-6S=%NX34Z^OM-Q-F514UE9*-:U
M=#-EH@:2H--2QU$$<,K4R&2T<C"+FE=T>1F+JR[8Z9?V3<+99E.19%2/R9\E
MX@H.*9,PBI\NAS7.*G+<QJZVF3-98:9'J::.2L:!)"-<<:(D4B-<E,Q_AU8M
MB9.<=L+-/HLY/($3D%@A[DI9Y2'=1^8JYFIS#)6D*^6QOH-]9ZTT8E:/I _D
M1*IB+"]?-8Y\SKOQ=6R)&KT\#,E(U*Y+U 20-039:LIA$O*6189F?6JCXP @
M!&=&L*?L4X?I9ZF2',*Q$ESJGSJG!I,J:JI'BXHH>*Y:-,Q[D*Z6CGS"ACBY
M4LY"TSD/S9XZ>>'QN?#FHKRV5NQJY2R2=G7LC2&34*PHI77,$,](YIM.;%RL
MD'$.HK"E<S5K6@I1W%*-Y.5@X:";N7A3,U?:R\6U2T\M.*"AU2T:T7.TS"01
M+ET.6@LP?XS3%#S$1CRUEED8)9@HIR]B>4S9C0Y@W$.?&*BSN3/4H#W%Z/OC
M\55_%A$2O3,],LM7F!I*F2%DFJ*.FI%>75"S2>1GX;51:*8G:GS#E)[7<.SE
M2EJC67Q*FYBF[>D9/+E*#9E3&OE.R=.)8ONRP3; 6\S.0Z#!HL\12:"FXJMQ
MA4,*X_!M"DM?'.D\R&HYA:IHNXS-<RM=1'\9%"24CEN5 4E<48>P_+(FX=0\
M4<134?#%5EL^6T$PRUJ=(\JS\<04L5A1 QR25($%;5Q:*JKIXX$:1!#9YI8(
MQ+$X(Q#0\004E)3,/0(-*!CY28!J$H^;I+KK@N]!D@V:^>8RY@'R6Z1."A\'
M/(CCV95\N9U]5F$R1QR5<IE=(M016( (74S-IVVNQ/MQLWA'ANEX/X:R;AFB
MJ*BJI<FHTHX*BKY?>941F;7-R4CCUDN;Z$ PTF]>F!;,%3KY%(#R5,?1UK8'
M .%"%:K"PD@*;@?A&,D'2AR>AA1)SW HEL<9&1?;ZO7W]?MUVOC\Q?>GD-7*
M6ZC.%P.L9P@YOLM#QRAC&-_8FKF)5XHI1-W!,&$.W$A?0H#P'UUZAX8HQ0\/
MY536LPHHI).@)><&9R=AOJD/T;W-R?(O%M=\(<2YM4ZKH:^:*,[;10%85M[+
M)<>E[; 6$_\ PIY)ECMY975X<NHJE;BDY+%T-/0C51[/P%HI"D/(MI%1LF '
M4A) EN<,5"HF\P7S)-42F32#CSI^B S1),TR#)C*ZI'1U;N%%T%16&)$+BQ\
M2P1$+O=>8U]V6WK[]"A0'+\MXHSTTT,\E164$<?.6P>FR]9Y)(@]BRQSS5#Z
MFW6\$8L2"<7LM(JNL;E(6*KQS+WS,H)).Y@C-=JZD4 5(=8ZH.A,[ %!; KY
M;E55PGY:9%%#' QC:29G30H9M16,>84V4!FWOI! !L=[DF]L>EUBC997:RQA
MG(!9790U]*Z@%5P UB551<'RVQ.ZA)1HVF'F$74H^?3#.-<)1(1A7L7!>P%"
M,EG#)\BQ]K37?E=MC.4'DGY#?DR[1) #+G/D]#).\U*=&LAD9;1:CX#IEU/N
M1L2;'J0?($8P3/8:>/*\R1YHXU,4T9>2I$;F21#+ $CN 2K*R64 W(4C5OCC
M=_?I<]DP_BJL1=FE/9&QL@VPT&EE2+3:IF]HA*J16=QM'6"48K'5"Q.C=3=V
MDU!NT<NH:41,'LVS\ICC,NIV2PN%$HIR&)%B L\BHP(VTZH[] Z;$Z!J2_+)
M6[$L%NJR,0;]?BPS*;>9) \[[X81C*U:3N9JU)3,F\&>I"T^Z=KVR'*T\Z*L
M#5I)-7HQ#&&4D9^JJ>\5926C6^.;:2#=).+=$-9=NC8CS=32K51O2SP1O$JK
M>,PO;2Y#1%0SMR0[+:*S540:RP/H&C%."=J<K/%(Z.&/BUA;, 0RL"H#M;Y3
M%(W()#*2%88VV4:^0+&0N6/HMJJ=$GLDQ3IV)N#]L^CRK*NT)>NY#C:RA)R:
M3A%)T_42;XYML<BY7(V3MJ+4RCX=;Y_V<Y'F"RS4U3/E]<(MFB[O-#-I+2:*
MB@:H7E-J<J'CK:9QYT[D8V=PQVG9ME*K15M+#F5%S6(UR205$%UTDQU.EDE4
MJFHQR4\H7<)-;K#VF[58.W9'#<#9<BO"KIV)C:Y*G2D:K[KK*AQA6[ME"RKI
MM&N)E-\G7E&+-0\2P?-22*[91DHX0*;6MY^$JM#34T?/D:*H0@/".9*(V,JK
M&L<I4?&&QNVR6!8L"V,VJ.-Z>K%54-''&)J29!(LIL"8](:36% (15L%%B3:
MPO8)#=9BRZS>;,#ST1$/(NLV;&>2*U%+2#X#M59Q:W4F9:NT$11*#))Y!'8H
MJ>6+I(CB/53,L/Y,FIK,\CDRC*\O>2#D,:J)JE>;'(PE2I615?06 O#?0 2=
MGN20;8GEV<19AF%8BSB8+%+R#R3&6A:E:)FN]F($Q!+  :=).QN9N-GITVA4
MA-RJDFW2,)N.XIMR%4,/04 YY 1X I2\B/  'PZ@M9^. -[L3;J1<6'MW%OK
M/NF]! C\QH %@3>WMWW%KW]-[#"9=R =* "!NH>DAS"0P (B0P  "///</7C
M[?IKH)54HI!!W4DWZV-[>8W]MO*]]\5!$2)-MA8GU]GI;\WLPR5J 7)71#IB
M<IBF["43 (' >0.'?L(\]NW4'J.K67<DWL%.H-T8&][CV^A!'L'K<K;2!:]Q
M8J;$$6M8]=MR-[]>F-2C.],''^8\CU$B7EMHBURH,"   4(MVX,_B^ #MTA'
MN6Y0 ![<=/J Z]_\&9M\-\*Y#F98&2JRVGYYU!OU3"G(J=3;B_/BDN3CYV\<
M9/\  /%V?97H*1TV95!@%K?J6>0U%-I&W[!+&+#[X'TQM@?L::7=Y)K;VD2
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M+)NJJPTS@;,X 55N"#>[A&H2:EXAH>+K4F_=2\&,_&C%QRK[S&[3A*6;*$0
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MB9A$6C$A4'"**29Q R:2XDY.8XFV:N59?ED$.54:<N"EB$B [M-+(Q:::4@
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MMZJ$3?V'=@1;:UK7&-.<;2F7BC-"?O)(X /9%"J;6N>H-S8[LUK=!*])0.D
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M'9MMEEECBHNXPK0$ECF'D3'90#1B)N1#GN+81#Y>O'(<#K ZY=-94@; 3/\
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M<&2%)4I>1,)#JN40 Q0 3'3*F<2I@8XB)0[92]+#&HU.@OT9F"CTL";7MO\
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M3A-Y0MP^4#.#+NH_'<6Z"LJ.CF,!F-S<<5]Z?XA\Y1& )(M^!'J!VFH0P%,
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M;?Z#[=\99);L(?4!XX^O<>0].1^G<>_;U[:X/0CIU'T[?P8[K<GSMU/6]AZ
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M"IQ<8Z>'$?IP5$>W;UXY[!S6IT,DT,:]99$C /F695_+M[NOEBK31&HJZ:G
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MR2"S%Y'*L6AV;ALND=([=1$R8D\HQ3CR3CCDI3!W !U.\HF,I( Z,+,C!2K
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MG#ZH'J=JG(EC*EET$.$G[9XU%RU<(*J=H^&<WE-HXZ<W:%8V-73*E1WB!JB
MT[M*JR":-&*,I(NI!(L<=)>+,EA%Y)J@%5J&E1:*L=X!2SK3U'/182T1AE=
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MX6192D>N'(&0?1[E)TV4["']J72(< Y /A /37IJ6))X7AE4-',LD<B_>Z9
MRO\ , 3;I;8^S'RAH*ZIRVOH\RHI#%5T%73UM+*";QU%-,D\+@@@^&1%/4$V
MZXV@<67UAD[']5OL,J4S.RP[60,DF<W+)\)#)2D>KR?^W1L@DY9*?4Z(F !
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M'8 #Z:BL36.M94B"2BRIRII)$,HHHH8"$3(0HF,<YS<%*0H (G,(@!2@)A[
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M5'%22'+J*)F+%8J=VYEVOHU,D+/(5!UN[6( &(2/@(,G(%*7@JGG% H]N *
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M=)/NQYQ *@GY++?RL00US>_I:V_3?%HU?:M&T''-60B46K%% A.@P$50(W3
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MLF!2"164= =,A5U%/+$02*"1!-C= ]0>(\PCAC;N+)S):AXW$?>4C18X59@
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MGTAP(<#K#*JL'*AT[JL40"VMORQ>X\CJ_)?H!CVI2TNIY VSZWOY_?'IMN"
M"+;^=ABM%KE95)\H^18,BNE%4SJJ @CU&\D2'*1,#I'30*)B <X)$*!S!U*
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MW&DAM.&FJ5SR,M7FKW(64&B4! IFC&$@W;.8^RR)3++O'2*,NYF5C^T-1='
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MB4W2 3K<89^ZV6LIXE?8<J-VVZ_LDDB=+>1/H2.L4O V2!U>3+ZN6Q.[R!;
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MP$-:8QO<"WF?G^WS_:V'"B+'+XCO4=D*NIG=L%2^R6**(82)RT,X.45T>WP
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MJ7RV51#4<V02/!4>,H68*IY<JL0H*VU*U[[ S0L;!M7)O^MT2(-9H%GK$4R
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M7%H88(U6*-FV)F<Z^6B*MAK!$(:I*YSDE&2;Q/'\^3\B1=VV:ST&Y4$WP&4
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MBE'>ZM!WYT-S#2MN(M0Z23GY0ZB*][:P,;:&L6QH;!IA@TPP:88-,,<" "'
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M?V&XVQ@V9<)2FI-;EM2J,6$AI93I167=##(JD)8BRJZ%1TUJ-QI=^,ELRO\
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MP>J8#).;TT* \BFC94#D-]G]<Q*YP /E\?(<CWXXTQQ8;]=_:?;^?&>B-D&
MXQ4JKB"FIP2& Y4YJQR"B74 "'<D>,?U ;GXBG$Q1'GX0#@-,+#K]OM_!Z#$
MAZGC>AT9($:C4*_7R@3H%6-C&R#M0../RKWH,\6$0[&,LN<QN.^F  '086W
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M&$I@,Z IN2CP/80[?J^0_HOHZ(/^R'<VV -NGM'EN;VQTG AOOK MN-NOO\
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MYAHH[*'6,8R3B4167]@4,DLY0!D#APWCLT[,:BEI7GR^O:NFB\34[4ZPM)&
M2W*(FDO(+7"$>/HI+67&8\"?HL\HS_B&DRCBS(H^%\NKB((LYAS)LPAI:IV
MA[]'+1T?)I'-T>I#N(6*M(@BUR)<(KN5;%127;P17:*Z::R"Z3Y(Z"R*I0.D
MLBHF)B*(J$,4Z9RF,!R&*8IA P<:W[H;E68@BX(MN#<BUB!OY$6V(-_3'M1:
M"-T62.<2QNJO&\05TD1UU))&ZL0T;J0ZN+J5(8$@@X3+K=H#;G_0CU\<]_>'
M3SP'T\LWT^NJRT ;]D/]A_\ S _5]&+9Z73T>_S?3A+O-ZXM>H0HX' /E[UZ
M?ESS_:!_C_EU5&5WZ3'^P_\ YL6K"QM<'W?;[>["5=[^CM@,(8\(?@1XYFC!
MR !W'LT']7Z0Y#5<9+?]GM_Z/U_Y]NF_7I]&*3R:+;7)]ML)5[XCRS/D/VLD
ME!+SSS/F+Z?<P'^GKJJ,A6US5'WB(_E;%NU58:@EQOM<WV^;[>["1>^**NTY
M_P!*9!0?E_HE5)R'^]A^-=QP\K=*H[]+Q6_^<^6+9LR*G]9%O/XP[?\ 4%]\
M)=YXL[IJ(A^TXV-P C_JK5#T_P#S0/\ %JJ.&D-K5DA_]$F__6Q0?.=)MR+D
M]!S/HOX?M]>$NZ\8E\WYXPBT/]!_#%8O\'N0WW\?355>%5._?7_M2;^[Q?;Y
ML6\F?Z#;NU_7XS_^482[SQJ9%J80_:)8FX_^_9<!'_\ <(AS^H!^0^@:JCA%
M6O:N?V?%(?F'B'Y3Y>1O:MQ01TI-_3F7O[K+A-N_')D6H&']H%B;CGC_ $=+
MASQ_\G>W/;58<&*=N_O?VP+8#YI/M[<6[<7.I [DOOYY'_\ #W^V^$H[\>V3
M;"(!MV8&X'@.;\N'U^E<'^GS#59>!T.YS%K'_P W&W_^S\^*+<9NM_U AM?_
M '0P&QM?]9]<)IW^R#)9L(@&VR.4X^N1')?X/P7$?Z?KJKP$C"_PE(/9W=/F
M_9?H\STQ:MQW(O\ .Z/^Z'Z>OZSA-NOV15,MA-_UL<6< _\ ?)=!_#^"? _+
MT_YM51V?QD@?"<ES_P":IMUW_7@-_?[O91;M D6_\C$.^WZJ9;^O6 V\_+V6
MPG'7[)*F&PB'XK,480$?3)KL.W/KWJ(_I[=O350=GD9( S20GS'=4%OG[P<4
M#VCN#_*N.WKWM[?^[>_R'LZX3SG]DRS;<!'\5.(-QZ .47@?Q4X0[?P_9KO^
MES'M_)23U([JFW6V_/'7W?EQ0;M+E&_P5'[/U6=_II_;_!A/N/V4!.(<C^*7
M#& /KE9X'SX[\4L>/Z?H[KV;1GKFL@%_Z40[>O\ LC\GX\6[]JDB#^5$9/\
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M"\_+L/N\?G_3C7;N3=.8M_<?K],51PI*1<UL8_\ 0L?Q2?P>W& <^(#7FXB
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MX_JU5 ^;S/O/X_3%X-V ]+'TZW_)]B<(.0<?$<>>P<A]/3GTY^_MV'Y\<:J
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MANQ6H:U+O<ABYW+8<QU9(EXE DFKA@+'F!GF():0E#IRQV#3)2D^:*OU99H
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M<693XKXKKE^04D5145E'2K9\G[]3 /,U/45>7U#U=%2GF:X)>\1J;LUH"=)
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M4=NY=.$KB-CEFU:8V"R))2_O"=8U=S%NVC5TV/+J1;0'RL+&A*K1K!HN[(V
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MHO+Y_P N,.KZ!]H!S^D1$?X=6\A^I3[>N)>#?<]?3YA^?&-#U$/I_G[ZM<2
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MP;:;K$BK>PN!JTZK>1)VVMAX;EN8J2MDEI=*AN;*8,QK9\K"KV?6@X^,NDQ
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M65*7VZ?L#\I$S/Y=^J7S%E>A-%!,$FC-!JS;MVZ>*3S25$K2R&[-]"CR51Y
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M./+_ %/!EK]\5CS_ !1LO_&=<_IJ9=^U-;_;X/\ %QQ_J-^)OW:Y%_>S,/\
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MN<1]K>W'F'P$?$%/V6NF$2AZ\_AM:5../L_!PO/V=PX^WGMR.SG+QTI:(?\
MH5^WV^? ]I<I_9,Q/_.O^.J'V^O(Q?['LWD3TI&-+IE/%L/75WK4LX[AW\W-
MR2,:*Q >#'LWB$<@N[!N!Q0(NX01,IT =4A?BU?47 F6TT\<IIJ6T;!QHB3<
MJ;@VTV/4_P >V+.L[1:FHIWBCFK@S!AXF*C2RE2"PJ)".I\OFZXVJJIMYK&,
M,,8SQ)C]JNVAL4U2)JE?;K+( X=,8YHB@JH\5Y2;"_=N"JOEU ,B@9TX7$!*
M0Y>G8,6F)0@%D   'E;H>F-:32O/+)-(;O(Q9B=[DX\@XWLA 'B%?*C\@!W
ME ?TGF0$/NXY^STU6$B#R/SK?_Y\4\>4<?6X3 7\%WH@/[LTI7@[>G< EA'T
M^SMV#MIS$ONI^K?VV!%CT]F&'BQW4SUQJ[7=LSM)%\8H+%.NW<=**7/EE*=N
M<Y.XB)C]^P])0Y @'/3=]=MB !8 F_GUV]1;Z,,.1KIA@TPP:88-,,&F&#3#
M!IA@TPP:88-,,&F&#3#$(]UN57;1-KBZN.A1?2R!'5H<HF_*H1:P_P!:Q93%
M$#I*/P 5W78I_9/)( B1P<-1M?4,@Y2&Q9;N0+D"XL![]_FQ?4<&H\UA=5-E
M'JWO]GGL<,3BW%<C;I%M&-"^2BF5-9^^4)U)L6HC\1Q#D>M53@023 2B=00Y
M,4O6<MA! TDE@.GRF(%@/*^_7<6MU.VV+^>=8D-_ED;"WTCYM_3Z !BQ^G4.
MN4A@FRA&1$U!(4'3Y4H*/GB@  &.LN/Q 4?DB3I2+R/23D1$9R*%(19 !ZFV
MY/7\?EB'EE>5KN2?0>0^WKA9AV  ^FJN*6#3#'@D8QA+LUX^3:-WS)R04W#5
MVB1=!9,P" D424 2&#CTY#DH_$ @;OKAE# A@"#U!QR"0;@D'U&*_<VX5<XR
M5/>*.5=6J><0TQ#\J+*P9U3@5-TW.8QC*Q9U#@F?S3"=F<2 8RJ1^4X2KI#
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M*ZR;Q.J$;^$K(R2;AKVTFU]K@L&I."TI%98ATT73UPX9%-^<#8W2 ")A  ,
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MQVV)\G.W4[[L2956CE\-XU?8N4:K)JK",ZK***"DD<I0(LL'FIF!02' 2B'
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M*VL=H>(]7PK\;EI7"F44-LLK?T,?M-P"CJHA#^>ZL@T]O;W%.]]_A2WH"MD
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MH,+>)-1,C8BSMER_TB=Q,TP8QA+1(UM]*H6*<L6/;K!MIO&ULB2%CH%-->]
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M=@.F)G:Q[&T,&F&#3#!IAB)6U4!(^W/D./!B[K\H< (@/256#H[@H>H\=15
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M&_:AHY3"'?N2#:E$.W;D! 0'Y\@//?5IQ'_-!G/MS&J/TS.0?7I:V)/LHO\
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M!*,-B;6WM<7R4KA#(\&>.3F/$#SY&*S,B:(B$GM=VOMU926)&R$P:,CDE,%
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M,1_S,Z?#5/\ N=X?_M&8?YSP_2\S+^JCVE_W=PI_HA@_%>M?[[S=C_C1B/\
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MAHX(J6ASWCZAHX%T4U'1\>\4TU)2Q7)6"F@CS(1PPQ@Z8XU%D4 8RGXG-/\
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MTA;[]M02K78+D&-.[)7,CU&CQUCNC.SR\55(";9LJDSB-Q5WSQ&Q=%02EFR
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=!IA@TPP:88-,,&F&#3#!IA@TPP:88-,,&F&/_]D!

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>4
<FILENAME>g554088g63f13.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g554088g63f13.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[1WF4&AO=&]S:&]P(#,N,  X0DE-! 0
M      \< 5H  QLE1QP"   "    .$))300E       0S<_Z?:C'O@D%<':N
MKP7#3CA"24T$.@      Y0   !     !       +<')I;G1/=71P=70    %
M     %!S=%-B;V]L 0    !);G1E96YU;0    !);G1E     $-L<FT    /
M<')I;G13:7AT965N0FET8F]O;      +<')I;G1E<DYA;65415A4     0
M    #W!R:6YT4')O;V93971U<$]B:F,    , %  <@!O &\ 9@ @ %, 90!T
M '4 <       "G!R;V]F4V5T=7     !     $)L=&YE;G5M    #&)U:6QT
M:6Y0<F]O9@    EP<F]O9D--64L .$))300[      (M    $     $
M !)P<FEN=$]U='!U=$]P=&EO;G,    7     $-P=&YB;V]L      !#;&)R
M8F]O;       4F=S36)O;VP      $-R;D-B;V]L      !#;G1#8F]O;
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M(%5N=$8C4')C0%D            08W)O<%=H96Y0<FEN=&EN9V)O;VP
M#F-R;W!296-T0F]T=&]M;&]N9P         ,8W)O<%)E8W1,969T;&]N9P
M       -8W)O<%)E8W12:6=H=&QO;F<         "V-R;W!296-T5&]P;&]N
M9P      .$))30/M       0 \     !  $#P     $  3A"24T$)@
M#@             _@   .$))300-       $    >#A"24T$&0      !
M !XX0DE- _,       D           $ .$))32<0       *  $
M 3A"24T#]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@
M     0 R     0!:    !@       0 U     0 M    !@       3A"24T#
M^       <   _____________________________P/H     /__________
M__________________\#Z     #_____________________________ ^@
M    _____________________________P/H   X0DE-! @      !     !
M   "0    D      .$))300>       $     #A"24T$&@     #-0    8
M            !#L   >@          $                          0
M           'H   !#L                      0
M       0     0       &YU;&P    "    !F)O=6YD<T]B:F,    !
M    4F-T,0    0     5&]P(&QO;F<          $QE9G1L;VYG
M  !"=&]M;&]N9P  !#L     4F=H=&QO;F<   >@    !G-L:6-E<U9L3',
M   !3V)J8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<
M    !V=R;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R
M:6=I;@    UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y
M<&4     26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $
M %1O<"!L;VYG          !,969T;&]N9P          0G1O;6QO;F<   0[
M     %)G:'1L;VYG   'H     -U<FQ415A4     0       &YU;&Q415A4
M     0       $US9V5415A4     0      !F%L=%1A9U1%6%0    !
M   .8V5L;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !
M   ):&]R>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L
M=     EV97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A
M=6QT    "V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90
M  !.;VYE    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M          QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO
M;F<      #A"24T$*       #     (_\        #A"24T$$0       0$
M.$))3004       $     3A"24T$#      3P     $   "@    60   >
M *;@   3I  8  '_V/_M  Q!9&]B95]#30 "_^X #D%D;V)E &2      ?_;
M (0 # @(" D(# D)#!$+"@L1%0\,# \5&!,3%1,3&!$,# P,# P1# P,# P,
M# P,# P,# P,# P,# P,# P,# P,# $-"PL-#@T0#@X0% X.#A04#@X.#A01
M# P,# P1$0P,# P,#!$,# P,# P,# P,# P,# P,# P,# P,# P,# P,_\
M$0@ 60"@ P$B  (1 0,1 ?_=  0 "O_$ 3\   $% 0$! 0$!          ,
M 0($!08'" D*"P$  04! 0$! 0$          0 " P0%!@<("0H+$  !! $#
M @0"!0<&" 4###,!  (1 P0A$C$%05%A$R)Q@3(&%)&AL4(C)!52P6(S-'*"
MT4,')9)3\.'Q8W,U%J*R@R9$DU1D1<*C=#87TE7B9?*SA,/3=>/S1B>4I(6T
ME<34Y/2EM<75Y?569G:&EJ:VQM;F]C='5V=WAY>GM\?7Y_<1  (" 0($! ,$
M!08'!P8%-0$  A$#(3$2!$%187$B$P4R@9$4H;%"(\%2T? S)&+A<H*20U,5
M8W,T\24&%J*R@P<F-<+21)-4HQ=D154V=&7B\K.$P]-UX_-&E*2%M)7$U.3T
MI;7%U>7U5F9VAI:FML;6YO8G-T=79W>'EZ>WQ__:  P# 0 "$0,1 #\ [%W^
M,7ZG,>YCL\AS201Z%_(.T_X!-_XX_P!3?_+ _P#;%_\ Z07E+LHT67UMLH+'
M76._2T^I!)+='65.V^U,>I/<]MF_$W,=N!&,T:@%HT]'Z+=WT%9]B/C_ "_P
M6#WCX?R_PGU?_P <?ZF_^6!_[8O_ /2"Y[K]#_K;U.GJW0;Z<K QZOLMU=]E
M^--H+[?H>G59[67U/]5JXEG47@!HLQ70&@;L=KB=HVM+II]S]OYZ[G_%SCE_
M0\DL>UP&8Z?I#_!4?O-0E 0'$+O;5,9\9X37=S?^9_6@1^AQ#$@@YV09D#4^
MWZ;'>YB7_,_K&X 58VV0YS3GW[H#-CF-?Z?M8^[]-]'_ ()=I^S^H;Y&57L_
M=].2>?SY]OYOYBBWI^>);]LK-NT?X,1S])[/\]K/>F>X>X_%?PCL\:?J?UF3
M%.*!V!ZADG_OJ#=]2?K(_P!0UVX]+76!S:VY5A#1M<-@<ZO<NZ9T_J0+39EU
M/ @O:*ML_OAKY]O^:K Q+(U+3J.Y_P#(I>[(=E& /1\[J^H_UF9:Q[[L:YC2
M"ZIV5:&N _,<YC&OVN_D.5C_ )H]8 +?0P]SIC=GY!(C]P0U=F>G=2(AN96W
M3_1 F?%+]GYGJ#?E5DD'8 P!P'MW;20[V_Z3_K:1RR[A0A$="\+D?4GZQV6E
MU%F/CU<,K&7:\@3_ (2Q]?Z2S^7[/ZBBWZC?6@,L'VFB7  ?K+^SFN_T?DN\
M_9W5-Q)S*ML^T"GMWW>[Z2/7AWMKA[V/? #G"0"9YVQ[4?=EX?8CVX]C]KYU
M_P Q?K1_W*H_]BG_ /I-'I^IOU@JKVV?9+K"3ML?F7 Z[=K=C&M;[-O_ $UW
M_P!DL\6_>?\ R*K/P<YI'ZY4TN.U@?6/I$EWL^COL]']'M_ZXA[LO!0Q1&P/
MVO!N^HOUG+G%N1CM:22UOVJPP)T;N-?NVIZ_J-]: 73DT:L>/Z2_DM<!_@UZ
M#5A936D6VLM=.C@W9\MHWJ8Q+==6\'N?#^JC[TO#[%>U'Q^UX#&^I?U@JGU_
MLN3)!&[,N80!])H-31]-2'U/ZVQGO9B$]W'.O:!QX-#5WCL.XM<&O:UQ! =J
M8)X=&U5G=.ZAL(LS*BV1+C2.WYH:XN;[G>G_ &T/=EW"1"(Z/'_\S^L 1Z&+
M,G4]0R>.S1[4V)]3/K$SJN+D^KCUT5Y%-CJFY5CX:Q['/#?49N?NV_G+M6]/
MZB+ YV56ZL'W5^E!(\/4GV_YJL58MHM826P'-/)['^JE[DO!7 .VS__0Y;US
MC9E[Z;RQ[GV-(-0<"W?O<US+-['-]BD[JMS_ *64TZSI16),%GNV@;_:_P#.
M1#U++QK;:J,NZNMMML,#&D#<\FR-S_\ "1[TS^H]0<"'Y%^VQA)'HM +"#N<
MWW?0V[O>U7:\!_+_  6I>]$_R_PD=O4K;:W569+=KQM<!16TQ._;+ QS?=^Z
MN]_Q:W4U="R1)>#F.,AL?X*C^4N&=U?J,^_-R)@#W5MF /9])_[GT%W'^+NH
MY'1<NWU"YSLUY>YS8)<:Z7./M<Y,R_)]5^(W/>].O_HST+3D-:!]OM=&DNHI
M)^:=MEP&S[=:YP!,FFJ?<-K-W]1V]Z-]C/[X^X_WH8P'^NYWVEQ$2:2 6"?:
M'-,;V_1_TBKWY?8SK;[I:?MENA$CT:H(!G^SN9[/9_75G[73$P[GP'_DD/[&
M?WQ]Q_O3_8SM^F.? H*0N?=O<6YEK6EQ+6&FIVT$SZ>YWN<UGT6)F67-(#\V
MQY)#H--0T;.]@V_18[<Q&^QG]\?<4-V \W,<,ES8&M0 +' =W[@[;]+\QZ-_
MRI3'=D;8^W6AVON%%/<#EGT?:_<K0RJH/TC $F!K^*']C/[X^[_:G&&X3[P>
M.Q\?BDIC==ZA!JOLH+000UC'@S&KFV3]&/:@^K8QP]3.L(<Z&@TTCW%KMK6?
M^?$ATF\ C[?=J>2&$@>[V!Q9_*_Z"B[IMS2S=U"T%S@ -K/<?I;7;*_H;6N2
MT[C[%?0LMV200<^V3P112#'_ ))6_M=))@.')B!X?UE3/2L@_P#>A:/@RO\
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MLP,:UAKLW.8[D3'&OYL*K=TGI]36[<2V\'VD5NES6ZV3[W-_/_E+HDD1:M'
M9T?ISF;S0]CK(>]CG&=W_"0=N_W>]6V8U7J-=+I#@>1S/]5:B21OJH4__]DX
M0DE-!"$      %4    ! 0    \ 00!D &\ 8@!E "  4 !H &\ = !O ',
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M-38   .@ 0 #     ?__  "@ @ $     0  !Z"@ P $     0  !#L
M    !@$#  ,    !  8   $:  4    !   !'@$;  4    !   !)@$H  ,
M   !  (   (!  0    !   !+@("  0    !              !(     0
M $@    !.$))30/]       (          #_X0$P34T *@    @ !P$2  ,
M   !      $:  4    !    8@$;  4    !    :@$H  ,    !  (   $Q
M  (    >    <@$R  (    4    D(=I  0    !    I    -    /
M 0   \     !061O8F4@4&AO=&]S:&]P($-3-B H5VEN9&]W<RD ,C Q.#HP
M-SHS,2 P-CHR-CHU-@   Z !  ,    !__\  * "  0    !   'H* #  0
M   !   $.P         & 0,  P    $ !@   1H !0    $   $> 1L !0
M  $   $F 2@  P    $  @   @$ !     $   $N @( !     $
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M8F-G<X.$HJ3&*%=H=X:2HZ:RL\(I@HBGN/_$ !P! 0 " P$! 0
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M]^73[Y\WR%_C_P#;?MP^]7'\N'Z OZYA\:_8E^F0#_K?4_ORZ??/F^0?\?\
M[7#[U<?RX?H"_KF'QK]B7Z9 /^M]3^_+I]\^;Y"_Q_\ M</O5Q_+I^@+^N8?
M&OV)?ID _P"M]3^_+I]\^;Y"_P ?V?\ VU]_[\/O5Q_+A^@+^N8?&OV)?ID
M_P"M]3^_+I]\^;Y"_P ?_M</O5Q_+A^@#]<P^-?L2_3(!_UOJ?WY=/OGS?(7
M^/[/_M?'7A]ZN/Y=/T!?US#XU_Q+],@'_6^I_?ET^^?-\A?X_P#VN'WJX_ET
M_0%_7,/C7[$OTR ?];ZG]^73[Y\WR%_C_92X?>KC^7#] 7]<P^-?L2_3(!_U
MOJ?WY=/OGS?(/^/_ -KA]ZJ/Y=/T ?KF'QK]B7Z9 /\ K?4_ORZ??/F^0?\
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M'\NGZ /US']/_8UMD\/L3;(..]G4%DY/,(R'%)R_;SY*.4B=A:Z4S0Y)5D*
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M<2 6-@"3:^X$[NW=V=?9CCU.(PTPQZ?]AE^:5;-'Z]R=]A;(VO,<LOQ;S/\
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MCA [D  NPC2- S<2$CC6]]**H 'WI<]I[\9X:7/:>_##4W/:>KK\>?R8C]O
M>/VG#47/:>\XG#4W/:>\X>.K#47;M/KPOB4N>$+#?MHD=?\ DJ+:Q!.LG?\
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M.D<%?37V+UV[GM/?X\;L?E^&IN>T^@G[;XC?^_\ 81AI<]I]!/I[^-^W#?\
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M24G_ ##2$QB,%G4-=P ZL\;HC1ZU=T95)8$8OTNRK!X.0#,#[PCW>?#EC@]
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M-"]0M;W'6PN75K[#13N_.25@T6?6P5793H)V9".LC;31:,B0D)TL5FS.@4U
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M6RREC1DV<.W%UE$6R"RU]B=V<<;2R)$@N\CI&ER%&IR%4%F(506(!9B .)(
M.-<TT<$4DTC6CAC>60@%B$C4LY"J&=B%4V5 68]%06(&.VQ>M";)F2'N47C
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M=Y2?:=WGP)"@D[@HN?(!Q)\@&\^3$%@.5(#D])TI!Y"F9O8M!)%VS4'E@Q1
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M;&)7V0I%&85E7'S8"FD;3)#414\T*34RE(!&[S0E8UND'V8I%BYWB<"$M$*
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MK(K6I(V(*E;EL-F'D<VB>[BXY2;9R2E(ML7L[M[WQ^-61=W#<< J5JG:\M;
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M1B4N$*4S-%= [*"R@E"0UKW%DIBM7&J234Q#A4)>>:FAR-J 4(E<(9 ]6%E
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M%1Q4B]($ZBZQ!V.E "2 +6MSLWSJ7.!3&:%(I(&K'9HR=+M65DU6]D-]*J9
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M54[H&IEJ$"E'9@C:ATGFWUAIL $2IN,E3Z/E7,0;4?VO,?C72"LKA<#GSA%
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MF1A"LID(!V]Y]W3Y.CS='1QX:Y&.UAZ^C=QYZ4I[M./-IABZ'/TY*?K]U_\
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M3R!'>%86<!=IOW6B[;4Q^R?+@I%"<C1>4I&EHHA&"S>&.B#^9W$L*LA,.8/
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M9<-55&)*9-'[2]1)2VZYN\:MW"5:UL513OI6VGT=R?S2BCR/*8WDD#)E](K
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M\J&)?:^7K3W7H/YR7Z-4_H</<FM^)#]*I?TV/3+L.FS#FR"]DDV8I9*(L''
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M&-$6[Q/ UE1%4:HG>,V '2)^$=6,!E]$H $", JJ-322&R3)4+=I&9R5F1)
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M0QFUPV2*V,G"P$R]?/13M=LH[97OGB2"]B#QPDKJ2KJHXA"CS",,[!=(W&1
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M>P6^S5!8$G<L:J@WLQ)L"223<G&Z"FAIDV<*A$U%K%W??8+>[LS$64 "]@
M !;$MY"?^/"^:G.6&=7Z[Z.;KIY*:TW/Q6/_ '3C=;S=_CQPQ7D)_P"/"^'^
M^XRE?17NOVN;S4TN?B/\TX6\H]GC]V*<E*N^G=HO?SUWEA?3U?FRG57=Y]U>
MO3?\5_FG"WE'?X]?UXV$@E*4C ^EJB*M.4[_ "Z"R+A.OYL7X6JH7J)W5IS7
M4MOK6VN^VNZM*TUHX8W @[QC\JSLG=MM>R+;</#_ +:;-W-Y,@':4YN?ATZ^
MG>3@'N!DW]FT? G^83R^O'RURC_&#.O[4KO]3)C1?D6]7NU^WKM6\_>?;CBX
M<FWJ]VOV]+>?O/MP\^')M]:U^WI8>7O/MPOAR+>KW:_;TL/+WGVX8<BWJ]VO
MV]+>?O/MPPY%O5[M?MZ6'@D_7AXXD?5AR+>KW:_;TMY^\^W##D6]7NU^WI8>
M7O/MPPY%O5[M?MZ6\_>?;AAR+>KW:_;TMY^\^W##D6]7NU^WI;S]Y/UX>.-O
MJQZ@=AEMI3LE6S1P_OW)_P!A;(^O,<L?Q<S/?_V<'&Y_^:A^NWH]./4<C/QF
MRO\ K)?53S$>O']U6OG_ !](8:88:GLQ';AJ,3AIAAI;V>//U87]OCS=>&F&
M(1(YV'!N40S-1N<EKUZU&CHHQ?-^^BKQXW4>IJD;*54O$"6X]!R4?E':-4T!
MS951LD\=WM63FM/5Q0D1KIEJ794CIE=0Y9U+!G%RR1*@VCR$=% ;!F*AO,9S
MRIH,KECR^G>',L^J:F&BH\CIJJ#GLE341-4))5J#(V7T,5)'-755=41:(J2%
MWBCJ)WIZ:>9I55JDG5>B=%JIV=MHC==>E17DT[9VJ^^VR^Y/E;^16ZRRZMNZ
MM;:5KNI9WV%P+V%[7(OU\?+YO-CTD9<HADT"0JNL(69 Y%V",RHS*#N4E%8@
M7*@W Y-/'BV_&?CQ?=AIAAJ?3X]%_3B/1X]-O1AJ/3B?1AIAAIAB4.?E+#_M
MGD?]%1;U].H'PSU]%/3O;=X]>'\GLWMZ.&_QZL1?4X8:88:>/JP\?7AIAAJ?
M-Z_W]W7Y\1Y_5^[OZO-AJ,3CA<.&[-NN[=KHM6K5%5PY<N%+$6[=!"RY59==
M92MJ:**2=MRBJJEUMB=EMUUUU*4T9E4,S$*B@LQ)L%4"Y9B=P XDD@>;&J::
M*GAEGJ)8X8((WFGGF=8XHHHE+RRRR,52..-%9G=R%1068V!Q$ <U8RDR_91N
MU L$#6I)%9,W=V*#+RKI!-T@'#J(6K)E7#9FL@\+N;%D68^UVQ:IJO7JKQ =
M6BJ4GDD6"TD45A).&O'M& 98XRMP[JA#2&^A0RJ"SZE7S^6<I*?.\SJZ;)A%
M7Y9EHCCK\ZAJ%DHC7S1+419=ES1"1*Z:*GDAGS"9)(X*-:BFA5ZFH>HCHYKJ
MSCTN&F&&F[#?AIAAIAAIAA7FXZD6[.S]MO'M$'@?,?V>7=QW=G5PQ*)OQF,H
MK_O\4_GBM/>U"[T0]J@VW^GM'CAUX7WL.QB 3;ML.SQUXB^F)PT[/'CQZ';X
M\>/2TPPT\>?O\>3#QYN[QY<-/'CQ^UX\>/V-,,0^<3Z'8U W2B=R ?%XZD]8
M#W!LJI<@,9N23BQHR[N=\BY%B@LXOL2J[=W(M$[[[+55TZWV;ZU764E!#SBL
MG2GA#HAEDN(U:1@J:V (0%B!J:RCK87 QVN3_)S/>569#)^3F65.<9H]/4U4
M=!1*LE7-#21&:H-/!J$E0\<09]C"LDS*K%8R 3B^!#(V1!QAX.O>Z%&6#4F-
M<J-7;*]PQ>HVN&RUS1^@U>MZJHWV7]I=-D%TZ74M52LNWVTW121S11S1,7BE
M19(V*.A97%P=+A67<1<, PO8@&^.?7T55EE=69;71K#6T%3-25<230U"Q5%/
M(T4T8GII):>71(C+KAEDC8J2KL+'%TUGBKAIAAIX\>C#QX].&F&&F&&I\EO:
M?KQ'EO[!]6)7&Z;V$S\D5WTW]?A-&NO6)XI_2/EW:6\_EZN&(-[^@]HW[M_#
ML.[COQ%-2!?AXZL9$VX^.O#3##3##3QX\?M>/'C]C3##3##4[^SCN''U8C=V
M\-YX>O$#?3X5<<8Q:.J-9)(W3IXD]9,'R*C>.LQ2B29@A(W+>CFHNC.]9)FV
M8*H]W$2JZ#))%)&U\]856JXMJE/"5J)W9@RHPM L9&T>=A<(!\%5/3=R% 7I
M,OEJOE70^Z=+D>4O!G&<3SU$=134M2C0Y33T+HF85><3PK/S+F[2)3PTLD?.
M:RNEBIHHU1:FII9YJT=WB_KQZKM\Y[NJW[=_;AIN\?5Z/,.OR7C?X^OT^<]7
MELTW>KU^3]I]F&_U^KR_L'MPU%O5B;^O#3Q[/7AX]OJPT\?;]6'C[/KPT\?;
MAX^S'HQL^_W*X_\ K@U_33^FJDVZ1O\ N_\ I7&Y/@CQUX_+G[)W\T6VX?W4
MV;_L@'=?3/)S^(,F_LVC_P A,?+?*3^/\[_M2N_U$F/4*#[ 6RQD+9EP%.P,
M(=4RK&=@W:"VFMH(=?+Y=<C-!!+&FU"PQ'E%@SJ=M2#>*?-V&84"D(D"FQ"&
M;,C0Y(P,(-U"MJOEZC/<SI\PK87G'-I,ZH,OHSLHP876?+C54S-HZ7.:2KDE
MC+W9>;S:67HC'JZ;(,KJ,NH9E@/.4R?,*ZM&UD)E!AS%*:I"![*M+54D:.%&
MEC/ &5KM>ZX@[$KC;'LUR'(\DNC^1XC&Y#G'&$8 RZ+KQT+*K&?8Z)?M01C)
M0\FP*(JN'4;FE!S-@W8*.12]HUN\<KWW7J,[HK.5-3/!#'3B.GF=*.H>2*76
MT9.>0Y?)3LI&X/%KUWLX)*V%KB:/DK2T]3+)4EZB)'K*=(Y8S&D@&25-?',I
M#;V239Z NH$!6-[@&Z9.[&;A+(<BF@V*MJXMC$5E,\*49XV@SZ8Y$?LL7]C9
MV<]I8F $WG9TU'%DI7+)-([AH/O<P<M3QIX\J=79ND1K'73<I*VG5&D85,DB
M0IJJ9ME AJ,^K\O1VT0,R[*../4VIP44#0&!9]U5R:H:BPB!IXU$\Q6F@VD[
MBFR6@K#&I>4!]J\C%5L"&8G600%U])=B "-H_G:3(Y"R2T!0?#IK+N-C)Z+8
M]&6/E@&R?#]JPMC3(49MR$O-QDY#A)B.BTD6"1QS' +UX%(]]B*I5R&$= <K
M9-5&A@IB\M4M-4HDD[:=>939:DT$@AV+1.\+2())%=QJ 4:06YHY(1L*UA45
M"I%3&IIW>.!0P7+H,R:"6,S;59E298GV:LB-I-V+.J3)3L/^#+\O23&(G.N;
MY!9&<P;->S@:>!,.1A^_!Y:VDHU))P+EY9DC/[J)85A,8&AVIJ0K=Q'B\C=%
MVC,4R'C$'Q#5]UE<*:.H:BHTVE+7UZ!ZJ55DILODCA:)&: ?PN:0L4CL8T0(
M6<L]ES')++VJ&@2NKI-%50Y>Y2EB+15=?$\R32*LQ',XD2SN0KM(64!0 6QX
MR[$?$FD9OF$NSA)Q$+'P'9&EYB>A,;O)9%:.-H3:&D^$YNB#N#KK$)"S@@N-
M+RD6D-05*E;K[FCUHS33JK7>W*J8R;**CB:9ILRB2!Z@1RVHJ"*KBVA<!4:5
MI1&^H@+:ZECNQI7DE#LVDEK95B1,N9IT@VL=JNN>DE*:-\BQI&TB:1J<@@@$
M&T#QEL&PE3;>S-L0FPYB3R:;;-\T+[+QXX:'-WZF65<0",YXLD2:V.Y24C)@
M+,Q(HQ'12!2][8Y$2@>])QL')DNX!.ZHSN<Y-1YPCQQ)#F$29E&BN0*?G345
M0A$Z+*C0LZR.1;2T9"NT>\Z*?(Z<9S69/)'),\V7R29;([+K,_-EK(&782F-
M]NJF- Q(TR@E5D&D>B^7NQ4[&Y%W?7$=7H*'Y=(1#"&)938=D4N-B<N;-Q#:
M,<[9AF+@',Q00E4AEX39Y"M(2 /JW1ZXIF(%0,V#6U3[U<"EY39NH'.BLDM*
MLE94Q:4B1Z7,!0>Y22N(V,:1M72&5T74%I'N6MO]!5\E\H)8TP=(ZDQTE,^J
M25UJ: UAS5XXS*-<DBT2&&-FT7K(@!&.&I^/>Q)83F;F%$"F;LR1:/Y>+[&X
M#'(DCBF+^'<<,[7JV:0PMME$.XFS%F,;Q0MB+OWW0#<OES\1D0EVU9-5WEBJ
M/4EY55L0F HZ1Y*6/-I9V%1+L95RL4KMS9A"2QE6IT .%$<L;!G8#?S(N25%
M*R,U95Q15#Y7' C4\9GADS-JN)!4KM5 6-Z;:=$$O%(C +?'0@W8E,-3%FQR
M0KM%3,)A,EB3$T\2=E8-$VV21Y/)V>\L8&<.R,>LG#@,M%(P0P^<DSGO0:('
MR5I^,Q<<S4*N[W>LI^5-9"S4_,(6JTJ:B*RRRFF=:>AIJX*LFR#B61:J.,:E
M"*5>0]!2#A3\D:6=5J/="9*1Z:&4%H8^<!Y:VIHF+1K*5V4;4KR$I)JL\404
M,Q9<*YZ[''C3$6S<:RJ"S/+I5D2,8"PMM#E0:\%&#,?E(AEK/)K %HT$>OD=
MTH3,,3@]K)D*%8RU04"+WL5ZIDJ5Y%N@Y15-7F24CT<4<$M95T2N)7:99*:B
M2MU.NC9E"KF,Z';I@$$J=6*N8<FJ>CRR6KCK)I:B"CIJV1&@5(&CJ*V2BTH^
MLR:M4>T75&O0-FLV[$,[#+\TJV:/U[D[["V1M;>67XN9G_5T_P#JH<5^1GXS
M97_63?Z:;']U.OP#P!QQ](>#AJ/)X\>.K#R^/'CKPU(X^"/5]GHQ!X> ?7]O
MIPU'CQZ,3X\>G#3##3QW[OMMAX[M_P!E\-V_FU/CNZ^'[<1X_9X]&(YX(1JD
MLK.N\[3PNJ!MC'?ZMM_=O>&U]>2H-MNK=VNB-7U]R]UU$Z*W5W67*53MMLII
M--!SGGFR7G.PYN)OY>QUZ]!/"VO>; ,;6)MNQQON>R7W?/*CW.IQR@.5KDAS
M30W.#E:U3UG,A=M CYTQF+!1(3I4N4 7$CUM\>.KUV\N.UX\=?JOY,-/'U>.
M_#Q]?CNPT\>.&'CQQPU/5]G7WV\_E\EL1U_;U=U_-Y/+?#4>/'HQ/CQZ<-3]
M=_3X\^_LZ\1]5O1X\V[MZL-1B<2ES\I0;]L\D_HJ+:Q_EM_17ZWQ/4/.?J&(
MMK+$8:88:>/'CSX>/'CS8:88:?N\>/)A^_QX\N&IZOW?O\>3$=?[_P!WCRXI
M=92^VZRZVE]M]*VW6UMI=;=;=2M*VW6UI6E:5IOI6E:5I6F_?PWZBVZ]MWV=
M?[?VXA@K JP5E/1964,I!%B&5@5((-B""""001?$>BD3CD' ,(Q$Q#,$ &6K
M6L1C&RZQNAW0X5=N+J<NZ]2^]=RNLNJHI???>HI====7?K53TT%'"E-31+##
M'<)$MR!J9F8[[FY=F-R;DF^^Y..1D.0Y-R9RJDR7(*"GRO*J(2<VHZ562&+:
MRO/*>FS.S2S222R/(S,SNQ8WW"1:V^/'[N['9\>/W]^&F&&I\>;QX.[$>//X
M\#?AJ,3AJ?V>?T>.STQ^WS>GQV^AJ/'CQY,3X\>/+A7C2M.O4VO;RV';X\V,
M3P/;OX;OK]9'UXE$W^7&4?L\5_GJVL5^ G]$>SCPX>C$\2W9J:W??QUXB^IM
MUXG#U]?7JZ]3]7GW&VX_5B-WDO\ 5>]O3O\ %\-1B<-^[GX<]?:IOK[5.-?)
MIYO';B.''QV>G"G'C3FKIP\?9B>/BV&GCQX_8\>/'[8'D/'4&R<$;Q[(@9O(
M8VB7'%+P9%Z]1"DG[)2Z@Y$T.;.VS(\RM=K)K)AS*3\8L_29.;F2CMJU42JU
ME!2YC$*>LA%1 )%E,+LXB=H[L@E1659D!Z6SE#QW ;3J ([_ "<Y5Y]R.S"3
M-N3>9/E&9R4=10+F,$5,U=305>A:@Y?530R3Y=4R(NQY[0/3UH@DF@CG6*>9
M))%'0P:/ A */(V-@0D>V8"6Z;E=[8BP;)T3;)V.W2[ERXML2MMMM57<+*7T
MION4NKQUOBA2FCC@B79QPH(D2[,45!8#4Q9C:UKLQ;=9B<<O,<PJ\WKZS-,P
MFYS6YA42UE7/LX8A-45#M)+)LJ=(H$UNQ;1%$D8)Z*CJO6MG[]_VXI_NW?9A
MJ#W^7QV8D=WD\=N&F'EQQJ*I(V=L54L23I6VE;U+[;+*5ONI;;2MUU:6TK==
M6EMN^OY:ZM+:;ZUI34V)-A<G?NX\!O\ 0 +D]0'8,02!O) !( /;?AO\I.[M
M)[3BO;$^V52[99VVEE%*I<JWME$[KJVVJ5LW\JEE;K;K:7;N36ZVM*5WTKI8
MVO8VX7ZKBUQ?MWC=Y1VC"XX7W[O7P[['N/8<?>HQ.)7&_D"9_M5X?QEC>L6X
MIVZOJ1L8GR?%/#KWKPM;U>?$4UEC+#3S[L/-OPT]/CQQ^W#T>/'#[,-,,-/'
MCS8>/'GPU/U>CZO%N%\1]?I^OQ?C;#0?M-]_V$^?U[L#Z>S=Y?3;OX8CHN)1
ML*<D4D%AV;$[+E!RLC)HV74<EKQ+2C$=5S=6ZMNYJVK6Q.U.U.VMU]ZM]+E5
M+[[M$=/!%-/41Q*DU28S/*/A2F%=,>H\#I7<!]IQQZ+(,FR_,\XSFBR^GI\T
MS]Z-\YK8E(GKVH*?FM'MB686@A+*H0(+L[MJ=G8R+6['9PTPPTPPTPPT\##P
M<-/'CNP\>._#4W]7CP?-B+>OQX'GQZ,;/W]RN/\ ZX-_TT_U3F_"-YE_]"XW
MI\$>GZSC\N?LG?S1;;A_=39O^R"=U],\G/X@R;^S:/\ R$Q\M\H_Q@SK^U*[
M_4R8U&:Y!GS&U.UE.)@SM1BSV#(VM9,:;VI0DDNX<D8<G1)[92R*OW+MTX>Q
MZVE!#I9RX579WJ+*77=0TU.U]4$+7D68WB0WF72%F-UWRJ%4+)\( "QW"W+%
M34BVFHF73$T TRN+0N6+1<?P;%V)3X)U'=O.+TIF;,"S0</6RODM5@(8W#!+
M%2=RF]F+&WB'T?O'#FUQ6J+)C<!*$PES1M8DWJ((OQM4^XG;A!37S*CNQYI3
M7=M3G8179@ZR:FZ.\ZU5[G?J56X@'&P5U: HYY4V1=*#;/9%TE-*[]RZ&9+#
M^0S+P.)SC':HS_B&0EI3"LH2ML=-16;1!T_*%7AU1$=D"#6XVD;X?0NL\M&R
M*^%(L@0V2L:(' [,8)3&OFU!;&B&FIRN@JHUBEIHM"2PR@(H2[03&HC#Z I>
M,3$R-&Q*.S,6!U->Q39OF-*[/%52ZFBFAN[;32L\(@D*!KA'V05%=0&72I!!
M4$02W,>7K$I2WLRKDFQ"<K.G,V0MG4HM1F+A\R4&O7$J2H4I9(5G8Y94>Z5+
MT=WN&*JC1:Z]"^Y.N\T=(=G>EI_>0!#[S%[R 0PV71Z%F ("V (!QHY_7#:V
MK*H;=M4UIY/?6M8L_2Z1()!)WD$]N.NRRQE,:1D)@=DO(+ O+F-HN5E64SD;
M4E)QEB%K6P=(7R!)-T:8V-K+&]K0DJY;VH66HT3HG;2VDM24K+&C4T#)"VN)
M6AC98VN3JC#*0C:C>ZV-]]\8+5U:-(Z550KS+HE=975I%L!ID((UK8 6:XL,
M?8_+>5Q(<5'163\B#(^!<)NP8(?-9(R#!72)9L>1<B1;8DFQ'.$CK-H:36:(
M(J6%FK<C;=1X@DM9#4=([M(U+3M(X(=S#&78%#&0S%;L"A*;R>B2.!.)6LK$
M1(TJJA4C-XT69PL9U!P46]E(=0X(_E -Q M:_&!/:S"F0ZS>7UG]'M"7AS62
MFJS'OC1*B%"'A/W;W[[NHA2B-'?=W;Z)4HG13D4I;K/F\&Q-/L8MAIT['9IL
MM/Q1'IT:;[[6M?&!J:@S<Y,\W.-6K;[1MMJX:MI?5>VZX/#'W;D3(-E@1*R=
MS*Q*-''DHCB=LH.6V1^2D7";LA(@EE'U+11U^[11=/2["C<@Z<I)+KN%%4[+
MZ.;4]W.PA)D18I"8DO)&HLL;G3=T4;E5K@#<!B><U/0_A$UHI&EC&T:R2,06
MD3?N=B 2PWD@=@QWU\M95=%79USDW(3@X_-!)(^,KS22+%GLBC2:Z,;/NR*A
M*YVY-1Y)RY2!E5EKWPE-PM8P7;VJJ4NP%'2!!&*6G"!'C"""/0(Y+&2,+IL$
MDL-: :6L+@V&,C65A=I#55!D:1)2YE<L98K[*2][ZX[G0QWK<V._ +EG*L;>
M,R,=R;D( 0'!7$;'O@DTD@IXPCKLBX+N@+-RP)-UFH5R6>.RC@6A?8Q6(NG+
MY1"YRNJK?+T=)(&$E+3R!G$C!X8V#2!0@<AE(+A %#'>% %[#".LK(F5HZJH
MC9$:-2DSK:-F+L@LPZ+.Q<C@6).+4\GDY(,%11":2Q\+6##XZL->2,PZ'JQX
M04J<$@E6:[R]NH&%F[KS X7>G5BQ*WW$&R"3NM5M9"G@5@ZPQ*RLT@98T#!V
M39LX(6X8Q] M>Y3HFXW8Q-54LAC:HF9"BQE#(Y79HVM8])-M"N2X7@&)(WX]
M%.PS?-*MFC]>Y.^PMD;7GN67XMYG_0@_U4./0\C/QERO^LF_TTV/[J=?/V/I
M##4^/'CJ\^(\>/'7YL-1B<-3XX]6[QV\;XCQPZ]_CLX6PU'CQYL3X\>?#3QX
M^O#QX^K%CDT=$R^.'XH>;U=A),%*1\PUHI>C<X&&&2X]\C8LG6U1%11LX4M3
M62NM52OK:HE=:I;;6FZ&1X98IHVM)$ZR(;7LRG4O'<>D-XZ^';;3/%'/#+!(
M+QRQO&XO:X==!W@@C<VXWW<=VXX\V04-VO8JQQ3:QD$E:E)6\D4ER_):1Z-2
M$D7G@Z40^+0X7+!3QW6C&(J8BCW<55 A$2VN=(OB3\J/-.!=CCTSSY/,:O7%
M"4A"0T4.UEC5(&AGFF:!D'2F%;(&&T61@K!%0H&MY$4V>P"CV<TVJ5I)JZ;8
M0N\E2L\$4*U$;-T:<T4;+[V\88J79ED*:MPL JY/N93YODQ23D5FL\)^#,@D
MS,.%O-1URV:.F]!D8%C6:T>'AUU5@UB+Y^=[Y+,UB[,LHU>IM6W'S(4FJG-*
M(E!ITVD<3.^SD!8':3.Q$C.+/<+'IU:"MUNW=RHUNFIYZ9G(JGV4DR)$SQ%5
M*Z((XU,:H24 9I=6EI X5E1=@-<SS]7;?N\6QUO-U]EN_P 7PT\WCR\!AY_'
MDXG#3KL>J_CV>7#JN.NWCV^3#3AY/K'HPX^7ZCZ<-1B<-,,2ES\I0;]L\D_H
MN+ZQ'PS_ $5^ML#P[_J&(MK+##3U^>^'J\UL-,,-/'C]O?AX\?L[L-,,-3[/
M)[/V^7$>WR^W]GDQJ]M)XJ-Y)5Q?2/.3+&BDR\"LBN RJ25[[",R;47R. ?7
M*KH]I9&G$<C+6\@U[84&[U%!UMERZU]>ME=7'3"JVJQO[SMJ99 3IKH2132K
M8&[1K-,P4]%C\+>!CBYQ12U9H]B95_A&PJVB*C5ETZ@U43$D65S#""PZ:[].
MXL#KL[KMDV"LO/'1V;H$F\C>>"<3C<-AO<ZXP;/#JD;$P>6W,2:(@5*8 D''
M$CA<'+%P+Q=F2+-V#VPPP6Z2^XI>B"Q4Y4Q#;32RU.Z1Z:(2/40Z@SM'4ZV2
M.-XD=;I&Q705XY^Z )7LTM2'VQYO3PT]. R)52F&*FJ K"*.6D$:23-'.T;-
MKD ?6K>C@M5VN,'+/VJC%\LQ:*O62RZ#I5F[4;IWN&JKIK;8V<J-UJWI7KM[
M;4%KK*J(VT3NMI3S4FD.X4AE#,%8 @%019@K79=0%[,21>QW@X]?'J*(74HY
M52RDABK$;U++96TDD7  W7MOQWM8>KP/W^VV,_7X/[O9?#4>/'U>G$^/'U^C
M#3##4^.OM\?OQ'CJ[/'[L-1B<-2.(\_5U?7]N(-[$#U]?;XW<<2B;_+C*/V>
M*_SU;6*[D3RH/'CZ\+W+>1F\W?W_ +MV-1=IC&)[+('',: /BH5RQR@TDMTG
M$+W(N(@]!0+(+B*2M5.U=OW<V!SZ^).U!=]5D"5UMC)X@JR6<;NME57'125,
ML@1PU*8A$X!$ZR5%/MH1<$*9*?;#7N*;VN"!CD9S1RUL='%$TD96N64S1DJ8
M#'2U1BG:Q74L=1L24-U?<C J3C4S%S#:\&LP:1R/SB"D2^03TI\'(Y? SD-L
M*3+:HR&;RBC/C9E(@92B[/#;Z-E,<K@W(IRY[N)4M3<'TAPI'L5;Y.3)LY*>
MH2.GCB$DPJ8YBM-E--%2\WCC9(C*]8DBU(D#A2%WA"[-PJ)<]01;6.JII):J
M:8Q4YI):?54YO4R52U4D@:40I0-"]/L0MP7M>72@SI"VN8\?X-QJWM2R=)I-
M%LGCT,BLC=L:,3$O"4Y 29G+1%_(8,2P:YLNP(L%VKA,JJ,364;N+E;*-JT)
MC15.85)O21134C-3%-LD*3Z%:/6&UM&^YE93>,,03<$D]"F7,*7+*, 5DDT%
M8HK%D,3SR4XE=9-E\".2.VETTD2%"1<,-V'0[';,*0L>5E2\R<''X-A&SV/B
MHK%K@ X:&<#SU>0DBK=N%<*NBS7*=D/&]K;GKPG;:WLZ#'8A^0O5N.V2I,4B
M$&S5VD6H5ZP2*8Z^FV:*-H $>E,S$[+5;>'5T6U!$Y0/3EYN<;1HDA:D>.C:
M$B3+:DRLR[-F:05HACWS%/Y)5E9[]XTAMILV<I"AEC# )$'$0L!&!(J$J%91
M%,A'8D:DJ ,58/O3:E\'!A4GA;5M8Q36*A#EK]BW-R%H/5MB,Y&6B>0*\DPJ
M"Z.]1IBFIHYTB+OJN5KY'CG)$A"R1Z6*1,RKG*O*)4FCC,B10&GV<D:4^UEI
MZJ2!YECBT667+HHY:=0$):.4LHDD5<7=03M85B,W+$,B9(L.#8KB5A$6(J%0
M)"V1OJJMB.0'JPQ$*8*!I&:09)1M^9HZ>B8I4H2.#H<LHFFR:8!\HV].JTU+
MLWFK'E9YZD[( ,E.C-M$#Q*6:4(55Y@B(9U'2:=&?;"J=ZJL$J14"TZI!1@S
M,;253M'ID>.9U18V8LT<0>21*<_ 6Q.$=J6;9"5'R:(S=ACZP_A\_4$>?0,T
MQ$&(1M!X#.IOA,AC86/*.;5(0AD,X8:VW%4;:";:*.["=J(Q+,'*:>G5HIH&
MJ-G6IM(TJ4=TGRS,(],D4DDH!$QIHT-D/OA.G22YQMG-34,L\%4M.LV6R"&5
MJ:6.-J?,\ME+QS111%B*=:F24%I/@GIZ@L>)%LU)YQC<YA.&9.[>LX9",,0K
M)19!1 #5R)=R&,I8S$8D(WM6ZCJYHSE,.R!DFPG:OW6LYO%BJ$G(QFLRKAFA
MH98)ZZ(*\U173TL?X32ZQ2\ZDK%U$+J,<]-2Z=RA=3E [ECMR89E#44V7SL4
MIZ;+:>JD%XRR/)$*2.B;2"VD34]75;346;H1AM" "R-"^UR]E\ZL/,LL L;K
MSJ+W77@FN,C,Y!1RY?.S8TCCYVI'&P\J/4>C,#KO^ZPI=PPC1HRF/(DBJ1@L
MGD4R98J?0:)ZH4\@]\YVE.\O\ *FJ7:LZ.%:O"V=%:5$U*B&-#KU9XTM1M%K
MTI351:MF*.2JB@/N@&YHQA6.2,NN6ZR49E@:70S2+(Y[D@7VL%X\:M&$,M#9
M$OE@FTD*UX#&+P8$P^BZGU("2QJ@.$NG1.1DF:.-+LAIN:FE6M[N2]R,1=Z5
MEC='[D"6+4E&T0I T8+U:N]8RTYJ$J];6$2'G0I2$B!"PZG;^5E,<[,,P1Z]
M)37,CD04;I'0"2IYJ]( C%I6CYH*L/M2&,^E4(!$ DU^U=D%GE^$BI-D]^9&
M #$,-WBQ.-HA$+%'FQ]"Y0A=&7B=CR3B,CE,[R(;;1HK(78D8!-&4&+FUJQ1
M),[$(RB T4S14BHTL<\8+551-89S-"^U5K0M2IE\<EVV0+R(C,IN :D_NY5)
M7TRRUK2"&2"0K'1T].-610RC8, TZ5;YG(@"M.T:1O+H>R*R]G+PW:EF)"61
M8 %RV0QRO"@#<<D91QJN5(%0[S"\B"R4?>X# 4QDQO(I9 ;/PQM\5&4(B'K@
MW:/%/(X.:Q1OE,*PR2O1+5":74T9JPBI(N81O&PVKWAT\UTR(B$I(-!+AV+,
M8\[J&GAACKGI#30Z!*M&7,D;Y?+'*OO42I4:A5!XY'9 R-M-*&)%[A +M:V.
M"TI"I31-P]2$Q9"5%1D.4R;;B9EEW))%G>X"CV= -TR3!OHPL_3; >^-D1?*
MKVL*3!-1)/%7R<:8I.;V5I)MDCSBEYX]%2*Q#DB4P;5)EC)?3MD"LVR&HYM%
MG@:2>,55W2*!99$I>>"B2OK'L8T00BH,30%K1%C#(2%VU@/0G&2<M2QW!TYX
M04*S2R*@[9237$M 3@@=M'-Z$GCH*/=/6 MVX==L5=L6+E5FV<W*I-:VH6IV
M6^;JS":F<TZA(=M(8D#LX5-9T*'8*S@+:S,JL1\+?CUM$)Q24PJF,E1L8Q.Y
MC6(O)H&MVB4E8V9KED1F12;+T<9DC7R!,_VJ]6__  FC7K[FJC?"3^D?_2WE
M^WTXL'ZE/H^#VXBFL_8?V?9B?:/V_;AJ,3AJ;>-_#MX<,1?QNX]G'CAJ,3AI
M]O[\/L_=AJ1[?J.[T]O5B#[/K&_T=G7C%.;XB]F^*IJ##JO6TE3$7G88]&WV
M6$1TYBRR,EA)!E<I>DG<LTE(D2M5NLI8V>(VJLG=:M'*]MUN@G6GJX9'"F,M
MLYE?X+P2WCG4[C8-$SK<=)2=2D,!:EF,#5-%/&A82A1+3LGPUJ(2):=EWBY$
MR(=)-G%T(()QIZUB.TU#))"XY&9%* L-:XZ#G#!-A#XU+[)+DZ3^'AS,)66M
MR#EN^0D%TD(A3 )DD88".W*-& I,JGWW'I]MI\LGCJ)9(H7F>I9$1IYH=E2Q
M;!*-865"-&R5DF8J7W%WL0C8\_S?-Z:>FB@GJ%ITI$DD=*>&?;5<O.7K'G$C
M:Q+M65XT#QQWT(H<;1<;9X!6GRN+@-,FIG_#!LZ.,R#V37C.^YILS.$&XR0+
MLA0H*W#)'!R;8FT K,*/@;5RB+?.B#EJH_<<?,13<[E-*8]B1&56/:%(R8UU
MQ!G9S(T3ZE:0-I<C4H4-H'<RHU1HHA6;;;J9%9YM&N0+(P24JB(L8D0*XBMK
MC#Z6+$:SF75'R\/)X\V.CY./E\>?#3V=5_3ZO1;#V]=O1Z_3?#48G#4^-W=V
M7]0.(\;^_MMZR,-1B<-,,>C&S]_<KC_ZX-_TT_U4G_"MYE_]"XW)\$>GZSC\
MWWLC1#8Z3V^-LBR61':9=R>S:3S%;(',=R+BL>!<&*3DS0@L&9$\6DR+0:HY
M[;<S;O2#UTDA6RQ9RM?2Z^OT1R?7-?</*=G-0B/W/I= >GF9PNQ33J85*@L1
MQ(4"]]P&/FSE V5#/,XVD-:TGNC6!RM1"JE^</J*@TS66]]()8V N2;XTO[Y
M[#7SD[67\J6'?O/5_%KKZ,X_G\O^BU'ZWCD:\GM_RU=]+A[/_P!E[=WC=7OG
ML,_.3M9?RHX=^\_Y_<TT9Q_/Y>?_ +6H^VK&&O)_^GK_ *5#Y/\ ]5\_7BG?
M/8:^<C:R\O\ KI8=^\_Z\WEU.C./Y_+OHM1^M8C7E%O^7KO*>=0^7>/X+;R^
MKRX=\]AKYR-K+^5+#OWGO7JU&G./Y_+_ *-/^MXG7D__ $]=]*AX_1/'9AWS
MV&OG(VLOY4L._>>^"FFG./Y_+_HT_P"MX:\G_P"GKO-SJ'Z^:>STX=\]AKYR
M=K+^5'#OE_\ (_YNCK\VFC./Y_+_ *+4?K?5^[#7D_\ T]=U\*J&_7_^JV[.
M/[,.^>PUT0G:Q_E2P]O^P]Z^YIHSC^?R_P"BU'ZWB->4=5/7#_[J'O\ ^5[M
MWG&'?/8:^<C:R_E2P[]Y[31G'\_E_FYK4?K=L3KR?_IZ_P"E0_JGV>W#OGL-
M?.1M9?RI8=^\]J=&<?S^7?1:C]:PVF3_ /35_P!+A_5/1W>7#OGL-?.1M9?R
MI8=^\_\ B\NHT9Q_/Y?]%J/UO#7D_P#T]=]*AMYO^5OZO9A0GL-=,)VLO1E'
M#OWG_P ?DTT9Q_/Y>?\ [6H^VKP#Y/UT]=]*A_5?;?R=?I1V(-79')=D8V:Q
M\%B^T>-E3TM/VHI[+L@8P+1YO<MB:>6.KR(\-C(,2<TJQJZM;VM2;6MCNY!5
M6JJ-EZ*GG.5HS,<GLR,\M"T8CA++'!.CG^$Q6TL:B10;@<5(MY>'I.2#96>4
M66B&&L64R2!&DGB>,'82CI*L$;;QV-N./[FO%3$:;OSPDG'_ ,:*\G^X?+K\
M(UM^3W'V_;[<?0.[R]X]GHX8>*F(^R$EW\W%45U[N;N'T>WY=S6_Y-O,>/SO
M'#RXC=Y?5P[+^3S'#Q4Q#V0DOU45[M>X=-;?D]Q]OMMY<-W7X\>+8>*F(=!"
M2_5!7M?(.FMOR>X^WQY>IY[^KV'#Q4Q'_'Y-]4%='/\ WCJ=H_:O<>K_ +Q\
MPPL/+U[[CV=]N/5;#Q4Q#V0DO1P[8*KO]ICIM'[5[COMP_E?7?"P\O&_$"U^
M(X>L6)XX>*F(>R$D^JBON'W>-.;4:V_)]()^W#=UW[[?8</%3$:?JA)?J@O[
MA]'GU.T<]A/F/YV_U8D =0/EX=^X"W=AXJ8AS=\)+]5%5]YCT4Y_6FHVCG?=
M>X_G8BP&ZQ'#=Z/-YL*8IB%?U0DOU07\##IX[N?36WY/<?SL-WE[_P!F'BIB
M'LA)?JHJO7Q^0.-.'1IK;\GN/YV'?ZO9Z?/Y,/%3$?\ 'Y+Z5!7IK\@\V_VM
M-;_D_-/YV&[R]_[.SK].'BIB'LC)/2J*^X??TUO^3W'\[$BW7?T$>S#Q4Q#V
M0DGU07[7R#IK;\GN/M[/;AN\O?\ L]G9Y</%3$/9"2_517W#J=HU_P"3W'ZK
MV/V=AQ%AY>OQ?CN]=_2;VMC&+71P>TN?2'M")DLYLNHH,[;51PR")JVW5JRY
M'(I8W2K9R;=]+JJ<JMU.32W'6VIK:>"C@?*>T=N)X ;R>)ZO(!U>3R8LGBHB
M/LA)?JHKCNZOS!TTYO6FIUO^3W'\[$;NSQW8>*B(\_?"2UW<^Y45]P_BZ=-;
M_D]Q_.Q/1\M_./9VVP\5,0]D)+S<?[(*^X?7KTUM;^3W&W=J^W$;O''OM]F*
M>*J(>R$E^J"ON'36_P"3W'\[$[NP]X]AZOMQ7Q4Q#I(27T*BON&N[36WY/<?
MSL-WEOX\GCCNX8>*F(>R$EYO^^"O/_B/KUZ:W_)[C^=B-WE[QP\N[ZL/%3$.
M?N^2[N'_ %T57S?WCUT][SZ:W_)^:?SL-UM]SZ1[,/%3$..XA)?JHOH_]0]>
MG4[1^%UMYCY?RO+O[<.C?R^@>K?V;M_5AXJ(C[(27KK_ &07P\_YAX;MWNTU
M&M_R?FG\[$[NP]_[,/%3$./YX27ZJ*W<_D8UTUM^3W'\[$;NKZ[_ &##Q4Q#
MV0DOU07]P^GS::W_ ">X_G8;NN_>+?5X\V[#Q4Q'V0DOU07[7R#S^O-QTUO^
M3\T_7JPW;_A;_*-WHMAXJ8A[(27K_MHKR_[A]?3IK?\ )[C^=B=WE]6[AY//
MNW=6'BIB'LA)?JHKCOYO[QW^OFWM;_D]Q_.PW>4>:WL[.'E'9BGBIB'-WPDO
M'_QHKVN#'IZ--;=J_-/YV(W>7O'L\7Q>Y+C**NY";=+OY#:LY*/EU+4E!O:Z
M7JN%+[J6<ME=?2REU:[J7777<G=OK6O'4"1]( TV&[@>H_TOW_5-@"=QN=YZ
MMYWVMXMV=ME\5,0Y^^,D\W;!>_\ F.LMH_:.X[S\[$6&[CN[+#[">ZV*>*F(
M>R$D^J"N/_N.HUO^3W'\[#=V'O'D\GDP\5,0]D)+]5%?<.IVC]H\NX_G>3"P
MZA;LX>SR]5L5\5,0]D))T4XJBN??S\6/1[=.?4:W_)Z^H_G>/)@;>7JZ^SQ^
MPX>*F(>R$EZZ?V45Y:?XCU^O3IK;\F_;8_G?;AN] \WE\F[=AXJ8AS=\)+6O
M_GA/W#Q]&FM_R>XG[<-WE]7LW6]-[=6%,4Q#V0DOU45]P_BTUO\ D]Q_.PW>
M7U>ST>7R8IXJ(?2M:]\))OX4K6B@K?6E-]:<>X>:F^N[RUK6G/IK?A=;>8_G
M8;KWW]X_-Q7Q4Q'V0DOU45Z?[Q]SW^&^=H_:M_,>'SOM]&&[K%QYQV^;[,4\
M5,1I^J$E^J"ON'T:C:/N%U[C]6KSX *.H^KZ[>8>C%?%1$*5K^>$DITUKVP5
MQK3=;OKN8^2F[?QW4I3JTUO^3Z WVMU7[/;A9>.^]_)O'EW<;6'H%^&'BIB'
M#\\)+T_]=%</_</Q^33:/OWKW-O_ /R\I]N! ZO)V>D</-O]6'BIB'/0A)=W
M_G17W#3GX]5>GHTUO^3W'T?RL-WE\MK>H6XX>*J(</SPDOE_LHK[A^WIK?\
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MDFBXRV]R&=Q24F9, 'NF19/E-5W+<E$R:!-E6ZU=A=>UL5M[=<X3;S-05=/
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M-%L5D5$EXM<_9D+7C]2PFC@F<U U>\12!EID=3M>DE/ELV5!=2N&7:05#LS
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MTXIH'5XY%?X&HNM])8ZAI(&,I\@I*@0J\CV@FS"1=<5/,KIF56:NHC9)874
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M>GUYVS;M3N;OX^.S$:E^*W"^X'N/CR]F'C7BGL5(?JPW=Z\/QZ;-K<4[FO\
M7;$W7L.[?PX^3X1/;ZMW:\:\5]BI!]5&^_O]?>;-OC+YK-W>/1AJ7AI(OP.^
MPW=>_P _EX7&*4RM$[:4I:(/VTIS4HH,I2G/7FINISUU&S;M7SV;V^@=5NS$
MW7=T3O\ 1NX>PG?<F^_'UXV(KQ_.J0_5AN_CY:^>N_=\&IV;;]Z]Q]OMQ%UM
MP/5U'>;;[WZO-Z-YMBE,KQ2GZE2'CPXK#.OS4Z=!&Y(WIU#@WMP++V?63V;M
M_'L'K(P\;$5]BI#QY_[,-U&S;M7N;NXX77L-_,?5O/[=PL"<4NRK$[[;K+PY
M^ZR^VMMUERHRZVZE:;KK;J5WTK;=2NZM-U:5IOIQI739O\901P(U WX;B#B=
M2V^";-N((/ ]O2]?FZL4LRK$D[;;+ Y].RRG)LLL4&6V6VTX6VVVV[J6VTMW
M4I2E*4I3A2G1J=FWQD[FW^+>??O\F-Q\4CQOMTCZ-Q&[MW8^O&Q%>/YTR'K_
M +<-XZ;-NU.YO;U>+X:A\4]Q[3>W2\WGX[MY%?&Q%>@5(:?^F&[N;=Q]?3IL
MV[4\UFW>O[?3C*Z]8;R6WW\O'CY+<>WJIXUXM[%2#ZN-Z-W/3CT=%>KT4;-^
MU/7]C?7[<1=3OLP\EB?8;=?;OZL4\:\5]BI#3_TPWU]_=7KW<8V;=J]S>WQ;
MO7'Q3;J[=_5:_$><#[+VMD^-VQP>Z[V'>T*FB[:RSMC#ME+T&(152ZZN_DUL
MK:Y2I92W==RK;^5NINWP(V#-O7> ?Y5M]]VXWN+6XG$W72+@[NSC>^\\>!\U
M[7Z\67QKQ3V*D/U8;K+9MVH/0WMZOMQ *]:G@;\;^C>./U=Y>-B*^Q4AZ^"P
MVG'X--#=J]S;_7[#A=>QN/8=P]=SU]E^&[#QKQ7V*D'-_P!]&_@KU>M:ZC9M
MVKW-[;8:EW=$V[=X]1]7["<4\:\5X_G3(.;F[<-^UZ]._?PG9M;BG<U_KM@"
MO8W=8>MK[^N_;V;S7QKQ3V*D/U8;ILV[4[FW>OV\< 5[#YNWU^HV]&^[QKQ3
MV*D/U8;ILV^,G<WCNPU#K0^3]VKT[R/K.%,L17?^E,@I_P"F&UK^#=Z=^HV;
M?&7N;=X].&I;7*GS>";[^O=V\,?'C4B-%;EJ!3M%K[:67K4O%T5NLMXVV7*4
MIRZVTKS6UK6E-3H?AJ6U^QO;B+J+FQ)L.K]MSN\MK\;;L??C7BGL3(?JPWU]
M?;;-NU.KJ;T]?U=F[#4N_HM??;<;>.L<0>L]BF6(K[$R#CPK_9AOVNO[?DTV
M;?&4\.IO3UCQV8FX^*?J^TV_>".!Q\4RI$:*56H%/45NLHG<KRQ7;+K*5WT3
MK?2G*K;2O&EM:\FE>-.-:Z:'X:EM>]B&[]Q[.-OLW1=;_ .\#S]>Z]^H\+BW
M>+_?C8BM=WYTR'H_Z\-\V[AYOATV;=J=S>;M].^W=AJ%_@GK/C?Z-U]Q[1?#
MQKQ7V*D/U8=Z\_O^G39MVH/0UOK/JW8FZC^2Q'K]6[QQWVP\:\4]BI!]6&Z;
M-NU!\X_:>SU^G$:E'4QW\+'Z_7>UO-UTKEB*^Q,AKS\.W#?7U]-&ANU!Y+-O
M]?CUXFX[";CC:UO_ ,O41[,7R2Y/C+.0FVBPP[>LV*/D%+DU1]J5UZ3A2VZM
ME+]]U+*W6UK;2[CNW;Z;]8K&VD'HBXO8AMUSZ.'I&&H$]9L=Y\@L.-[=OEO:
MV[?BR>->*^Q4AW?^>&\_KO\ @Z=9;-NU>YNSRD#[?5>;K\4_4/1O-_V[]^'C
M7BOL5(:_^F&Z;-NU.YM_<?9]>()'8>[AZ+W/5;CUWZL*97BOL3(?JPWU][W=
M-FW:G<W?QM^[SX77XK=6_JXB_7<;OM[+X>->*>Q,A^K#=-#=J=S>W]F[O7'8
M>/[MU[^B]]_5:V'C7BGL5(:\_P#UX;Z^YT:;-K\4'H:WUWPN/BFWDX]0^-Y;
M^CCAXUXK3]2I#U5_LPWC^#V^'7J-F_:O<?;;"Z]A\FX^O?\ :+]7#?3QKQ7=
M^E4AK7_SPWU\_P &IT-VIW-[?V877L;T#?\ 61;LOO\ *=UZ^->*>Q4A^K#=
M1H;M7N/MQ-UW;O/Q]O7NZ]V_CAXUXKQ_.F0=/_7AM>C=Z\WO5U.S;M3N;NW'
MQVXBZ_%)O;A?=Y;;_6>K#QKQ7V)D'U8;^'ITV;?&3SV;S=I\_@877XI[_3Y.
MVW'L\IPIE>*^Q4AX_P#CAOK^'W(T-VKW-[<+J;;K>>_U7%N\^?B</&Q%?8J0
M\U*?VX;]KJ\O'WVS;M7N;VCAXW877K'<#Q[SNXW\EN%\/&O%/8F0_5ANIV;=
MJ=S;O+Q'G]F(U+V'JX@]>^VXGAP.X>?M>->*UYQ,A^K#?6OO_ V;?&0^AO'E
M]'HQ-Q\4CQ?A<WW;MQWW[KX'R?&G#617I##MM&@+NE7EJCZW7I]^0S:EB7)K
MNHIVQPG=6MU*V\BR_P#VVZE<3&UUWJ23NM?L/'S6-N'I%CB0R]AL1OW=AX\;
MCB.OS^6QURO%*_J3(>/'^W#*\_17[6^FIV;;MZ]S>O?B-2_%8'C^XWM<;N/7
M?JP\:\4]BI#]6&ZG0W:G<V[N/MP)7J!XCJ/EOUV[.ST7&%<KQ7V*D'#_ ,<-
M]^F_?^'R::&[4ZNIMWK[_5A=>QN[CQZ^'81W'#QKQ7F[U2'R?V8;2GO^WS::
M&[4[F^T]7B^%UOO5OK%]W6.'K'FM;#QKQ7V*D/U8;S^OIIN]ILV[4ZNIO;W[
M_-Y%U[#_ "NWAU=OU>PUIE>*\W>J0;NKMPVGEZ_)[U-^@C8]:=7;[>_U8%E^
M*W7OL;^;Q?=QQ\^->*\?SID/-TK#>FF[=[^_W--FWQD[G[?'H\M\+K\4^C__
M *ZO-;=U#A7QL13V*D'U4;OX>M/AU&S?M4>AO;AJ7L-]_43;@.T;NO?U6\^'
MC8BN_P#2J0U\O;AM??\ P\_DXM#=J]Q]N)NO8>/EX6]>_AVX>-B*^Q,A]*PR
MOM[]_KT\VIV;=J>>S>WJ\;L8ZA\4\.%C[?-UFX'4=V*>->*[OTID._R+#?MZ
M;-NU=WD;?Z^OAZ\3=;&RGR;_ ">.L]>_%?&O%:5W]ZI!]6&^O3Z]#9MVIW-W
M\?K]MFI?BF_F)'5NO?S\/,-_%XUXI[%2'ZL-TV;=J>:S^W[?-A<?%/$[_![A
MYM_:KE>*\/SJD'U8;7[5?+[?7OJT-NWKW-[?JPNHXJ3?S\=W9OZ[;]^[T8>-
M>*>Q,@^JC?QZC9M\9>YM_K\=G8NOQ3Z3Y>%A^WSG&V^*C+0]!Q)-DBY;MEE2
M-EB3NJ55Z50(ND;ZW51K5.M+K[+JV[N/)K2E>._5=UT,5XVMV]8N.('4>S&X
M&XOC\L/LG?S1;;A_=39O^R"=U].<G/X@R;^S:/\ R$Q\M<H_Q@SK^U*[_4R8
MT7UVL<7#3##3##3##3##3##3##3##3##3##3#'I_V&;YI5LT?KW)WV%LC:\O
MRR_%S,_ZNG_U46/4<C/QERO^LF_TTV/[J:>OKP][7X >NWCQN[?/CZ0\>/;A
MIX\'=B/'@;\-/'JX_5OZ_+AX]?#Z]W5Y,-/W>/'DX8?O\>/+QPTZ_'IZOL[\
M.KQZ.O[>[#3=X 'CQZ6_P2?'CT-/M\F'V>7&))&\GIR9V05B$= X:H.:&BN1
MF1*G;73"MSEL[B(U&B+=T'DCMZDWJH1;JO+6L<5<O&3MB;495:\Z9ZR6K%&D
M)AI=F)9*Y7N66[*],BV5XYW8*2]V @+LC1RE-/@,XJ.569\HUY+TV6U&6<G9
M*2#,J[E=35B[2>DU2PU&042B**;+<YGJ4BU5<;U @R=YZFEFILR>F:#+"2=B
M*::*=O)32LL33MWW7<FRRVEMEO*NK===NMI2F^ZZMU>>M:UXZZ  L!P %A]E
MR3Z\>]1%B1(T%D1511<FRJH4"YNQL -Y)).\DDX^],9X:88:D^?T>3S\/+V=
MF('F]/E\W'R=O;AIXXBW<>O#QP-^\=6&GC?X^O=NP\;O'U;]^&H\WCQXOB?/
MX\>+8E+GY2@W[9Y)_146UB/A'^BOUOB>H><_9B+:RQ&&GG\>L8>;QZCAIAAI
MAAJ?1W]X\W?O[<1Z>[N/G[MW9AIX'K[M^'@^KOW8I6NZE:]7'IK[E*5K7S4I
M6O52M>&H\>3QV8;^H;^&_J)MQ\G:;]6-;\"Y"S1.R4X\:..ZP4"-)+)8_>*!
MR Q[+0/?P\W:R DV*&ER$?>N1C872^(D@C4DPK;<77)N6QIF/'</)ZW-:QZS
MW0HN:0QR%:)ME)&U3")9E6=UDE9X6:-4'-I(ED3?*7*RHB?JG_$;DSR"Y.TO
M)[[C^5(Y19C54J/REIUKJ6LAR7,?<_+I)LMIIJ.@CI<RACJY:IQG5)F,U)4Z
MA0QTL<N7SU-3LCKN>/'CRX_+/'CQY,-3]?[OV]OF&(^K]_[.SSG#3L\=?MOA
MV^.KV6PT^WMX=8]-NWU8?9V<>H^B_9Z\-.H^C?X[<.L>G=X[,-1B<*^OK7AJ
M1N/I\'$'AZM_EZKXE$W^7&4?L\5_GBVH7\&G]!?3X^S$?RF_IMZ//V;O8;<,
M1?3&6&F&&I\>/-^[MQ'CQY_W]F&GHX_4#^[C?#T\/K(_?PMAJ-W7X^K$[^KQ
M]>&G[</V8POGB99*@\'2*XD@UV1IRYD((:,B5R3M-F2:NW>\K4@=0O3915JV
M&IN'%) :OH*07219*6J.7[6RO+S>JKJ2C$F64?/JQJB"..F.I5D5F]]#3 A*
M950,VWEN@(5--W%O=?\ #O(N2G*#E"U'RVY1#DMR=BRS,:NKSI7@>>FF@A_@
M2TN7R*U1G$TM4T439;0+SMX7DJ%98::9AD"$D#Q6'QDG*&7>Z1OP8UV=8=[5
M ]&95=JDH_;4%K%CJK"U%S52RQLH9)J)64MMO>+7;[M7J5YI*:GDJ$T3O#&T
MR;-HM,A52Z[,R2E &N ID=@ "6)WGS>?TV74F=YO291/SK*J;,:N'+JDU:5Q
MGHHYY$IIC6)19<E2TD05C,E!2(Y)*0(MEQ*-;SOWGOQR!NW#NPT\#QVX>#X[
M,-1B<-3]?GW;OM]/FQ'U>;?O^ST>?#4>#Y^S$^!YNW#3#$KC7R!,_P!JM.G=
MN_1-&N.L3O*?TK?_ (MC$]?]%K6\Z\/K\^(IK,>K?]G#L/#$GU[OMX]HXX:C
M$X:88:88:G=;N\=_UXC??O\ '=]6&HQ.(]+"AD)&C1>/@:R@P-8+/64>L>][
MUC%[>E%5&#5W5J\ML>KHVJVL4U$.U.'G:&ZJS9-6]RCIJ9)8H)988><2HA=(
M XC,I7>45B"H=@"$N I:P)522.1GU;F.69-F.893E9SS,:*EDJ:;*5J>:2Y@
MT-G>E@G,%0%J9(@ZTJO%HEJ-E%))"CM,F%I,;RK%L723(K&./)-E4HD+6CF-
MD6[\B/&)NBK2P=#+K12G:6;JK1RJG)9N[K>Q'$U%B[^^L9#-!R7+J)<QI\NG
MKE@:?,'$9@H KNL8>50E(=FW1>S6J*IKQQR%I7]X1$'7_P"#V01\HN4&6U/_
M !'S<\G*?/A-/FI:MIX:;D?DT=)55-)1T\4Q:#,LRHB8ILQC@5\PS_,1+EV6
MR)#[FQTV1L4&YQ(X!'362(^C%)L^;N5)!'&[:K= *\M?.4Z#D;JF#G=R35&Q
M)*PQ8^M0-VVT+-V(Q!XF.:WLNFJIZ*&6N@6GJG#&:%00(F#L- .UEUA0 -H&
MTR_A%5%947TO+&@R#+.4N:4/);,WSGD_320IEF:R2B1\P@:FA<U4@%#EYIWF
MD9W:A:FVF7D\RDJ*N2!ZJ;(FKOBQ\>SR8\SXN/'M\N&G=Z_-U=_BV'?ZO/U]
MWB^&@^P^O=]O@X'[1ZM_V>!AI]7#B+^/+:V'U\>!MX\E[X:=OL\6P[/;XOAJ
M/'CQY<3X\>/)CT8V?O[E<?\ UP;_ *:?ZJS_ (5O^[_Z5QN3X(]/UX_+G[)W
M\T6VX?W4V;OL@G=?3')S^(,F_LVC_P A,?+?*/\ &#.O[4KO]3)C1?7:QQ<-
M,,-,,-,,-,,-,,-,,-,,-,,-,,-,,>G_ &&;YI5LT?KW)WV%LC:\ORR_%S,_
MZNG_ -5#X[\>HY&?C+E?]9-_IIL?W4Z^?\?2&,:13* B6SS(V/6@24#"V-48
MHZ)/CHI(8*.LI@I)VXU_&;KGJI)\P1>Q XR7>/AHQNY4;I.A%Y08Y1?7VIJ5
MH:>FJ"\3+4F4*L;EGC,(B+++T0JL1*C!0S, ;2!&!!IP5B3U%53"*9'I-EK:
M5-"2"7:!6AN=;H#$ZERBJQ%XRZV;$#8;4F%",AEPAO.H[>*B :!$7,J2,,'
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MOI)JR9)98X(S*ZP1EY-"@LS!20H"("[%V4 *22#8'N3/*..\=-AKN>S*/1!
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M(A6][A^FZ,-G1+NUO94S)\M1'2B2%FDDB)<-.QC445&TBPEVTE&K#5*6<.;
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MS:[>%JYBE-FT5$)A3:F=X\O>D-?%&JQ:C-'6;%B%(6.!9" [:[YW'M>4!!2
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M@S='W3 58E?,Y4]CD/I)I5>20)7NS2,9&J/&-PZ\HH5.=]3)#F9G4T]7.LL
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MW:/FK[,1IC_*[SX\F*> $%]@G'1S&'U?-QY6FT;M'S5]F&F/\KOXVX6\##P
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M1NT?-7V8G3&>);O.*^ ,%]@G'FJ7?4\N_P#V?ITVC=H^:OLPTQ]K=Y\>7%/
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MIC%09'65E+$0K(\4=I)EC4WQOEY(5\<59*M123+1M4QNT1J"CRT<2RU42R-
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MJ7M[R2K"\LZ=OE[M-EM)22[>%'VVPYOM))IYG,.V>?2S322%O?'+:B2W5?2
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MI(16UE1$^R8;:EDC4^^M.K"!ZEXC(S@5!*@-?T7QO&2<,Q_"(D;/DI6;C<4
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MZY<=N;I/AS<84?:*W*!14CRM(LTK5%$(I$9"FQG3,!(K;.26/:"6C -G;2%
M)1M:+NH,Z-?61Q+$T$2T]>9HY%<.9J:3+#&Z;2**79F"M)&J)-18:0RA7D[,
M-VS@TI,8\%/L>FX];E<9!Y;!GC@\#()NX#D6#9LG$8/&DFEU+PIFK7!YQF5C
M5U75K)0R*5:FB7:"R(_&;)GB6H9:B.3FCSPSKH=2*BFGHX)8D+:=HEZV-EF4
M#4J/>- T9;;39TD[P(U-)%SN.">G8NC*U/4P5T\4CZ;[-P*%U>$EB&="LC=-
M4Q3&=MR83!"-3Q>*Q^$XF?R^#/JOGTB8N#;R!2S8H.[33UA)%2K9F"C[X.5H
M-HK(VY=J-L'LU&SJQ%O:\).;DN1P0[:GVTD]6L%0NE4.A9X<ZCRQ70)K>167
M61&49KD-^0.?#G\]1L9]A'!2/40$%I \KT\W)^7-RDFI8T1T?9@R*ZJ5%K#X
M33:*;>D7D3@0(>XXEX&12.9O,>1L01HZ'*'9D+F^,(P8%LF\D"1D^W2& ,M1
MJ?JN"T=&N5XJ,ESYJQ59QZY\\KS9#-'K9:B%XHH142R)9Q' T%3*CLT<DD;%
MY*5Z8!'8;9HA<&0)BU#RB@F9$---'++4-2Q1L'5I*A9Z2)T F2&4:(ZR*I)D
MB0F%9R 1%K.^]:5WUZ:TIY^CU\WNZX./1&U]W#%V5_2-GY"9'G_6PKWMWKT8
MCX3>CZL2?@KZ?KQ::5W>_P *UZ.-*>N^M/)TY8QQ3S[^-.OKW5XUZNG3#&']
MH'($@Q1@_+.38J'%GY# (!)Y<*#FGCAB)?.0 IR2HD0<-++W5&MJ;>]55%O5
M)9S1/N9-RTN5HY2N9?3I5UU'2R.T:5-3% SHH9E$CA;J"0+[^)N!Q((Q1S.J
MDHLNK:R%$EEIJ6:=(Y"0C-%&S@,5(;3NN;$$\ 1>^(%&-I!0WD@= 2F/WH9N
M1FTAQ6G)49(.*M:9/AV.TLDRD'031HP+>#30.F68#)<NBWN*E!5.V AXXJ'?
MOK$N6Z*9JA*A7*PQU1BV3H>;35'-HGU$LID9BI:(%M"MO=F1U%>+-#)5I3/3
M-&&J):/:B5)!SN"FYS+'H 5A$J!PL[6#LGP%1XW;6X9MYDH>/>C\D8[D<AD)
M>>YJ"8T=0]&ARDO'07:KOP$R8$([$!)Z1Q]8(G)H9<HNW!R$I(6;,X_;C%#2
M: E_TGR%)7#4]1''&M/0/4B9M.Q:HRGW09A),Z1R"0Q3!5,D8C+*"Q74PYB<
MH6A5UJJ:665ZC,4I>;KKVZ4N<>YRAXX4EEB,>V@WB*1IPKE%U@*9JKMG&6Z[
M91#$4T=D#X($7;P&1VLL?'(=1''65<A26T\O)+$BBZM66,GC(<S< 1[RKM\(
MN6;MFCI^X'5ADRD'55P*D;NIJ(]4\<W\(IJ=-F([BVJH!9ED9;*Y!)55:S[M
M273313F298V%-*4IWA_@]342"0R=(M:G*HIC1M3*&4 EUR!AS:V"9LR89A43
MB+BD=#1HR>>2M:1C71(:N(<Q%J@*DL0'M73F,K2.LG=NHA>0,56D ^+2%ZV:
M6ILK[;-%;E+T-)'/),#+)+'&L0C(C?:"8ZDF8@.(C%:;2A$;21 LU[FQ0YQ'
M7ULM+%#:.*.1VEVR-(AB:%=,L" M%M3*=@S-[ZL4I"+IMC!T>VSYU(YPF2;0
M$S;")#CO"T^QU!0U(Y)9M-!N1<;;8.2&Z=JZ+\=:&D$G882AXQH!77(V"CJ"
MK!!VZ9F7)=&])DT$<&AJB/;QU-;3U$[B6*"!Z6IRBF;HLK,R1-6S,\B@:T*L
M #&J&C%GL\LVL4TG-Y*2BJ:6"-HY:BH2II<YJK7!41R3)01(L3$Z)18ET<L)
MO3;L!(V#R+K'I16-MV>+5YR<#R!N[<PLEEK)V0L2 0%\6,"(],"1T!,,>/V4
MW#NP8,M&;UEV:K!R4%/6&M7N%(2R+4H)&:I%/&Z$;=:6EIZN1]LCR0(CPU"F
M!U>19-Q!"L,;AG\9TL:9S&$I6J'CDUFG-74U5)''LFCCF>2.:E;;QLD3P@E"
MK.C6LXG;V7/PH=+ANS[DYK:69&Y$*:2M)] VY.& \6N<LNCPPC-(X#[].; K
M-R#5:@614-X3W,T&<F( G5TA;Y/D(CF:%LQI3H*(YBM4:9FJ12")UAD?0#(P
M<&1HG$9NT:N-!TIRB,D"SKEM4HD$LJ+,&@U4\5(:QID,\:%[1@H1&LD>UTJL
MKHVT%PE>WH"C+YP'IB?(!*1$Y8!C>/XJU$RA]*)L,.PB:9!:3E %'X;("%L&
M?@(&?2"'HTC,4G)E%40=LC+H8?M#8PY#)*H?G=,L2PO)/,SQ+% Z30TY@:1Y
MXUVPDJ(R\<NQ(2S1[19$U9S\HHX6*"DJ))6FBCIX4CF>:=):>HJ5J-G%!*P@
M,=-*$EB$RM(-F^R*R%;O'=J>3Y$R]AJ-QR"&X= Y5*)9&Y2O-J"Q\ON.", M
M,LW1@A#E>V&XL] OI"&8/W2SB]=<D'.,7+1H/4#OS6$F514])6R25"33PQ0R
M1"'4T6AZ]J7:B;<DHD6-V4  !&0AF<.%V)FT]16T$,=.\-//+-',9M FU)EO
M/-DT/PX6C=XU9]1ULK@ (8VDWD]?7?[]-^[7#QW\/7VOQ]7DZ],,*;O-3T5X
M>GI]&[IX4IIABZG*5[\%.']_NN/#_OUU./K3KZ-0.'I/UG$GCZ!]0Q:N>OG^
M#J]?)PU.(PZ/)TT]O=T=6F&'-QIS^7U]=_DWU88KT\>'/[_FW='/2FF&%*[O
M=Z>OWN/P:88I[71Y^OX?)OW>?3##[6[C2GD]KAT\_FWZ88KT>]NK[E?PTIOW
M<^[AIAA_T>?G]--_53ANIS;M,,4]W=NZ^;V_-3[5=,,/=][VNG\>_ITPQ6E*
M;J^YNW[]]>:GK2O3Y-,,4X_@I7H]WAQ]O3##X=_&N^OP>[2GX&&+N+^1S.[V
M*IS?LD-X\>GG\FH/5Y_L.)'!O,/K&+37_95\_DIZ??X[N'/SZ#@/,/JQ&*5Y
MOA]-?7T>74X8</M^OX.'OL,.G?OW>7\6F&%/-[?-7U\G53IIIAAT<_N^_7?Y
M.FE.NM>;3#%:U]KGZ]W73HW>;AZ>&YAA3GI[6^F_H]W?S='#GK2N_3#"E?+[
M>^M.C=NW]/EKS4YM,,4]?7T>6E>.F&'E\O#ANYMV[\6_\+##?T;Z[O/OIZ*:
M88<.GFZ=W&O#IX]?K3FTPPW;O-S\]-^ZOP^]YN=AA7R\_P '1NZN?FX^CI88
MV'@?RKCO\IY_/%]5\6,?F=]D;V7<B23;ZVRI QEFSTT9&MI7,91HV/;56S3&
M33=N]G1EPDD6CTARL,.A""=BEMKH68',23):ER#QJ@O9>G;]&\G\S@CR/*8S
M!F#%,OI4)CRVOD0E84OHD2G*.O8RDJ1O!(Q\T\H<NE?/<W<5&7J'S&L<"3,J
M&-P&G<@,CSAT8 C4K ,IZ) (QI?39!RA7_#39D^O%V4:>_F377]UJ?\ Z?,O
M_"LQ_5L<?W+F_P"HRW_Q3+_UC#XD+*'SZ;,OUXNRC]^3RZ>ZU/\ ]/F7_A68
M_JWD.'N7-_U&6_\ BF7_ *QA\2%D_P"?39E^O%V4?OR:>ZU/_P!/F7;_ !5F
M/ZMA[ES?]1EO_BF7_K&'Q(63_GTV9?KQ=E'S_P#SR:GW6I_^GS/_ ,*S']6P
M]RYO^IRW_P 4R_\ 6,/B0LG\_AILR[OW8NRC]^33W5@_Z;,__"LQ_5L/<R;C
MSG+;?VIE_P"L8?$A9/\ GTV9?KQ=E'R='CD\M-1[K4_'F^96_LK,?U;#W+F_
MZG+?_%,O_6,/B0LGTYYILR_7B[*/WY-2,VIS_P#+YE_X5F/ZM@<LF'_S.6_^
M*9?^LX?$A90^?39E^O%V4?OR:CW6I_\ I\R_\*S']6P]RYO^HRW_ ,4R_P#6
M,/B0LH?/ILR_7B[*/WY-/=:G_P"GS+=Q_P#A68[O\-A[ES?]1EO_ (IE_P"L
M8?$A90^?39E^O%V4?OR?CU/NM3CC3YE_X5F/ZMA[ES?]1EO_ (IE_P"L8?$A
M9/\ GTV9?KQ=E'[\FGNK!_T^9_\ A68_JV'N7-_U.6_^*9?^L8]+^P\;-L[@
MW9(=F.6&I9@-T*"G9TY>H1C:>V=)F<N24Q3.VW*8QF)90-2(I5*Y>U1Q8-&.
MKVS:Q=VO:FU;KJI^:Y6YC#-R?S*-8:Y6>.$ RY=6Q)NJ(CTI)(%1;]19@/20
M,>DY(9?+%RCRQVGH&"RR$K%F%'+(?>91T8XYF=K=853P./[U>^(3YXXS_&,'
M_I"O/YN'1K\&N?B/\TX^@[=5Q?\ I+[<1TB!QR8)M#9>S'10RPJ/N8EB#N)O
M"3.X00N+";FKYPNHZ;][2E]Y)AVI6SN-_?<[;]K<5JI7:L\Z(T:-4(C:@R*S
MJC:UT-J4$ ZEZ))!)7=PW8U-!"[B1XH7D73ID98V==F^M=+D:AH?I"Q&EMXW
MF^+$CC?"3>O*;QG#B%?!(C -Z32!V?H%,/[BI:%UY-*;XH4)W7D",>KO$O7M
MU73EHJO6M]<S5UC<9JLVF2HWR2_\Q&+)/\+\,@W))\-1N! W8UBBI;6%-36V
M+4]A%%;8,27@M:VQ9B2T7P&.\J3CA&8PP8%'6!P\4PR*%)HH-[!HYE F3&QN
MU-(25NC:T;=K0HFA(VK4ZC9R-R1AL@2LI1VBFM;+UM9(VMYZMWN3K:65FNR&
M(G47)N8V:.][Z&*WL;8A*&BC01QTM(B6 ")#"JV$HF TA0MA*!* !;6 WP@#
MCJK8BV?G#U@27@^#UR J2%)@*>K"L>J.ALL.$69@S)F+B].Y5J>*EQP\J1+(
M7)OGI-@S?N5U'39%9.175P#**BL"O$L#@2S -"BE$B8![-&J%D5#=0C,H 4V
MQ!R^A9D<T=&7CE>=&,$!9)Y&#R2HVFZRR, [R AF8!B2P!QR%,98I+&,6EU'
M$09UPV>-2: BA9J*, PDX=BL@A;HA1BC=^541 RJ0(-4VJK5&Q<FLZ6L772:
MJ(0M94JE4@,AYY'''4.P=I'2*6.95UECN+Q1DW!W+8$ L#+T5,\E)(8U4T<C
MRTZ*45%>2*2 MI XA)I--B!J:Y!(%NX6QQA,](GDN-QG#IB5D@CN-$9,4:P1
M\>?QY\P<BGH-X6==M(.1+L6]>#7(Y9>]HN/=N62J5S5=5&Z$JZN.,0I+5)$L
M@E6)7D$:RJRNL@0-I#JZJX8"X8!@;[\2]%22RF:2FI7G*&)I6BA:4Q,K*8VD
M*ES&RLRE"VDJ2I!4D&XRR'XIG@]@)G [%TQ%BGR),6-E%T-/L!I%!LX9(OF#
M0JHZ0:.TF;MTT3<H66+6M7+AO2^B*RMEV,534P,SPR5,3LI5VC>1&=6(+*Q5
M@6!(!-R;D \<934M-4*L=1!3SHA#*DR12*C!2H95<$*P5B-0 (4D7L<8Q/;-
MNS'(;DN[(/AELW4F#*<G60X?CEHRF1T<-F YBI-6M&UZ4E;L[IU)"C9,A2]5
MN9>WDD%DUU''=%I,US*/A4U9]Z>%"TLS-"CM$S; E_>B=A&IT 70%>'"J^49
M;+<&BI &G6HE"PP!9Y4$P7G"Z")0#/*X#W(D;7<$'5-E\88+=(,FKF)877:C
MGB) >V680%1NQ>H1=K"$731"ZE46SA&&L642351MLOLC3-H#MNH,;(M;- K*
MP%B)ZL%@58B66Y4RF8@G7<C;,TUK_A27^$2<6#0T9M>EI" 0R^\P6#"(0!E&
MFP(@5800 =DJI\%5 [$/QSA7'MR=\#CF((6HC8322OBK>#1^])(U<&N,6)W"
MJM+K+2U\;CUY*VVM*/K@0BYUVZHUG5&)JNKJ+\XFJI[Z;[9Y)+Z-86^MC\$2
M2!>P.P%@QPAHZ2F(-/34U.5#@;&.*.P?9F3X(&YS%$7[="7^"+6.N$]G&HLJ
M$\7>!*ACIIK(S0JH+&_>TO(&-[I1B;),JH]SO2K*]\]JU?N4U73?NUY5%6WN
MI:E^?NAF&M).=5VTC0QH^WG#I&P 9%8."$("W4'2=*W!L,:_<S+M#Q\QH=G(
M^TDCYO3Z'D6Y$CKHLSJ78JY!92Q((O?'>0Q+@-M>@HWA6$D+VP8;'6]R(O'Z
M?:  >/DHH(")<FRE+! R+FBT:'CK:4:- !-\';I)CW:[=3$UU:;WJ*P@R-*0
M992#(\B3/)\/X;RHDC/\)I$5R=2@C(4%$+$4E(+1I$MH81[VD;0QQBR_ 2&1
MXD7X*QNR* K$&P-\$8"'&,;EH^'QO$T\52J1SB(A8BXA$< -Y?*(>1@9.1/!
M@M-O8Y+>"Y<D/1=6J)5KW315U1RJT8W-MAS&M=:E9))YC5Q1P3/,9))#%%,L
MZ1JS,;+M41B+'<MA8$XP&642M2M%3PPBCFEGAC@6*&(330FG>1DC4!FV3,G5
MQN=5AIS7WP"?/'&>G_"0'[W=_5SZI7/Q'^:<7?2OSE]N+NH0$=XV=U3\>HG<
M4)6T4K( U$[K[6@JMR=JM7W:[U++:V77V6W5N3M43NOI2BMF_$7U-T'WV_D^
M3QW'&1 L.DO ]>ZU[_;BTT(A:;]\CC/\8P?17A3B_P"CJX^GGUE<_$?YIQ%O
M*OSAYNW#OB$^>.,_QC!\_7P(4TN?B/\ -.%O*/G#VXMQ9&'GQ1,$=(0DT$-,
M'8HP'+%XV1%E19!NHT?CB+!V[5:O6+UJJJV=M'"2B#E!11)9.].^ZVN2O(C*
MZ"5'1@R.H*LK*;JRL""K*0"""""+C?C%XUD1HY%1XW5D='TLCHP*LK*UU964
MD,I!!!((MB' <;82BI^V5QF,8=CTGM#-([;(P;6""SM #!B.&,@E"S+M#^@M
MH-$BQ[=C1QW,BQ%CFMB5J#)JFENDK*R6/92SU<D6T:79O)*T9E8LS2%"VDN6
M=V+VU:F8WN3C1'14<,@FBIJ6*81B(2I%"DHC1$18Q(JAPBI'&@75I"HB@!5
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M=7H [N._#48G#3QX\>C#QX\>G#3#'HQL_?W*X_\ K@W_ $T_U4G_  K>9?\
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M+W%B-UL1M$ +%UTB]VU"PL=)WWL+$:2-UFW<3OZ:08"L8LEJ \:J<7#IATY
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MSW+@I'H)Y#7E&D:)(8*9Z[:J%GI35)'*U/5,D"@,Z2Q-(8VB4MC#40V8\PA
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M7;35TTASC*ZJ.C>00)41SU0>G C2>-E2,B2=)2JO=V$<37%B!(R@+ <AQG:
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MT_[#-\TJV:/U[D[["V1M>7Y9?BYF?]73_P"JBQZCD9^,N5_UDW^FFQ_=3K\
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M G#>TD*&"QI%)B,<JV,?$^)34M)CW9&ZZQ5Y>==6%5& [LRY31"5UC5C&B%
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M 0L?;.:-K3Q)))NR=#F)8@/'(RDI@EJXDD5I#^#D:,P1U@HWF:06T=/4XC8
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MC,CJFTCE][=2&1B\2 D7NNH'<3:K5T5/6B%:F))TAFVRQR*KQE]E+#TU96#
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M"B2CY8C$(R_5)KDG1)5X"&.5'[DS'T(F7</;UFM]SI<I%VK:.$%5JWWO ;=
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MZI<!7#](, #J+$&Y.*KT-%)*\\E'3/-(ACDE>GB:1XRNS*.Y4ED*#0RDD%
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MRBT^C7R!,_VJ?_$T:UJ;<4XCI?\ L;?C(]?7T6X>CQ]F(IJ<98@4\Q=C_)Z
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M(B2(V)L+T;4WK]\[LI:NZ74O-6USK(K5=4RS]*93/(5E-@@,@UV<E55+O<V
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MS:^)GK1XX;O'#TG?VXL>.._QQ] W=F/1C9^_N5Q_]<&_Z:?ZJ3_A6Z_@[_\
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MOG'"P[!W##P=BO']"@'S]SN-WI_->_=[M.;=6NFM_CM\XX6'8.X8IX/17YU
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>U2I?VU91;^UUO4Y/)Y?)_P!G7?NW\-^ZF&,\?__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>5
<FILENAME>g554088g80a28.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g554088g80a28.jpg
M_]C_X  02D9)1@ ! 0$#P /   #_[14.4&AO=&]S:&]P(#,N,  X0DE-! 0
M     $X< 5H  QLE1QP!6@ #&R5'' (   ( /QP"4  (<G(R.30V,3@< @4
M)4UI8W)O<V]F="!7;W)D("T@-34T,#@X(%!R;R!3=7!P+F1O8W@X0DE-!"4
M     !!'>6/L4JK'-2N^HW6R\%@U.$))300Z      #E    $     $
M  MP<FEN=$]U='!U=     4     4'-T4V)O;VP!     $EN=&5E;G5M
M $EN=&4     0VQR;0    ]P<FEN=%-I>'1E96Y":71B;V]L      MP<FEN
M=&5R3F%M951%6%0    !       /<')I;G10<F]O9E-E='5P3V)J8P    P
M4 !R &\ ;P!F "  4P!E '0 =0!P       *<')O;V93971U<     $
M0FQT;F5N=6T    ,8G5I;'1I;E!R;V]F    "7!R;V]F0TU92P X0DE-!#L
M     BT    0     0      $G!R:6YT3W5T<'5T3W!T:6]N<P   !<
M0W!T;F)O;VP      $-L8G)B;V]L      !29W--8F]O;       0W)N0V)O
M;VP      $-N=$-B;V]L      !,8FQS8F]O;       3F=T=F)O;VP
M $5M;$1B;V]L      !);G1R8F]O;       0F-K9T]B:F,    !
M4D="0P    ,     4F0@(&1O=6) ;^            !'<FX@9&]U8D!OX
M         $)L("!D;W5B0&_@            0G)D5%5N=$8C4FQT
M        0FQD(%5N=$8C4FQT                4G-L=%5N=$8C4'AL0&;Y
MRL         *=F5C=&]R1&%T86)O;VP!     %!G4'-E;G5M     %!G4',
M    4&=00P    !,969T56YT1B-2;'0               !4;W @56YT1B-2
M;'0               !38VP@56YT1B-0<F- 60           !!C<F]P5VAE
M;E!R:6YT:6YG8F]O;      .8W)O<%)E8W1";W1T;VUL;VYG          QC
M<F]P4F5C=$QE9G1L;VYG          UC<F]P4F5C=%)I9VAT;&]N9P
M   +8W)O<%)E8W14;W!L;VYG       X0DE- ^T      ! #P     $  @/
M     0 ".$))300F       .             #^    X0DE- _(       H
M /_______P  .$))300-       $    >#A"24T$&0      !    !XX0DE-
M _,       D           $ .$))32<0       *  $          CA"24T#
M]0      2  O9F8  0!L9F8 !@       0 O9F8  0"AF9H !@       0 R
M     0!:    !@       0 U     0 M    !@       3A"24T#^
M<   _____________________________P/H     /__________________
M__________\#Z     #_____________________________ ^@     ____
M_________________________P/H   X0DE-! @      !     !   "0
M D      .$))300>       $     #A"24T$&@     #-0    8
M     54   2'          $                          0
M   $AP   54                      0                         0
M     0       &YU;&P    "    !F)O=6YD<T]B:F,    !        4F-T
M,0    0     5&]P(&QO;F<          $QE9G1L;VYG          !"=&]M
M;&]N9P   54     4F=H=&QO;F<   2'    !G-L:6-E<U9L3',    !3V)J
M8P    $       5S;&EC90   !(    '<VQI8V5)1&QO;F<         !V=R
M;W5P241L;VYG          9O<FEG:6YE;G5M    #$53;&EC94]R:6=I;@
M  UA=71O1V5N97)A=&5D     %1Y<&5E;G5M    "D53;&EC951Y<&4
M26UG(     9B;W5N9'-/8FIC     0       %)C=#$    $     %1O<"!L
M;VYG          !,969T;&]N9P          0G1O;6QO;F<   %5     %)G
M:'1L;VYG   $AP    -U<FQ415A4     0       &YU;&Q415A4     0
M     $US9V5415A4     0      !F%L=%1A9U1%6%0    !       .8V5L
M;%1E>'1)<TA434QB;V]L 0    AC96QL5&5X=%1%6%0    !       ):&]R
M>D%L:6=N96YU;0    ]%4VQI8V5(;W)Z06QI9VX    '9&5F875L=     EV
M97)T06QI9VYE;G5M    #T53;&EC959E<G1!;&EG;@    =D969A=6QT
M"V)G0V]L;W)4>7!E96YU;0   !%%4VQI8V5"1T-O;&]R5'EP90    !.;VYE
M    "71O<$]U='-E=&QO;F<         "FQE9G1/=71S971L;VYG
M  QB;W1T;VU/=71S971L;VYG          MR:6=H=$]U='-E=&QO;F<
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M '0 ;P!S &@ ;P!P    $P!! &0 ;P!B &4 ( !0 &@ ;P!T &\ <P!H &\
M<  @ $, 4P V     0 X0DE-!"(      49-30 J    "  ( 1(  P    $
M 0   1H !0    $   !N 1L !0    $   !V 2@  P    $  @   3$  @
M !X   !^ 3(  @   !0   "< 3L  @    D   "PAVD !     $   "\
MZ  <"^P  "<0 !P+[   )Q!!9&]B92!0:&]T;W-H;W @0U,V("A7:6YD;W=S
M*0 R,#$X.C W.C,P(#$T.C(V.C Q ')R,CDT-C$X       #H $  P    '_
M_P  H ( !     $   2'H , !     $   %5          8! P #     0 &
M   !&@ %     0   38!&P %     0   3X!*  #     0 "   " 0 $
M 0   48" @ $     0              2     $   !(     3A"24T#_0
M    "           _^$!2$U- "H    (  @!$@ #     0     !&@ %
M 0   &X!&P %     0   '8!*  #     0 "   !,0 "    '@   'X!,@ "
M    %    )P!.P "    "0   +"':0 $     0   +P   #H   #P     $
M  /      4%D;V)E(%!H;W1O<VAO<"!#4S8@*%=I;F1O=W,I #(P,3@Z,#<Z
M,S @,30Z,C8Z,#$ <G(R.30V,3@       .@ 0 #     ?__  "@ @ $
M 0  !(>@ P $     0   54         !@$#  ,    !  8   $:  4    !
M   !-@$;  4    !   !/@$H  ,    !  (   (!  0    !   !1@("  0
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MO (\C;ZPW$'DW@@\]5XU:5[+;<)66M_Y7@,,-[CJDZW!R#A0(._E&.6NO/\
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M-5XH6'T)?6YG-_\ ?IQQTC]/&_\ 5(7)T_W:J\GN$TX5&KUJ(N=EM-EK]0L
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MU5"HLVM)5<*F(DFHH<$TS"1-,YS !2B(7JT3T>0G77%*$;CK*FRTIP>0ZQD
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MNK#7)[R)HZX/GTO&HLVJ0JK$'D3)&\ZBV>2XQ.G+2VR&/'82VAA29<@O)>0
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M(EW1T?\ PP3"B@\_^Y?<QS%7S[\(8\Q4Y!D<P@!$W;<YC".X *18AC"([PW
M!0$=^\-WEWAY=;A8)0L#.2A0&!DY*3C<-YR=V!SFM*@^4@G \I&2>;*@"?V
MFO0G\_'%C[:YJ^.HM9DUQ77LYW_*E@RY?,IDM]8F957#MIJ$8QI*9XV%B*)1
M'ZKXJ00[21E5GT@ND3QD)CF%7S\V*6FTNRG,\)7$8C-16(Q9<;09C;BE/J).
MV>&ID*5R#..85Z6K2&(N\-1$?W=N9(DO2I#Y6VMQ,1YE"61A(;84% %(RHJQ
MO(WFB<73^R=?)'$V2[(^V5J/=Y39]D2W^E*U+%\15G-MB\TN6+4B47;&<M2J
M9:B4(B#UZM(P4I8K'![B0I$72GAY9$I%U8;E1D>-'F47 <'=+LC70VJ&E15E
MHH?>2I[73N6E#12=;YXT1RTR78LQQ-H;?7;U*D-%F.$*6B<X@D)="F6W$QTH
M45%*EK3A*=Y!'#D!/8F)3]J.,B'6SG 5=/*DY.TRP5QY3+E?+=77+J@J_(NI
MU]:,1N-,:)@I8%J7:J#/KUMMQI-K9H7D6::"U&%7O;6U2A<G'3%2EQMPNLL-
M. 2/RKKFL67,JU%.-NM[0A"%)<5FKY"+"EFZ#%M:8$I2D/(V+LAQ*C&RPVC4
MVS)" 2TIAPH*3A2$ZH%6AX1QYLGN*'5TL",<,J2"61G!ZS+8ND*.WE"8Q5JY
M2H15G@JFQ0F%>2DTF:X2M_6-;DY4[YJH*K8YMT_1T74/N&>N:4EC#S<M#Y2)
M&UPDMN.DH +:E)*&4I0!A>\C?K=*/%*8S)@(A)7M]9AV*IH$Q2UO0XVSATZK
M@!VCJM8*UDUSY5OU)0X.Q_C6;RM3'M^=67#4W Q]6SG-YLF,BI0=?&+>ISE3
ML<2BXP:PJ$6HB"</&*LFSE^S+#<4[1HU!WCAQW^,'"4Q'DQPW-2M2X0A-L%Q
MP+&HM)4)>V4 4K.\!6>76K-/?8XMB.[*:+ZUPUM);F+FKD;)M2?*0O\ NB6@
M0"!G6*<#<$UITW=.[I'S<4.,(CNW@!0#I$1'H  Z1^H!'HUV([<?3C=]&_GY
MJX/.1DC]GT'_ ,N3]E9S[<Q#4RP8/P&0Y0+@; ="@)IJF.]-.^7ILMDV\K&*
M43%*X/(6IJS<B B/^0)IB <GQ1TMC ?1-GG/Y_<)#C9(W[!I1892!C?@-XYQ
MO'-6]ON6%V^WC=XNMK#;B=Z0)+Z>$R#D8.\O <N=W+G)K9GEO;$QS!3>','L
M)FQW(]S@-AI:6EYF]UV0PSB=&B'J,]+2-.AVR#E>(M[Y1 \9<W;Z49)-DR*G
M7)QTC)FY:':)#B)<TI;:2PY>M1*6%)F2"\IQ"4/$8"FTA66AJ$YSOP<5V,V^
M14.PK>E2GEOMV4K<+P,.(&]FXI3(ULA9U<.;TC5 "@<55N3,P)4&Z90L6T-F
M2EW:HR6VA@^];,<&AD>MY/L-'J=8RF,SD2W1J==D[ ^H]1/0>2CQC7;EIRRH
M@T2AT'!R"M9&B%]B*W;HDAEU-GG,7-9C.QTO.N14H9;)7JB0X'-920A /SX-
M7R9B8K\IVZS&7V57B'(M38?:E.1VVI2EN/#9Y,=L-X2"I1'+Y(.*HA!6JXEM
M>;92UY+Q0X:;0NWQ@/(6+@K&2*C:U):B5W*TK;9BVRR4#*/?DQ"M(B<9<LO8
M_%BQ715T3(AQ4CJY2'9;4(-QI8-OL<YB5M(SB A]48-H;;VB<NJ);( 1\XSD
MU@2&8,B>X]*BE%QOD)^)LY+;A<83*=6M;H:40TV$NI5ES=NYZF*6T!AT-IK/
M^T/9,P7FKQ.%KP\QW0Y&YY ;[0+>7G;9E9.3M#G$M!CV59=5G'DQC>J3=461
M9/9J/B(ZW-52S#X[1-NXL,"8;; M[<-MQ<U DO)9C*@E#;44H:X2\2ZE;X?6
M'!K:JW"WDH1G?D-Q@BZ7"X.3'&40G3&:6[(3/2IV1*"W>#,8;4W&++*VU:I6
MEI+F4K5R5B[A2!QYAKA8&"-3NM2)C$\WDBR4>VHVB&;5QI7[WB&Y3-79GG#/
MDXZ.<1KB;:P I.G;==M(-@;J%(L)2:VTQU^9HHK;,.E]*8[+[6S6MS7CRVD.
M^2A*E*"D(4H'(\E0W[S6FA-,0M,$AAYL1U*D/,.A:6V]23$<<9\K:)2G44XA
M)R%84DY Y#D#7FD-<8S9_P 7[7>4L*Y0SC%7;,EPCUKY<J_ELL5C$F.S$K=
MMEOB,EU2OR<[8;RD64IT+9,EM(MFJS \BX%J)F+G7+VK2ITFTQID>&IB"T4L
ML.1RJ3M4[5]MHQ7'$I;:RAUQN."LDZH)W5M0EIXP8EXDPI4P2ISH4\\B1J1=
MA^18<<$EIO6==\MEIR5JH( *B,XG.76&SW5JEM8XOQ+!;.?BJ=IVS?D:5;C,
M5Q19JBO'V&,RTXH*B>0I&+5FZ+XO2L%;JT!/6%S&66<>&0-8&S]@0,<15P=7
M;)$IRX90]<8R%I;64J.6EQ0Z!%2=1[<VM3B1K(0@$((P<DENUM-7:)$9MA2Z
MS;7UME;0 2$GA2F\R'$%3)4I:4-NE27%K(*@<UC]PB..]D:I8?K+S!4)1T90
MM^K[*E6>C2],44L6-W5'>N90UH0C<RWVW6.0+.M(YX:SV&BX_68/'CB(,R$%
MR"OLM'9%W?F.)G*>*#'6IYM]+HV3Z7@$;(JA1VFTE"EI*&W7@K52HG(K4:31
M;/'@LFWM,)<,A 8=96S^6CJ8.MM4HF2''5!80=JMEC9DE&/+W[>>!"QA\B=C
MH;FY;\E(99OUDLH*F(!55(>$.A4XDN_>(F1%6'DG20CN+N>"9,! XF-RNFDK
M;W?8@Y3$8;;QS!Q>77 /HUTCEY1S8KK]!(FPLNW(PJ9(<=!YRVWAE _84+(R
M 2#GDQ6XW7(UVE-*4TI32E-*4TI32E-*5K9X3W9PSCM5X-@,1X44JB"SB^1E
MBMRUJG74&W4AX..DA8-&YVL9)'<J*R[QHZ.F=,B1"L2'XPG H!T&C=QA6N>N
M7,VQ CK;:V* XH*<4G*B"M&[42I//G6SS;^8TIMEPNT!N)!V()D)<>VSA0"A
MM*]0)PVO)*U)4?T<:H&_)K0CS&^VQZ3AGKY*]TM=UQVLG1.ZLGOJX#B)??U'
MK*^XIS&VVQZ3AGKY*]TM..UDZ)W5D]]3B)??U'K*^XIS&VVQZ3AGKY*]TM..
MUDZ)W5D]]3B)??U'K*^XIS&VVQZ3AGKY*]TM..UDZ)W5D]]3B)??U'K*^XIS
M&VVQZ3AGKY*]TM..UDZ)W5D]]3B)??U'K*^XIS&VVQZ3AGKY*]TM..UDZ)W5
MD]]3B)??U'K*^XIS&VVQZ3AGKY*]TM..UDZ)W5D]]3B)??U'K*^XIS&VVQZ3
MAGKY*]TM..UDZ)W5D]]3B)??U'K*^XIS&VVQZ3AGKY*]TM..UDZ)W5D]]3B)
M??U'K*^XIS&VVQZ3AGKY*]TM..UDZ)W5D]]3B)??U'K*^XIS&VVQZ3AGKY*]
MTM..UDZ)W5D]]3B)??U'K*^XIS&VVQZ3AGKY*]TM..UDZ)W5D]]3B)??U'K*
M^XIS&VVQZ3AGKY*]TM..UDZ)W5D]]3B)??U'K*^XIS&VVQZ3AGKY*]TM..UD
MZ)W5D]]3B)??U'K*^XIS&VVQZ3AGKY*]TM..UDZ)W5D]]3B)??U'K*^XIS&V
MVQZ3AGKY*]TM..UDZ)W5D]]3B)??U'K*^XIS&VVQZ3AGKY*]TM..UDZ)W5D]
M]3B)??U'K*^XIS&VVQZ3AGKY*]TM..UDZ)W5D]]3B)??U'K*^XIS&VVQZ3AG
MKY*]TM..UDZ)W5D]]3B)??U'K*^XIS&VVQZ3AGKY*]TM..UDZ)W5D]]3B)??
MU'K*^XIS&VVQZ3AGKY*]TM..UDZ)W5D]]3B)??U'K*^XIS&VVQZ3AGKY*]TM
M..UDZ)W5D]]3B)??U'K*^XIS&VVQZ3AGKY*]TM..UDZ)W5D]]3B)??U'K*^X
MIS&VVQZ3AGKY*]TM..UDZ)W5D]]3B)??U'K*^XIS&VVQZ3AGKY*]TM..UDZ)
MW5D]]3B)??U'K*^XIS&VVQZ3AGKY*]TM..UDZ)W5D]]3B)??U'K*^XIS&VVQ
MZ3AGKY*]TM..UDZ)W5D]]3B)??U'K*^XIS&VVQZ3AGKY*]TM..UDZ)W5D]]3
MB)??U'K*^XIS&VVQZ3AGKY*]TM..UDZ)W5D]]3B)??U'K*^XIS&VVQZ3AGKY
M*]TM..UDZ)W5D]]3B)??U'K*^XIS&VVQZ3AGKY*]TM..UDZ)W5D]]3B)??U'
MK*^XIS&VVQZ3AGKY*]TM..UDZ)W5D]]3B)??U'K*^XIS&VVP'3X3AGKY*]TM
M..UEYA.SS?FR>7[:G$2^_J/65]Q6QK.O!P;1=EV%ME_93QBMC\DG0966N>6E
MI:T/8V,>VR1"3>D1AW24$Z5E6B,I9YS<NY:M!!)FP4!,#;RDY^!I%;FKY<[I
M*$@H?0AF&$M)6M+8V:25@N )PE .!K<A&<;ZZ.X:,W-RPVJTQ>#A4=Q;\S7>
M*$*<45J2&U;,E6%+(R0D;\XW8K7+S&VVQZ3AGKY*]TM=!QVLG1.ZLGOJYSB)
M??U'K*^XJ(\!OMLC_P!IPSY_^7DKO_.ICIQVLG1.ZLGOJIQ#OV[?".!@9DKW
M#["H\QQML^DX9_7NOLH&_P __='Z_P"/KTX[63F$[JR>^H=!+\<C6A8)R093
MG+S?[D<E?/,;[;'I.&=WF^7DI^?^]+</]6G':R=$[JR>^JIT%OQWE4,DC!_.
MW=__ /AY/FJ(\!OMLB.\7.&>C_W\E-_]85$-W[0TX[63<<3MWZLGOJH-!+\!
M@&$,]$IS'S;MC@X^>H<QOML^DX9Z^2G=+I_IWZ<=K&>5,[JR?\73\WU?54:"
M7X9PJ&,]$IP?7AD"@\!OML=(BYPT/[+Y*?L#H^20?Q_5JO':R9W"=U=(^?EV
MP^D53B)?L<L'I_O+GT_ D[_VU<.Z\#'MBS4!C6M0JN(4F5,J"S)^+B[R:7A=
MGG+%,V&??)E+5E..D";Z)AT%S FHLUA6QCIE "AJ*QIC:$.277$RPIYW(U8Z
M3JM);:0VG<X!G*%*._=G&<YJ2_H1>UHBMH,,I894DY?4/RSCKCCJA^1Y"%(3
MG&3J@8 2*MZ' ;[; #O\)PSU\E>Z6I/':R=$[JR>^J,=!+Z1C\QZRON*AS&V
MVQZ3AGKY*]TM..UDZ)W5D]]5>(E^'/"^GA*\_P#X.;FKZYCC;8W"'A&&.D-W
M_+R5\G[!J0_T?T?4&G':R=$[JR>^JG$._8QK0^7(_.E[C]AG?NYQR5\\QOML
M>DX9Z^2G='=^6G'6Q]$[F_\ =D\W_P![ZNBG$2_;]\+!_2_.G=_/\#T_77US
M'&VQQN-X1ACKY*]TOXWZ<=K)T3NK)[ZJ<0[]C&M#QT&4LCZMA_+%0YC?;8W[
M_"<,^7?TWR4'IZI 'Y;]..UDZ)W54]]51H)?P,:T+'1PIW5]79?XU > XVUR
M^5SAGS!_O\E>Z7U:<=K-S)FGIS&0/YO?RJO$2^],(?1)7S?_ &/\:R9VJ>"3
MVKLMWJG!0%L7)X^QGAW%N)::69N,A'R"K*F5AN6<?.62-<>)-SR=Q?V61(!5
MQ%1!RBHH4J@G -=;-*[5$8=X1PLR)$N3+?*&$J&N^L:HSM1^BTEM.< >2*V=
MUT0N\N0SP;@@C1H46&R%R%)5JL(\I6 TK&NZMQ9WG)4":QFYC;;8])PSU\E>
MZ6MCQVLG1.ZLGOJUG$2^_J/65]Q3F-MMCTG#/7R5[I:<=K)T3NK)[ZG$2^_J
M/65]Q3F-MMCTG#/7R5[I:<=K)T3NK)[ZG$2^_J/65]Q3F-MMCTG#/7R5[I:<
M=K)T3NK)[ZG$2^_J/65]Q3F-MMCTG#/7R5[I:<=K)T3NK)[ZG$2^_J/65]Q3
MF-MMCTG#/7R5[I:<=K)T3NK)[ZG$2^_J/65]Q5=8OX$+:ICLDX_D<@N<3C1(
M^Z5E_<B1MSDGL@K6&4RS=3B#)HI6&Y'+IQ').$$$3KH%.HH4#*IA]((\K36U
MF-(3'3,+ZF7$M:[ 2G74A24Y4'58P2#G!^BI$706[IE1E23##"9#*GM1]2U;
M)+B5.:J2TD*.J#A)(!.XD"JFV@.")VW\VYNRGEE9?#Z9;Y>)ZPLT'%\DRK-(
MIT^5"&8J%+552)F91)&33DR*'33!$")B)"EUCM^EMDAP8L3$S\W80V2F.% K
M RXH*+PSEPJ(^8UDN.AU^G3IDM1A?G+[K@'"5@I0I1U$?V&[5;U4_2#5H!X#
M?;9'_M.&>ODI^T?^Z7G'4SCM9.B=U9/?5#XB7[G,(_.92R?FY6.:H<QMML>D
MX8_8%\E #\JD&G':R=$[JP[ZG$2_=,+]LIP_S8J/,;[;'I&&/K_[]RF[I_5\
MDMW\=._3CM9.B=U5/?4XB7[IA8YAPIP@?1E@\O/TU'F.-MGTG#'DW?\ +R5\
MG5+^/KTX[63HG=63WU6\0[]@C6AX)UB.%+P2><C8?-V4YCC;9](PQ^SY>2N[
M^KY)_P!GZ]..UDZ)W5D]]5>(E^\Z'S#/"EY&.3!V'SF@<!OML;A#PG#([_\
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M2E-*4TI5C]H*7?0.-IZ7C5>2>,(V7?("8 .D9Q'PDD];<LD;Z"R17""9CI*
M)#\4 , [@#12RVR^ZG<MME:TG ." 3R'=S8K8V:(Q<+W98$I)7&FW2#&D("B
MDK9>D-MN)"DD%)*5'>*TKLMJ+/KUHW=DL-73*NF50I#U>,XQ0'ZAW-A#^K7(
MKTGFMK4A3BB4G!(2Q@]!&0#R8Y17V3'\ &@<AEMY-O? <3K &XW(D D[O(5J
M[N3=7:^<SG_UDJO5>-[-JSC5+\]?JQ^RLWO>]!/0'OO&Z>U3YS.?_62J]5XW
MLVG&J7YZ_5C]E/>]Z">@/?>-T]JGSF<_^LE5ZKQO9M.-4OSU^K'[*>][T$]
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MLVG&J7YZ_5C]E/>]Z">@/?>-T]JGSF<_^LE5ZKQO9M.-4OSU^K'[*>][T$]
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M_FWN.V="DX)-XI&5ES4XZ=2L]NC>3B5N4(W!]7XV::P$LZ9(*"W07D62X&2
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MI5]J%G5]2ZY$UI_3J[;VM7M![G3UYI>4;JUZPF0*EX00D:[;)R#8JI0=E9O
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MFHH??NWB!#!OW@ :B6]8*<;AG_9YP>@\V[>!^P"I,U/EA7+NY1R8^K'^%9?
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MIQR^?\A^&E*<<OG_ "'X:4IQR^?\A^&E*<<OG_(?AI2G'+Y_R'X:4IQR^?\
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M$$RI)(IE333( %(0A  "E*4.@   W!YM;"O(P !@;@*YM*5\F*!BB40W@("
M@/D'?Y]*5@7?:C+8=MQY^&(HG4)1\#R/<H%,<L%(G/RIV+G_ *B2!E1,=F<^
M\BJ0B@80.0QC:=UM41TK2#L5G.L#@-J)Y#OY#OQR?LW5LVUHD-!LC#J0$\NY
M21R$#E"OV]/-R9&TC,M=L+9!"5>(Q<IQ"@<5S%39.C[@^FBN;Z*(F\HI+&)N
M'_,,8!W:V#4A"QO(!'+T<W(?VU#<84A2L D X^?]U7<))1RJ?*IOV:B6[?RA
M'*)B;O/Q@.)=WZ]^[6?6'2/K%8<'H/U5;&\9AJM/0430<ISLP9,?!HJ-5(L
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MC4=!_)I)2Z E 6?T+\"?A^M^F3,31W25YF%I6"&&7"D,1;YJI!2['P-FU<5
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MI2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*Q!V[?\
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M>P,,0HK(V)CX:CLMC@Y4I?!\(0/R(4M2ME^AE2B022367I)I#/.9U^O,U7C
MW;6EW.;(5XT+;3)N6L\^L\/++##1EYX1LV6D;35;2!/IO:*V@++*U^=L><LO
MS\W4I%67JLQ-Y*N4K*5J57;H-%I. ?OIE=W#OUFK5NW5=QZS==1%!)(YQ(F4
M-8V[/:6D.M-6V TT^@-O-MPX[:'4 DA#J4-I"T@G("@<'Z:F2=--,)K\.5-T
MKTDF2;<\J1;Y,N^W22_!?6A#:WXCS\MQR.\M"$(4ZTI+BD)"2K5 %<S':2VA
MXR?L%KC<\9ECK1;4F*%JL;')]V:3ME1C$!:QJ4_+H3B<A+D8-3&;,BR#AP5H
MW$46X)$,8!M79;2XTVPNV6]3+.ML6C"BEIK74%+*&RUJ)4H@%2DI!41E1/)5
MS>F^F;,R;<&=+M)F9]Q#:9\UJ^W1N7-2RC9LIE2$2@[(2RWEME+RUAI!*$!*
M=U5O*[7F;'F&:'A&(N%@J-6IJ624)=Q5;5;(A_DAOE"PIV.=;9#3;S9(ZQ-V
M[LKA!FDX9<4R#QX#L'*C@ZHQ6]'[:FXRK@Y':?>D&*6TNQV'$0N!,J99X*5-
ME364*\H:Q&4HU0D @[:3X2-*'M&K1HO&N,RVP;8B](DKM]QN,9R](ODM$R4B
M\)1)#4Q*'$$-I6C5*7%[0+*B:M?%9PS/!0T'783+>38> JY9@E9@XN^6J/B*
MZ6PM73&>+!QK2519Q))MD^>M)8C!%N21;/'2#P%DG"I#SUVNW.N./.0(;CKV
MIMG7(S*W'MDL.-[5Q2"M>S6E*T:RCA24D;P".?CZ4Z31(L2#%TBOL:' X2(,
M2/=[@S&A\,0XU+X*PU(0TQPIIYUJ3LDI+[;KB'=8+6#3ZV0[\XI\5CU>[6Y>
MA04LM/PE)6L<PK4H>=<"X,XFHJN'>#$1TJN+MT*T@S9HNU!<N!.L(KJ\?*(4
M1,AR6(S E.MAIR2&6A(6T-4!M3P1KE&$I 25:H"4@ 8J(J]7A=M8LR[I<5VB
M+(5+BVM4V2JWQI2];7DQX2G3&8D+UUZSS32'%:ZBI1))J<7?,F7<FLHF-R3E
M/(V08Z $PP3"[W>S6ME"B=($#&BFL[)OT(\YD2E1$[4B1A2*5,1X@  8XULM
M\-3BXD.+%6\ '5QX[+*W<'6&T4VVDK\KRO*S@X(Q6>Z:2Z1WQIAB]W^]7AF+
MG@K5TNLZX-120$DQVY;[K;!*0$G9)3E/D\@ J2I9 O:-,<8Y2NEL2QZ[F"6)
MU14['+IT]Q/IIIHDFUJT1X6&5ER))))DDCLC/"$3(4%MQ=9#"BF2F9P:/PM+
M>R3)V+9D!K).S#Y270V=964!82<D@"HZ;S=D6U5F1<[@BSKDIFKM*9LD6UR8
ME*4B4N"'>#*DA*4@/EHN@)2$K 2 +^XXVT=HBA9 QY?93)%NR@7&DXRGJ]3L
MK7&Y7.EIO(Z+DX5BJ$*^L1/ G4=&S,DC#R$6X8R,.HX%>.<H'* &U,W1VU28
MLF*W$8@\,;4V])A,,,2%)6XAU:=HEHZR5N(2I:'$K;7C"DFNNLGA.TRM%XLU
MWD7NY7X6.6U,AVW2"YW.Y6O:LL/Q63P5R6-DIAF2\F.['6R]'*M9A:"-\ZVC
M-MK+^T-,1KUV\=T&'8TYG2G->JMUR3*DL<2QM;ZZMOEG/WFY6NUVXS.R/"/X
MEM/SCZ/@E&#$81G'J(G.I99]&K?:6UI"4RG%2%2@ZZQ#;#3BV!')CLQ&&&(^
M600LMMA;FLK:*4#BI6FGA1TCTRE,O+<=L\9JV-6I<.!=;W*X;%:N#US0+G-N
MURN%QN.SF.AUAN9*=8C;)K@S+122JP*^9,N.G,R\<Y1R(X=V.Q0UOL#M>Z61
M5S.6VN"8U>M$PX/)"K)V&",<QH>9>G7D8T3"+)PB([];46VW@-I$*($LLKCM
M)X*QJH8< #K*1L\);=P"XV,(60"I)&ZN/5I)I$M<EQ=^O*W)DV-<I;B[I.4N
M5<86MP.?(6I\J?FQ-91C2G2IYDD[-:<FIY-;1.T!9'Z4K8<XY?G9-&,GH5&1
MF<DW*4?(P]J9M(^SQ23M],KN$XVQ,&#%E.,"*%:RK1DU;OD5TFZ1"XVK/:64
ME#5LM[:%+;<*6X45"2MDE3*\): UF5*4II7Z394HI(R:ERM,],)SJ7YNE>DD
MMY#,N,EZ3?;H^ZF//;0U.CAQV4I89F--MM2F@0W(;;;0ZE:4) M\PN%LBJ]/
M5&+L]@CJK:5XIU9JTQF9)I 6)S!+*.(1Q.0Z#E..EEHAPJJO%J/VRYV"RJBK
M44CG,892XD=QUM];+2WF0M++RFVU.M)=&'$H<*==*7$X2L ^4D '(K3M7*X1
MX<JWQYTQB!/6PY.@LR7VHDQR*LN15RHR%AF0J,M2EQU.H665DJ;U5$DULXSW
MG)V\)(NLR94<2*=@A+:1^OD&V+/26JLQR</6[,1RI+&6)8*]$HHQ<),E.$C%
MQZ2;)DY1;$*D$=-IMB4Z@M\$)V2V-41(^"PZO:.L'\G_ &3J\J<;&$+))4"H
MYK:*TMTJ6Z'EZ3:0+>$R+< ZJ\W)3G#X+*8T*=KJDE7#(<="6(LDG;1V4AME
M:$  77V>ML?+^SY<D+5'2;B],4(Z],DZK=;)=AAF+K(Z;<EPLE>=URS0,[4[
MG,"U24=6ZMRL;/+FY7EGBHJF'6ON^CUOND8LJ2(JRN,=O&8B!Q0B$EAEX.L.
M-OQT9.&7D+0-V ,#'0:'>$K2/0^YMW!E]R[,H8NK(MUSGW7@S2[TE*;C-AN0
MI\27;KI("$E5R@R&)9.=9Q6:Z>T-M99'VBLN5G,D^VB*O8J5"U.OU%.MK3[Q
M6)9TMXO(P3Q[8+9,V.V6.<3D7*KQS.V*>DI%=04R'6XB*8!6TV*+:8#T!M;K
M[,A;[KY>V0US)2E+P0TPAEAEO40$);9;;&KDG*LJK'IEX1+YIGI%"TDEHCP)
MEKC6^);4PURW3&;MCA>BN.3+C)FW"=+#RB\Y+G2Y#[B^580$H31^:\_WC-5V
MOUNDSEJL=D>YI9$L-#JDE.M:*>\^+2Q[NU(0+V5?(EF7IC/G)GRIUG3<\B[;
MMED6AB(!GMUIC0(\6.C6>,2,8C4EY+7"1&UBH,%U"$DM@:B2C]%00DE.L,UK
MM*-,;KI1=;O<GE>+V;W<TWF;:;?(EHM2KJ&0TN>F(Z^Z@R7"75[5>NXWMG$-
MJ2V=6OB/VF]I")L$O;(O/V:HVT6!C%1L]8V.4KPTG9N.@DU4H1A+R[><3D))
ME#I+KI131XX70CTUEBM") J?C9%V2SN-(8<M5M6RVIQ;31@QBTVMW>M:&]EJ
M)4H[U$)&3OQRYM9TZTVCS)%PCZ7Z41[A+:CL2IS-_NS4R4S$!3%:DR42P\^W
M&2I0CMNK6AD*4EM*4J4#T7VT1GV3@)NJ26;\NR%6LSF0>V2M/,E71Q 6!Y+.
M#NY9U-1"DV9C*.)1RJHO(K/4%U7BRBBK@YU#B;5PL]K0XA]NW04/LMI0R\B)
M'2ZTE"0EL-N!O63LP$A 3A*0D#&*Q.Z9:7/Q),![2C2)V!-<>=FP'+W<UPIC
MLE:G9#DJ*J467W'W%J6\MU"E.K4I2RHJ)/;R/M"9-R1DR'RP[F/DG;:Q$4Z"
MIR]"5DJNA28JA0[&%JS6I';R*TC"#&-V*;I-9K(\OXR6=/BJE57,.K8=HA0X
M;D%+9>8><D.R$R0A[A#DIU;KRG@I&HX%E91JJ3J[,)24[C66]Z97R^7R-I"Y
M)-ON,"-;8EM7:5/04VQBTQFXT!%O+;I=C;!#06%(=U]LIQW6UEDUWR[5FU 2
M=6M!-HW.Q;,YB6\"YL1<MWX)QQ!LW;J09PRTJ$_X>K%,W[]\^;1YW!FB#QXZ
M=)HE7<+**6^(K*6PR;1;"RE9<2UP"+J)<4E*5.!.R_34E"4E7Z12 DG5  R>
MZ!IYPM4\::Z7"<N.B(N:-)+R):XC;CCS<54@3=J8[;SSKR&"K9H<<6M*0I1-
M=V4VGLIS^+,C8ULDT]M#K+5ZI-SR+D2TS$]8\@VM''4._BZ=592=F)5V+BNP
MJ\DO+-D543O"ODFB9796;9)L3$FQPFI\28RTEE,&-(8BQ66VF8K1EN)6^^EM
MM"</+"$HU@=74*LH*CFL[^GE_EZ/WJQS93D]S2&Z6NXWB\SY,R;>)[=FC/L6
MZWORY,ATKA1UR%R$I4DN;5+8V@:0&SCKK=UQ5-*4TI32E-*4TI32E-*4TI32
ME-*4TI32E-*4TI7&LLDW2,JJ;BE+T  =)C&'?N*4OE,8V[<!0Z?K\@:IOYAV
M?MZ.GZ!50"HX'X^<UO\ N"SX+&2R/(06T)M$UPZ==3!K,8YQQ-- .@[;J$%=
ME;K@P5 14;G 4UX&ON$R>,#\1_(I^+02;O/)M-=-DQ4N6FT._E<EN9,;4<HR
M1K,1E@#*AC4>=3JX&4I.2<?:_@"\ /"S$TTTUAD1/R<BR6.6V/SM)&NU<K@P
ML;F$G"X4)S^W\B3*;V&S:<]9$-#,8)BBPCT@212(4!Z"@90_% #**" !O.;<
M >8I0*0@%(4I0\34HK45*Y22<<V2<G]N><DGY^7/W<A"4)"4@ #F  '(!G ^
M@?4!S5-M6U=32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI3
M2E-*4TI32E-*4TI6(&W</_FKYM_U5Y,_N!9!_P!FMUH\,WFV?]8P/^]LC_&N
M)\(XSH)I?R_ZLWT[M_\ _;)-?GJ,738K1N4ZZ)3@F4#%,LF42CYA*8=X"'U[
M]?5H2K&[D_Y)_;S]-?CBM*BI1"5;ST&NWX6S])0^_2^.JZJ_PD]M6ZB_-5ZI
M[*>%L_24/OTOCIJK_"3VTU%^:KU3V4\+9^DH??I?'357^$GMIJ+\U7JGLIX6
MS])0^_2^.FJO\)/;347YJO5/93PMGZ2A]^E\=-5?X2>VFHOS5>J>RGA;/TE#
M[]+XZ:J_PD]M-1?FJ]4]E/"V?I*'WZ7QTU5_A)[::B_-5ZI[*>%L_24/OTOC
MIJK_  D]M-1?FJ]4]E/"V?I*'WZ7QTU5_A)[::B_-5ZI[*>%L_24/OTOCIJK
M_"3VTU%^:KU3V4\+9^DH??I?'357^$GMIJ+\U7JGLIX6S])0^_2^.FJO\)/;
M347YJO5/93PMGZ2A]^E\=-5?X2>VFHOS5>J>RGA;/TE#[]+XZ:J_PD]M-1?F
MJ]4]E/"V?I*'WZ7QTU5_A)[::B_-5ZI[*>%L_24/OTOCIJK_  D]M-1?FJ]4
M]E/"V?I*'WZ7QTU5_A)[::B_-5ZI[*>%L_24/OTOCIJK_"3VTU%^:KU3V4\+
M9^DH??I?'357^$GMIJ+\U7JGLIX6S])0^_2^.FJO\)/;347YJO5/93PMGZ2A
M]^E\=-5?X2>VFHOS5>J>RGA;/TE#[]+XZ:J_PD]M-1?FJ]4]E/"V?I*'WZ7Q
MTU5_A)[::B_-5ZI[*>%L_24/OTOCIJK_  D]M-1?FJ]4]E/"V?I*'WZ7QTU5
M_A)[::B_-5ZI[*>%L_24/OTOCIJK_"3VTU%^:KU3V4\+9^DH??I?'357^$GM
MIJ+\U7JGLIX6S])0^_2^.FJO\)/;347YJO5/93PMGZ2A]^E\=-5?X2>VFHOS
M5>J>RGA;/TE#[]+XZ:J_PD]M-1?FJ]4]E/"V?I*'WZ7QTU5_A)[::B_-5ZI[
M*>%L_24/OTOCIJK_  D]M-1?FJ]4]E/"V?I*'WZ7QTU5_A)[::B_-5ZI[*>%
ML_24/OTOCIJK_"3VTU%^:KU3V4\+9^DH??I?'357^$GMIJ+\U7JGLIX6S])0
M^_2^.FJO\)/;347YJO5/93PMGZ2A]^E\=-5?X2>VFHOS5>J>RGA;/TE#[]+X
MZ:J_PD]M-1?FJ]4]E/"V?I*'WZ7QTU5_A)[::B_-5ZI[*>%L_24/OTOCIJK_
M  D]M-1?FJ]4]E/"V?I*'WZ7QTU5_A)[::B_-5ZI[*>%L_24/OTOCIJK_"3V
MTU%^:KU3V4\+9^DH??I?'357^$GMIJ+\U7JGLIX6S])0^_2^.FJO\)/;347Y
MJO5/93PMGZ2A]^E\=-5?X2>VFHOS5>J>ROA1\S3(93PA(0+T\4BA#G$?J I2
MCO$PCN   -XZ85D#&2<X&",XY>GFWFJAM9_V5 =)2<#Z3C=7H%X++@L9'(<G
M7MH;:&KYT*^W,TF\<8YF6IP*X3 P+LK=<HYPB'*-%.*DXKU?5Z901+(2298D
M$T)'R73;3<1TNVFTNY=.LU-FM$>3YT>*YG>=X0ZZ,:N5)22>3[5\ 7@!5+5#
MTTTTAXB M2[+8Y38!DJ3E;%RN<=Y'E10K5=A0E!0?(0_+2&=FV]ZR(:&8P3%
M)@P2!-%(H ([B@=0^[Z2B@E .,<WU^0I0 "D*4I0#7B:E%:BI1R3D_-DG)W?
M.3DDY-?=R$)0 E("0.89_P 23S=-375M74TI32E-*4TI32E-*4TI32E-*4TI
M32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI5$Y H<)DBL2=2L:";N%F
M&CN/DF2Z0+M7T?(-%V$@Q=H"8H+-7K-RNW73XQ>,0^X!#6:/(=BNH?944.-J
M2M"DG!2M"@I"@>E*@"/GJ'<($6YPY,":RB1$F,.QI+#B=9MZ.^VIIYE:=V4.
M-K4A6\'!.^L%^:IV*?JP5C7JL3M^NAXY:2?&\W[8]E>;>XEX+?D58.HI]KDZ
M/FY23OIS5.Q5["L:]5B=OTXXZ2?&\W[8]E/<2\%OR*L'44^W3FJ=BKV%8UZK
M$[?IQQTD^-YOVQ[*>XEX+?D58.HI]NG-4[%7L*QKU6)V_3CCI)\;S?MCV4]Q
M+P6_(JP=13[=.:IV*O85C7JL3M^G''23XWF_;'LI[B7@M^15@ZBGVZ<U3L5>
MPK&O58G;]...DGQO-^V/93W$O!;\BK!U%/MTYJG8J]A6->JQ.WZ<<=)/C>;]
ML>RGN)>"WY%6#J*?;IS5.Q5["L:]5B=OTXXZ2?&\W[8]E/<2\%OR*L'44^W3
MFJ=BKV%8UZK$[?IQQTD^-YOVQ[*>XEX+?D58.HI]NG-4[%7L*QKU6)V_3CCI
M)\;S?MCV4]Q+P6_(JP=13[=.:IV*O85C7JL3M^G''23XWF_;'LI[B7@M^15@
MZBGVZ<U3L5>PK&O58G;]...DGQO-^V/93W$O!;\BK!U%/MTYJG8J]A6->JQ.
MWZ<<=)/C>;]L>RGN)>"WY%6#J*?;IS5.Q5["L:]5B=OTXXZ2?&\W[8]E/<2\
M%OR*L'44^W3FJ=BKV%8UZK$[?IQQTD^-YOVQ[*>XEX+?D58.HI]NG-4[%7L*
MQKU6)V_3CCI)\;S?MCV4]Q+P6_(JP=13[=.:IV*O85C7JL3M^G''23XWF_;'
MLI[B7@M^15@ZBGVZ<U3L5>PK&O58G;]...DGQO-^V/93W$O!;\BK!U%/MTYJ
MG8J]A6->JQ.WZ<<=)/C>;]L>RGN)>"WY%6#J*?;IS5.Q5["L:]5B=OTXXZ2?
M&\W[8]E/<2\%OR*L'44^W3FJ=BKV%8UZK$[?IQQTD^-YOVQ[*>XEX+?D58.H
MI]NG-4[%7L*QKU6)V_3CCI)\;S?MCV4]Q+P6_(JP=13[=.:IV*O85C7JL3M^
MG''23XWF_;'LI[B7@M^15@ZBGVZ<U3L5>PK&O58G;]...DGQO-^V/93W$O!;
M\BK!U%/MTYJG8J]A6->JQ.WZ<<=)/C>;]L>RGN)>"WY%6#J*?;IS5.Q5["L:
M]5B=OTXXZ2?&\W[8]E/<2\%OR*L'44^W3FJ=BKV%8UZK$[?IQQTD^-YOVQ[*
M>XEX+?D58.HI]NG-4[%7L*QKU6)V_3CCI)\;S?MCV4]Q+P6_(JP=13[=.:IV
M*O85C7JL3M^G''23XWF_;'LI[B7@M^15@ZBGVZ<U3L5>PK&O58G;]...DGQO
M-^V/93W$O!;\BK!U%/MTYJG8J]A6->JQ.WZ<<=)/C>;]L>RGN)>"WY%6#J*?
M;IS5.Q5["L:]5B=OTXXZ2?&\W[8]E/<2\%OR*L'44^W3FJ=BKV%8UZK$[?IQ
MQTD^-YOVQ[*>XEX+?D58.HI]NG-4[%7L*QKU6)V_3CCI)\;S?MCV4]Q+P6_(
MJP=13[=.:IV*O85C7JL3M^G''23XWF_;'LI[B7@M^15@ZBGVZ<U3L5>PK&O5
M8G;]...DGQO-^V/93W$O!;\BK!U%/MTYJG8J]A6->JQ.WZ<<=)/C>;]L>RGN
M)>"WY%6#J*?;IS5.Q5["L:]5B=OTXXZ2?&\W[8]E/<2\%OR*L'44^W3FJ=BK
MV%8UZK$[?IQQTD^-YOVQ[*>XEX+?D58.HI]NG-4[%7L*QKU6)V_3CCI)\;S?
MMCV4]Q+P6_(JP=13[=.:IV*O85C7JL3M^G''23XWF_;'LI[B7@M^15@ZBGVZ
M<U3L5>PK&O58G;]...DGQO-^V/93W$O!;\BK!U%/MTYJG8J]A6->JQ.WZ<<=
M)/C>;]L>RGN)>"WY%6#J*?;IS5.Q5["L:]5B=OTXXZ2?&\W[8]E/<2\%OR*L
M'44^W3FJ=BKV%8UZK$[?IQQTD^-YOVQ[*>XEX+?D58.HI]NG-4[%7L*QKU6)
MV_3CCI)\;S?MCV4]Q+P6_(JP=13[==Z,X+O8UB)!C*,,'XV0?1SMN^9KA4T%
M!1=-52K-UBIKNUD#&24(4Y 524)O#Z1#!T:HK3#2):%MKNLQ2'$E"TEXX4D\
MJ3@:P_\ I4">2LK'@8\&,9YF0SH78$/,.)=:7P!"M5QM25MJU5*4@ZJDYPI)
M"MP(P"#GW#0S*"8IL&"8)H)@'U!QU#[OI**F\ISF'RB/04  A0 I0 .;4I2R
M5*)).>7?RDGE.\\N\D[SOYZ].0A+:0A "4CD S_B34UU;5U-*4TI32E-*4TI
M32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI32E-*4TI6!.V
M-MZ8WV, KKS)C:;&,M$BXAHE6!@!L#M609QS64<E<(#-PI6S<K9VB"1P,N8Z
M@' 0*&[6PB0')8.S*<I3K*UE:H"=92?-5G]'YN7'-D[*T6:XWQ^2S;Q'UHJ&
MEN;=Q3>0[K!(3JH6I1RG& -V<G<*P5Y^_95]$R-^&P!_;>M3?$4GI:^V _\
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ML5-J\3/Q#M'"G$XB+DI_H&14$J@&W )=XZD!0.,8.0" "G)!Y"!D']V?FK=
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MQ-=75U",&FE4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2H" &
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M&Y.?<4F*TR7W' AU9#(&L5ZB4J64A.5'"<A()(&#56V' &8*E5#W:R4>4AH
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ML*1LRC<4+"BG&^PZL9(H&;%7CWJ)GAN(T*JU73,Z-R@)"#8ITP%<2JF!,P)
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MCU_)OW:@(HMT6R93',!C&WG-N B9-ZBIB$(8Q6[!4HA*$#66LG 2.G/+K<N
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MTFDJ2A3C=L0HJ0@G5,M?('7<8.H,9;:.Y/*1DG.[M%%- A4TDRI)D*4A$R%
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MN/3_ &5<BO!^[<RY^47V;[\L?<4O'5>P*A^*0H$(7C'F!-Q2E "E+OW 4I0
M-P!NIPB'C'"F\=&J<?5J50>$71D<D^,.4[BX-YQD[FOF%<?-[[</Z-5Z\_\
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M)Z3]9ILV_@T>JGLJ P\0 "(14: @&\!!BUZ/_P#+3)Z3]9ILV_,1ZH[*[Y0
MI0 H  %X@      ;BAN  \@;NC<'U:I5]<FE*:4II2FE*:4II2FE*:4II2FE
M*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4II2FE*:4I
8I2FE*:4II2FE*:4II2FE*:4II2FE*__9

end
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>6
<FILENAME>g554088g96q94.jpg
<DESCRIPTION>GRAPHIC
<TEXT>
begin 644 g554088g96q94.jpg
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M 0$! 0$! 0'_P  1"  Q :(# 1$  A$! Q$!_\0 '@   @(# 0$! 0
M      D("@8'"P4$ P'_Q !,$  !! (! @0"!08&$ <!   % @,$!@$'"  )
M"A$2$Q05(3EXMK<6(CAV=[47&B,Q.M<8)"4T-T%76')SD9:7L[35)C(V5F*!
MF,'_Q  = 0 " @,! 0$             !P4& P0( @$)_\0 4Q$  @(! P(#
M P0+"@H+ 0$  0(#! 4 $1(&$P<A,10B0391=;0(%2,R-V%Q<W2!LQ<S-4)2
MH;&RM=06)#1#4U5B=I25.%16<H*2HK;$TM.1P?_:  P# 0 "$0,1 #\ _?\
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M1NT['X*Z1*?@^Y U(8;Q:@FL+6SN/]@#-P-RL[R0Q,3M]WK2+WHT7^,\<DS
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MMN05E5KX2K<EFC[4Y7\?'I\F13C&OZKN0>+==6N&*LU:L<6DEY\%G.?;8DV
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MS-D-./UT+6A$V$/L3 MYO\I+,P2)D9$N$V$ABZ]UAU%9S&2L5UE=<=4F>"O
MK$1R&)BC69 /)WD8%D+?O<?%5 /,M9^A.EJ>"Q%2T\$;96[!'8M670&6(3H)
M$J1,03%'$C*L@0CNRAG8D!%1A7,OA?HGG1I.T:4WE419J"7%D&ZK;?ET1VWZ
MVLS\92!MRI!AUOXL08%RTQY#K++Z(!N(T\%.QR :=-@OP6)R]W#7([E*5D9&
M4RQ<B(K$8/O0S)Z,C#<;D<D)YH5<!A8\W@\?GZ$U"_"CJZ,(9N*F:K*1LL\#
MD;I(AV.P(60 QR!D9E--#P[>X=C<0NYQN+M_WPDYD-L2=M;7)T!A]WY5 W=Q
M\78R+5B&H?\ -#'QM;JMZ!2,M(9<,(E %27'OE$!M+9Z\J5\KT[4SL*CG M6
M='V]YJ=_MKVVV]>,DL+C?[S:3;;FVDGX;7;.%ZJN].6&]RRUNM)'N>"W\;W6
M$B[^G**&Q&=MB^\>^_!1K O$$?74ZU_5;C)]Z9W6;H?Y'VOSF2_8KK7\1OES
M4_,XK]N^N@[TC==&:7=W;?JR^<GV;ME_N)_J>Z7^46&^D*_]<:K76/R6SWT9
M:_J'2#/"-_X*^;'[0-,_=R_=7?Q1_P IP_YBW^T@TO?!S_(\[^DTOV5C6!>+
M1J-4K55X//URL5ZOOD;+R$R0>"!1HIV?EH=I];69KD",PN5EM;[RV\OY7E"G
MG5)\LN+SG+X82RR39@222.%BI<0[LP'O6?0$G;]6M?QAAABAP)BBCC+2Y+D4
M14+;+2^^*@;^I]?G.K!7:WU?K0GVXN#Y$EKNBD"$WC#IR3,G3JD ES)<EZE"
M5O2)4E\>X^^^ZO.5N.NK6XM6<J4K.<YSU1^I+%A<_F56>95&1M@*LK@ =YO(
M -L!^33&Z4J56Z9P+-6KLS8FB69H8RS$UXR225W))\R3YG3)A(<2!@,"@8L<
M%%Q?=^%&B848= C>^\Y(>]B'#:9CL^](==?=]MM/N/.N.K\UK4K-?9F=BSLS
ML=MV8EF.PV&Y.Y.P  _$-M6=$2-0D:*B#?944*HW))V50 -R23L/,DG7/R[3
M?](TO/[;N=?[NW!T\>J/D%7_ $3"_P!-;7.?1WX2Y_T[/_U+NI%>)XY;[#VM
MR3U+V[-8RB#U=K,2FVRZUH6_EIV\[DV5(4QK^O$F<+PB5%K-8F""01EQ;;#I
M:\RI$IAQX4*DL:'ASBX*V/M9ZP%[DAEBAD8;B&I7&\\BGX&20,KGU"P@ [.X
M,GXJ9FS<RE/IJH6,<0@FGB0[&Q>M':M&P^(BB9&C!.Q>P2PW1"+*W;/[7&@.
MW7IRJ@ZU4JW8]\S@<)[;.\)HJ--MMDM$N*VLT-KQ>8PHA7*$/E*<@ *V+7"C
M.#XS! T@B?E$2<I?=0]27\];E>262.D'/LU(,1%'&#[AD13QDF(\WD;D>1*H
M50*H:/2_2>.Z:I11Q0Q2Y!HU-R^R!II92-W6-V'**NI)6.).(*@-)RD+.9+\
MLN%G&SFUK8GK'D5K$!=A<N%)CA;&J'%B7JCSGD*PR<HMP1'67K9:(\K#Z<Q'
ME#R"4K@FQY05)F#Y,=C,OD,/86S0LR0L&!:/D3#,!ZI-%OPD4CR\QN/52K ,
M)3,8/%YVJ]3)58YT92$EX@6(&/I)7FVYQ.#L?(\6VXR*Z$J8^]L_MA:/[96J
M[%2-9SR5WO-]+H+;)VS8H4<?8;<V+?))J81L;$?E0PH"JCB4EB"-B/NXDDYQ
M<S*>4^22Q$WNH>H[G45F.:RJPPP)PKU8R6CBY!>Z_(@%WE9068@;*%0#9=S&
M]+=*T.EJ<E>JS3V+#\[5R10LDW MV4"@D1QQ*Q"H"=W9W));84F]B[(UWQH\
M0CMW:7/.CD+AJ^K\L]L64X(*@LV7$:G66-8UZ%NF*W+0O-B 4\,8UQ<((MAN
M4^Z'"L)'0R4QB,.E.""O/D>A:M;"3+#9DQE6-&5^WO+$8_;8>X/WMYG2>)F.
MPY.>1526"+M6JV+\1[MOJ&NT]2+,6Y71X^[M!*)/M=/VFW[L<*/5F51N2B#B
MK, AOUZBY&<0>:5%DMZBVEI?D%2BPQ*3=5'%*[:5,CGDHQ\!<-?E$K, \Y0I
MO#HFT@!\AM*V\.Q$X4GS2-K'Y7$3 VJURC,K;I*RR1[M_*BG7W'_ .]&[#\>
MNAJ>3PN<KD4[='(P.OOPJ\4VRG;W9J[^_'Y$;I+&I&XW&O(XW\$>)W$6X;8O
M'''3%6U.;W5+!R[TBL(E,"',5Y$[ X?7 KTAX93P:7R4V:]7ZM&$@W9SJ9/R
M]*V6/:]7\UD\I%5AOVY;24PXA[A!8<^/)I'V#2OLH >0LX4;<O,[^<9T_A\-
M-<GQE&&F]YHS8$((0]H-P6-"2D,8+,W;B"1\COQ\ALO'Q 7Z$U,^T71ON%M/
MJZ>%WRBL?1-GZU2US#]F;^"G%?[\8G^QNHM2QX9ZQI>Y^V;H;5>Q S)^E7KC
M\ K]@&/>2<NPYD)7HDQ'O2I<,D/DH8(B2+/E)&DXD2?%6W)C-+3!]07+&/ZP
MR=VI(8K%;*RRQ./@RMZ,/1D<;HZ'R=&96W!(TQ_"[ 8KJGP%Z/Z>S=5;F*R_
M1=*E=KMY<HI8O)XVV)BGAD"3UIUVD@L1QS1D.BD(]XK;/N'9^YP73C%O0O)5
MQWV<0AR8ENE-/($LP9SCT:A;BA,)PXU&96RRY5=CQHF58AN0Y:G7B&:@/1(8
M^;IP=>].5\SC8Q]MJ:,K5U(YEEV-J@Q]203WZA;[X,!LO?8KR;X=]09/[&;Q
M9RO0'5]F0]$Y^:*2+)2!A62&5G3#]31( 5C4JK8[.1Q>4312%FG^UD <%0[7
MWK>X%(,3FS [B+HM;:$,K^)A8:H;9%:X8WR3E&(EYW.4'N2B*TJ;G!:Q#=:3
M(EKJ(],LD:#P[Z6$:F-\]D]SN.+;V>'O/\>5;'HX5/59)F!V43OQ^5HLC]E7
MXSO:F%J#PUZ1*@(>Y%QQ"SDQ0>6W;RW5%B R3D%9JM"-E#R'&P]QJ'>N%# /
M;GM(,*/AB0P:V:D%"18^.U$'C1@ZQ08< ?!B,)0Q%APXK+4>-'90AIEEM#;:
M4H3C&*5X=N\O5D,DCM)))7O/([DL[N\3,SLQW+,S$EB3N223KH7[*RM7I^"%
M^I5ABK5:N3Z;KUJ\"+%#!!#<CCAABC0!(XXHU5$10%55"@ #6S^S=]6]QQ_T
M-L_CELSK2Z_^5V7_ "T?[-IZL'V+_P" SH?\G4?_ +LSNE"\9_K^]K?KWR!^
MY![J^YC\%]+]%Q7UJ'7-/0?_ $RNH_I?K/\ LFWJUGTD=?HGHZ-&JF'B"8S%
M>Y,\=KL$4F+;%ZM<0J2QCRDIQ5KX2(UZ1GT^2E+:FER6&5Y_._D_1C/DA.$O
M+PL)EP^6KR><'MHV!]/NU9$E'ZUC3?X?'XG7YP_9H1I2Z]Z(RU0]O)'I]@9$
M\I!]KLQ//2?R\RRRV9^!]?=V!\AM;+94M;32W$>VXMM"EMY^GT+4G&5(\_\
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M&[AELQ2QCBI;=UF@=BHVW/&1#M_&&E!>$W_38Y$?9:(?BSK'JT^)_P#!./\
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MBM6?09VDC).4J^'4=HNPS)TZPE?EZ?>1 V+77'$^?J]#C>?+RZT/"^5#C<E
M".Y'>25A\>$T"HA_)R@DV_(=27C#!(N6Q-D@]J7'20(?AW*]F220;_/QLQ']
M>OPTGX6\[O?3VKMU4OG31Y-4VO0*GL$ MO21F3EL;; <(W'B/O-[-0G,N"F9
M\%.;RVTXQ,COL/,LNMK:07/$A*5JS3FPLPEK3RP2 W$'O1.4)'^+^AVW4^8(
M(()!WU\H^$\F0I5+T&?KF&Y7ALQ[47.RS1JX4D6OOEY<6'D0P((!&VMG_P 4
M8V)_GPTO_@4<_K/ZU_W4J_\ J:;_ (U/[OK;_<;L_P"OH/\ E\G]ZU,+@)X;
MJ[\+>7VD^3Y'EG6;Y!U*<-F)-1&ZD*UV:<;+T^Q5?X5DS)OI9F#A"CN)#JUC
MI/N,LN,)2A3J7416<\0(<OBKF.7%R0M:1$$K6ED"<)8Y-R@A4M]YL/>'F=]3
M73OAC/@\S1RK9B*PM.21S"E-XFDYPRQ<0YL.%_?-S[IW (^.^E&>(BG1J[WD
M:$>,.8A"H%!XY&Y,Q[\QI P;9S"YDOU9^C+3&(4K"U?S8RRYC/TISU9^A%,G
M25B-1NS39! !YDLT2 #]>XU3O$IA'UM6D?R1:V,D)/IQ6:0L?R#B?_YKH3H6
MEQ*5H4E:%IPM"T9PI*TJQC*5)5C.<*2K&<9QG&<XSC.,XSY=(O71VEK=XRPB
M*SVON;A$W-9@0Y6B+17F'GUI0APO;%PZL A)RK.,9>(G3 Z PC&?4M^2VA.%
M*5C&;#TI&\G4>'5%+$78I"!\$BWD=OR*BLQ_$-5?K61(NE,ZTC!5./EC!)VW
M>4K%&OY6D=5 ^)(TB;PC?^"OFQ^T#3/W<OW5T\4?\IP_YBW^T@U0/!S_ "/.
M_I-+]E8UX?B[/_2'!']9.0_[LTUUZ\+?W_,_FJ/]>UK'XR?O'3_YW)?U*6K$
M?:I^K6X*_9:TQ]QQ'5$ZF^4.:^DK?[9M,KI+Y,=/_1%#ZM'J?O4'JPZY\/:;
M_I&EY_;=SK_=VX.GGU1\@J_Z)A?Z:VN<>COPES_IV?\ ZEW6-]YR2]QU[_8S
M>=^B2,TQ.Q.'6^X:G&''<$:-K\+K, =7&:PE69+39G6%J')0TE7J=B+9\LN8
M5CK)TD!?Z'>E 1WO9\M2.QV*S3O9D3<_ \+,3;GYP=8^MR<9XB)D+ ;L>TX7
M(KN-^5>LE6.3B//<!ZDJ;?.NVVNAF+*#3@P<:#3X94.8@0R@HH/D-2X!(:0C
MMRX,^#+84MB3#F17FI$:0RM;3S+B'&U*0K&<HIE9&9'4JRL596!#*RG8J0?,
M$$$$'S!UT@CK(BR(RNCJKHZD%65@"K*1Y%6!!!'D0=]??UYUZT=&C2V.?':A
MX=]Q:#!F;TIA(1LD(-R(K>YM=$(]:V0(&8<=?9$2ITF 5"6@)'DO//Q1-M!F
MXXQ<F<X$R*D3YC[U@PG4V5P#,*4JO7=N<E2=3)7=MMBX 97C<@ %XG0MLH?D
M% %8ZAZ0PO4JJ<A R6D7A%>K,(K2)N2$+%7CEC!)(2:.0+NQCX%B35ZY">%P
MY4:5D2-E<*>1XC:!:M..FJ_6S2)^D]M17H^%*C1*G;AADM5"1Y/T8:GD3&NX
MR\J7Z%,KPAMUCT?$C&VP*^7Q[5UD]R21.-RJ0?4R1,BRJGSJJSG\OP5&2\)\
MM1)M8+)I;>(F2.*0-1N*1OQ6&9'>%Y/@&9ZH/XOC*GL%=VKD]L;D(9[>7- M
M8+O<H JZ-Z[NMY9=3M:NV_6*),BZ:QV-.E);(653 D78",4W8,OVP05 3Q!:
M>8B$H":_&=;]+XZO13/8A4AA9H3/#"1[,\5G;M6:X'E'NS(I1/N;+(&54*GG
M+^'G6&5LY*3IO./)/.J3BM/8!%R.:IN9ZEECLTI")(P>3>9'C='9PR]MGGB
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M6<3)[-HLHVX3,60K?+G,66-5UF_&R#!210YL$R3J\M) U+C"SIHR 54.M+F
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M_I5=5GJWY39OZ0G_ *VG!X&_@@\._P#=?&_LSJ;'5=TUM'1HTH?OB?5^7O\
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M1?O410BKN23LJ@ ;DD^0]23KU.O.O6L'L>L=;7 @V7MVO:/:2S,9J&R3L=3
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MVTRRTWA+;333:4H;;0E*$(3A*<83C&.M$DDDDDDG<D^9)/J2?B3J2
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!V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
